## Introducing PHARMAC

<table>
<thead>
<tr>
<th>Part I</th>
<th>General Rules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part II</td>
<td>Alimentary Tract and Metabolism</td>
</tr>
<tr>
<td></td>
<td>Blood and Blood Forming Organs</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular System</td>
</tr>
<tr>
<td></td>
<td>Dermatologicals</td>
</tr>
<tr>
<td></td>
<td>Genito-Urinary System</td>
</tr>
<tr>
<td></td>
<td>Hormone Preparations</td>
</tr>
<tr>
<td></td>
<td>Infections</td>
</tr>
<tr>
<td></td>
<td>Musculoskeletal System</td>
</tr>
<tr>
<td></td>
<td>Nervous System</td>
</tr>
<tr>
<td></td>
<td>Oncology Agents and Immunosuppressants</td>
</tr>
<tr>
<td></td>
<td>Respiratory System and Allergies</td>
</tr>
<tr>
<td></td>
<td>Sensory Organs</td>
</tr>
<tr>
<td></td>
<td>Various</td>
</tr>
<tr>
<td></td>
<td>Extemporaneous Compounds (ECPs)</td>
</tr>
<tr>
<td></td>
<td>Special Foods</td>
</tr>
<tr>
<td></td>
<td>Vaccines</td>
</tr>
<tr>
<td>Part III</td>
<td>Optional Pharmaceuticals</td>
</tr>
<tr>
<td>Index</td>
<td>240</td>
</tr>
</tbody>
</table>

©Pharmaceutical Management Agency

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.
Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC’s role:

“Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided.”

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.health.nz/about.

Glossary

Units of Measure

gram ............................................. g  microgram ..................................... mcg  millimole .................................... mmol
kilogram .................................. kg  milligram ................................... mg  unit ........................................... u
international unit .................... iu  millilitre ..................................... ml

Abbreviations

application ................................ app  enteric coated ............................ EC  solution ...................................... soln
capsule ..................................... cap  granules ................................. grans  suppository ............................... suppos
cream ...................................... crm  injection ................................. inj  tablet ......................................... tab
dispersible ......................... disp  liquid ..................................... liq  tincture ..................................... tinc
effervescent ...................... eff  lotion ...................................... lotn
emulsion ......................... emul  ointment ................................... oint

HSS  Hospital Supply Status
<table>
<thead>
<tr>
<th>ANATOMICAL HEADING</th>
<th>Price (ex man. Excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMICAL A - Restricted see terms below</td>
<td>10.00</td>
<td>100</td>
<td>Brand A</td>
</tr>
<tr>
<td>CHEMICAL B - Some items restricted see terms below</td>
<td>1,589.00</td>
<td>1</td>
<td>Brand B1, e.g. Brand B2</td>
</tr>
<tr>
<td>CHEMICAL C</td>
<td>15.00</td>
<td>28</td>
<td>Brand C</td>
</tr>
<tr>
<td>CHEMICAL D - Restricted see terms below</td>
<td>38.65</td>
<td>500</td>
<td>Brand D</td>
</tr>
<tr>
<td>CHEMICAL E</td>
<td>e.g. Brand E</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Restricted
- Item restricted (see above)
- Item restricted (see below)

- Some items restricted
- Limited to five weeks' treatment

From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C.

Indicates only presentation B1 is Restricted.

Oncologist or haematologist

Limited to five weeks' treatment

Either:
1. For the prophylaxis of venous thromboembolism following a total hip replacement; or
2. For the prophylaxis of venous thromboembolism following a total knee replacement.

Products with Hospital Supply Status (HSS) are in **bold**.
General Rules for Section H of the Pharmaceutical Schedule are included in Section A General Rules and are located on the PHARMAC website.
Antacids and Antiflatulents

Antacids and Reflux Barrier Agents

ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE
Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg
Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone
30 mg per 5 ml
e.g. Mylanta

SIMETICONE
Oral drops 100 mg per ml
Oral drops 20 mg per 0.3 ml
e.g. Mylanta Double Strength

SODIUM ALGINATE WITH MAGNESIUM ALGINATE
Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet
e.g. Gaviscon Infant

SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg
e.g. Gaviscon Double Strength
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate
160 mg per 10 ml ............................................................4.95 500 ml Acidex

SODIUM CITRATE
Oral liq 8.8% (300 mmol/l)

Phosphate Binding Agents

ALUMINIUM HYDROXIDE
Tab 600 mg

CALCIUM CARBONATE – Restricted see terms below
Oral liq 250 mg per ml (100 mg elemental per ml) ........................................39.00 500 ml Roxane

Initiation
Only for use in children under 12 years of age for use as a phosphate binding agent.

Antidiarrhoeals and Intestinal Anti-Inflammatory Agents

Antipropulsives

DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE
Tab 2.5 mg with atropine sulphate 25 mcg

LOPERAMIDE HYDROCHLORIDE
Tab 2 mg .................................................................10.75 400 Nodia
Cap 2 mg – 1% DV Oct-19 to 2022 .................................................................6.25 400 Diamide Relief

Rectal and Colonic Anti-Inflammatories

BUDESONIDE – Restricted see terms below
Cap 3 mg

Initiation – Crohn's disease
Both:

continued…
continued...

1. Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
2. Any of the following:
   2.1 Diabetes; or
   2.2 Cushingoid habitus; or
   2.3 Osteoporosis where there is significant risk of fracture; or
   2.4 Severe acne following treatment with conventional corticosteroid therapy; or
   2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
   2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
   2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation – Collagenous and lymphocytic colitis (microscopic colitis)
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation – Gut Graft versus Host disease
Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

HYDROCORTISONE ACETATE
Rectal foam 10%, CFC free (14 applications) .................................................26.55 21.1 g Colifoam

MESALAZINE
Tab EC 400 mg .................................................................49.50 100 Asacol
Tab EC 500 mg .................................................................49.50 100 Asamax
Tab long-acting 500 mg ....................................................59.05 100 Pentasa
Tab 800 mg .................................................................85.50 90 Asacol
Modified release granules 1 g ........................................141.72 120 g Pentasa
Suppos 500 mg .................................................................22.80 20 Asacol
Suppos 1 g .................................................................54.60 30 Pentasa
Enema 1 g per 100 ml ..................................................41.30 7 Pentasa

OLSALAZINE
Tab 500 mg .................................................................93.37 100 Dipentum
Cap 250 mg .................................................................53.00 100 Dipentum

SODIUM CROMOGLICATE
Cap 100 mg

SULFASALAZINE
Tab 500 mg .................................................................14.00 100 Salazopyrin
Tab EC 500 mg .................................................................13.50 100 Salazopyrin EN

Local Preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE
Oint 5 mg with hydrocortisone 5 mg per g ....................................................15.00 30 g Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g ..................................................9.90 12 Proctosedyl

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchoacaine hydrochloride 5 mg per g ..................................................6.35 30 g Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchoacaine hydrochloride 1 mg ..................................................2.66 12 Ultraproct

† Item restricted (see ➥ above); † Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
### Management of Anal Fissures

**GLYCERYL TRINITRATE**

Oint 0.2% ........................................................................................................ 22.00 30 g Rectogesic

### Rectal Sclerosants

**OILY PHENOL [PHENOL OILY]**

Inj 5%, 5 ml vial

### Antispasmodics and Other Agents Altering Gut Motility

**GLYCOPYRRONIUM BROMIDE**

Inj 200 mcg per ml, 1 ml ampoule .................................................. 17.14 10 Max Health

**HYOSCINE BUTYLBROMIDE**

*Tab 10 mg – 1% DV Dec-17 to 2020* .............................................. 8.75 100 Buscopan

Inj 20 mg, 1 ml ampoule .................................................. 9.57 5 Buscopan

**MEBEVERINE HYDROCHLORIDE**

Tab 135 mg ................................................................................. 18.00 90 Colofac

### Antiulcerants

### Antisecretory and Cytoprotective

**MISOPROSTOL**

Tab 200 mcg ................................................................................. 41.50 120 Cytotec

### H2 Antagonists

**CIMETIDINE**

Tab 200 mg

Tab 400 mg

**RANITIDINE**

*Tab 150 mg – 1% DV Oct-17 to 2020* .............................................. 12.91 500 Ranitidine Relief

*Tab 300 mg – 1% DV Oct-17 to 2020* .............................................. 18.21 500 Ranitidine Relief

Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020 .................................. 5.14 300 ml Peptisoothe

Inj 25 mg per ml, 2 ml ampoule .................................................. 8.75 5 Zantac

### Proton Pump Inhibitors

**LANSOPRAZOLE**

*Cap 15 mg – 1% DV Sep-18 to 2021* .............................................. 4.58 100 Lanzol Relief

*Cap 30 mg – 1% DV Sep-18 to 2021* .............................................. 5.41 100 Lanzol Relief

---

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omeprazole actavis 10</td>
<td>1.98 Per 90</td>
</tr>
<tr>
<td>Omeprazole actavis 20</td>
<td>1.96 Per 90</td>
</tr>
<tr>
<td>Omeprazole actavis 40</td>
<td>3.12 Per 90</td>
</tr>
<tr>
<td>MidWest</td>
<td>42.50 Powder for oral liq.</td>
</tr>
<tr>
<td>Dr Reddy’s Omeprazole</td>
<td>33.98 Per 5</td>
</tr>
<tr>
<td>Omezol IV</td>
<td>11.46 5g vial</td>
</tr>
<tr>
<td>Panzop Relief</td>
<td>2.02 Per 100</td>
</tr>
<tr>
<td>Panzop Relief</td>
<td>2.85 Per 100</td>
</tr>
<tr>
<td>Gastrodenol</td>
<td>14.51 50 Tab 120 mg</td>
</tr>
<tr>
<td>Glucobay</td>
<td>3.50 Per 90</td>
</tr>
<tr>
<td>Glucobay</td>
<td>6.40 Per 90</td>
</tr>
<tr>
<td>Proglicem</td>
<td>110.00 Cap 25 mg</td>
</tr>
<tr>
<td>Proglicem</td>
<td>280.00 Cap 100 mg</td>
</tr>
<tr>
<td>Proglycem</td>
<td>620.00 Oral liq 50 mg per ml</td>
</tr>
</tbody>
</table>

### Bile and Liver Therapy

**L-ORNITHINE L-ASPARTATE** – Restricted see terms below

- Grains for oral liquid 3 g
- Restricted (RS1261)

Initiation

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

**RIFAXIMIN** – Restricted see terms below

- Tab 550 mg – 1% DV Sep-17 to 2020
- Restricted (RS1416)

Initiation

For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

### Diabetes

#### Alpha Glucosidase Inhibitors

**ACARBOSE**

- Tab 50 mg – 1% DV Sep-18 to 2021
- Tab 100 mg – 1% DV Sep-18 to 2021

#### Hyperglycaemic Agents

**DIAZOXIDE** – Restricted see terms on the next page

- Cap 25 mg
- Cap 100 mg
- Oral liq 50 mg per ml

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.*
### Insulin - Intermediate-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin - Intermediate-Acting Preparations</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN ASPART WITH INSULIN ASPART PROTAMINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen</td>
<td>52.15</td>
<td>5 NovoMix 30 FlexPen</td>
</tr>
<tr>
<td><strong>INSULIN ISOPHANE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge</td>
<td>42.66</td>
<td>5 Humalog Mix 25</td>
</tr>
<tr>
<td>Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge</td>
<td>42.66</td>
<td>5 Humalog Mix 50</td>
</tr>
<tr>
<td><strong>INSULIN NEUTRAL WITH INSULIN ISOPHANE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Insulin - Long-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin - Long-Acting Preparations</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN GLARGINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>94.50</td>
<td>5 Lantus SoloStar</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>94.50</td>
<td>5 Lantus</td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>63.00</td>
<td>1 Lantus</td>
</tr>
</tbody>
</table>

### Insulin - Rapid-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin - Rapid-Acting Preparations</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN ASPART</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml syringe</td>
<td>51.19</td>
<td>5 NovoRapid FlexPen</td>
</tr>
</tbody>
</table>
# ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per $</td>
<td></td>
</tr>
</tbody>
</table>

## INSULIN GLULISINE
- Inj 100 u per ml, 10 ml vial: $27.03 1 Apidra
- Inj 100 u per ml, 3 ml cartridge: $46.07 5 Apidra
- Inj 100 u per ml, 3 ml disposable pen: $46.07 5 Apidra Solostar

## INSULIN LISPRO
- Inj 100 u per ml, 10 ml vial
- Inj 100 u per ml, 3 ml cartridge

## Insulin - Short-Acting Preparations

## Oral Hypoglycaemic Agents

### GLIBENCLAMIDE
- Tab 5 mg – 1% DV Oct-18 to 2021: $6.00 100 Daonil

### GLICLAZIDE
- Tab 80 mg – 1% DV Sep-17 to 2020: $10.29 500 Glizide

### GLIPIZIDE
- Tab 5 mg – 1% DV Dec-18 to 2021: $3.27 100 Minidiab

### METFORMIN HYDROCHLORIDE
- Tab immediate-release 500 mg – 1% DV Feb-19 to 2021: $8.63 1,000 Apotex
- Tab immediate-release 850 mg – 1% DV Feb-19 to 2021: $7.04 500 Apotex

### PIOGLITAZONE
- Tab 15 mg – 1% DV Oct-18 to 2021: $3.47 90 Vexazone
- Tab 30 mg – 1% DV Oct-18 to 2021: $5.06 90 Vexazone
- Tab 45 mg – 1% DV Oct-18 to 2021: $7.10 90 Vexazone

### VILDAGLIPTIN
- Tab 50 mg: $40.00 60 Galvus

### VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE
- Tab 50 mg with 1,000 mg metformin hydrochloride: $40.00 60 Galvumet
- Tab 50 mg with 850 mg metformin hydrochloride: $40.00 60 Galvumet

## Digestives Including Enzymes

### PANCREATIC ENZYME
- Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))
- Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Sep-18 to 2021: $34.93 100 Creon 10000
- Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 1% DV Sep-18 to 2021: $94.38 100 Creon 25000
- Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur. u/protease)

### URSODEOXYCHOLIC ACID – Restricted see terms on the next page
- Cap 250 mg – 1% DV Sep-17 to 2020: $37.95 100 Ursosan

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Restricted (RS1647)

**Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis**

1. Patient has been diagnosed with Alagille syndrome; or
2. Patient has progressive familial intrahepatic cholestasis.

**Initiation – Chronic severe drug induced cholestatic liver injury**

All of the following:
1. Patient has chronic severe drug induced cholestatic liver injury; and
2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

**Initiation – Primary biliary cholangitis**

Both:
1. Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
2. Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

**Initiation – Pregnancy**

Patient diagnosed with cholestasis of pregnancy.

**Initiation – Haematological transplant**

Both:
1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
2. Treatment for up to 13 weeks.

**Initiation – Total parenteral nutrition induced cholestasis**

Both:
1. Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
2. Liver function has not improved with modifying the TPN composition.

### Laxatives

#### Bowel-Cleansing Preparations

- **CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE**
  - Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet
  - e.g. PicoPrep

- **MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE**
  - Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
  - e.g. Glycoprep-C

- **MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE**
  - Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – 1% DV Aug-19 to 2022
  - .................................................14.31 4 Klean Prep

#### Bulk-Forming Agents

- **ISPAGHULA (PSYLLIUM) HUSK**
  - Powder for oral soln – 1% DV Oct-17 to 2020
  - ....................................................6.05 500 g Konsyl-D

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Alimentary Tract and Metabolism

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
</table>

**Sterculia with Frangula** – **Restricted**: For continuation only

- Powder for oral soln

### Faecal Softeners

#### Docusate Sodium

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg – 1% DV Sep-17 to 2020</td>
<td>2.31</td>
<td>100 Coloxyl</td>
</tr>
<tr>
<td>Tab 120 mg – 1% DV Sep-17 to 2020</td>
<td>3.13</td>
<td>100 Coloxyl</td>
</tr>
</tbody>
</table>

#### Docusate Sodium with Sennosides

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021</td>
<td>3.10</td>
<td>200 Laxsol</td>
</tr>
</tbody>
</table>

#### Paraffin

- Oral liquid 1 mg per ml
- Enema 133 ml

#### Poloxamer

- Oral drops 10% – 1% DV Sep-17 to 2020 | 3.78 | 30 ml Coloxyl |

### Opioid Receptor Antagonists - Peripheral

#### Methylnaltrexone Bromide – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 12 mg per 0.6 ml vial</td>
<td>36.00</td>
<td>1 Relistor</td>
</tr>
</tbody>
</table>

**Restricted** (RS1601)

**Initiation – Opioid induced constipation**

- Both:
  - 1 The patient is receiving palliative care; and
  - 2 Either:
    - 2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
    - 2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

### Osmotic Laxatives

#### Glycerol

- Suppos 1.27 g
- Suppos 2.55 g
- Suppos 3.6 g – 1% DV Oct-18 to 2021 | 9.25 | 20 PSM |

#### Lactulose

- Oral liq 10 g per 15 ml | 3.18 | 500 ml Laevolac |

#### Macrool 3350 with Potassium Chloride, Sodium Bicarbonate and Sodium Chloride

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg</td>
<td>6.78</td>
<td>30 Molaxole</td>
</tr>
<tr>
<td>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Feb-18 to 2020</td>
<td>26.72</td>
<td>50 Micolette</td>
</tr>
</tbody>
</table>

#### Sodium Citrate with Sodium Lauryl Sulphoacetate

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml</td>
<td>26.72</td>
<td>50 Micolette</td>
</tr>
</tbody>
</table>

#### Sodium Phosphate with Phosphoric Acid

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 16.4% with phosphoric acid 25.14%</td>
<td>2.50</td>
<td>1 Fleet Phosphate Enema</td>
</tr>
</tbody>
</table>
Stimulant Laxatives

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>BISACODYL</td>
<td>Tab 5 mg – 1% DV Sep-18 to 2021</td>
<td>5.99</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Suppos 10 mg – 1% DV Sep-18 to 2021</td>
<td>3.74</td>
<td>10</td>
</tr>
</tbody>
</table>

SENNOSIDES

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tab 7.5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myozyme</td>
<td>Inj 50 mg vial</td>
<td>1,142.60</td>
<td>1</td>
</tr>
</tbody>
</table>

Initiation

Restrict (RS1545)

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
2. Any of the following:
   2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
   2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
   2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
   2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
3. Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
4. Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
5. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
3. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
4. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
5. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
6. There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
7. There is no evidence of new or progressive cardiomyopathy.

ARGININE

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
<td>Inj 600 mg per ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
</table>

### BETAININE – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral soln</td>
<td></td>
<td>$575.00</td>
<td>180 g</td>
</tr>
</tbody>
</table>

- **Initiation**
  - Metabolic physician

- **Re-assessment required after 12 months**

- All of the following:
  1. The patient has a confirmed diagnosis of homocystinuria; and
  2. Any of the following:
     1. A cystathionine beta-synthase (CBS) deficiency; or
     2. A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
     3. A disorder of intracellular cobalamin metabolism; and
  3. An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

- **Continuation**
  - Metabolic physician

- **Re-assessment required after 12 months**

### BIOTIN – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 50 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Initiation**
  - Metabolic physician or metabolic disorders dietitian

- **GALSULFASE – Restricted see terms below**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 5 ml vial</td>
<td></td>
<td>$2,234.00</td>
<td>1</td>
</tr>
</tbody>
</table>

- **Initiation**
  - Metabolic physician or metabolic disorders dietitian

- **Re-assessment required after 12 months**

### HAEM ARGINATE

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Notes
- **Item restricted (see above); Item restricted (see below)**
- **e.g. Brand** indicates brand example only. It is not a contracted product.
IDURSULFASE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 3 ml vial</td>
<td>4,608.30 Elaprase</td>
</tr>
</tbody>
</table>

**Initiation**

Metabolic physician

**Limited to 24 weeks** treatment

All of the following:

1. The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
2. Either:
   1. Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2. Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

IMIGLUCERASE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 iu per ml, 10 ml vial</td>
<td>1,335.16 Aldurazyme</td>
</tr>
</tbody>
</table>

**Initiation**

Only for use in patients with approval by the Gaucher Treatment Panel.

LARONIDASE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 U per ml, 5 ml vial</td>
<td>1,335.16 Aldurazyme</td>
</tr>
</tbody>
</table>

**Initiation**

Metabolic physician

**Limited to 24 weeks** treatment

All of the following:

1. The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
2. Either:
   1. Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2. Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 100 units/kg every week.

LEVOCARNITINE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 500 mg</td>
<td></td>
</tr>
<tr>
<td>Oral soln 1,000 mg per 10 ml</td>
<td></td>
</tr>
<tr>
<td>Inj 200 mg per ml, 5 ml vial</td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

Neurologist, metabolic physician or metabolic disorders dietitian

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
PYRIDOXAL-5-PHOSPHATE – Restricted see terms below

- Tab 50 mg
  - Restricted (RS1331)

Neurologist, metabolic physician or metabolic disorders dietitian

SAPROPTERIN DIHYDROCHLORIDE – Restricted see terms below

- Tab soluble 100 mg
  - Restricted (RS1656)

**Initiation**

Metabolic physician

*Re-assessment required after 1 month*

All of the following:

1. Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
2. Treatment with sapropterin is required to support management of PKU during pregnancy; and
3. Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
4. Sapropterin to be used alone or in combination with PKU dietary management; and
5. Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

**Continuation**

Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician

*Re-assessment required after 12 months*

All of the following:

1. Either:
   1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
   1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
2. Any of the following:
   2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
   2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
   2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
3. Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
4. Sapropterin to be used alone or in combination with PKU dietary management; and
5. Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE

- Cap 500 mg
- Powder
- Sln 100 mg per ml
- Inj 20%, 10 ml ampoule

SODIUM PHENYLButyRATE – Some items restricted see terms below

- Tab 500 mg
  - Restricted (RS1526)

**Initiation**

Metabolic physician

*Re-assessment required after 12 months*

For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine continued...
Continuation
Metabolic physician

Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.

TALIGLUCERASE ALFA – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

Inj 200 unit vial............................................................................................1,072.00 1 Eleyso

Initiation
Only for use in patients with approval by the Gaucher Treatment Panel.

TRIENTINE DIHYDROCHLORIDE
Cap 300 mg

Minerals
Calcium

CALCIUM CARBONATE
Tab 1.25 g (500 mg elemental) – 1% DV Mar-18 to 2020..........................7.52 250 Arrow-Calcium
Tab eff 1.75 g (1 g elemental)......................................................................2.07 10 Calsource

(Calsource Tab eff 1.75 g (1 g elemental) to be delisted 1 September 2019)

Fluoride

SODIUM FLUORIDE
Tab 1.1 mg (0.5 mg elemental)

Iodine

POTASSIUM IODATE
Tab 253 mcg (150 mcg elemental iodine) – 1% DV Mar-19 to 2020............4.69 90 NeuroTabs

POTASSIUM IODATE WITH IODINE
Oral liq 10% with iodine 5%

Iron

FERRIC CARBOXYMALTOSE – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

Inj 50 mg per ml, 10 ml vial.........................................................................150.00 1 Ferinject

Initiation
Treatment with oral iron has proven ineffective or is clinically inappropriate.

FERROUS FUMARATE
Tab 200 mg (65 mg elemental) – 1% DV Jan-19 to 2021.............................3.09 100 Ferro-tab

FERROUS FUMARATE WITH FOLIC ACID
Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 1% DV Jun-18 to 2021.............................4.68 60 Ferro-F-Tabs

FERROUS GLUCONATE WITH ASCORBIC ACID
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>FERROUS SULPHATE</td>
<td>Tab long-acting 325 mg (105 mg elemental)</td>
<td>2.06</td>
<td>Ferrograd</td>
</tr>
<tr>
<td></td>
<td>Oral liq 30 mg (6 mg elemental) per ml</td>
<td>10.80</td>
<td>Ferodan</td>
</tr>
<tr>
<td>FERROUS SULPHATE WITH ASCORBIC ACID</td>
<td>Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRON POLYMALTOSE</td>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td>34.50</td>
<td>Ferrosig</td>
</tr>
<tr>
<td>IRON SUCROSE</td>
<td>Inj 20 mg per ml, 5 ml ampoule</td>
<td>100.00</td>
<td>Venofer</td>
</tr>
</tbody>
</table>

### Magnesium

| Magnesium Ammonium Chloride Chelate | Cap 750 mg (150 mg elemental) |
| Magnesium Chloride | Inj 1 mmol per 1 ml, 100 ml bag |
| Magnesium Hydroxide | Tab 311 mg (130 mg elemental) |
| Magnesium Oxide | Cap 663 mg (400 mg elemental) |
| | Cap 696 mg (420 mg elemental) |
| Magnesium Oxide with Magnesium Aspartate, Magnesium Ammonium Chloride Chelate and Magnesium Citrate | Cap 500 mg with magnesium aspartate 100 mg, magnesium ammonium chloride 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) |
| Magnesium Sulfate | Inj 0.4 mmol per ml, 250 ml bag |
| | Inj 2 mmol per ml, 5 ml ampoule | 10.21 | DBL |

### Zinc

| Zinc | Oral liq 5 mg per 5 drops |
| Zinc Chloride | Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule |
| Zinc Sulfate | Cap 137.4 mg (50 mg elemental) |

### Mouth and Throat

#### Agents Used in Mouth Ulceration

| Benzylamine Hydrochloride | Soln 0.15% |
| | Spray 0.15% |
| | Spray 0.3% |

| Benzylamine Hydrochloride with Cetylpyridinium Chloride | Lozenge 3 mg with cetylpyridinium chloride |
Oropharyngeal Anti-Infectives

AMPHOTERICIN B
Lozenge 10 mg.................................................................5.86 20 Fungilin

MICONAZOLE
Oral gel 20 mg per g – 1% DV Sep-18 to 2021 ..................4.74 40 g Decozol

NYSTATIN
Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020 ............1.95 24 ml Nilstat

Other Oral Agents

SODIUM HYALURONATE [HYALURONIC ACID] – Restricted see terms below
Inj 20 mg per ml, 1 ml syringe
⇒ Restricted (RS1175)
Otolaryngologist

THYMOL GLYCERIN
Compound, BPC.................................................................9.15 500 ml PSM

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see terms below
Cap........................................................................................23.35 180 Clinicians Multivit & Mineral Boost
⇒ Restricted (RS1498)
Initiation
Limited to 3 months treatment
Both:
1 Patient was admitted to hospital with burns; and
2 Any of the following:
   2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
   2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
   2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – Restricted see terms on the next page
Cap.......................................................................................6.49 30 Clinicians Renal Vit

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### Restricted (RS1499)

**Initiation**

Either:

1. The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
2. The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of $< 15 \text{ ml/min/}1.73\text{m}^2$ body surface area (BSA).

#### MULTIVITAMINS

- **Tab (BPC cap strength)**

  **Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alphatocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mcg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mcg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg**

  e.g. **Vitabdeck**

- **Restricted (RS1620)**

  **Initiation**

  Any of the following:

  1. Patient has cystic fibrosis with pancreatic insufficiency; or
  2. Patient is an infant or child with liver disease or short gut syndrome; or
  3. Patient has severe malabsorption syndrome.

  **Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg**

  e.g. **Paediatric Seravit**

- **Restricted (RS1178)**

  **Initiation**

  Patient has inborn errors of metabolism.

  **Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mcg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)**

  e.g. **Pabrinex IV**

  **Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mcg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)**

  e.g. **Pabrinex IM**

  **Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)**

  e.g. **Pabrinex IV**

**VITAMIN A WITH VITAMINS D AND C**

- **Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops**

  e.g. **Vitadol C**

  *(e.g. Vitadol C Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops to be delisted 1 August 2019)*

### Vitamin A

**RETINOL**

- **Tab 10,000 iu**
- **Cap 25,000 iu**
- **Oral liq 150,000 iu per ml**
- **Oral liq 5,000 iu per drop, 30 ml**
# ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Vitamin B</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXOCOBALAMIN</td>
<td>Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>1.89 3 Neo-B12</td>
</tr>
<tr>
<td>PYRIDOXINE HYDROCHLORIDE</td>
<td>Tab 25 mg – 1% DV Jan-18 to 2020</td>
<td>2.70 90 Vitamin B6 25</td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg – 1% DV Oct-17 to 2020</td>
<td>13.63 500 Apo-Pyridoxine</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 30 ml vial</td>
<td></td>
</tr>
<tr>
<td>THIAMINE HYDROCHLORIDE</td>
<td>Tab 50 mg – 1% DV Nov-18 to 2020</td>
<td>4.89 100 Max Health</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 1 ml vial</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td>e.g. Benerva</td>
</tr>
<tr>
<td>VITAMIN B COMPLEX</td>
<td>Tab strong, BPC</td>
<td>7.15 500 Bplex</td>
</tr>
</tbody>
</table>

## Vitamin C

<table>
<thead>
<tr>
<th>ASCORBIC ACID</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>8.10 500 Cvite</td>
<td></td>
</tr>
<tr>
<td>Tab chewable 250 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Vitamin D

<table>
<thead>
<tr>
<th>ALFACALCIDOL</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 0.25 mcg – 1% DV Aug-17 to 2020</td>
<td>26.32 100 One-Alpha</td>
<td></td>
</tr>
<tr>
<td>Cap 1 mcg – 1% DV Aug-17 to 2020</td>
<td>87.98 100 One-Alpha</td>
<td></td>
</tr>
<tr>
<td>Oral drops 2 mcg per ml – 1% DV Aug-17 to 2020</td>
<td>60.68 20 ml One-Alpha</td>
<td></td>
</tr>
<tr>
<td>CALCITRIOL</td>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>Cap 0.25 mcg – 1% DV Oct-19 to 2022</td>
<td>7.95 100 Calcitriol-AFT</td>
<td></td>
</tr>
<tr>
<td>Cap 0.5 mcg – 1% DV Oct-19 to 2022</td>
<td>13.75 100 Calcitriol-AFT</td>
<td></td>
</tr>
<tr>
<td>Oral liq 1 mcg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COLECALCIFEROL</td>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020</td>
<td>2.50 12 Vit.D3</td>
<td></td>
</tr>
<tr>
<td>Oral liq 188 mcg per ml (7,500 iu per ml)</td>
<td>9.00 4.8 ml Puria</td>
<td></td>
</tr>
</tbody>
</table>

## Vitamin E

<table>
<thead>
<tr>
<th>ALPHA TOCOPHERYL – Restricted see terms below</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 156 u per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1632)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation – Cystic fibrosis Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Cystic fibrosis patient; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis
For the treatment of osteoradionecrosis.

Initiation – Other indications
All of the following:

1 Infant or child with liver disease or short gut syndrome; and
2 Requires vitamin supplementation; and
3 Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

ALPHA TOCOPHERYL ACETATE – Restricted see terms below

Cap 100 u
Cap 500 u
Oral liq 156 u per ml

Restricted (RS1176)

Initiation – Cystic fibrosis
Both:

1 Cystic fibrosis patient; and
2 Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis
For the treatment of osteoradionecrosis.

Initiation – Other indications
All of the following:

1 Infant or child with liver disease or short gut syndrome; and
2 Requires vitamin supplementation; and
3 Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.
Antinaemics

Hypoplastic and Haemolytic

EPOETIN ALFA – Restricted see terms below

- Inj 1,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022 ................... 250.00 6 Binocrit
- Inj 2,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022 ................... 100.00 6 Binocrit
- Inj 3,000 iu in 0.3 ml syringe – 1% DV Apr-19 to 2022 ................... 145.00 6 Binocrit
- Inj 4,000 iu in 0.4 ml syringe – 1% DV Apr-19 to 2022 ................... 96.50 6 Binocrit
- Inj 5,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022 ................... 125.00 6 Binocrit
- Inj 6,000 iu in 0.6 ml syringe – 1% DV Apr-19 to 2022 ................... 145.00 6 Binocrit
- Inj 8,000 iu in 0.8 ml syringe – 1% DV Apr-19 to 2022 ................... 175.00 6 Binocrit
- Inj 10,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022 ................... 197.50 6 Binocrit
- Inj 40,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022 ................... 250.00 1 Binocrit

Initiation – chronic renal failure
All of the following:
1 Patient in chronic renal failure; and
2 Haemoglobin is less than or equal to 100g/L; and
3 Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4 Patient is on haemodialysis or peritoneal dialysis.

Initiation – myelodysplasia*
Re-assessment required after 2 months
All of the following:
1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for
   myelodysplastic syndrome (WPSS); and
4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5 Patient has a serum epoetin level of < 500 IU/L; and
6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*
Re-assessment required after 12 months
All of the following:
1 The patient’s transfusion requirement continues to be reduced with epoetin treatment; and
2 Transformation to acute myeloid leukaemia has not occurred; and
3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation – all other indications
Haematologist
For use in patients where blood transfusion is not a viable treatment alternative.
Note: Indications marked with * are unapproved indications
### EPOETIN BETA – Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

**Initiation – chronic renal failure**

All of the following:

1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   - 3.1 Both:
     - 3.1.1 Patient does not have diabetes mellitus; and
     - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   - 3.2 Both:
     - 3.2.1 Patient has diabetes mellitus; and
     - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

**Initiation – myelodysplasia**

*Note: Indications marked with * are unapproved indications.

**Continuation – myelodysplasia**

**Initiation – all other indications**

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative.

### Megaloblastic

#### FOLIC ACID

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.8 mg</td>
<td>21.84</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>12.12</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Oral liq 50 mcg per ml</td>
<td>26.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml vial</td>
<td>1,000</td>
<td>Apo-Folic Acid</td>
</tr>
</tbody>
</table>
Antifibrinolytics, Haemostatics and Local Sclerosants

ALUMINIUM CHLORIDE – **Restricted** see terms below
- Topical soln 20% w/v
  - **Restricted (RS1500)**

**Initiation**
For use as a haemostatis agent.

APROTININ – **Restricted** see terms below
- Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial
  - **Restricted (RS1332)**

**Initiation**
Cardiac anaesthetist
Either:
1. Paediatric patient undergoing cardiopulmonary bypass procedure; or
2. Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – **Restricted** see terms below
- Tab 25 mg ................................................................. 1,550.00 28 Revolade
- Tab 50 mg ................................................................. 3,100.00 28 Revolade
  - **Restricted (RS1648)**

**Initiation – idiopathic thrombocytopenic purpura - post-splenectomy**
Haematologist
*Re-assessment required after 6 weeks*
All of the following:
1. Patient has had a splenectomy; and
2. Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
3. Any of the following:
   3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
   3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
   3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

**Initiation – idiopathic thrombocytopenic purpura - preparation for splenectomy**
Haematologist
*Limited to 6 weeks treatment*
The patient requires eltrombopag treatment as preparation for splenectomy.

**Continuation – idiopathic thrombocytopenic purpura - post-splenectomy**
Haematologist
*Re-assessment required after 12 months*
The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

**Initiation – idiopathic thrombocytopenic purpura contraindicated to splenectomy**
Haematologist
*Re-assessment required after 3 months*
All of the following:
1. Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

continued…
continued…

2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and

3 Either:
   3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
   3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

**Continuation – idiopathic thrombocytopenic purpura contraindicated to splenectomy**

Haematologist

*Re-assessment required after 12 months*

All of the following:

1 The patient’s significant contraindication to splenectomy remains; and
2 The patient has obtained a response from treatment during the initial approval period; and
3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
4 Further treatment with eltrombopag is required to maintain response.

**Initiation – severe aplastic anaemia**

Haematologist

*Re-assessment required after 3 months*

Both:

1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
2 Either:
   2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
   2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

**Continuation – severe aplastic anaemia**

Haematologist

*Re-assessment required after 12 months*

Both:

1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

**FERRIC SUBSULFATE**

Gel 25.9%
Soln 500 ml

**POLIDOCANOL**

Inj 0.5%, 30 ml vial

**SODIUM TETRADECYL SULPHATE**

Inj 3%, 2 ml ampoule

**THROMBIN**

Powder

**TRANEXAMIC ACID**

Tab 500 mg .......................................................... 20.67 100 Cyklokapron
Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021 ......................... 6.95 5 Tranexamic-AFT
Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021 ......................... 10.95 5 Tranexamic-AFT

**Anticoagulant Reversal Agents**

**IDARUCIZUMAB** – Restricted see terms on the next page

1 Inj 50 mg per ml, 50 ml vial .......................................................... 4,250.00 2 Praxbind

*Item restricted (see above); Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
**Blood Factors**

**EFTRENONACOG ALFA [RECOMBINANT FACTOR IX]** – Restricted see terms below

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprolix</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 250 iu vial</td>
<td>612.50</td>
<td>1</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>1,225.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>2,450.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>4,900.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>7,350.00</td>
<td>1</td>
</tr>
</tbody>
</table>

**EPTACOG ALFA [RECOMBINANT FACTOR VIIA]** – Restricted see terms below

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>NovoSeven RT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg syringe</td>
<td>1,178.30</td>
<td>1</td>
</tr>
<tr>
<td>Inj 2 mg syringe</td>
<td>2,356.60</td>
<td>1</td>
</tr>
<tr>
<td>Inj 5 mg syringe</td>
<td>5,891.50</td>
<td>1</td>
</tr>
<tr>
<td>Inj 8 mg syringe</td>
<td>9,426.40</td>
<td>1</td>
</tr>
</tbody>
</table>

**FACTOR EIGHT INHIBITOR BYPASSING FRACTION** – Restricted see terms below

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEIBA NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 U</td>
<td>1,315.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 1,000 U</td>
<td>2,630.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 2,500 U</td>
<td>6,575.00</td>
<td>1</td>
</tr>
</tbody>
</table>

**MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII]** – Restricted see terms below

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xyntha</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 250 iu prefilled syringe</td>
<td>210.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 500 iu prefilled syringe</td>
<td>420.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 1,000 iu prefilled syringe</td>
<td>840.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 2,000 iu prefilled syringe</td>
<td>1,680.00</td>
<td>1</td>
</tr>
<tr>
<td>Inj 3,000 iu prefilled syringe</td>
<td>2,520.00</td>
<td>1</td>
</tr>
</tbody>
</table>
NONACOG ALFA [RECOMBINANT FACTOR IX] – Restricted see terms below

- Inj 250 iu vial.................................310.00 1 BeneFIX
- Inj 500 iu vial.................................620.00 1 BeneFIX
- Inj 1,000 iu vial.........................1,240.00 1 BeneFIX
- Inj 2,000 iu vial.........................2,480.00 1 BeneFIX
- Inj 3,000 iu vial.........................3,720.00 1 BeneFIX

(BeneFIX Inj 250 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 500 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 1,000 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 2,000 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 3,000 iu vial to be delisted 1 November 2019)

Initiation
When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

NONACOG GAMMA, [RECOMBINANT FACTOR IX] – Restricted see terms below

- Inj 500 iu vial.................................435.00 1 RIXUBIS
- Inj 1,000 iu vial...............................870.00 1 RIXUBIS
- Inj 2,000 iu vial............................1,740.00 1 RIXUBIS
- Inj 3,000 iu vial............................2,610.00 1 RIXUBIS

Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Restricted see terms below

- Inj 250 iu vial.................................210.00 1 Advate
- Inj 500 iu vial.................................420.00 1 Advate
- Inj 1,000 iu vial...............................840.00 1 Advate
- Inj 1,500 iu vial.........................1,260.00 1 Advate
- Inj 2,000 iu vial.........................1,680.00 1 Advate
- Inj 3,000 iu vial.........................2,520.00 1 Advate

Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – Restricted see terms below

- Inj 250 iu vial.................................237.50 1 Kogenate FS
- Inj 500 iu vial.................................475.00 1 Kogenate FS
- Inj 1,000 iu vial...............................950.00 1 Kogenate FS
- Inj 2,000 iu vial.........................1,900.00 1 Kogenate FS
- Inj 3,000 iu vial.........................2,850.00 1 Kogenate FS

Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

RURIOCOTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – Restricted see terms on the next page

- Inj 250 iu vial.................................300.00 1 Adynovate
- Inj 500 iu vial.................................600.00 1 Adynovate
- Inj 1,000 iu vial.........................1,200.00 1 Adynovate
- Inj 2,000 iu vial.........................2,400.00 1 Adynovate
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

### Antithrombotics

#### Anticoagulants

**BIVALIRUDIN – Restricted** see terms below

- **Initiation**

  Either:
  1. For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
  2. For use in patients undergoing endovascular procedures.

**CITRATE SODIUM**

- Inj 4% (200 mg per 5 ml), 5 ml ampoule
- Inj 46.7% (1.4 g per 3 ml), 3 ml syringe
- Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

**DABIGATRAN**

- Cap 75 mg
- Cap 110 mg
- Cap 150 mg

**DALTEPARIN**

- Inj 2,500 iu in 0.2 ml syringe
- Inj 5,000 iu in 0.2 ml syringe
- Inj 7,500 iu in 0.75 ml syringe
- Inj 10,000 iu in 1 ml syringe
- Inj 12,500 iu in 0.5 ml syringe
- Inj 15,000 iu in 0.6 ml syringe
- Inj 18,000 iu in 0.72 ml syringe

**DANAPAROID – Restricted** see terms below

- Inj 750 u in 0.6 ml ampoule

**DEFIBROTIDE – Restricted** see terms below

- Inj 80 mg per ml, 2.5 ml ampoule

**Vitamin K**

**PHYTOMENADIONE**

- Inj 2 mg in 0.2 ml ampoule
- Inj 10 mg per ml, 1 ml ampoule

**Antithrombotics**

**BIVALIRUDIN – Restricted** see terms below

- **Initiation**

  For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**CITRATE SODIUM**

- Inj 4% (200 mg per 5 ml), 5 ml ampoule
- Inj 46.7% (1.4 g per 3 ml), 3 ml syringe
- Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

**DABIGATRAN**

- Cap 75 mg
- Cap 110 mg
- Cap 150 mg

**DALTEPARIN**

- Inj 2,500 iu in 0.2 ml syringe
- Inj 5,000 iu in 0.2 ml syringe
- Inj 7,500 iu in 0.75 ml syringe
- Inj 10,000 iu in 1 ml syringe
- Inj 12,500 iu in 0.5 ml syringe
- Inj 15,000 iu in 0.6 ml syringe
- Inj 18,000 iu in 0.72 ml syringe

**DANAPAROID – Restricted** see terms below

- Inj 750 u in 0.6 ml ampoule

**DEFIBROTIDE – Restricted** see terms below

- Inj 80 mg per ml, 2.5 ml ampoule
DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag

ENOXAPARIN SODIUM
Inj 20 mg in 0.2 ml syringe .......................................................... 27.93 10 Clexane
Inj 40 mg in 0.4 ml ampoule .......................................................... 37.27 10 Clexane
Inj 60 mg in 0.6 ml syringe .......................................................... 56.18 10 Clexane
Inj 80 mg in 0.8 ml syringe .......................................................... 74.90 10 Clexane
Inj 100 mg in 1 ml syringe ......................................................... 93.80 10 Clexane
Inj 120 mg in 0.8 ml syringe ....................................................... 116.55 10 Clexane
Inj 150 mg in 1 ml syringe ....................................................... 133.20 10 Clexane

FONDAPARINUX SODIUM – Restricted see terms below
- Inj 2.5 mg in 0.5 ml syringe
- Inj 7.5 mg in 0.6 ml syringe
- Restricted (RS1184)
Initiation
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance.

HEPARIN SODIUM
Inj 100 iu per ml, 250 ml bag
Inj 1,000 iu per ml, 1 ml ampoule ............................................. 98.53 50 Hospira
Inj 1,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021 .............. 58.57 50 Pfizer
Inj 5,000 iu in 0.2 ml ampoule ...................................................... 28.40 5 Hospira
Inj 5,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021 ............ 203.68 50 Pfizer

HEPARINISED SALINE
Inj 10 iu per ml, 5 ml ampoule .................................................. 56.94 50 Pfizer
Inj 100 iu per ml, 2 ml ampoule
Inj 100 iu per ml, 5 ml ampoule

PHENINDIONE
Tab 10 mg
Tab 25 mg
Tab 50 mg

PROTAMINE SULPHATE
Inj 10 mg per ml, 5 ml ampoule

RIVAROXABAN
Tab 10 mg .............................................................. 83.10 30 Xarelto
Tab 15 mg .............................................................. 77.56 28 Xarelto
Tab 20 mg .............................................................. 77.56 28 Xarelto

SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag

WARFARIN SODIUM
Tab 1 mg .............................................................. 6.86 100 Marevan
Tab 2 mg
Tab 3 mg .............................................................. 9.70 100 Marevan
Tab 5 mg .............................................................. 11.75 100 Marevan

Item restricted (see ➔ above); Item restricted (see ➔ below)
e.g. Brand indicates brand example only. It is not a contracted product.
## Antiplatelets

### Aspirin

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>1.60</td>
<td>Ethics Aspirin EC</td>
</tr>
<tr>
<td>Suppos 300 mg</td>
<td>12.50</td>
<td>Ethics Aspirin EC</td>
</tr>
</tbody>
</table>

### Clopidogrel

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 75 mg</td>
<td>5.44</td>
<td>Arrow - Clopid</td>
</tr>
</tbody>
</table>

### Dipyridamole

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>10.90</td>
<td>Pytazen SR</td>
</tr>
</tbody>
</table>

### Eptifibatide – Restricted see terms below

- **Inj 2 mg per ml, 10 ml vial – 1% DV Oct-19 to 2021** | 138.75 | Integrilin |
- **Inj 750 mcg per ml, 100 ml vial – 1% DV Nov-18 to 2021** | 405.00 | Integrilin |

### Prasugrel – Restricted see terms below

- **Tab 5 mg** | 108.00 | Effient |
- **Tab 10 mg** | 120.00 | Effient |

### Ticagrelor – Restricted see terms below

- **Tab 90 mg** | 90.00 | Brilinta |

### Ticlopidine

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Ticlopidine is not included in the list as it is not included in the Hospital Supply Status (HSS) list.

**Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.**
### Fibrinolytic Agents

<table>
<thead>
<tr>
<th>Brand or Generic</th>
<th>Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Item restricted (see above)</th>
<th>Item restricted (see below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALTEPLASE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg vial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg vial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| TENECTEPLASE     |              |                             |     |                             |                            |
| Inj 50 mg vial   |              |                             |     |                             |                            |

| UROKINASE        |              |                             |     |                             |                            |
| Inj 10,000 iu vial |              |                             |     |                             |                            |
| Inj 50,000 iu vial |              |                             |     |                             |                            |
| Inj 100,000 iu vial |              |                             |     |                             |                            |
| Inj 500,000 iu vial |              |                             |     |                             |                            |

### Colony-Stimulating Factors

#### Drugs Used to Mobilise Stem Cells

**PLERIXAFOR – Restricted see terms below**

- Inj 20 mg per ml, 1.2 ml vial..............................................................8,740.00 1 Mozobil

**Initiation – Autologous stem cell transplant**

**Haematologist**

**Limited to 3 days treatment**

All of the following:

1. Patient is to undergo stem cell transplantation; and
2. Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
3. Any of the following:
   3.1 Both:
      3.1.1 Patient is undergoing G-CSF mobilisation; and
      3.1.2 Either:
         3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$/$L$ on day 5 after 4 days of G-CSF treatment; or
         3.1.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
   3.2 Both:
      3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and
      3.2.2 Any of the following:
         3.2.2.1 Both:
            3.2.2.1.1 Has rising white blood cell counts of $> 5 \times 10^9$/L; and
            3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$/L; or
         3.2.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
         3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or
   3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

**Granulocyte Colony-Stimulating Factors**

**FILGRASTIM – Restricted see terms on the next page**

- Inj 300 mcg in 0.5 ml prefilled syringe – 1% DV May-19 to 2021 ...............96.22 10 Nivestim
- Inj 300 mcg in 1 ml vial........................................................................520.00 4 Neupogen
- Inj 480 mcg in 0.5 ml prefilled syringe – 1% DV Mar-19 to 2021 ............161.50 10 Nivestim
BLOOD AND BLOOD FORMING ORGANS

Price
(ex man. excl. GST)
Per
Brand or Generic Manufacturer

Restricted (RS1188)
Haematologist or oncologist

PEGFILGRASTIM – Restricted see terms below

- Inj 6 mg per 0.6 ml syringe.................................................................1,080.00 1 Neulastim

Restricted (RS1262)
Initiation
For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE

- Inj 100 mg per ml, 10 ml vial
- Inj 100 mg per ml, 50 ml syringe

CALCIUM GLUCONATE

- Inj 10%, 10 ml ampoule

COMPOUND ELECTROLYTES

- Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021.................................................................44.10 18 Plasma-Lyte 148
- Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021...................................................27.24 12 Plasma-Lyte 148

COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]

- Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – 1% DV Jun-18 to 2021............211.92 12 Plasma-Lyte 148 & 5% Glucose

COMPOUND SODIUM LACTATE [HARTMANN’S SOLUTION]

- Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021......................................................23.40 18 Baxter
- Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021.........................................................15.72 12 Baxter

GLUCOSE [DEXTROSE]

- Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021........................................16.80 10 Fresenius Kabi
- Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021........................................77.50 50 Fresenius Kabi
- Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021....................................52.50 30 Fresenius Kabi
- Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021......................................143.40 60 Baxter Glucose 5%
- Inj 5%, 100 ml bag – 1% DV Jun-18 to 2021.....................................24.00 20 Fresenius Kabi
- Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021.................................111.96 12 Baxter Glucose 10%
- Inj 10%, 500 ml bag – 1% DV Jun-18 to 2021.................................109.98 18 Baxter Glucose 10%
- Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020..............................29.50 5 Biomed
- Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021.................................337.32 18 Baxter Glucose 50%
- Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020.................................14.50 1 Biomed
GLUCOSE WITH POTASSIUM CHLORIDE
Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag

GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride
0.45%, 3,000 ml bag
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride
15 mmol/l, 500 ml bag
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride
0.18%, 1,000 ml bag – 1% DV Jun-18 to 2021 ........................................203.40 12 Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride
0.45%, 1,000 ml bag – 1% DV Jun-18 to 2021 ......................................159.96 12 Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride
0.9%, 1,000 ml bag – 1% DV Jun-18 to 2021 ......................................282.72 12 Baxter

GLUCOSE WITH SODIUM CHLORIDE
Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag
Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag – 1% DV
Jun-18 to 2021 .................................................................163.32 12 Baxter
Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag – 1% DV
Jun-18 to 2021 .................................................................163.20 12 Baxter
Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag – 1% DV
Jun-18 to 2021 .................................................................173.40 12 Baxter

POTASSIUM CHLORIDE
Inj 75 mg (1 mmol) per ml, 10 ml ampoule
Inj 225 mg (3 mmol) per ml, 20 ml ampoule

POTASSIUM CHLORIDE WITH SODIUM CHLORIDE
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag
– 1% DV Jun-18 to 2021 ..........................................................476.64 48 Baxter
Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag
– 1% DV Jun-18 to 2021 ..........................................................163.08 12 Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag
– 1% DV Jun-18 to 2021 ..........................................................253.32 12 Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag
– 1% DV Jun-18 to 2021 ..........................................................772.32 48 Baxter

POTASSIUM DIHYDROGEN PHOSPHATE
Inj 1 mmol per ml, 10 ml ampoule ..................................................151.80 10 Hospira

RINGER'S SOLUTION
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l,
chloride 156 mmol/l, 1,000 ml bag

SODIUM ACETATE
Inj 4 mmol per ml, 20 ml ampoule

SODIUM BICARBONATE
Inj 8.4%, 10 ml vial
Inj 8.4%, 50 ml vial .................................................................19.95 1 Biomed
Inj 8.4%, 100 ml vial ...............................................................20.50 1 Biomed
### SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 5 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>2.80 20</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 10 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>7.00 50</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>5.40 50</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 20 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>6.63</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>160.90 480</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td>Restricted (RS1297)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

For use in flushing of in-situ vascular access devices only.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>162.91 480</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td>Restricted (RS1297)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

For use in flushing of in-situ vascular access devices only.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 20 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>5.00 20</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 23.4% (4 mmol/ml), 20 ml ampoule</td>
<td>33.00 5</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 0.45%, 500 ml bag</td>
<td>71.28 18</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 3%, 1,000 ml bag</td>
<td>91.20 12</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 50 ml bag</td>
<td>109.80 60</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 100 ml bag</td>
<td>78.24 48</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 250 ml bag</td>
<td>44.64 24</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 500 ml bag</td>
<td>22.14 18</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 1,000 ml bag</td>
<td>15.12 12</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 1.8%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(InterPharma Inj 0.9%, 5 ml ampoule to be delisted 1 December 2019)

(Pfizer Inj 0.9%, 10 ml ampoule to be delisted 1 December 2019)

(Multichem Inj 0.9%, 20 ml ampoule to be delisted 1 December 2019)

### SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>48.70 5</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

### WATER

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 ml ampoule</td>
<td>7.00 50</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 10 ml ampoule</td>
<td>6.63 50</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 20 ml ampoule</td>
<td>7.50 30</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 250 ml bag</td>
<td>5.00 20</td>
<td>Multichem</td>
</tr>
<tr>
<td>Inj 500 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj, 1,000 ml bag</td>
<td>19.08 12</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

### Oral Administration

#### CALCIUM POLYSTYRENE SULPHONATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
<td>169.85 300 g</td>
<td>Calcium Resonium</td>
</tr>
</tbody>
</table>

#### COMPOUND ELECTROLYTES

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral soln.</td>
<td>2.30 10</td>
<td>Enerlyte</td>
</tr>
</tbody>
</table>
### BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]</strong></td>
<td></td>
</tr>
<tr>
<td>Soln with electrolytes (2 x 500 ml) – <strong>1% DV Nov-18 to 2021</strong></td>
<td><strong>6.55</strong></td>
</tr>
<tr>
<td><strong>PHOSPHORUS</strong></td>
<td></td>
</tr>
<tr>
<td>Tab eff 500 mg (16 mmol)</td>
<td></td>
</tr>
<tr>
<td><strong>POTASSIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)</td>
<td><strong>8.90</strong></td>
</tr>
<tr>
<td>Tab long-acting 600 mg (8 mmol) – <strong>1% DV Oct-18 to 2021</strong></td>
<td><strong>8.90</strong></td>
</tr>
<tr>
<td>Oral liq 2 mmol per ml</td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM BICARBONATE</strong></td>
<td></td>
</tr>
<tr>
<td>Cap 840 mg</td>
<td><strong>8.52</strong></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td></td>
</tr>
<tr>
<td>Oral liq 2 mmol/ml</td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM POLYSTYRENE SULPHONATE</strong></td>
<td></td>
</tr>
<tr>
<td>Powder – <strong>1% DV Sep-18 to 2021</strong></td>
<td><strong>84.65</strong></td>
</tr>
</tbody>
</table>

**Plasma Volume Expanders**

**GELATINE, SUCCINYLATED**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4%, 500 ml bag – <strong>1% DV Jun-18 to 2021</strong></td>
<td><strong>120.00</strong></td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

**CAPTOPRIL**
- Oral liq 5 mg per ml ................................................................. 94.99 95 ml Capoten
- **Restricted (RS1263)**

**Initiation**
- Any of the following:
  1. For use in children under 12 years of age; or
  2. For use in tube-fed patients; or
  3. For management of rebound transient hypertension following cardiac surgery.

**CILAZAPRIL**
- Tab 0.5 mg – 1% DV Sep-19 to 2022 .............................................................. 2.09 90 Zapril
- Tab 2.5 mg ............................................................................. 7.20 200 Apo-Cilazapril
- Tab 5 mg ........................................................................... 12.00 200 Apo-Cilazapril

**ENALAPRIL MALEATE**
- Tab 5 mg ........................................................................... 3.84 100 Ethics Enalapril
- Tab 10 mg ......................................................................... 4.96 100 Ethics Enalapril
- Tab 20 mg ........................................................................ 7.12 100 Ethics Enalapril

**LISINOPRIL**
- Tab 5 mg – 1% DV Dec-18 to 2021 .............................................................. 2.07 90 Ethics Lisinopril
- Tab 10 mg – 1% DV Dec-18 to 2021 .............................................................. 2.36 90 Ethics Lisinopril
- Tab 20 mg – 1% DV Dec-18 to 2021 .............................................................. 3.17 90 Ethics Lisinopril

**PERINDOPRIL**
- Tab 2 mg – 1% DV Sep-17 to 2020 .............................................................. 3.75 30 Apo-Perindopril
- Tab 4 mg – 1% DV Sep-17 to 2020 .............................................................. 4.80 30 Apo-Perindopril

**QUINAPRIL**
- Tab 5 mg – 1% DV Nov-18 to 2021 .............................................................. 6.01 90 Arrow-Quinapril 5
- Tab 10 mg – 1% DV Nov-18 to 2021 .............................................................. 3.16 90 Arrow-Quinapril 10
- Tab 20 mg – 1% DV Nov-18 to 2021 .............................................................. 4.89 90 Arrow-Quinapril 20

### ACE Inhibitors with Diuretics

**CILAZAPRIL WITH HYDROCHLOROTHIAZIDE**
- Tab 5 mg with hydrochlorothiazide 12.5 mg ................................................. 10.18 100 Apo-Cilazapril/ Hydrochlorothiazide

**QUINAPRIL WITH HYDROCHLOROTHIAZIDE**
- Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021 ........ 3.83 30 Accuretic 10
- Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021 ........ 4.92 30 Accuretic 20

### Angiotensin II Antagonists

**CANDESARTAN CILEXETIL**
- Tab 4 mg – 1% DV Sep-18 to 2021 .............................................................. 1.90 90 Candestar
- Tab 8 mg – 1% DV Sep-18 to 2021 .............................................................. 2.28 90 Candestar
- Tab 16 mg – 1% DV Sep-18 to 2021 .............................................................. 3.67 90 Candestar
- Tab 32 mg – 1% DV Sep-18 to 2021 .............................................................. 6.39 90 Candestar

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
CARDBVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 12.5 mg – 1% DV Nov-17 to 2020</td>
<td>$1.39 Losartan Actavis</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Nov-17 to 2020</td>
<td>$1.63 Losartan Actavis</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Nov-17 to 2020</td>
<td>$2.00 Losartan Actavis</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Nov-17 to 2020</td>
<td>$2.31 Losartan Actavis</td>
</tr>
</tbody>
</table>

Angiotensin II Antagonists with Diuretics

LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE

Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Jan-19 to 2021 | $1.88 Arrow-Losartan & Hydrochlorothiazide

Angiotensin II Antagonists with Neprilysin Inhibitors

SACUBITRIL WITH VALSARTAN – Restricted see terms below

 Restricted (RS1649)

Initiation

Re-assessment required after 12 months

All of the following:

1. Patient has heart failure; and
2. Any of the following:
   2.1 Patient is in NYHA/WHO functional class II; or
   2.2 Patient is in NYHA/WHO functional class III; or
   2.3 Patient is in NYHA/WHO functional class IV; and
3. Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; and
4. Patient is receiving concomitant optimal standard chronic heart failure treatments.

Continuation

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

Alpha-Adrenoceptor Blockers

DOXAZOSIN

Tab 2 mg – 1% DV Sep-17 to 2020 | $6.75 Apo-Doxazosin
Tab 4 mg – 1% DV Sep-17 to 2020 | $9.09 Apo-Doxazosin

PHENOXYBENZAMINE HYDROCHLORIDE

Cap 10 mg
Inj 50 mg per ml, 2 ml ampoule

PHENTOLAMINE MESYLATE

Inj 5 mg per ml, 1 ml ampoule
Inj 10 mg per ml, 1 ml ampoule

PRAZOSIN

Tab 1 mg | $5.53 Apo-Prazosin
Tab 2 mg | $7.00 Apo-Prazosin
Tab 5 mg | $11.70 Apo-Prazosin

Item restricted (see above); Item restricted (see below)
e.g. Brand indicates brand example only. It is not a contracted product.
# Cardiovascular System

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Terazosin**
- **Tab 1 mg**
  - Price: 0.59
  - Brand: Actavis
- **Tab 2 mg**
  - Price: 7.50
  - Brand: Apo-Terazosin
- **Tab 5 mg**
  - Price: 10.90
  - Brand: Apo-Terazosin

## Antiarrhythmics

### Adenosine
- **Inj 3 mg per ml, 2 ml vial**
- **Inj 3 mg per ml, 10 ml vial**
- **Restricted (RS1266)**

**Initiation**
For use in cardiac catheterisation, electrophysiology and MRI.

### Ajmaline
- **Restricted** see terms below
- **Inj 5 mg per ml, 10 ml ampoule**
- **Restricted (RS1001)**

**Cardiologist**

### Amiodarone Hydrochloride
- **Tab 100 mg – 1% DV Dec-19 to 2022**
  - Price: 3.80
  - Brand: Aratac
  - Price: 4.66
- **Tab 200 mg – 1% DV Dec-19 to 2022**
  - Price: 5.25
  - Brand: Cordarone-X
  - Price: 7.63
- **Inj 50 mg per ml, 3 ml ampoule**
  - Price: 11.98
  - Brand: Aratac
  - Price: 9.98

**Cardiologist**

### Atropine Sulfate
- **Inj 600 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021**
  - Price: 12.07
  - Brand: Martindale

### Digoxin
- **Tab 62.5 mcg**
  - Price: 6.67
  - Brand: Lanoxin PG
- **Tab 250 mcg**
  - Price: 14.52
  - Brand: Lanoxin
- **Oral liq 50 mcg per ml**
- **Inj 250 mcg per ml, 2 ml vial**

### Disopyramide Phosphate
- **Cap 100 mg**
- **Flecainide Acetate**
  - **Tab 50 mg**
    - Price: 38.95
    - Brand: Tambocor
  - **Cap long-acting 100 mg – 1% DV Dec-19 to 2022**
    - Price: 39.51
  - **Cap long-acting 200 mg – 1% DV Dec-19 to 2022**
    - Price: 61.06

**Cardiologist**

### Flecainide Acetate
- **Cap long-acting 100 mg to be delisted 1 December 2019**
- **Cap long-acting 200 mg to be delisted 1 December 2019**

### Ivabradine
- **Restricted** see terms on the next page
- **Tab 5 mg**

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### CARDOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

- **Restricted (RS1566)**
  - **Initiation**
    - Both:
      1. Patient is indicated for computed tomography coronary angiography; and
      2. Either:
        2.1 Patient has a heart rate of greater than 70 beats per minute while taking a maximally tolerated dose of beta blocker; or
        2.2 Patient is unable to tolerate beta blockers.

#### MEXILETINE HYDROCHLORIDE
- Cap 150 mg...................................................................................................162.00 100 Mexiletine Hydrochloride USP
- Cap 250 mg...................................................................................................202.00 100 Mexiletine Hydrochloride USP

#### PROPafenONE HYDROCHLORIDE
- Tab 150 mg

### Antihypotensives

#### MIDODRINE – **Restricted** see terms below
- Tab 2.5 mg
- Tab 5 mg

- **Restricted (RS1427)**
  - **Initiation**
    - Patient has disabling orthostatic hypotension not due to drugs.

### Beta-Adrenoceptor Blockers

#### ATENOLOL
- Tab 50 mg – 1% DV Sep-18 to 2021...............................................................4.26 500 Mylan Atenolol
- Tab 100 mg – 1% DV Sep-18 to 2021.............................................................7.30 500 Mylan Atenolol
- Oral liq 5 mg per ml .........................................................................................21.25 300 ml Atenolol-AFT

#### BISOPROLOL FUMARATE
- Tab 2.5 mg – 1% DV Dec-17 to 2020..............................................................3.53 90 Bosvate
- Tab 5 mg – 1% DV Dec-17 to 2020.................................................................5.15 90 Bosvate
- Tab 10 mg – 1% DV Dec-17 to 2020...............................................................9.40 90 Bosvate

#### CARVEDILOL
- Tab 6.25 mg – 1% DV Dec-17 to 2020...........................................................2.24 60 Carvedilol Sandoz
- Tab 12.5 mg – 1% DV Dec-17 to 2020..........................................................2.30 60 Carvedilol Sandoz
- Tab 25 mg – 1% DV Dec-17 to 2020...............................................................2.95 60 Carvedilol Sandoz

#### CELIPROLOL
- Tab 200 mg ...................................................................................................21.40 180 Celol

#### ESMOLOL HYDROCHLORIDE
- Inj 10 mg per ml, 10 ml vial

---

- Item restricted (see ➤ above);
- Item restricted (see ➤ below)

*E.g. Brand indicates brand example only. It is not a contracted product.*
## CARDIOVASCULAR SYSTEM

**LABETALOL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>8.99</td>
<td>Hybloc</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>11.36</td>
<td>Hybloc</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>29.74</td>
<td>Hybloc</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td>Presolol</td>
</tr>
</tbody>
</table>

( Hydraclon Tab 50 mg to be delisted 1 August 2019)
( Hydraclon Tab 100 mg to be delisted 1 December 2019)
( Hydraclon Tab 200 mg to be delisted 1 February 2020)

**METOPROLOL SUCCINATE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab long-acting 23.75 mg – 1% DV Mar-18 to 2020</td>
<td>1.03</td>
<td>30 Betaloc CR</td>
</tr>
<tr>
<td>Tab long-acting 47.5 mg – 1% DV Mar-18 to 2020</td>
<td>1.25</td>
<td>60 Betaloc CR</td>
</tr>
<tr>
<td>Tab long-acting 95 mg – 1% DV Mar-18 to 2020</td>
<td>1.99</td>
<td>30 Betaloc CR</td>
</tr>
<tr>
<td>Tab long-acting 190 mg – 1% DV Mar-18 to 2020</td>
<td>3.00</td>
<td>30 Betaloc CR</td>
</tr>
</tbody>
</table>

**METOPROLOL TARTRATE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg – 1% DV Oct-18 to 2021</td>
<td>5.66</td>
<td>100 Apo-Metoprolol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Oct-18 to 2021</td>
<td>7.55</td>
<td>60 Apo-Metoprolol</td>
</tr>
<tr>
<td>Tab long-acting 200 mg</td>
<td>23.40</td>
<td>28 Slow-Lopresor</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022</td>
<td>29.50</td>
<td>5 Metroprolol IV Mylan</td>
</tr>
</tbody>
</table>

**NADOLOL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 40 mg – 1% DV Oct-18 to 2021</td>
<td>16.69</td>
<td>100 Apo-Nadolol</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Oct-18 to 2021</td>
<td>26.43</td>
<td>100 Apo-Nadolol</td>
</tr>
</tbody>
</table>

**PINDOLOL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>13.22</td>
<td>100 Apo-Pindolol</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>23.12</td>
<td>100 Apo-Pindolol</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
<td>33.31</td>
<td>100 Apo-Pindolol</td>
</tr>
</tbody>
</table>

**PROPRANOLOL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>4.64</td>
<td>100 Apo-Propranolol</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Oct-18 to 2021</td>
<td>5.72</td>
<td>100 Apo-Propranolol</td>
</tr>
<tr>
<td>Cap long-acting 160 mg</td>
<td>18.17</td>
<td>100 Cardinol LA</td>
</tr>
<tr>
<td>Oral liq 4 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SOTALOL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 80 mg – 1% DV Oct-19 to 2022</td>
<td>32.58</td>
<td>500 Mylan</td>
</tr>
<tr>
<td>Tab 160 mg – 1% DV Oct-19 to 2022</td>
<td>10.98</td>
<td>100 Mylan</td>
</tr>
</tbody>
</table>

**TIMOLOL MALEATE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Calcium Channel Blockers**

**Dihydropyridine Calcium Channel Blockers**

**AMLODIPINE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg – 1% DV Sep-17 to 2020</td>
<td>1.72</td>
<td>100 Apo-Amlodipine</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Sep-17 to 2020</td>
<td>3.33</td>
<td>250 Apo-Amlodipine</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Sep-17 to 2020</td>
<td>4.40</td>
<td>250 Apo-Amlodipine</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### FELODIPINE
- Tab long-acting 2.5 mg - 1% DV Sep-18 to 2021: $1.45 per 30
- Tab long-acting 5 mg - 1% DV Dec-18 to 2021: $3.93 per 90
- Tab long-acting 10 mg - 1% DV Dec-18 to 2021: $4.32 per 90

#### ISRADIPINE
- Tab 2.5 mg
- Cap 2.5 mg

#### NICARDIPINE HYDROCHLORIDE – Restricted see terms below
- Inj 2.5 mg per ml, 10 ml vial
  - Restricted (RS1474)

**Initiation**
- Anaesthetist, intensivist or paediatric cardiologist

**Both:**
1. Patient is a Paediatric Patient; and
2. Any of the following:
   2.1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
   2.2 Patient has excessive ventricular afterload; or
   2.3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

#### NIFEDIPINE
- Tab long-acting 10 mg - 1% DV Aug-17 to 2020: $10.63 per 60
- Tab long-acting 20 mg: $9.59 per 100
- Tab long-acting 30 mg: $3.14 per 30
- Tab long-acting 60 mg - 1% DV Dec-17 to 2020: $5.67 per 30

#### NIMODIPINE
- Tab 30 mg
- Inj 200 mcg per ml, 50 ml vial

**Other Calcium Channel Blockers**

#### DILTIAZEM HYDROCHLORIDE
- Tab 30 mg: $4.60 per 100
- Tab 60 mg: $8.50 per 100
- Cap long-acting 120 mg - 1% DV Oct-18 to 2021: $33.42 per 500
- Cap long-acting 180 mg - 1% DV Oct-18 to 2021: $50.05 per 500
- Cap long-acting 240 mg - 1% DV Oct-18 to 2021: $66.76 per 500
- Inj 5 mg per ml, 5 ml vial

#### PERHEXILINE MALEATE
- Tab 100 mg - 1% DV Oct-19 to 2022: $62.90 per 100

#### VERAPAMIL HYDROCHLORIDE
- Tab 40 mg: $7.01 per 100
- Tab 80 mg: $11.74 per 100
- Tab long-acting 120 mg: $15.20 per 250
- Tab long-acting 240 mg: $25.00 per 250
- Inj 2.5 mg per ml, 2 ml ampoule: $25.00 per 5

---

*Item restricted (see ➡️ above); Item restricted (see ➡️ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
# CARDIOVASCULAR SYSTEM

## Centrally-Acting Agents

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength</th>
<th>Expiry Date</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLONIDINE Patch 2.5 mg, 100 mcg per day</td>
<td>1% DV Sep-17 to 2020</td>
<td>$7.40</td>
<td>4 Mylan</td>
</tr>
<tr>
<td>CLONIDINE Patch 5 mg, 200 mcg per day</td>
<td>1% DV Sep-17 to 2020</td>
<td>$10.04</td>
<td>4 Mylan</td>
</tr>
<tr>
<td>CLONIDINE Patch 7.5 mg, 300 mcg per day</td>
<td>1% DV Sep-17 to 2020</td>
<td>$12.34</td>
<td>4 Mylan</td>
</tr>
<tr>
<td>CLONIDINE HYDROCHLORIDE Tab 25 mcg</td>
<td>1% DV Oct-18 to 2021</td>
<td>$8.75</td>
<td>112 Clonidine BNM</td>
</tr>
<tr>
<td>CLONIDINE HYDROCHLORIDE Tab 50 mcg</td>
<td>1% DV Oct-18 to 2021</td>
<td>$34.32</td>
<td>100 Catapres</td>
</tr>
<tr>
<td>CLONIDINE HYDROCHLORIDE Inj 150 mcg per ml, 1 ml ampoule</td>
<td>1% DV Oct-18 to 2021</td>
<td>$25.96</td>
<td>10 Medsurge</td>
</tr>
</tbody>
</table>

## Diuretics

### Loop Diuretics

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength</th>
<th>Expiry Date</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUMETANIDE Tab 1 mg</td>
<td></td>
<td>$16.36</td>
<td>100 Burinex</td>
</tr>
<tr>
<td>BUMETANIDE Inj 500 mcg per ml, 4 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FUROSEMIDE [FRUSEMIDE] Tab 40 mg</td>
<td>1% DV Mar-19 to 2021</td>
<td>$8.00</td>
<td>1,000 Diurin 40</td>
</tr>
<tr>
<td>FUROSEMIDE [FRUSEMIDE] Tab 500 mg</td>
<td>1% DV Mar-19 to 2021</td>
<td>$25.00</td>
<td>50 Urex Forte</td>
</tr>
<tr>
<td>FUROSEMIDE [FRUSEMIDE] Oral liq 10 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FUROSEMIDE [FRUSEMIDE] Inj 10 mg per ml, 2 ml ampoule</td>
<td>1% DV Oct-19 to 2022</td>
<td>$1.15</td>
<td>5 Frusemide-Claris</td>
</tr>
<tr>
<td>FUROSEMIDE [FRUSEMIDE] Inj 10 mg per ml, 25 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Osmotic Diuretics

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength</th>
<th>Expiry Date</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MANNITOL Inj 10%, 1,000 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>$747.24</td>
<td>12 Baxter</td>
</tr>
<tr>
<td>MANNITOL Inj 20%, 500 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>$1,096.92</td>
<td>18 Baxter</td>
</tr>
</tbody>
</table>

## Potassium Sparing Combination Diuretics

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength</th>
<th>Expiry Date</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE Tab 5 mg with furosemide 40 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE Tab 5 mg with hydrochlorothiazide 50 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Potassium Sparing Diuretics

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength</th>
<th>Expiry Date</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMILORIDE HYDROCHLORIDE Tab 5 mg</td>
<td>Oral liq 1 mg per ml</td>
<td>$30.00</td>
<td>25 ml Biomed</td>
</tr>
<tr>
<td>EPLERENONE</td>
<td>Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPLERENONE Tab 25 mg</td>
<td>1% DV Sep-18 to 2021</td>
<td>$11.87</td>
<td>30 Inspra</td>
</tr>
<tr>
<td>EPLERENONE Tab 50 mg</td>
<td>1% DV Dec-18 to 2021</td>
<td>$17.00</td>
<td>30 Inspra</td>
</tr>
</tbody>
</table>

**Initiation**

Both:

---

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

1. Patient has heart failure with ejection fraction less than 40%; and
2. Either:
   2.1 Patient is intolerant to optimal dosing of spironolactone; or
   2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

### SPIRONOLACTONE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.38 100 Spiractin</td>
<td></td>
</tr>
<tr>
<td>$11.80 100 Spiractin</td>
<td></td>
</tr>
<tr>
<td>$30.00 25 ml Biomed</td>
<td></td>
</tr>
</tbody>
</table>

### Thiazide and Related Diuretics

#### BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$12.50 500 Arrow-Bendrofluazide</td>
<td></td>
</tr>
<tr>
<td>$20.42 500 Arrow-Bendrofluazide</td>
<td></td>
</tr>
</tbody>
</table>

#### CHLOROTHIAZIDE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$26.00 25 ml Biomed</td>
<td></td>
</tr>
</tbody>
</table>

#### CHLORTALIDONE [CHLORTHALIDONE]

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$8.00 50 Hygroton</td>
<td></td>
</tr>
</tbody>
</table>

#### INDAPAMIDE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.60 90 Dapa-Tabs</td>
<td></td>
</tr>
</tbody>
</table>

### METOLAZONE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$6.96 500 Lorstat</td>
<td></td>
</tr>
<tr>
<td>$9.99 500 Lorstat</td>
<td></td>
</tr>
<tr>
<td>$15.93 500 Lorstat</td>
<td></td>
</tr>
<tr>
<td>$27.19 500 Lorstat</td>
<td></td>
</tr>
</tbody>
</table>

### Lipid-Modifying Agents

#### Fibrates

#### BEZAFIBRATE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$19.01 90 Bezalip</td>
<td></td>
</tr>
<tr>
<td>$12.89 30 Bezalip Retard</td>
<td></td>
</tr>
</tbody>
</table>

#### GEMFIBROZIL

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$19.56 60 Lipazil</td>
<td></td>
</tr>
</tbody>
</table>

### HMG CoA Reductase Inhibitors (Statins)

#### ATORVASTATIN

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$6.96 500 Lorstat</td>
<td></td>
</tr>
<tr>
<td>$9.99 500 Lorstat</td>
<td></td>
</tr>
<tr>
<td>$15.93 500 Lorstat</td>
<td></td>
</tr>
<tr>
<td>$27.19 500 Lorstat</td>
<td></td>
</tr>
</tbody>
</table>

#### PRAVASTATIN

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.72 100 Apo-Pravastatin</td>
<td></td>
</tr>
<tr>
<td>$8.06 100 Apo-Pravastatin</td>
<td></td>
</tr>
</tbody>
</table>

#### SIMVASTATIN

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$0.95 90 Simvastatin Mylan</td>
<td></td>
</tr>
<tr>
<td>$1.52 90 Simvastatin Mylan</td>
<td></td>
</tr>
<tr>
<td>$2.63 90 Simvastatin Mylan</td>
<td></td>
</tr>
<tr>
<td>$6.00 90 Simvastatin Mylan</td>
<td></td>
</tr>
</tbody>
</table>
Resins

CHOLESTYRAMINE
Powder for oral liq 4 g

COLESTIPOL HYDROCHLORIDE
Grans for oral liq 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Restricted see terms below

- Tab 10 mg – 1% DV Mar-18 to 2020 ................................................................. 2.00 30 Ezetimibe Sandoz

 Initiation
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. Any of the following:
   3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 x normal) when treated with one statin; or
   3.2 The patient is intolerant to both simvastatin and atorvastatin; or
   3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – Restricted see terms below

- Tab 10 mg with simvastatin 10 mg ................................................................. 5.15 30 Zimybe
- Tab 10 mg with simvastatin 20 mg ................................................................. 6.15 30 Zimybe
- Tab 10 mg with simvastatin 40 mg ................................................................. 7.15 30 Zimybe
- Tab 10 mg with simvastatin 80 mg ................................................................. 8.15 30 Zimybe

 Initiation
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX
Cap 250 mg

NICOTINIC ACID

- Tab 50 mg – 1% DV Oct-17 to 2020 ................................................................. 4.12 100 Apo-Nicotinic Acid
- Tab 500 mg – 1% DV Oct-17 to 2020 ............................................................... 17.89 100 Apo-Nicotinic Acid
<table>
<thead>
<tr>
<th>Nitrates</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERYL TRINITRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td>$100.00</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml ampoule</td>
<td>$4.45 per 250 dose Nitrolingual Pump Spray</td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule</td>
<td>$15.73 per 30 Nitroderm TTS 5</td>
<td></td>
</tr>
<tr>
<td>Oral pump spray, 400 mcg per dose</td>
<td>$4.45 per 200 dose Glytrin</td>
<td></td>
</tr>
<tr>
<td>Oral spray, 400 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 25 mg, 5 mg per day</td>
<td>$18.62 per 30 Nitroderm TTS 5</td>
<td></td>
</tr>
<tr>
<td>Patch 50 mg, 10 mg per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISOSORBIDE MONONITRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Oct-17 to 2020</td>
<td>$18.80 per 100 Ismo-20</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 40 mg</td>
<td>$7.50 per 30 Ismo 40 Retard</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 60 mg – 1% DV Sep-17 to 2020</td>
<td>$8.29 per 90 Duride</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other Cardiac Agents</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LEVOSIMENDAN – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 5 ml vial</td>
<td>$18.80 per 100 Ismo-20</td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1007)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation – Heart transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 For the treatment of heart failure following heart transplant.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation – Heart failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiologist or intensivist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sympathomimetics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADRENALINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 in 1,000, 1 ml ampoule</td>
<td>$4.98 per 5 Aspen Adrenaline</td>
<td></td>
</tr>
<tr>
<td>Inj 1 in 1,000, 30 ml vial</td>
<td>$5.25 per 10 Aspen Adrenaline</td>
<td></td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml ampoule</td>
<td>$49.00 per 10 Aspen Adrenaline</td>
<td></td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml syringe</td>
<td>$27.00 per 5 Hospira</td>
<td></td>
</tr>
<tr>
<td>DOBUTAMINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-19 to 2021</td>
<td>$61.13 per 5 Dobutamine-hameln</td>
<td></td>
</tr>
<tr>
<td>DOPAMINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>$29.73 per 10 Max Health Ltd</td>
<td></td>
</tr>
<tr>
<td>EPHEDRINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$36.04 per 10 Max Health</td>
<td></td>
</tr>
<tr>
<td>ISOPRENA L [ISOPROTERENOL]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)

* e.g. Brand indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Dose/Package</th>
<th>Price Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>METARAMINOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5 mg per ml, 20 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NORADRENALINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.06 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.06 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.1 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.12 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.12 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.16 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022</td>
<td>45.00 10</td>
<td>Noradrenaline BNM</td>
<td></td>
</tr>
<tr>
<td><strong>PHENYLEPHRINE HYDROCHLORIDE</strong></td>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>115.50 25</td>
<td>Neosynephrine HCL</td>
</tr>
<tr>
<td><strong>Vasodilators</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALPROSTADIL HYDROCHLORIDE</strong></td>
<td>Inj 500 mcg per ml, 1 ml ampoule – 1% DV Dec-18 to 2021</td>
<td>1,765.50 5</td>
<td>Prostin VR</td>
</tr>
<tr>
<td><strong>DIAZOXIDE</strong></td>
<td>Inj 15 mg per ml, 20 ml ampoule</td>
<td>1,125.00 5</td>
<td></td>
</tr>
<tr>
<td><strong>HYDRALAZINE HYDROCHLORIDE</strong></td>
<td>Tab 25 mg</td>
<td>37.95 60</td>
<td></td>
</tr>
<tr>
<td><strong>MILRINONE</strong></td>
<td>Inj 1 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>99.00 10</td>
<td>Primacor</td>
</tr>
<tr>
<td><strong>MINOXIDIL</strong></td>
<td>Tab 10 mg</td>
<td>70.00 100</td>
<td>Loniten</td>
</tr>
<tr>
<td><strong>NICORANDIL</strong></td>
<td>Tab 10 mg</td>
<td>27.95 60</td>
<td>Ikorel</td>
</tr>
<tr>
<td><strong>PAPAVERINE HYDROCHLORIDE</strong></td>
<td>Tab 20 mg</td>
<td>33.28 60</td>
<td>Ikorel</td>
</tr>
<tr>
<td><strong>PENTOXIFYLLINE [OXPENTIFYLLINE]</strong></td>
<td>Tab 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM NITROPRUSSIDE</strong></td>
<td>Inj 15 mg per ml, 1 ml vial</td>
<td>217.90 5</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Endothelin Receptor Antagonists

**AMBRISENTAN** – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price Per Brand or Manufacturer (ex man. excl. GST)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>$4,585.00</td>
<td>30 Volibris</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>$4,585.00</td>
<td>30 Volibris</td>
</tr>
</tbody>
</table>

**BOSENTAN** – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price Per Brand or Manufacturer (ex man. excl. GST)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 62.5 mg</td>
<td>$141.00 60</td>
<td>Bosentan Dr Reddy’s</td>
</tr>
<tr>
<td>Tab 125 mg</td>
<td>$141.00 60</td>
<td>Bosentan Dr Reddy’s</td>
</tr>
</tbody>
</table>

**Initiation**

Either:

1. For use in patients with a valid Special Authority approval for ambrisentan by the Pulmonary Arterial Hypertension Panel; or
2. In-hospital stabilisations in emergency situations.

**Continuation**

**Pulmonary arterial hypertension**

*Re-assessment required after 6 months*

Either:

1. All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
   1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
   1.4 Any of the following:
      1.4.1 Both:
         1.4.1.1 Bosentan is to be used as PAH monotherapy; and
         1.4.1.2 Either:
            1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
            1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
      1.4.2 Both:
         1.4.2.1 Bosentan is to be used as PAH dual therapy; and
         1.4.2.2 Either:
            1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
            1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
      1.4.3 Both:
         1.4.3.1 Bosentan is to be used as PAH triple therapy; and
         1.4.3.2 Any of the following:
            1.4.3.2.1 Patient is on the lung transplant list; or
            1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
            1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
            1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy; or

2. In-hospital stabilisation in emergency situations.

*Continuation – Pulmonary arterial hypertension*

*Re-assessment required after 6 months*

Any of the following:

continued…
continued...

1 Both:
   1.1 Bosentan is to be used as PAH monotherapy; and
   1.2 Patient is stable or has improved while on bosentan; or

2 Both:
   2.1 Bosentan is to be used as PAH dual therapy; and
   2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or

3 Both:
   3.1 Bosentan is to be used as PAH triple therapy; and
   3.2 Any of the following:
      3.2.1 Patient is on the lung transplant list; or
      3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
      3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
      3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Restricted see terms below

- Tab 25 mg – 1% DV Sep-18 to 2021 ............................................................... 0.64 4  Vedafil
- Tab 50 mg – 1% DV Sep-18 to 2021 ............................................................... 0.64 4  Vedafil
- Tab 100 mg – 1% DV Sep-18 to 2021 ............................................................. 6.60 12  Vedafil
- Inj 0.8 mg per ml, 12.5 ml vial

- Restricted (RS1643)

Initiation – tablets Raynaud’s Phenomenon
All of the following:
1 Patient has Raynaud's phenomenon; and
2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Initiation – tablets Pulmonary arterial hypertension
Any of the following:
1 All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 Any of the following:
      1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
      1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
      1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
   1.3 Any of the following:
      1.3.1 PAH is in NYHA/WHO functional class II; or
      1.3.2 PAH is in NYHA/WHO functional class III; or
      1.3.3 PAH is in NYHA/WHO functional class IV; and
   1.4 Either:

continued…
continued...

1.4.1 All of the following:
   1.4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
   1.4.1.2 Either:
      1.4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
      1.4.1.2.2 Patient is peri Fontan repair; and
   1.4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm-5); or
   1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient’s young age; or
2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
3 In-hospital stabilisation in emergency situations.

Initiation – tablets other conditions

Any of the following:
1 For use in weaning patients from inhaled nitric oxide; or
2 For perioperative use in cardiac surgery patients; or
3 For use in intensive care as an alternative to nitric oxide.

Initiation – injection

Both:
1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
2 Any of the following:
   2.1 For perioperative use following cardiac surgery; or
   2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
   2.3 For use in congenital diaphragmatic hernia.

Prostacyclin Analogues

EPOPROSTENOL – Restricted see terms below

- Inj 500 mcg vial..........................................................36.61 1 Veletri
- Inj 1.5 mg vial...........................................................73.21 1 Veletri

Initiation

Either:
1 For use in patients with a valid Special Authority approval for epoprostenol by the Pulmonary Arterial Hypertension Panel; or
2 In-hospital stabilisation in emergency situations.

ILOPROST

- Inj 50 mcg in 0.5 ml ampoule..............................................380.00 5 Ilomedin
- Nebuliser soln 10 mcg per ml, 2 ml.................................1,185.00 30 Ventavis

Initiation

Any of the following:
1 For use in patients with a valid Special Authority approval for iloprost by the Pulmonary Arterial Hypertension Panel; or
2 For diagnostic use in catheter laboratories; or
3 For use following mitral or tricuspid valve surgery; or
4 In-hospital stabilisation in emergency situations.
<table>
<thead>
<tr>
<th>Anti-Infective Preparations</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibacterials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROGEN PEROXIDE</td>
<td>$8.56</td>
<td>Crystaderm</td>
</tr>
<tr>
<td>Crm 1% - 1% DV Oct-19 to 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 3% (10 vol)</td>
<td>$1.40</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td>(Pharmacy Health Soln 3% (10 vol) to be delisted 1 July 2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAFENIDE ACETATE – Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder 50 g sachet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAFENIDE ACETATE – Restricted (RS1299)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For the treatment of burns patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MUPIROCIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM FUSIDATE [FUSIDIC ACID]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 2% - 1% DV May-19 to 2021</td>
<td>$1.59</td>
<td>Foban</td>
</tr>
<tr>
<td>Oint 2% - 1% DV May-19 to 2021</td>
<td>$1.59</td>
<td>Foban</td>
</tr>
<tr>
<td>SULFADIAZINE SILVER</td>
<td>$10.80</td>
<td>Flamazine</td>
</tr>
<tr>
<td>Crm 1% - 1% DV Aug-17 to 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antifungals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMOROLFINE</td>
<td>$15.95</td>
<td>MycoNail</td>
</tr>
<tr>
<td>Nail soln 5% - 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CICLOPIROX OLAMINE</td>
<td>$5.72</td>
<td>Apo-Ciclopirox</td>
</tr>
<tr>
<td>Nail soln 8% - 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 1% – Restricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For continuation only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLOTRIMAZOLE</td>
<td>$0.70</td>
<td>Clomazol</td>
</tr>
<tr>
<td>Crm 1% - 1% DV Jan-18 to 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 1% – Restricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For continuation only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECONAZOLE NITRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1% – Restricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For continuation only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foaming soln 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KETOCONAZOLE</td>
<td>$2.99</td>
<td>Sebizole</td>
</tr>
<tr>
<td>Shampoo 2% - 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METRONIDAZOLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 0.75%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MICONAZOLE NITRATE</td>
<td>$0.74</td>
<td>MultiChem</td>
</tr>
<tr>
<td>Crm 2% - 1% DV Jan-18 to 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotn 2% – Restricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For continuation only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tinc 2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYSTATIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 100,000 u per g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antiparasitics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIMETHICONE</td>
<td>$4.98</td>
<td>healthE Dimethicone</td>
</tr>
<tr>
<td>Lotn 4% - 1% DV Oct-19 to 2022</td>
<td></td>
<td>4% Lotion</td>
</tr>
</tbody>
</table>
## DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### MALATHION [MALDISON]
- Lotn 0.5%
- Shampoo 1%

### PERMETHRIN
- Crm 5% – 1% DV Dec-17 to 2020
- Lotn 5% – 1% DV Oct-17 to 2020

### PHENOTHRI
- Shampoo 0.5%

## Antiacne Preparations

### ADAPALENE
- Crm 0.1%
- Gel 0.1%

### BENZOYL PEROXIDE
- Soln 5%

### ISOTRETINOIN
- Cap 5 mg – 1% DV Oct-18 to 2021
- Cap 10 mg – 1% DV Oct-18 to 2021
- Cap 20 mg – 1% DV Oct-18 to 2021

### TRETINOIN
- Crm 0.05% – 1% DV Jun-18 to 2021

## Antipruritic Preparations

### CALAMINE
- Crm, aqueous, BP – 1% DV Nov-18 to 2021
- Lotn, BP

(PSM Lotn, BP to be delisted 1 July 2020)

### CROTAMITON
- Crm 10% – 1% DV Sep-18 to 2021

## Barrier Creams and Emollients

### Barrier Creams

### DIMETHICONE
- Crm 5% tube – 1% DV Oct-19 to 2022
- Crm 5% pump bottle
- Crm 10% pump bottle – 1% DV Sep-18 to 2021

### ZINC
- Crm
- Oint
- Paste

---

*Item restricted (see ➕ above); † Item restricted (see ➕ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
### Price

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orion</td>
</tr>
<tr>
<td>Boucher</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>Pharmacy Health SLS-free</td>
</tr>
<tr>
<td>Pharmacy Health</td>
</tr>
<tr>
<td>AFT</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>O/W Fatty Emulsion Cream</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>healthE</td>
</tr>
<tr>
<td>e.g. AlphaKeri: BK; DP; Hydroderm Lotn</td>
</tr>
<tr>
<td>e.g. Alpha Keri Bath Oil</td>
</tr>
</tbody>
</table>

### ZINC AND CASTOR OIL

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm</td>
<td>$1.63 20 g Orion</td>
</tr>
<tr>
<td>Oint – 1% DV Jul-18 to 2020</td>
<td>$4.25 500 g Boucher</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 30 g.</td>
<td></td>
</tr>
<tr>
<td>Oint, BP – 1% DV Nov-17 to 2020</td>
<td>$1.26 20 g healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 30 g or less.</td>
<td></td>
</tr>
</tbody>
</table>

### ZINC WITH WOOL FAT

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm zinc 15.25% with wool fat 4%</td>
<td>e.g. Sudocrem</td>
</tr>
</tbody>
</table>

### Emollients

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### AQUEOUS CREAM

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 100 g – 1% DV Oct-18 to 2021</td>
<td>$1.05 100 g Pharmacy Health SLS-free</td>
</tr>
<tr>
<td>Crm 500 g – 1% DV Dec-18 to 2021</td>
<td>$1.92 1 healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of 100 g or less.</td>
<td></td>
</tr>
</tbody>
</table>

#### CETOMACROGOL

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm BP, 500 g – 1% DV Sep-18 to 2021</td>
<td>$2.48 500 g healthE</td>
</tr>
<tr>
<td>Crm BP, 100 g – 1% DV Sep-18 to 2021</td>
<td>$1.42 1 healthE</td>
</tr>
</tbody>
</table>

#### CETOMACROGOL WITH GLYCEROL

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 90% with glycerol 10%,</td>
<td>$3.20 100 g Pharmacy Health</td>
</tr>
<tr>
<td>Crm 90% with glycerol 10%,</td>
<td>$2.82 500 ml Pharmacy Health Sorbolene with Glycerin</td>
</tr>
<tr>
<td>3.87 1,000 ml Pharmacy Health Sorbolene with Glycerin</td>
<td></td>
</tr>
</tbody>
</table>

#### EMULSIFYING OINTMENT

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint BP – 1% DV Oct-17 to 2020</td>
<td>$1.84 100 g Jaychem</td>
</tr>
<tr>
<td>Oint BP, 500 g – 1% DV Oct-17 to 2020</td>
<td>$3.59 500 g AFT</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of less than 200 g.</td>
<td></td>
</tr>
</tbody>
</table>

#### GLYCEROL WITH PARAFFIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%</td>
<td>e.g. QV cream</td>
</tr>
</tbody>
</table>

#### OIL IN WATER EMULSION

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm, 500 g – 1% DV Jan-19 to 2021</td>
<td>$2.19 500 g O/W Fatty Emulsion Cream</td>
</tr>
<tr>
<td>Crm, 100 g – 1% DV Dec-18 to 2021</td>
<td>$1.44 1 healthE Fatty Cream</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
</tr>
</tbody>
</table>

#### PARAFFIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint liquid paraffin 50% with white soft paraffin 50% – 1% DV Jan-19 to 2021</td>
<td>$1.97 100 g healthE</td>
</tr>
<tr>
<td>White soft – 1% DV Sep-18 to 2021</td>
<td>$0.79 10 g healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.</td>
<td></td>
</tr>
</tbody>
</table>

#### PARAFFIN WITH WOOL FAT

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lotn liquid paraffin 15.9% with wool fat 0.6%</td>
<td>e.g. AlphaKeri: BK; DP; Hydroderm Lotn</td>
</tr>
<tr>
<td>Lotn liquid paraffin 91.7% with wool fat 3%</td>
<td>e.g. Alpha Keri Bath Oil</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## DERMATOLOGICALS

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UREA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 10%</td>
<td>1.37</td>
<td>100 g healthE Urea Cream</td>
</tr>
<tr>
<td><strong>WOOL FAT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Corticosteroids

#### BETAMETHASONE DIPROPIONATE
- **Crm 0.05%**
- **Oint 0.05%**

#### BETAMETHASONE VALERATE
- **Crm 0.1% – 1% DV Oct-18 to 2021**: 3.45 $ 50 g Beta Cream
- **Crm 0.1% – 1% DV Oct-18 to 2021**: 3.45 $ 50 g Beta Ointment
- **Lotn 0.1% – 1% DV Dec-18 to 2021**: 18.00 $ 50 ml Betnovate

#### CLOBETASOL PROPIONATE
- **Crm 0.05%**: 2.20 $ 30 g Dermol
- **Oint 0.05%**: 2.20 $ 30 g Dermol

#### CLOBETASONE BUTYRATE
- **Crm 0.05%**

#### DIFLUCORTOLONE VALERATE
- **Restricted**: For continuation only
  - **Crm 0.1%**
  - **Fatty oint 0.1%**

#### HYDROCORTISONE
- **Crm 1%, 30 g**: 1.11 $ 30 g DermAssist
  - **Note**: DV limit applies to the pack sizes of less than or equal to 100 g.
- **Crm 1%, 500 g**: 16.25 $ 500 g Pharmacy Health

#### HYDROCORTISONE ACETATE
- **Crm 1%**: 2.48 $ 14.2 g AFT

#### HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN
- **Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 1% DV Sep-17 to 2020**: 10.57 $ 250 ml DP Lotn HC

#### HYDROCORTISONE BUTYRATE
- **Crm 0.1%**: 3.42 $ 30 g Locoid Lipocream
- **Oint 0.1% – 1% DV Mar-19 to 2021**: 13.70 $ 100 g Locoid
- **Milky emul 0.1% – 1% DV Mar-19 to 2021**: 13.70 $ 100 ml Locoid Crelo

#### METHYLprednisolone ACETONATE
- **Crm 0.1%**: 4.95 $ 15 g Advantan
- **Oint 0.1%**: 4.95 $ 15 g Advantan

#### MOMETASONE Furoate
- **Crm 0.1% – 1% DV Nov-18 to 2021**: 1.51 $ 15 g Elocon Alcohol Free
- **Oint 0.1% – 1% DV Nov-18 to 2021**: 2.50 $ 50 g Elocon Alcohol Free
- **Lotn 0.1% – 1% DV Nov-18 to 2021**: 2.90 $ 50 g Elocon

#### TRIAMCINOLONE ACETONIDE
- **Crm 0.02% – 1% DV Sep-17 to 2020**: 6.30 $ 100 g Aristocort
- **Oint 0.02% – 1% DV Sep-17 to 2020**: 6.35 $ 100 g Aristocort

---

*Item restricted (see ➤ above); Item restricted (see ➤ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
Corticosteroids with Anti-Infective Agents

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETAMETHASONE VALERATE WITH CLIQUINOL – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.1% with clioquinol 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Restricted (RS1125)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 For the treatment of intertrigo; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 For continuation use.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.1% with sodium fusidate (fusidic acid) 2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE WITH MICONAZOLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1% with miconazole nitrate 2% – 1% DV Sep-18 to 2021</td>
<td>2.00</td>
<td>Micreme H</td>
</tr>
<tr>
<td>HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>3.35</td>
<td>Pimafucort</td>
</tr>
<tr>
<td>Oint 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>3.35</td>
<td>Pimafucort</td>
</tr>
<tr>
<td>TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gramicidin 250 mcg per g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis and Eczema Preparations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACITRETIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg – 1% DV Sep-17 to 2020</td>
<td>17.86</td>
<td>Novatretin</td>
</tr>
<tr>
<td>Cap 25 mg – 1% DV Sep-17 to 2020</td>
<td>41.36</td>
<td>Novatretin</td>
</tr>
<tr>
<td>BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021</td>
<td>52.24</td>
<td>Daivobet</td>
</tr>
<tr>
<td>Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021</td>
<td>19.95</td>
<td>Daivobet</td>
</tr>
<tr>
<td>CALCIPOTRIOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 50 mcg per g – 1% DV Jul-17 to 2020</td>
<td>45.00</td>
<td>Daivonex</td>
</tr>
<tr>
<td>COAL TAR WITH SALICYLIC ACID AND SULPHUR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 12% with salicylic acid 2% and sulphur 4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHOXSALEN [8-METHOXYPSORALEN]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotn 1.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCEIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020</td>
<td>3.86</td>
<td>Pinetarsol</td>
</tr>
<tr>
<td>POTASSIUM PERMANGANATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scalp Preparations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scalp app 0.1% – 1% DV Oct-18 to 2021</td>
<td>7.75</td>
<td>Beta Scalp</td>
</tr>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scalp app 0.05%</td>
<td>6.96</td>
<td>Dermol</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCORTISONE BUTYRATE</td>
<td></td>
</tr>
<tr>
<td>Scalp lotn 0.1% – 1% DV Mar-19 to 2021</td>
<td>7.30</td>
</tr>
</tbody>
</table>

### Wart Preparations

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMIQUIMOD</td>
<td></td>
</tr>
<tr>
<td>Crm 5%, 250 mg sachet – 1% DV Aug-18 to 2020</td>
<td>21.72</td>
</tr>
<tr>
<td>PODOPHYLLOTOXIN</td>
<td></td>
</tr>
<tr>
<td>Soln 0.5%</td>
<td>33.60</td>
</tr>
</tbody>
</table>

### Other Skin Preparations

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIPHEMANIL METILSULFATE</td>
<td></td>
</tr>
<tr>
<td>Powder 2%</td>
<td></td>
</tr>
<tr>
<td>SUNSCREEN, PROPRIETARY</td>
<td></td>
</tr>
<tr>
<td>Crm</td>
<td></td>
</tr>
<tr>
<td>Lotn</td>
<td>3.30</td>
</tr>
<tr>
<td></td>
<td>5.10</td>
</tr>
</tbody>
</table>

### Antineoplastics

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUOROURACIL SODIUM</td>
<td></td>
</tr>
<tr>
<td>Crm 5% – 1% DV Sep-18 to 2021</td>
<td>7.95</td>
</tr>
<tr>
<td>METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Crm 16%</td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1127)</td>
<td></td>
</tr>
<tr>
<td>Dermatologist or plastic surgeon</td>
<td></td>
</tr>
</tbody>
</table>

### Wound Management Products

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CALCIUM GLUCONATE</td>
<td></td>
</tr>
<tr>
<td>Gel 2.5%</td>
<td>e.g. Orion</td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above);Restricted see terms below

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Anti-Infective Agents

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID Soln 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACETIC ACID Soln 5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLORHEXIDINE GLUCONATE</td>
<td>1.21</td>
<td>healthE</td>
</tr>
<tr>
<td></td>
<td>2.98</td>
<td>healthE</td>
</tr>
<tr>
<td>CLOTRIMAZOLE Vaginal crm 1% with applicator</td>
<td>1.60</td>
<td>Clomazol</td>
</tr>
<tr>
<td>CLOTRIMAZOLE Vaginal crm 2% with applicator</td>
<td>2.10</td>
<td>Clomazol</td>
</tr>
<tr>
<td>MICONAZOLE NITRATE Vaginal crm 2% with applicator</td>
<td>3.88</td>
<td>Micreme</td>
</tr>
<tr>
<td>NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)</td>
<td>4.45</td>
<td>Nilstat</td>
</tr>
</tbody>
</table>

### Contraceptives

#### Antiandrogen Oral Contraceptives

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYPROTERONE ACETATE WITH ETHINYLestersadiol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with ethinylestersadiol 35 mcg and 7 inert tablets</td>
<td>4.67</td>
<td>Ginet</td>
</tr>
</tbody>
</table>

#### Combined Oral Contraceptives

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHINYLestersadiol WITH DESOGESTREL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mcg with desogestrel 150 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 30 mcg with desogestrel 150 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHINYLestersadiol WITH LEVONORGESTREL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets</td>
<td>2.18</td>
<td>Microgynon 20 ED</td>
</tr>
<tr>
<td>Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets</td>
<td>1.77</td>
<td>Levlen ED</td>
</tr>
<tr>
<td>ETHINYLestersadiol WITH NORETHISTERONE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 35 mcg with norethisterone 1 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 35 mcg with norethisterone 500 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NORETHISTERONE WITH MESTRANOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg with mestranol 50 mcg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**GENITO-URINARY SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### Contraceptive Devices

#### INTRA-UTERINE DEVICE

- IUD 29.1 mm length × 23.2 mm width ............................................................. 31.60 1 Choice TT380 Short
- IUD 33.6 mm length × 29.9 mm width ............................................................. 31.60 1 Choice TT380 Standard
- IUD 35.5 mm length × 19.6 mm width ............................................................. 31.60 1 Choice Load 375

### Emergency Contraception

**LEVONORGESTREL**

- Tab 1.5 mg ................................................................. 4.95 1 Postinor-1

### Progestogen-Only Contraceptives

**LEVONORGESTREL**

- Tab 30 mcg
  - Subdermal implant (2 × 75 mg rods) – 1% DV Mar-18 to 2020 ................... 106.92 1 Jadelle
  - Intra-uterine system, 20 mcg per day ...................................................... 269.50 1 Mirena

**MEDROXYPROGESTERONE ACETATE**

- Inj 150 mg per ml, 1 ml syringe ................................................................. 7.25 1 Depo-Provera

**NORETHISTERONE**

- Tab 350 mcg – 1% DV Sep-18 to 2021 ............................................................ 6.25 84 Noriday 28

---

- Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)
  - e.g. *Brand* indicates brand example only. It is not a contracted product.
## Obstetric Preparations

### Antiprogestogens

**MIFEPRISTONE**  
Tab 200 mg

### Oxytocics

**CARBOPROST TROMETAMOL**  
Inj 250 mcg per ml, 1 ml ampoule

**DINOPROSTONE**  
- Pessaries 10 mg  
- Vaginal gel 1 mg in 3 g
  - Price (ex man. excl. GST) $52.65 Per 1 Prostin E2  
- Vaginal gel 2 mg in 3 g
  - Price (ex man. excl. GST) $64.60 Per 1 Prostin E2

**ERGOMETRINE MALEATE**  
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020  
- Price (ex man. excl. GST) $105.00 Per 5 DBL Ergometrine

**OXYTOCIN**  
Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021  
- Price (ex man. excl. GST) $3.98 Per 5 Oxytocin BNM

**OXYTOCIN WITH ERGOMETRINE MALEATE**  
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021  
- Price (ex man. excl. GST) $15.00 Per 5 Syntometrine

### Tocolytics

**PROGESTERONE** – **Restricted** see terms below  
- Cap 100 mg  
  - Price (ex man. excl. GST) $16.50 Per 30 Utrogestan

**TERBUTALINE** – **Restricted** see terms below  
- Inj 500 mcg ampoule  
  - Price (ex man. excl. GST) $15.00 Per 25 Syntometrine

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### Oestrogens

**OESTRIOL**
- Crm 1 mg per g with applicator – **1% DV Oct-17 to 2020** ........................................ 6.62 15 g **Ovestin**
- Pessaries 500 mcg – **1% DV Oct-17 to 2020** .................................................. 6.86 15 **Ovestin**

#### 5-Alpha Reductase Inhibitors

**FINASTERIDE** – **Restricted** see terms **below**
- Tab 5 mg – **1% DV Dec-17 to 2020** ................................................................. 4.81 100 **Ricit**
- **Restricted (RS1131)**

**Initiation**
- Both:
  1. Patient has symptomatic benign prostatic hyperplasia; and
  2. Either:
     1. The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
     2. Symptoms are not adequately controlled with non-selective alpha blockers.

#### Alpha-1A Adrenoceptor Blockers

**TAMSULOSIN HYDROCHLORIDE** – **Restricted** see terms **below**
- Cap 400 mcg ............................................................... 11.25 100 **Tamsulosin-Rex**
- **Restricted (RS1132)**

**Initiation**
- Both:
  1. Patient has symptomatic benign prostatic hyperplasia; and
  2. The patient is intolerant of non-selective alpha blockers or these are contraindicated.

#### Urinary Alkalisers

**POTASSIUM CITRATE** – **Restricted** see terms **below**
- Oral liq 3 mmol per ml – **1% DV Oct-18 to 2021** ............................................. 31.80 200 ml **Biomed**
- **Restricted (RS1133)**

**Initiation**
- Both:
  1. The patient has recurrent calcium oxalate urolithiasis; and
  2. The patient has had more than two renal calculi in the two years prior to the application.

**SODIUM CITRO-TARTRATE**
- Grans eff 4 g sachets – **1% DV Sep-17 to 2020** .............................................. 2.34 28 **Ural**

#### Urinary Antispasmodics

**OXYBUTYNIN**
- Tab 5 mg ................................................................. 8.85 500 **Apo-Oxybutynin**
- Oral liq 5 mg per 5 ml ................................................................. 60.40 473 ml **Apo-Oxybutynin**

**SOLIFENACIN SUCCINATE** – **Some items restricted** see terms on the next page
- Tab 5 mg – **1% DV Dec-18 to 2021** ................................................................. 3.00 30 **Solifenacin Mylan**
- Tab 10 mg – **1% DV Dec-18 to 2021** ............................................................... 5.50 30 **Solifenacin Mylan**

---

1 Item restricted (see ➥ above); 1 Item restricted (see ➥ below)

_e.g. Brand_ indicates brand example only. It is not a contracted product.
Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**Restricted (RS1274)**

Initiation
Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

TOLTERODINE TARTRATE — Restricted see terms below

- Tab 1 mg ................................................................. 14.56 56 Arrow-Tolterodine
- Tab 2 mg ................................................................. 14.56 56 Arrow-Tolterodine

**Restricted (RS1273)**

Initiation
Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.
HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### Anabolic Agents

**OXANDROLONE**
- Tab 2.5 mg
  - Restricted (RS1302)

**Initiation**
For the treatment of burns patients.

### Androgen Agonists and Antagonists

**CYPROTERONE ACETATE**
- Tab 50 mg – 1% DV Dec-18 to 2021 ................................................. 13.17 50 Siterone
- Tab 100 mg – 1% DV Dec-18 to 2021 .............................................. 26.75 50 Siterone

**TESTOSTERONE**
- Patch 5 mg per day ........................................................................ 90.00 30 Androderm

**TESTOSTERONE CIPIONATE**
- Inj 100 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020 ...................... 76.50 1 Depo-Testosterone

**TESTOSTERONE ESTERS**
- Inj testosterone decanoate 100 mg, testosterone isocaproate 60 mg,
  testosterone phenylpropionate 60 mg and testosterone propionate
  30 mg per ml, 1 ml ampoule

**TESTOSTERONE UNDECANOATE**
- Cap 40 mg – 1% DV Nov-18 to 2021 .............................................. 21.00 60 Andriol Testocaps
- Inj 250 mg per ml, 4 ml vial ............................................................ 86.00 1 Reandron 1000

### Calcium Homeostasis

**CALCITONIN**
- Inj 100 iu per ml, 1 ml ampoule ......................................................... 121.00 5 Miacalcic

**CINACALCET** – Restricted see terms below
- Tab 30 mg – 1% DV Sep-18 to 2021 .................................................. 210.30 28 Sensipar
  - Restricted (RS1540)

**Initiation**
Nephrologist or endocrinologist

*Re-assessment required after 6 months*

Either:

1. All of the following:
   1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
   1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous
first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
   1.3 The patient is symptomatic; or

2. All of the following:
   2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
   2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to
3 mmol/L); and
   2.3 The patient’s condition has not responded to previous first-line treatments including bisphosphonates and sodium
thiosulfate.

continued…

* Item restricted (see ➔ above); Item restricted (see ➔ below)

*e.g. Brand indicates brand example only. It is not a contracted product.*
Continuation
Nephrologist or endocrinologist

Both:
1. The patient's serum calcium level has fallen to < 3mmol/L; and
2. The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

Zoledronic Acid

- **Inj 4 mg per 5 ml, vial** – 1% DV May-19 to 2021
  - Price: $38.03
  - Brand or Generic Manufacturer: Zoledronic acid Mylan

Initiation – bone metastases
Oncologist, haematologist or palliative care specialist

Any of the following:
1. Patient has hypercalcaemia of malignancy; or
2. Both:
   2.1. Patient has bone metastases or involvement; and
   2.2. Patient has severe bone pain resistant to standard first-line treatments; or
3. Both:
   3.1. Patient has bone metastases or involvement; and
   3.2. Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

Initiation – early breast cancer
Oncologist

All of the following:
1. Treatment to be used as adjuvant therapy for early breast cancer; and
2. Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
3. Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids

**BETAMETHASONE**
- Tab 500 mcg
- Inj 4 mg per ml, 1 ml ampoule

**BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE**
- Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

**DEXAMETHASONE**
- Tab 0.5 mg – 1% DV Oct-18 to 2021
- Tab 4 mg – 1% DV Oct-18 to 2021
- Oral liq 1 mg per ml
  - Price: $0.99
  - Brand or Generic Manufacturer: Dexamethsone

**DEXAMETHASONE PHOSPHATE**
- Inj 4 mg per ml, 1 ml ampoule
- Inj 4 mg per ml, 2 ml ampoule
  - Price: $14.19
  - Brand or Generic Manufacturer: Max Health

**FLUDROCORTISONE ACETATE**
- Tab 100 mcg
  - Price: $14.32
  - Brand or Generic Manufacturer: Florinef

**HYDROCORTISONE**
- Tab 5 mg – 1% DV Sep-18 to 2021
- Tab 20 mg – 1% DV Sep-18 to 2021
- Inj 100 mg vial
  - Price: $5.30
  - Brand or Generic Manufacturer: Solu-Cortef

Products with Hospital Supply Status (HSS) are in **bold**
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

### METHYLPREDNISOLONE (AS SODIUM SUCCINATE)

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Dec-18 to 2021</td>
<td>$112.00</td>
<td>Medrol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Dec-18 to 2021</td>
<td>$194.00</td>
<td>Medrol</td>
</tr>
<tr>
<td>Inj 40 mg vial – 1% DV Dec-18 to 2021</td>
<td>$18.90</td>
<td>Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 125 mg vial – 1% DV Dec-18 to 2021</td>
<td>$28.90</td>
<td>Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Dec-18 to 2021</td>
<td>$22.78</td>
<td>Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Dec-18 to 2021</td>
<td>$27.83</td>
<td>Solu-Medrol</td>
</tr>
</tbody>
</table>

### METHYLPREDNISOLONE ACETATE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 mg per ml, 1 ml vial – 1% DV Dec-18 to 2021</td>
<td>$44.40</td>
<td>Depo-Medrol</td>
</tr>
</tbody>
</table>

### PREDNISOLONE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Jun-18 to 2021</td>
<td>$6.00</td>
<td>Redipred</td>
</tr>
<tr>
<td>Enema 200 mcg per ml, 100 ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PREDNISONE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Jun-17 to 2020</td>
<td>$10.68</td>
<td>Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Jun-17 to 2020</td>
<td>$12.09</td>
<td>Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Jun-17 to 2020</td>
<td>$11.09</td>
<td>Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jun-17 to 2020</td>
<td>$29.03</td>
<td>Apo-Prednisone</td>
</tr>
</tbody>
</table>

### TRIAMCINOLONE ACETONIDE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$20.80</td>
<td>Kenacort-A 10</td>
</tr>
<tr>
<td>Inj 40 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$51.10</td>
<td>Kenacort-A 40</td>
</tr>
</tbody>
</table>

### TRIAMCINOLONE HEXACETONIDE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Hormone Replacement Therapy

#### Oestrogens

##### OESTRADIOL

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 25 mcg per day</td>
<td>$6.12</td>
<td>Estradot</td>
</tr>
<tr>
<td>Patch 50 mcg per day</td>
<td>$7.04</td>
<td>Estradot</td>
</tr>
<tr>
<td>Patch 75 mcg per day</td>
<td>$7.91</td>
<td>Estradot</td>
</tr>
<tr>
<td>Patch 100 mcg per day</td>
<td>$7.91</td>
<td>Estradot</td>
</tr>
</tbody>
</table>

##### OESTRADIOL VALERATE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Sep-18 to 2021</td>
<td>$12.36</td>
<td>Progynova</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Sep-18 to 2021</td>
<td>$12.36</td>
<td>Progynova</td>
</tr>
</tbody>
</table>

##### OESTROGENS (CONJUGATED EQUINE)

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 300 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 625 mcg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Progestogen and Oestrogen Combined Preparations

##### OESTRADIOL WITH NORETHISTERONE ACETATE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg with 0.5 mg norethisterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with 1 mg norethisterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## OESTROGENS WITH MEDROXYPROGESTERONE ACETATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Progestogens

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDROXYPROGESTERONE ACETATE Tab 2.5 mg</td>
<td>3.75</td>
<td>Provera</td>
</tr>
<tr>
<td>MEDROXYPROGESTERONE ACETATE Tab 5 mg</td>
<td>14.00</td>
<td>Provera</td>
</tr>
<tr>
<td>MEDROXYPROGESTERONE ACETATE Tab 10 mg</td>
<td>7.15</td>
<td>Provera</td>
</tr>
</tbody>
</table>

### Other Endocrine Agents

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CABERGOLINE – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>➥ Tab 0.5 mg – 1% DV Sep-18 to 2021</td>
<td>3.75</td>
<td>Dostinex</td>
</tr>
<tr>
<td>➥ Restricted (RS1319) Initiation Any of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Inhibition of lactation; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Patient has pathological hyperprolactinemia; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Patient has acromegaly.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLOMIFENE CITRATE Tab 50 mg</td>
<td>29.84</td>
<td>Mylan Clomiphene</td>
</tr>
<tr>
<td>DANAZOL Cap 100 mg</td>
<td>68.33</td>
<td>Azol</td>
</tr>
<tr>
<td>DANAZOL Cap 200 mg</td>
<td>97.83</td>
<td>Azol</td>
</tr>
<tr>
<td>GESTRINONE Cap 2.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METYRAPONE Cap 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PENTAGASTRIN Inj 250 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other Oestrogen Preparations

| Description                                                                 | Price  | Brand       |
| ETHINYL OESTRADIOL Tab 10 mcg – 1% DV Sep-18 to 2021                          | 17.60  | NZ Medical and Scientific |
| OESTRADIOL Implant 50 mg                                                   |        |             |
| OESTRIOL Tab 2 mg                                                          |        |             |

### Other Progestogen Preparations

| Description                                                                 | Price  | Brand       |
| MEDROXYPROGESTERONE Tab 100 mg                                              | 101.00 | Provera HD  |
| NORETHISTERONE Tab 5 mg                                                     | 18.29  | Primolut N  |
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Pituitary and Hypothalamic Hormones and Analogues

#### CORTICOTRORELIN (OVINE)
**Inj 100 mcg vial**

#### THYROTROPIN ALFA
**Inj 900 mcg vial**

### Adrenocorticotropic Hormones

#### TETRACOSACTIDE [TETRACOSACTRIN]
- **Inj 250 mcg per ml, 1 ml ampoule** ................................................................. 75.00 1 Synacthen
- **Inj 1 mg per ml, 1 ml ampoule** ................................................................. 690.00 1 Synacthen Depot

### GnRH Agonists and Antagonists

#### BUSERELIN
**Inj 1 mg per ml, 5.5 ml vial**

#### GONADORELIN
**Inj 100 mcg vial**

#### GOSERELIN
- **Implant 3.6 mg, syringe** ............................................................................... 66.48 1 Zoladex
- **Implant 10.8 mg, syringe** .......................................................................... 177.50 1 Zoladex

#### LEUPRORELIN ACETATE
- **Inj 3.75 mg prefilled dual chamber syringe** ............................................. 221.60 1 Lucrin Depot 1-month
- **Inj 11.25 mg prefilled dual chamber syringe** ........................................... 591.68 1 Lucrin Depot 3-month

### Gonadotrophins

#### CHORIOGONADOTROPIN ALFA
**Inj 250 mcg in 0.5 ml syringe**

### Growth Hormone

#### SOMATROPIN – Restricted see terms below
- **Inj 5 mg cartridge – 1% DV Oct-18 to 2021** ............................................. 34.88 1 Omnitrope
- **Inj 10 mg cartridge – 1% DV Oct-18 to 2021** ........................................... 69.75 1 Omnitrope
- **Inj 15 mg cartridge – 1% DV Oct-18 to 2021** ........................................... 104.63 1 Omnitrope

**Initiation – growth hormone deficiency in children**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

1. Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2. All of the following:
   2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and

continued…
continued...

2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
2.5 Appropriate imaging of the pituitary gland has been obtained.

**Continuation – growth hormone deficiency in children**
Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
2. Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
3. Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
4. No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed since starting growth hormone.

**Initiation – Turner syndrome**
Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. The patient has a post-natal genotype confirming Turner Syndrome; and
2. Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is < 14 years.

**Continuation – Turner syndrome**
Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
2. Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
3. A current bone age is 14 years or under; and
4. No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed since starting growth hormone.

**Initiation – short stature without growth hormone deficiency**
Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. The patient’s height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
2. Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4. The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

continued…
**HORMONE PREPARATIONS**

| Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer |

---

**Continuation – short stature without growth hormone deficiency**
Endocrinologist or paediatric endocrinologist  
Re-assessment required after 12 months  
All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred.

**Initiation – short stature due to chronic renal insufficiency**
Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist  
Re-assessment required after 12 months  
All of the following:

1. The patient’s height is more than 2 standard deviations below the mean; and
2. Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
4. The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5. The patient is under the supervision of a specialist with expertise in renal medicine; and
6. Either:
   6.1. The patient has a GFR less than or equal to 30 ml/min/1.73 m² as measured by the Schwartz method  
     (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²) in a child who may or may not be receiving dialysis; or
   6.2. The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months.

**Continuation – short stature due to chronic renal insufficiency**
Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist  
Re-assessment required after 12 months  
All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
7. The patient has not received renal transplantation since starting growth hormone treatment; and
8. If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

**Initiation – Prader-Willi syndrome**
Endocrinologist or paediatric endocrinologist  
Re-assessment required after 12 months  
All of the following:

continued…

---

© Item restricted (see above); Ⅰ Item restricted (see below)  
e.g. Brand indicates brand example only. It is not a contracted product.
continued...

1. The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and

2. The patient is aged six months or older; and

3. A current bone age is < 14 years (female patients) or < 16 years (male patients); and

4. Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and

5. Either:
   5.1 Both:
      5.1.1 The patient is aged two years or older; and
      5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
   5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation – Prader-Willi syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and

2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and

3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and

4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred; and

5. No malignancy has developed after growth hormone therapy was commenced; and

6. The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initiation – adults and adolescents
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months

All of the following:

1. The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and

2. The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and

3. The patient has severe growth hormone deficiency (see notes); and

4. The patient’s serum IGF-I is more than 1 standard deviation below the mean for age and sex; and

5. The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test. Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

continued...
At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Continuation – adults and adolescents**
Endocrinologist or paediatric endocrinologist  
**Re-assessment required after 12 months**

Either:

1. All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and  
   1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and  
   1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and  
   1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or

2. All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and  
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and  
   2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and  
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

### Thyroid and Antithyroid Preparations

**CARBIMAZOLE**  
Tab 5 mg

**IODINE**  
Soln BP 50 mg per ml

**LEVOTHYROXINE**  
Tab 25 mcg  
Tab 50 mcg  
Tab 100 mcg

**LIOTHYRONINE SODIUM**  
Tab 20 mcg  
**Restricted (RS1301)**

**Initiation**  
For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy.

Inj 20 mcg vial

**POTASSIUM IODATE**  
Tab 170 mg

**POTASSIUM PERCHLORATE**  
Cap 200 mg

**PROPYLTHIOURACIL – Restricted** see terms below  
Tab 50 mg  
**Restricted (RS1276)**

**Initiation**  
Both:

1. The patient has hyperthyroidism; and  
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.
PROTIREDIN
Inj 100 mcg per ml, 2 ml ampoule

Vasopressin Agents

ARGIPRESSIN [VASOPRESSIN]
Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – Some items restricted see terms below

- Tab 100 mcg..........................................................25.00 30 Minirin
- Tab 200 mcg..........................................................54.45 30 Minirin
- Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020 ..................23.95 6 ml Desmopressin-PH&T
- Inj 4 mcg per ml, 1 ml ampoule
- Inj 15 mcg per ml, 1 ml ampoule
- Nasal drops 100 mcg per ml

Restricted (RS1339)

Initiation – Nocturnal enuresis
Either:
1. The nasal forms of desmopressin are contraindicated; or
2. An enuresis alarm is contraindicated.

Note: Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.

TERLIPRESSIN

- Inj 0.1 mg per ml, 8.5 ml ampoule ..................................................450.00 5 Glypressin
- Inj 1 mg per 8.5 ml ampoule ..........................................................215.00 5 Glypressin
## INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Antibacterials

#### Aminoglycosides

**AMIKACIN – Restricted see terms below**
- **Inj 5 mg per ml, 10 ml syringe**: $18.50 1 Biomed
- **Inj 5 mg per ml, 5 ml syringe**:
  - $18.50 1 Biomed
  - $265.00 5 DBL Amikacin

**GENTAMICIN SULPHATE**
- **Inj 10 mg per ml, 2 ml ampoule**: $25.00 5 DBL Gentamicin
- **Inj 40 mg per ml, 2 ml ampoule**: $17.50 10 Pfizer

**PAROMOMYCIN – Restricted see terms below**
- **Cap 250 mg**: $126.00 16 Humatin

**STREPTOMYCIN SULPHATE – Restricted see terms below**
- **Inj 400 mg per ml, 2.5 ml ampoule**: $2,200.00 56 dose TOBI

**TOBRAMYCIN**
- **Powder – Restricted (RS1475)**
  - **Initiation**
    - For addition to orthopaedic bone cement.
      - **Inj 40 mg per ml, 2 ml vial – 1% DV Sep-18 to 2021**: $15.00 5 Tobramycin Mylan

**Carbapenems**

**ERTAPENEM – Restricted see terms below**
- **Inj 1 g vial – 1% DV Aug-19 to 2022**: $70.00 1 Invanz

**IMIPENEM WITH CILASTATIN – Restricted see terms below**
- **Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022**: $60.00 1 Imipenem+Cilastatin RBX

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Infections

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Strength</th>
<th>Expiry Date</th>
<th>Price (excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cefepime</strong></td>
<td><strong>Restricted</strong></td>
<td>1 g vial</td>
<td>Oct-18 to 2021</td>
<td>3.75</td>
<td>Cefepime-AFT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.5 g vial</td>
<td>Feb-18 to 2021</td>
<td>5.69</td>
<td>Cefepime-AFT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Restricted</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(RS1049)</td>
</tr>
</tbody>
</table>

Clinical microbiologist or infectious disease specialist
## INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### Cephalosporins and Cephamycins - 5th Generation

**CEFTAROLINE FOSAMIL – Restricted** see terms below

- **Inj 600 mg vial** ............................................................................................1,450.00 10 Zinforo

  - **Restricted (RS1446)**

  **Initiation – multi-resistant organism salvage therapy**
  Clinical microbiologist or infectious disease specialist
  Either:
  1. for patients where alternative therapies have failed; or
  2. for patients who have a contraindication or hypersensitivity to standard current therapies.

### Macrolides

**AZITHROMYCIN – Restricted** see terms below

- **Tab 250 mg – 1% DV Sep-18 to 2021** .......................................................... 8.19 30 Apo-Azithromycin
- **Tab 500 mg – 1% DV Sep-18 to 2021** .......................................................... 0.93 2 Apo-Azithromycin
- **Grans for oral liq 200 mg per 5 ml (40 mg per ml) – 1% DV Dec-18 to 2021** .....................................................................................................14.38 15 ml Zithromax

  - **Restricted (RS1598)**

  **Initiation – bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections**
  Any of the following:
  1. Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
  2. Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
  3. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms*; or
  4. Patient has an atypical Mycobacterium infection.

  **Note:** Indications marked with * are unapproved indications

  **Initiation – non-cystic fibrosis bronchiectasis**
  Respiratory specialist or paediatrician
  **Re-assessment required after 12 months**
  All of the following:
  1. For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
  2. Patient is aged 18 and under; and
  3. Either:
     3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
     3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

  **Note:** Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

  **Continuation – non-cystic fibrosis bronchiectasis**
  Respiratory specialist or paediatrician
  **Re-assessment required after 12 months**
  All of the following:
  1. The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
  2. Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
  3. The patient will not receive more than a total of 24 months’ azithromycin cumulative treatment (see note).

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Initiation — other indications**

Re-assessment required after 5 days

For any other condition.

**Continuation — other indications**

Re-assessment required after 5 days

For any other condition.

**CLARITHROMYCIN** — Restricted see terms below

- Tab 250 mg – 1% DV Sep-17 to 2020 .................................................. 3.98  14  Apo-Clarithromycin
- Tab 500 mg – 1% DV Sep-17 to 2020 .................................................. 10.40  14  Apo-Clarithromycin
- Grans for oral liq 50 mg per ml .................................................. 23.12 50 ml  Klacid
- Inj 500 mg vial – 1% DV Dec-17 to 31 Aug 2020 .................................. 12.04  1  Martindale

**Initiation — Tab 250 mg and oral liquid**

Either:

1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.

**Initiation — Tab 500 mg**

Helicobacter pylori eradication.

**Initiation — Infusion**

Any of the following:

1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or

**ERYTHROMYCIN (AS ETHYLSUCCINATE)**

- Tab 400 mg .................................................. 16.95  100  E-Mycin
- Grans for oral liq 200 mg per 5 ml .................................................. 5.00  100 ml  E-Mycin
- Grans for oral liq 400 mg per 5 ml .................................................. 6.77  100 ml  E-Mycin

**ERYTHROMYCIN (AS LACTOBIONATE)**

- Inj 1 g vial .................................................. 16.00  1  Erythrocin IV

**ERYTHROMYCIN (AS STEARATE)** — Restricted: For continuation only

- Tab 250 mg
- Tab 500 mg

**ROXITHROMYCIN** — Some items restricted see terms below

- Tab dispersible 50 mg .................................................. 7.19  10  Rulide D
- Tab 150 mg – 1% DV Sep-19 to 2022 .................................................. 8.28  50  Arrow-Roxithromycin
- Tab 300 mg – 1% DV Sep-19 to 2022 .................................................. 16.33  50  Arrow-Roxithromycin

**Initiation**

Only for use in patients under 12 years of age.
## Penicillins

### AMOXICILLIN

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
<td>.................................................................</td>
<td>14.97</td>
<td>500</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td>.................................................................</td>
<td>16.75</td>
<td>500</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml</td>
<td>– 1% DV Feb-18 to 2020</td>
<td>1.20</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml</td>
<td>– 1% DV Feb-18 to 2020</td>
<td>1.31</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 250 mg vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>10.67</td>
<td>10</td>
</tr>
<tr>
<td>Inj 500 mg vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>12.41</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>17.29</td>
<td>10</td>
</tr>
</tbody>
</table>

### AMOXICILLIN WITH CLAVULANIC ACID

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg with clavulanic acid 125 mg</td>
<td>– 1% DV Oct-17 to 2020</td>
<td>1.88</td>
<td>20</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml</td>
<td>.................................................................</td>
<td>3.83</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml</td>
<td>.................................................................</td>
<td>2.20</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 500 mg with clavulanic acid 100 mg vial</td>
<td>.................................................................</td>
<td>28.18</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1,000 mg with clavulanic acid 200 mg vial</td>
<td>.................................................................</td>
<td>43.30</td>
<td>10</td>
</tr>
</tbody>
</table>

### BENZATHINE BENZYPENICILLIN

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 900 mg (1.2 million units) in 2.3 ml syringe</td>
<td>– 1% DV Dec-18 to 2021</td>
<td>344.93</td>
<td>10</td>
</tr>
</tbody>
</table>

### BENZYPENICILLIN SODIUM [PENICILLIN G]

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 600 mg (1 million units) vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>10.35</td>
<td>10</td>
</tr>
<tr>
<td>.................................................................</td>
<td>103.50</td>
<td>100</td>
<td>Sandoz</td>
</tr>
</tbody>
</table>

### FLUCLOXACILLIN

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
<td>– 1% DV Sep-18 to 2021</td>
<td>16.83</td>
<td>250</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td>– 1% DV Sep-18 to 2021</td>
<td>56.61</td>
<td>500</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml</td>
<td>– 1% DV Oct-18 to 2021</td>
<td>2.29</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml</td>
<td>– 1% DV Oct-18 to 2021</td>
<td>3.68</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 250 mg vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>9.00</td>
<td>10</td>
</tr>
<tr>
<td>Inj 500 mg vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>9.40</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>5.22</td>
<td>5</td>
</tr>
</tbody>
</table>

### PHENOXYMETHYLPENICILLIN [PENICILLIN V]

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
<td>– 1% DV Sep-18 to 2021</td>
<td>2.59</td>
<td>50</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td>– 1% DV Sep-18 to 2021</td>
<td>4.26</td>
<td>50</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml</td>
<td>.................................................................</td>
<td>1.48</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml</td>
<td>.................................................................</td>
<td>1.58</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

### PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below

#### Restricted (RS1053)

Clinical microbiologist, infectious disease specialist or respiratory specialist

### PROCAINE PENICILLIN

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1.5 g in 3.4 ml syringe</td>
<td>– 1% DV Sep-17 to 2020</td>
<td>123.50</td>
<td>5</td>
</tr>
</tbody>
</table>

### TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms below

#### Restricted (RS1054)

Clinical microbiologist, infectious disease specialist or respiratory specialist

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
### Quinolones

**CIPROFLOXACIN** – *Restricted* see terms below

- **Tab 250 mg – 1% DV Sep-17 to 2020** ............................................................. 1.45 28  **Cipflox**
- **Tab 500 mg – 1% DV Sep-17 to 2020** ............................................................. 1.99 28  **Cipflox**
- **Tab 750 mg – 1% DV Sep-17 to 2020** ............................................................. 3.15 28  **Cipflox**
- **Oral liq 50 mg per ml**
- **Oral liq 100 mg per ml**
- **Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021** ................................... 68.20 10  **Cipflox**

→ **Restricted (RS1055)**

Clinical microbiologist or infectious disease specialist

**MOXIFLOXACIN** – *Restricted* see terms below

- **Tab 400 mg** ..................................................................................................... 52.00 5  **Avelox**
- **Inj 1.6 mg per ml, 250 ml bottle** ..................................................................... 70.00 1  **Avelox IV 400**

→ **Restricted (RS1644)**

**Initiation – Mycobacterium infection**

Infectious disease specialist, clinical microbiologist or respiratory specialist

Any of the following:

1. Both:
   1.1 Active tuberculosis; and
   1.2 Any of the following:
      1.2.1 Documented resistance to one or more first-line medications; or
      1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
      1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
      1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
      1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
   2. Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or
   3. Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

**Initiation – Pneumonia**

Infectious disease specialist or clinical microbiologist

Either:

1. Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
2. Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

**Initiation – Penetrating eye injury**

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury.

**Initiation – Mycoplasma genitalium**

All of the following:

1. Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and
2. Either:
   2.1 Has tried and failed to clear infection using azithromycin; or
   2.2 Has laboratory confirmed azithromycin resistance; and
3. Treatment is only for 7 days.

**NORFLOXACIN**

Tab 400 mg ..................................................................................................... 135.00 100  **Arrow-Norfloxacin**
### Tetracyclines

**DEMECLOCYCLINE HYDROCHLORIDE**
- Tab 150 mg
- Cap 150 mg
- Cap 300 mg

**DOXYCYCLINE**
- Tab 50 mg – **Restricted**: For continuation only
  - Tab 100 mg ................................................................. 64.43 500 Doxine
  - Inj 5 mg per ml, 20 ml vial

**MINOCYCLINE**
- Tab 50 mg
- Cap 100 mg – **Restricted**: For continuation only

**TETRACYCLINE**
- Tab 250 mg
- Cap 500 mg ................................................................. 46.00 30 Tetracyclin Wolff

**TIGECYCLINE** – **Restricted** see terms below
- Inj 50 mg vial
- **Restricted** (RS1059)
  
  Clinical microbiologist or infectious disease specialist

### Other Antibacterials

**AZTREONAM** – **Restricted** see terms below
- Inj 1 g vial ................................................................. 182.46 5 Azactam
- **Restricted** (RS1277)
  
  Clinical microbiologist or infectious disease specialist

**CHLORAMPHENICOL** – **Restricted** see terms below
- Inj 1 g vial
- **Restricted** (RS1277)
  
  Clinical microbiologist or infectious disease specialist

**CLINDAMYCIN** – **Restricted** see terms below
- Cap 150 mg ................................................................. 4.10 16 Clindamycin ABM
- Oral liq 15 mg per ml
- Inj 150 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022 ........................................... 39.00 10 Dalacin C
- **Restricted** (RS1061)
  
  Clinical microbiologist or infectious disease specialist

**COLISTIN SULPHOMETHATE [COLESTIMETHATE]** – **Restricted** see terms below
- Inj 150 mg per ml, 1 ml vial...................................................... 65.00 1 Colistin-Link
- **Restricted** (RS1062)
  
  Clinical microbiologist, infectious disease specialist or respiratory specialist

**DAPTOMYCIN** – **Restricted** see terms below
- Inj 350 mg vial ........................................................................ 175.16 1 Cubicin
- Inj 500 mg vial ........................................................................ 243.52 1 Cubicin
  
  (Cubicin Inj 350 mg vial to be delisted 1 October 2019)
- **Restricted** (RS1063)
  
  Clinical microbiologist or infectious disease specialist

**FOSFOMYCIN** – **Restricted** see terms on the next page
- Powder for oral solution, 3 g sachet
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Quantity</th>
<th>Unit Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HEXAMINE HIPPURATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 g</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LINCOMYCIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LINEZOLID</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg – 1% DV Oct-18 to 2021</td>
<td>553.77</td>
<td>10 Zyvox</td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml – 1% DV Dec-18 to 2021</td>
<td>1,879.00</td>
<td>150 ml Zyvox</td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021</td>
<td>18.50</td>
<td>1 Linezolid Kabi</td>
<td></td>
</tr>
<tr>
<td><strong>NITROFURANTOIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Apr-19 to 2021</td>
<td>22.20</td>
<td>100 Nifuran</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Apr-19 to 2021</td>
<td>37.50</td>
<td>100 Nifuran</td>
<td></td>
</tr>
<tr>
<td><strong>PIVMECILLINAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM FUSIDATE [FUSIDIC ACID]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Jun-17 to 2020</td>
<td>34.50</td>
<td>12 Fucidin</td>
<td></td>
</tr>
<tr>
<td><strong>SULPHADIAZINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TEICOPLANIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 400 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRIMETHOPRIM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Oct-18 to 2021</td>
<td>16.50</td>
<td>50 TMP</td>
<td></td>
</tr>
<tr>
<td><strong>TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 80 mg with sulphamethoxazole 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020</td>
<td>2.97</td>
<td>100 ml Deprim</td>
<td></td>
</tr>
<tr>
<td>Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>VANCOMYCIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>2.37</td>
<td>1 Mylan</td>
<td></td>
</tr>
</tbody>
</table>
### Antifungals

#### Imidazoles

**KETOCONAZOLE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg</td>
<td>$1410</td>
<td>10 AmBisome</td>
</tr>
</tbody>
</table>

- Restricted (RS1410)

Oncologist

#### Polyene Antimycotics

**AMPHOTERICIN B**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj (liposomal) 50 mg vial</td>
<td>$3,450.00</td>
<td>10 AmBisome</td>
</tr>
</tbody>
</table>

- Restricted (RS1071)

Initiation

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:

1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg vial</td>
<td>$1071.00</td>
<td>10 AmBisome</td>
</tr>
</tbody>
</table>

- Restricted (RS1072)

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

**NYSTATIN**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500,000 u</td>
<td>$17.09</td>
<td>50 Nilstat</td>
</tr>
<tr>
<td>Cap 500,000 u</td>
<td>$15.47</td>
<td>50 Nilstat</td>
</tr>
</tbody>
</table>

#### Triazoles

**FLUCONAZOLE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 50 mg – 1% DV Feb-18 to 2020</td>
<td>$2.09</td>
<td>28 Mylan</td>
</tr>
<tr>
<td>Cap 150 mg – 1% DV Feb-18 to 2020</td>
<td>$0.33</td>
<td>1 Mylan</td>
</tr>
<tr>
<td>Cap 200 mg – 1% DV Feb-18 to 2020</td>
<td>$5.08</td>
<td>28 Mylan</td>
</tr>
<tr>
<td>Oral liquid 50 mg per 5 ml</td>
<td>$98.50</td>
<td>35 ml Diflucan</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 50 ml vial – 1% DV Oct-19 to 2022</td>
<td>$2.80</td>
<td>1 Fluconazole-Claris</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Oct-19 to 2022</td>
<td>$3.45</td>
<td>1 Fluconazole-Claris</td>
</tr>
</tbody>
</table>

- Restricted (RS1072)

Consultant

**ITRACONAZOLE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 100 mg</td>
<td>$2.79</td>
<td>15 Itrazole</td>
</tr>
<tr>
<td>Oral liquid 10 mg per ml</td>
<td>$869.86</td>
<td>24 Noxafil</td>
</tr>
</tbody>
</table>

- Restricted (RS1073)

Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist

**POSACONAZOLE** – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab modified-release 100 mg</td>
<td>$869.86</td>
<td>24 Noxafil</td>
</tr>
<tr>
<td>Oral liq 40 mg per ml</td>
<td>$761.13</td>
<td>105 ml Noxafil</td>
</tr>
</tbody>
</table>

*Item restricted (see ➝ above); Item restricted (see ➝ below)*

e.g. Brand indicates brand example only. It is not a contracted product.
**Restricted (RS1074)**

**Initiation**
Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

1. Either:
   1.1 Patient has acute myeloid leukaemia; or
   1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
2. Patient is to be treated with high dose remission induction therapy or re-induction therapy.

**Continuation**
Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

1. Patient has previously received posaconazole prophylaxis during remission induction therapy; and
2. Any of the following:
   2.1 Patient is to be treated with high dose remission re-induction therapy; or
   2.2 Patient is to be treated with high dose consolidation therapy; or
   2.3 Patient is receiving a high risk stem cell transplant.

**VORICONAZOLE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
<td>91.00</td>
<td>Vttack</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Sep-18 to 2021</td>
<td>350.00</td>
<td>Vttack</td>
</tr>
<tr>
<td>Powder for oral suspension 40 mg per ml – 1% DV Dec-18 to 2021</td>
<td>1,437.00</td>
<td>Vfend</td>
</tr>
<tr>
<td>Inj 200 mg vial – 1% DV Oct-19 to 2022</td>
<td>44.00</td>
<td>Neo Health</td>
</tr>
</tbody>
</table>

**Restricted (RS1075)**

**Initiation – Proven or probable aspergillus infection**
Clinical microbiologist, haematologist or infectious disease specialist

Both:

1. Patient is immunocompromised; and
2. Patient has proven or probable invasive aspergillus infection.

**Initiation – Possible aspergillus infection**
Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and
2. Patient has possible invasive aspergillus infection; and
3. A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

**Initiation – Resistant candidiasis infections and other moulds**
Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and
2. Either:
   2.1 Patient has fluconazole resistant candidiasis; or
   2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
3. A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.
INFECTIONS

Other Antifungals

CASPOFUNGIN – Restricted see terms below

- Inj 50 mg vial – 1% DV Dec-19 to 2022 .......................................................... 667.50 1 Cancidas
  220.28 Max Health
- Inj 70 mg vial – 1% DV Dec-19 to 2022 .......................................................... 862.50 1 Cancidas
  284.63 Max Health

(Cancidas Inj 50 mg vial to be delisted 1 December 2019)
(Cancidas Inj 70 mg vial to be delisted 1 December 2019)

- Restricted (RS1076)

Initiation

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:

1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

FLUCYTOSINE – Restricted see terms below

- Cap 500 mg

- Restricted (RS1279)

Clinical microbiologist or infectious disease specialist

TERBINAFINE

Tab 250 mg – 1% DV Jan-18 to 2020 .......................................................... 1.33 14 Deolate

Antimycobacterials

Antileprotics

CLOFAZIMINE – Restricted see terms below

- Cap 50 mg

- Restricted (RS1077)

Clinical microbiologist, dermatologist or infectious disease specialist

DAPSONE – Restricted see terms below

- Tab 25 mg ..................................................................................................... 268.50 100 Dapsone
- Tab 100 mg ................................................................................................... 329.50 100 Dapsone

- Restricted (RS1078)

Clinical microbiologist, dermatologist or infectious disease specialist

Antituberculotics

CYCLOSERINE – Restricted see terms below

- Cap 250 mg

- Restricted (RS1079)

Clinical microbiologist, infectious disease specialist or respiratory specialist

ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below

- Tab 100 mg
- Tab 400 mg ..................................................................................................... 49.34 56 Myambutol

- Restricted (RS1080)

Clinical microbiologist, infectious disease specialist or respiratory specialist
### INFECTIONS

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### ISONIAZID – *Restricted* see terms below

- **Tab 100 mg – 1% DV Oct-18 to 2021**
  - **$22.00**
  - **100**
  - **PSM**

- **Restricted (RS1281)**
  - Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician

#### ISONIAZID WITH RIFAMPICIN – *Restricted* see terms below

- **Tab 100 mg with rifampicin 150 mg – 1% DV Sep-18 to 2021**
  - **$85.54**
  - **100**
  - **Rifinah**

- **Tab 150 mg with rifampicin 300 mg – 1% DV Sep-18 to 2021**
  - **$170.60**
  - **100**
  - **Rifinah**

- **Restricted (RS1282)**
  - Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician

#### PARA-AMINOSALICYLIC ACID – *Restricted* see terms below

- **Grans for oral liq 4 g**
  - **$280.00**
  - **30**
  - **Paser**

- **Restricted (RS1083)**
  - Clinical microbiologist, infectious disease specialist or respiratory specialist

#### PROTIONAMIDE – *Restricted* see terms below

- **Tab 250 mg**
  - **$305.00**
  - **100**
  - **Peteha**

- **Restricted (RS1084)**
  - Clinical microbiologist, infectious disease specialist or respiratory specialist

#### PYRAZINAMIDE – *Restricted* see terms below

- **Tab 500 mg**

#### RIFABUTIN – *Restricted* see terms below

- **Cap 150 mg**
  - **$275.00**
  - **30**
  - **Mycobutin**

- **Restricted (RS1086)**
  - Clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist

#### RIFAMPICIN – *Restricted* see terms below

- **Cap 150 mg – 1% DV Sep-17 to 2020**
  - **$55.75**
  - **100**
  - **Rifadin**

- **Cap 300 mg – 1% DV Sep-17 to 2020**
  - **$116.25**
  - **100**
  - **Rifadin**

- **Oral liq 100 mg per 5 ml – 1% DV Sep-17 to 2020**
  - **$12.00**
  - **60 ml**
  - **Rifadin**

- **Inj 600 mg vial – 1% DV Sep-17 to 2020**
  - **$128.85**
  - **1**
  - **Rifadin**

- **Restricted (RS1087)**
  - Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician

### Antiparasitics

#### Anthelmintics

#### ALBENDAZOLE – *Restricted* see terms below

- **Tab 200 mg**
- **Tab 400 mg**

- **Restricted (RS1088)**
  - Clinical microbiologist or infectious disease specialist

#### IVERMECTIN – *Restricted* see terms below

- **Tab 3 mg**

- **Restricted (RS1283)**
  - Clinical microbiologist, dermatologist or infectious disease specialist

#### MEBENDAZOLE

- **Tab 100 mg**
- **Oral liq 100 mg per 5 ml**

- **$24.19**
- **24**
- **De-Worm**

---
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

PRAZIQUANTEL
Tab 600 mg

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE – Restricted see terms below

- Tab 20 mg with lumefantrine 120 mg
  - Restricted (RS1090)
  Clinical microbiologist or infectious disease specialist

ARTESUNATE – Restricted see terms below

- Inj 60 mg vial
  - Restricted (RS1091)
  Clinical microbiologist or infectious disease specialist

ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restricted see terms below

- Tab 62.5 mg with proguanil hydrochloride 25 mg
  - Restricted (RS1092)
  Clinical microbiologist or infectious disease specialist

CHLOROQUINE PHOSPHATE – Restricted see terms below

- Tab 250 mg
  - Restricted (RS1093)
  Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist

MEFLOQUINE – Restricted see terms below

- Tab 250 mg
  - Restricted (RS1094)
  Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist

METRONIDAZOLE

- Tab 200 mg
  - Restricted
  Clinical microbiologist or infectious disease specialist

- Tab 400 mg
  - Restricted
  Clinical microbiologist or infectious disease specialist

- Oral liq benzoate 200 mg per 5 ml
  - Restricted
  Clinical microbiologist or infectious disease specialist

- Inj 5 mg per ml, 100 ml bottle
  - Restricted
  Clinical microbiologist or infectious disease specialist

- Inj 5 mg per ml, 100 ml bag
  - Restricted
  Clinical microbiologist or infectious disease specialist

- Suppos 500 mg
  - Restricted
  Clinical microbiologist or infectious disease specialist

NITAZOXANIDE – Restricted see terms below

- Tab 500 mg
  - Restricted (RS1095)
  Clinical microbiologist or infectious disease specialist

- Oral liq 100 mg per 5 ml
  - Restricted
  Clinical microbiologist or infectious disease specialist

ORNIDAZOLE
Tab 500 mg

PENTAMIDINE ISETHIONATE – Restricted see terms below

- Inj 300 mg vial
  - Restricted (RS1096)
  Clinical microbiologist or infectious disease specialist

- Tab 7.5 mg
  - Restricted (RS1097)
  Clinical microbiologist or infectious disease specialist

PRIMAQUINE PHOSPHATE – Restricted see terms below

- Tab 7.5 mg
## Antiretrovirals

### Non-Nucleoside Reverse Transcriptase Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PYRIMETHAMINE</strong> – Restricted see terms below</td>
<td>Tab 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▶ Restricted (RS1098)</td>
<td>Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>QUININE DIHYDROCHLORIDE</strong> – Restricted see terms below</td>
<td>Tab 60 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▶ Restricted (RS1099)</td>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>QUININE SULPHATE</strong></td>
<td>Tab 300 mg</td>
<td>...............................................................61.91 500 Q 300</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM STIBOGLUCONATE</strong>   – Restricted see terms below</td>
<td>Tab 100 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▶ Restricted (RS1100)</td>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SPIRAMYCIN</strong> – Restricted see terms below</td>
<td>Tab 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▶ Restricted (RS1101)</td>
<td>Maternal-foetal medicine specialist</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antiretrovirals

#### Non-Nucleoside Reverse Transcriptase Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ETRAVIRINE</strong> – Restricted see terms above</td>
<td>Tab 200 mg</td>
<td>...............................................................770.00 60</td>
<td></td>
<td>Intence</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**INFECTIONS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
</table>

**NEVIRAPINE – Restricted see terms on the previous page**

- **Tab 200 mg – 1% DV Sep-18 to 2021** .........................................................60.00 60 **Nevirapine Alphapharm**
- **Oral suspension 10 mg per ml** .................................................................203.55 240 ml **Viramune Suspension**

**Nucleoside Reverse Transcriptase Inhibitors**

**Initiation – Confirmed HIV**

Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   - Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   - Patient has shared intravenous injecting equipment with a known HIV positive person; or
   - Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

**ABACAVIR SULPHATE – Restricted see terms above**

- **Tab 300 mg – 1% DV Jul-19 to 2022** .........................................................180.00 60 **Ziagen**
- **Oral liq 20 mg per ml** ................................................................................256.31 240 ml **Ziagen**

**ABACAVIR SULPHATE WITH LAMIVUDINE – Restricted see terms above**

- **Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022** .................63.00 30 **Kivexa**

**EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Restricted see terms above**

- **Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – 1% DV Jun-19 to 2022** .........................106.88 30 **Mylan**

**EMTRICITABINE – Restricted see terms above**

- **Cap 200 mg – 1% DV Jul-19 to 2022** .........................................................307.20 30 **Emtriva**

**LAMIVUDINE – Restricted see terms above**

- **Oral liq 10 mg per ml**
- **Cap 30 mg**
- **Cap 40 mg**
- **Powder for oral soln 1 mg per ml**

**STAVUDINE – Restricted see terms above**

- **Cap 30 mg**
- **Cap 40 mg**
- **Powder for oral soln 1 mg per ml**

**ZIDOVUDINE [AZT] – Restricted see terms above**

- **Cap 100 mg** .................................................................152.25 100 **Retrovir**
- **Oral liq 10 mg per ml** .................................................................30.45 200 ml **Retrovir**
- **Inj 10 mg per ml, 20 ml vial** .........................................................750.00 5 **Retrovir IV**

**ZIDOVUDINE [AZT] WITH LAMIVUDINE – Restricted see terms above**

- **Tab 300 mg with lamivudine 150 mg – 1% DV Sep-17 to 2020** ...............33.00 60 **Alphapharm**

---

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Protease Inhibitors

**Restricted (RS1573)**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:
- 1. Prevention of maternal foetal transmission; or
- 2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:
- 1. Treatment course to be initiated within 72 hours post exposure; and
- 2. Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**
Patient has percutaneous exposure to blood known to be HIV positive.

**ATAZANAVIR SULPHATE** – Restricted see terms above
- Cap 150 mg – 1% DV Jun-19 to 2022..................................................................141.68 60 Teva
- Cap 200 mg – 1% DV Jun-19 to 2022..................................................................188.91 60 Teva

**DARUNAVIR** – Restricted see terms above
- Tab 400 mg – 1% DV Jun-17 to 2020..................................................................335.00 60 Prezista
- Tab 600 mg – 1% DV Jun-17 to 2020..................................................................476.00 60 Prezista

**INDINAVIR** – Restricted see terms above
- Cap 200 mg
- Cap 400 mg

**LOPINAVIR WITH RITONAVIR** – Restricted see terms above
- Tab 100 mg with ritonavir 25 mg........................................................................183.75 60 Kaletra
- Tab 200 mg with ritonavir 50 mg – 1% DV Sep-17 to 2020..............................463.00 120 Kaletra
- Oral liq 80 mg with ritonavir 20 mg per ml.........................................................735.00 300 ml Kaletra

**RITONAVIR** – Restricted see terms above
- Tab 100 mg – 1% DV Jul-19 to 2022..................................................................43.31 30 Norvir

### Strand Transfer Inhibitors

**Restricted (RS1574)**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:
- 1. Prevention of maternal foetal transmission; or
- 2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

**Dolutegravir – Restricted** see terms on the previous page

- **Tab 50 mg**  
  $1,090.00  
  30 Tivicay

**Raltegravir Potassium – Restricted** see terms on the previous page

- **Tab 400 mg**  
  $1,090.00  
  60 Isentress

**Antivirals**

### Hepatitis B

**Adefovir Dipivoxil – Restricted** see terms below

- **Tab 10 mg**  
  $670.00  
  30 Hepsera

**Entecavir**

- **Tab 0.5 mg**  
  $52.00  
  30 Entecavir Sandoz

**Lamivudine**

- **Tab 100 mg**  
  $4.20  
  28 Zetam

**Oral liq 5 mg per ml**  
  $270.00  
  240 ml Zeffix

**Tenofovir Disoproxil**

- **Tab 245 mg** (300.6 mg as a succinate)  
  $38.10  
  30 Tenofovir Disoproxil Teva

### Hepatitis C

**Glecaprevir with Pibrentasvir**

Note: the supply of treatment is via PHARMAC’s approved direct distribution supply. Further details can be found on PHARMAC’s website https://www.pharmac.govt.nz/hepatitis-c-treatments/.

- **Tab 100 mg with pibrentasvir 40 mg**  
  $24,750.00  
  84 Maviret

**e.g. Brand** indicates brand example only. It is not a contracted product.
LEDIPASVIR WITH SOFOSBUVIR – **Restricted** see terms below

- **Tab 90 mg with sofosbuvir 400 mg**………………………………………………24,363.46  28 Harvoni

**Note:** Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

### Herpesviridae

**ACICLOVIR**

- **Tab dispersible 200 mg – 1% DV Oct-19 to 2022** ……………………………1.60  25 Lovir
- **Tab dispersible 400 mg – 1% DV Oct-19 to 2022** ……………………………5.38  56 Lovir
- **Tab dispersible 800 mg – 1% DV Oct-19 to 2022** ……………………………5.98  35 Lovir
- **Inj 250 mg vial – 1% DV Sep-18 to 2021** ………………………………………..9.60  5 Aciclovir-Claris

**CIDOFOVIR – **Restricted** see terms below

- **Inj 75 mg per ml, 5 ml vial**
  - **Restricted (RS1108)**
    - Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

**FOSCARNET SODIUM – **Restricted** see terms below

- **Inj 24 mg per ml, 250 ml bottle**
  - **Restricted (RS1109)**
    - Clinical microbiologist or infectious disease specialist

**GANCICLOVIR – **Restricted** see terms below

- **Inj 500 mg vial**…………………………………………………………………………....380.00  5 Cymevene
  - **Restricted (RS1110)**
    - Clinical microbiologist or infectious disease specialist

**VALACICLOVIR**

- **Tab 500 mg – 1% DV Sep-18 to 2021**………………………………………………5.75  30 Vaclovir
- **Tab 1,000 mg – 1% DV Sep-18 to 2021**…………………………………………11.35  30 Vaclovir

**VALGANCICLOVIR – **Restricted** see terms below

- **Tab 450 mg – 1% DV May-19 to 2021**…………………………………………..225.00  60 Valganciclovir Mylan
  - **Restricted (RS1112)**

**Initiation – Transplant cytomegalovirus prophylaxis**

*Limited to 3 months* treatment

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Initiation – Lung transplant cytomegalovirus prophylaxis**

*Limited to 6 months* treatment

Both:

1. Patient has undergone a lung transplant; and
2. Either:
   2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
   2.2 The recipient is cytomegalovirus positive.

**Initiation – Cytomegalovirus in immunocompromised patients**

Both:

1. Patient is immunocompromised; and
2. Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.
HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – **Restricted** see terms below

★ Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
- 1% DV Jun-19 to 2022 ........................................................................61.15 30  Teva

**Restricted** (RS1616)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Initiation – Pre-exposure prophylaxis

*Re-assessment required after 3 months*

Both:

1. Patient has tested HIV negative; and
2. Either:
   2.1 All of the following:
      2.1.1 Patient is male or transgender; and
      2.1.2 Patient has sex with men; and
      2.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
   2.1.4 Any of the following:
      2.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
      2.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
      2.1.4.3 Patient has used methamphetamine in the last three months; or
   2.2 All of the following:
      2.2.1 Patient has a regular partner who has HIV infection; and
      2.2.2 Partner is either not on treatment or has a detectable viral load; and
      2.2.3 Condoms have not been consistently used.

Continuation – Pre-exposure prophylaxis

*Re-assessment required after 3 months*

All of the following:

1. Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis; and
2. Patient has undergone testing for HIV, syphilis, and a full STI screen in the previous two weeks; and
3. Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months; and
4. Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce...
continued...

those risks; and
5 Patient has tested HIV negative; and
6 Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more
casual male partners in the last 3 months; or
         6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         6.1.4.3 Patient has used methamphetamine in the last three months; or
   6.2 All of the following:
      6.2.1 Patient has a regular partner who has HIV infection; and
      6.2.2 Partner is either not on treatment or has a detectable viral load; and
      6.2.3 Condoms have not been consistently used.

**Influenza**

OSELTMIVIR — **Restricted** see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new
course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Tab 75 mg
- Powder for oral suspension 6 mg per ml
  - **Restricted** (RS1307)

**Initiation**

Either:
1 Only for hospitalised patient with known or suspected influenza; or
2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new
course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Powder for inhalation 5 mg
  - **Restricted** (RS1369)

**Initiation**

Either:
1 Only for hospitalised patient with known or suspected influenza; or
2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

**Immune Modulators**

INTERFERON ALFA-2A
- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B
- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INTERFERON GAMMA – Restricted see terms below

Inj 100 mcg in 0.5 ml vial

Restricted (RS1113)

Initiation
Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – Restricted see terms below

Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020

500.00 4 Pegasys

Restricted (RS1340)

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Limited to 48 weeks treatment

Any of the following:

1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
2. Patient has chronic hepatitis C and is co-infected with HIV; or
3. Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – Chronic hepatitis C - genotype 1 infection

Gastroenterologist, infectious disease specialist or general physician

Re-assessment required after 48 weeks

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Either:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; and
4. Patient is to be treated in combination with boceprevir.

Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior

Gastroenterologist, infectious disease specialist or general physician

Limited to 48 weeks treatment

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Any of the following:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; or
   3.3 Patient received interferon treatment prior to 2004; and
4. Patient is to be treated in combination with boceprevir.

Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Limited to 6 months treatment

Patient has chronic hepatitis C, genotype 2 or 3 infection.

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

Limited to 48 weeks treatment

All of the following:

1. Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and

continued…
continued...

2 Patient is Hepatitis B treatment-naive; and
3 ALT > 2 times Upper Limit of Normal; and
4 HBV DNA < 10 log10 IU/ml; and
5 Either:
   5.1 HBeAg positive; or
   5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
6 Compensated liver disease; and
7 No continuing alcohol abuse or intravenous drug use; and
8 Not co-infected with HCV, HIV or HDV; and
9 Neither ALT nor AST > 10 times upper limit of normal; and
10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.
The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.
In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
Pegylated Interferon alfa-2a is not approved for use in children.
### Anticholinesterases

**EDROPHONIUM CHLORIDE** – **Restricted** see terms below  
- Inj 10 mg per ml, 15 ml vial  
- Inj 10 mg per ml, 1 ml ampoule  
  → **Restricted (RS1015)**

#### Initiation
For the diagnosis of myasthenia gravis.

**NEOSTIGMINE METILSULFATE**  
Inj 2.5 mg per ml, 1 ml ampoule – **1% DV Nov-17 to 2020**.................98.00 50 AstraZeneca  
**NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE**  
Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule........20.90 10 Max Health  
**PYRIDOSTIGMINE BROMIDE**  
Tab 60 mg .........................................................................................42.79 100 Mestinon

### Antirheumatoid Agents

**HYDROXYCHLOROQUINE**  
Tab 200 mg – **1% DV Sep-18 to 2021**........................................7.98 100 Plaquenil  
**LEFLUNOMIDE**  
Tab 10 mg – **1% DV Jun-17 to 2020**.................................2.90 30 Apo-Leflunomide  
Tab 20 mg – **1% DV Jun-17 to 2020**.................................2.90 30 Apo-Leflunomide  
**PENICILLAMINE**  
Tab 125 mg....................................................................................67.23 100 D-Penamine  
Tab 250 mg..................................................................................110.12 100 D-Penamine  
**SODIUM AUROTHIOMALATE**  
Inj 10 mg in 0.5 ml ampoule  
Inj 20 mg in 0.5 ml ampoule  
Inj 50 mg in 0.5 ml ampoule

### Drugs Affecting Bone Metabolism

#### Bisphosphonates

**ALENDRONATE SODIUM**  
Tab 70 mg – **1% DV Apr-19 to 2022**........................................2.44 4 Fosamax  
**ALENDRONATE SODIUM WITH COLECALCIFEROL**  
Tab 70 mg with colecalciferol 5,600 lu – **1% DV Apr-19 to 2022**.........1.51 4 Fosamax Plus  
**PAMIDRONATE DISODIUM**  
Inj 3 mg per ml, 10 ml vial – **1% DV Sep-17 to 2020**....................5.98 1 Pamisol  
Inj 6 mg per ml, 10 ml vial – **1% DV Sep-17 to 2020**....................15.02 1 Pamisol  
Inj 9 mg per ml, 10 ml vial – **1% DV Sep-17 to 2020**....................17.05 1 Pamisol  
**RISEDRONATE SODIUM**  
Tab 35 mg – **1% DV Oct-19 to 2022**........................................3.10 4 Risedronate Sandoz  
**ZOLEDRONIC ACID**  
Inj 5 mg per 100 ml, vial – **1% DV Oct-19 to 2022**...................60.00 100 ml Aclasta

---

*Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)  
e.g. Brand indicates brand example only. It is not a contracted product.*
**Restricted (RS1663)**

**Initiation – Inherited bone fragility disorders**
Any specialist
Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

**Initiation – Osteoporosis**
Any specialist

*Therapy limited to 3 doses*

Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

**Initiation – glucocorticosteroid therapy**
Any specialist

*Re-assessment required after 12 months*

All of the following:

1. The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

3. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Continuation – glucocorticosteroid therapy**
Any specialist

*Re-assessment required after 12 months*

Both:

1. The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Initiation – Paget’s disease**
Any specialist

*Re-assessment required after 12 months*

All of the following:

1. Paget’s disease; and

continued…

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

2 Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – Paget’s disease

Any specialist

Re-assessment required after 12 months

Both:

1 Any of the following:
   1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
   1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
   1.3 Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DENOSUMAB – Restricted see terms below

 semua Inj 60 mg prefilled syringe.................................................................326.00 1 Prolia

Restricted (RS1665)

Initiation

All of the following:

1 The patient has severe, established osteoporosis; and

2 Either:
   2.1 The patient is female and postmenopausal; or
   2.2 The patient is male or non-binary; and

3 Any of the following:
   3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or

continued…

e.g. Brand indicates brand example only. It is not a contracted product.
continued...

3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or
densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
3.4 Documented T-Score less than or equal to -3.0 (see Note); or
3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm
(e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February
2019 or has had a Special Authority approval for raloxifene; and

4 Zoledronic acid is contraindicated because the patient’s creatinine clearance is less than 35 mL/min; and
5 The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a
funded antiresorptive agent at adequate doses (see Notes); and
6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or
teriparatide.

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA).
Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture
demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD
measurement for treatment with denosumab.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO
definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below
-2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical
forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a
fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body
relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral
body above or below the affected vertebral body.
5 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate
sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly;
raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment
withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that
the patient achieves the minimum requirement of 12 months’ continuous therapy.

RALOXIFENE – Restricted see terms below
Tab 60 mg.......................................................................................................53.76 28 Evista

Initiation
Any of the following:

1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)
greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or
equal to -2.5) (see Notes); or
2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or
densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is
unlikely that this provision would apply to many patients under 75 years of age; or
3 History of two significant osteoporotic fractures demonstrated radiologically; or
4 Documented T-Score greater than or equal to -3.0 (see Notes); or
5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g.
FRAX or Garvan) which incorporates BMD measurements (see Notes); or

continued...
continued...

6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – Restricted see terms below

Inj 250 mcg per ml, 2.4 ml cartridge .............................................................. 490.00 1 Forteo

Initiation

Limited to 18 months treatment

All of the following:

1 The patient has severe, established osteoporosis; and

2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and

3 The patient has had two or more fractures due to minimal trauma; and

4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Jan-18 to 2020 ................................................................. 4.54 500 DP-Allopurinol
Tab 300 mg – 1% DV Jan-18 to 2020 ................................................................. 10.35 500 DP-Allopurinol
MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**BENZBROMARONE** – Restricted see terms below

- Tab 100 mg .................................................................................................................. 45.00 100 Benzbromaron AL 100

**FEBUXOSTAT** – Restricted see terms below

- Tab 80 mg .................................................................................................................. 39.50 28 Adenuric
- Tab 120 mg .................................................................................................................. 39.50 28 Adenuric

Initiation

Any specialist

All of the following:

1. Patient has been diagnosed with gout; and
2. Any of the following:

   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

   2.3 Both:

       2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and

       2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or

2.4 All of the following:

   2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and

   2.4.2 Allopurinol is contraindicated; and

   2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

3. The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

**COLCHICINE**

Tab 500 mcg – 1% DV Jan-19 to 2021 ............................................................... 9.58 100 Colgout

**FEBUXOSTAT** – Restricted see terms below

- Tab 80 mg .................................................................................................................. 39.50 28 Adenuric
- Tab 120 mg .................................................................................................................. 39.50 28 Adenuric

Initiation

Any specialist

Both:

1. Patient has been diagnosed with gout; and
2. Any of the following:

   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

   2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be...
continued…

The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

### Muscle Relaxants and Related Agents

**ATRACURIUM BESYLATE**
- Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Jun-18 to 2021......................... 10.00 5 Tracrium
- Inj 10 mg per ml, 5 ml ampoule – 1% DV Jun-18 to 2021......................... 12.50 5 Tracrium

**BACLOFEN**
- Tab 10 mg – 1% DV Oct-18 to 2021.............................................................. 4.20 100 Pacifen
- Oral liq 1 mg per ml...................................................................................... 11.55 1 Lioresal Intrathecal
- Inj 2 mg per ml, 5 ml ampoule – 1% DV Apr-19 to 2021.......................... 372.98 5 Medsurge

**CLOSTRIDIUM BOTULINUM TYPE A TOXIN**
- Inj 100 u vial.............................................................................................. 467.50 1 Botox
- Inj 300 u vial.............................................................................................. 388.50 1 Dysport
- Inj 500 u vial.............................................................................................. 1,295.00 2 Dysport

**DANTROLENE**
- Cap 25 mg..................................................................................................... 65.00 100 Dantrium
- Cap 50 mg..................................................................................................... 77.00 100 Dantrium
- Inj 20 mg vial............................................................................................... 800.00 6 Dantrium IV

**MIVACURIUM CHLORIDE**
- Inj 2 mg per ml, 5 ml ampoule.................................................................... 33.92 5 Mivacron
- Inj 2 mg per ml, 10 ml ampoule................................................................. 67.17 5 Mivacron

**ORPHENADRINE CITRATE**
- Tab 100 mg – 1% DV Jun-18 to 2021........................................................... 18.54 100 Norflex

**PANCURONIUM BROMIDE**
- Inj 2 mg per ml, 2 ml ampoule.................................................................. 260.00 50 AstraZeneca

**ROCURONIUM BROMIDE**
- Inj 10 mg per ml, 5 ml vial....................................................................... 25.95 10 DBL Rocuronium Bromide

**SUXAMETHONIUM CHLORIDE**
- Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020......................... 78.00 50 AstraZeneca

**VECURONIUM BROMIDE**
- Inj 10 mg vial

### Reversers of Neuromuscular Blockade

**SUGAMMADEX – Restricted** see terms on the next page
- Inj 100 mg per ml, 2 ml vial................................................................. 1,200.00 10 Bridion
- Inj 100 mg per ml, 5 ml vial................................................................. 3,000.00 10 Bridion

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Non-Steroidal Anti-Inflammatory Drugs

#### CELECOXIB
Note - The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.

- Cap 100 mg .......................................................... 3.63 60 Celecoxib Pfizer
- Cap 200 mg – 1% DV Aug-17 to 2020 .......................... 2.30 30 Celecoxib Pfizer

#### DICLOFENAC SODIUM

- Tab EC 25 mg – 1% DV Oct-18 to 2021 .......................... 1.23 50 Diclofenac Sandoz
- Tab 50 mg dispersible .............................................. 1.50 20 Voltaren D
- Tab EC 50 mg – 1% DV Oct-18 to 2021 .......................... 1.23 50 Diclofenac Sandoz
- Tab long-acting 75 mg – 1% DV Oct-18 to 2021 ......... 22.80 500 Apo-Diclo SR
- Tab long-acting 100 mg – 1% DV Oct-18 to 2021 ........ 25.15 500 Apo-Diclo SR
- Inj 25 mg per ml, 3 ml ampoule ............................... 13.20 5 Voltaren
- Suppos 12.5 mg ...................................................... 2.04 10 Voltaren
- Suppos 25 mg ...................................................... 2.44 10 Voltaren
- Suppos 50 mg ...................................................... 4.22 10 Voltaren
- Suppos 100 mg .................................................. 7.00 10 Voltaren

#### ETORICOXIB – Restricted see terms below

- Tab 30 mg
- Tab 60 mg
- Tab 90 mg
- Tab 120 mg

#### IBUPROFEN

- Tab 200 mg – 1% DV Feb-18 to 2020 .......................... 11.71 1,000 Relieve

- Tab 400 mg – Restricted: For continuation only
- Tab 600 mg – Restricted: For continuation only
- Oral liq 20 mg per ml – 1% DV May-19 to 2021 ........... 1.88 200 ml Ethics
- Inj 5 mg per ml, 2 ml ampoule
- Inj 10 mg per ml, 2 ml vial

#### INDOMETHACIN

- Cap 25 mg
- Cap 50 mg
- Cap long-acting 75 mg
- Inj 1 mg vial
- Suppos 100 mg

---

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

### KEToprofen
- Cap long-acting 200 mg ................................................................. 12.07 28 Oruvail SR

### MEFENAMIC ACID – Restricted: For continuation only
- Cap 250 mg

### NAPROXEN
- Tab 250 mg – 1% DV Dec-18 to 2021 ...................................................... 32.69 500 Noflam 250
- Tab 500 mg – 1% DV Dec-18 to 2021 ...................................................... 22.19 250 Noflam 500
- Tab long-acting 750 mg – 1% DV Oct-18 to 2021 .................................. 6.16 28 Naprosyn SR 750
- Tab long-acting 1 g – 1% DV Oct-18 to 2021 ......................................... 8.21 28 Naprosyn SR 1000

### PARECOXIB
- Inj 40 mg vial ......................................................................................... 100.00 10 Dynastat

### SULINDAC
- Tab 100 mg
- Tab 200 mg

### TENOXICAM
- Tab 20 mg – 1% DV Oct-19 to 2022.......................................................... 9.15 100 Tilcotil
- Inj 20 mg vial ......................................................................................... 9.95 1 AFT

### Topical Products for Joint and Muscular Pain

#### CAPSAICIN – Restricted see terms below
- Crm 0.025% ......................................................................................... 9.95 45 g Zostrix

**Initiation**
- Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.
**Agents for Parkinsonism and Related Disorders**

**Agents for Essential Tremor, Chorea and Related Disorders**

**RILUZOLE** – Restricted see terms below  
Tab 50 mg – 1% DV Aug-18 to 2021.................................130.00 56 Rilutek  

Initiation  
Neurologist or respiratory specialist  
Re-assessment required after 6 months  
All of the following:  
1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and  
2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and  
3 The patient has not undergone a tracheostomy; and  
4 The patient has not experienced respiratory failure; and  
5 Any of the following:  
   5.1 The patient is ambulatory; or  
   5.2 The patient is able to use upper limbs; or  
   5.3 The patient is able to swallow.  

Continuation  
Re-assessment required after 18 months  
All of the following:  
1 The patient has not undergone a tracheostomy; and  
2 The patient has not experienced respiratory failure; and  
3 Any of the following:  
   3.1 The patient is ambulatory; or  
   3.2 The patient is able to use upper limbs; or  
   3.3 The patient is able to swallow.  

**TETRABENAZINE**  
Tab 25 mg – 1% DV Oct-19 to 2022.................................91.10 112 Motetis  

**Anticholinergics**

**BENZATROPINE MESYLATE**  
Tab 2 mg ...........................................................................................................7.99 60 Benztrop  
Inj 1 mg per ml, 2 ml ampoule .................................................................95.00 5 Cogentin  

**PROCYCLIDINE HYDROCHLORIDE**  
Tab 5 mg  

**Dopamine Agonists and Related Agents**

**AMANTADINE HYDROCHLORIDE**  
Cap 100 mg.................................................................38.24 60 Symmetrel  

**APOMORPHINE HYDROCHLORIDE**  
Inj 10 mg per ml, 2 ml ampoule ....................................................119.00 5 Movapo  

**BROMOCRIPTINE**  
Tab 2.5 mg  
Cap 5 mg  

**ENTACAPONE**  
Tab 200 mg – 1% DV Sep-18 to 2021.................................22.00 100 Entapone  

---

Products with Hospital Supply Status (HSS) are in **bold**  
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

#### LEVODOPA WITH BENSERAZIDE
- **Tab dispersible 50 mg with benserazide 12.5 mg**: $13.25 100 Madopar Rapid
- **Cap 50 mg with benserazide 12.5 mg**: $13.75 100 Madopar 62.5
- **Cap 100 mg with benserazide 25 mg**: $15.80 100 Madopar 125
- **Cap long-acting 100 mg with benserazide 25 mg**: $22.85 100 Madopar HBS
- **Cap 200 mg with benserazide 50 mg**: $26.25 100 Madopar 250

#### LEVODOPA WITH CARBIDOPA
- **Tab 100 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020**: $17.97 100 Sinemet
- **Tab long-acting 100 mg with carbidopa 25 mg**: $37.15 100 Sinemet CR
- **Tab 250 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020**: $32.67 100 Sinemet

#### PRAMIPEXOLE HYDROCHLORIDE
- **Tab 0.25 mg – 1% DV Oct-19 to 2022**: $6.12 100 Ramipex
- **Tab 1 mg – 1% DV Oct-19 to 2022**: $20.73 100 Ramipex

#### ROPINIROLE HYDROCHLORIDE
- **Tab 0.25 mg**: $2.78 100 Apo-Ropinirole
- **Tab 1 mg**: $5.00 100 Apo-Ropinirole
- **Tab 2 mg**: $7.72 100 Apo-Ropinirole
- **Tab 5 mg**: $16.51 100 Apo-Ropinirole

#### SELEGILINE HYDROCHLORIDE
- **Tab 5 mg**: $132.50 100 Tasmar

#### TOLCAPONE
- **Tab 100 mg**: $132.50 100 Tasmar

### Anaesthetics

#### General Anaesthetics

#### DESFLURANE
- Soln for inhalation 100%, 240 ml bottle – 1% DV Sep-16 to 2020: $1,350.00 6 Suprane

#### DEXMEDETOMIDINE
- Inj 100 mcg per ml, 2 ml vial – 1% DV Sep-17 to 2020: $357.00 5 Precedex

#### ETOMIDATE
- Inj 2 mg per ml, 10 ml ampoule

#### ISOFLURANE
- Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020: $1,020.00 6 Aerrane

#### KETAMINE
- Inj 1 mg per ml, 100 ml bag: $27.00 1 Biomed
- Inj 10 mg per ml, 10 ml syringe: $14.00 1 Biomed
- Inj 100 mg per ml, 2 ml vial – 1% DV Jan-19 to 2021: $31.50 5 Ketalar

#### METHOHEXITAL SODIUM
- Inj 10 mg per ml, 50 ml vial

#### PROPOFOL
- Inj 10 mg per ml, 20 ml vial – 10% DV Dec-19 to 2022: $4.35 5 Fresofol 1% MCT/LCT
- Inj 10 mg per ml, 50 ml vial: $5.27 10 Fresofol 1% MCT/LCT
- Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022: $19.50 10 Fresofol 1% MCT/LCT

*(Provive MCT-LCT 1% Inj 10 mg per ml, 20 ml vial to be delisted 1 December 2019)*

---

*Item restricted (see ➡️ above); Item restricted (see ➡️ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEVOFLURANE</td>
<td>$840.00</td>
<td>6 Baxter</td>
</tr>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle – <strong>1% DV Sep-16 to 2020</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THIOPENTAL [THIOPENTONE] SODIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Local Anaesthetics

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARTICAINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARTICAINE HYDROCHLORIDE WITH ADRENALINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BENZOCAIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUPIVACAINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 4 ml ampoule – <strong>1% DV Sep-17 to 2020</strong></td>
<td>$50.00</td>
<td>5 Marcair Isobaric</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 20 ml ampoule sterile pack</td>
<td>$29.20</td>
<td>5 Marcair</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule sterile pack</td>
<td>$20.25</td>
<td>5 Marcair</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule sterile pack</td>
<td>$20.70</td>
<td>5 Marcair</td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 200 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 100 ml bag – <strong>1% DV Sep-17 to 2020</strong></td>
<td>$150.00</td>
<td>5 Marcair</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 200 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 500 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – <strong>1% DV Aug-19</strong> to 2022</td>
<td>$94.50</td>
<td>5 Marcair with Adrenaline</td>
</tr>
<tr>
<td>Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – <strong>1% DV Aug-19</strong> to 2022</td>
<td>$80.50</td>
<td>5 Marcair with Adrenaline</td>
</tr>
<tr>
<td>BUPIVACAINE HYDROCHLORIDE WITH FENTANY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
<td>$210.00</td>
<td>10 Bupafen</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag</td>
<td>$210.00</td>
<td>10 Bupafen</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe</td>
<td>$72.00</td>
<td>10 Biomed</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe</td>
<td>$92.00</td>
<td>10 Biomed</td>
</tr>
<tr>
<td>BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5% with glucose 8%, 4 ml ampoule</td>
<td>$38.00</td>
<td>5 Marcair Heavy</td>
</tr>
<tr>
<td>COCAINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paste 5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 15%, 2 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 4%, 2 ml syringe</td>
<td>$25.46</td>
<td>1 Biomed</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COCaine HYDROCHLORIDE WITH ADRENALINE</strong></td>
</tr>
<tr>
<td>Paste 15% with adrenaline 0.06%</td>
</tr>
<tr>
<td>Paste 25% with adrenaline 0.06%</td>
</tr>
<tr>
<td><strong>ETHYL CHLORIDE</strong></td>
</tr>
<tr>
<td>Spray 100%</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE]</strong></td>
</tr>
<tr>
<td>Crm 4%</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Gel 2% – 1% DV Nov-18 to 2021</td>
</tr>
<tr>
<td>Soln 4%</td>
</tr>
<tr>
<td>Spray 10% – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>Oral (gel) soln 2% – 1% DV Oct-17 to 2020</td>
</tr>
<tr>
<td>Inj 1%, 20 ml ampoule, sterile pack</td>
</tr>
<tr>
<td>Inj 2%, 20 ml ampoule, sterile pack</td>
</tr>
<tr>
<td>Inj 1%, 5 ml ampoule</td>
</tr>
<tr>
<td>Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule</td>
</tr>
<tr>
<td>Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>Gel 2%, 10 ml urethral syringe – 1% DV Nov-19 to 2022</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><em>(Pfizer Gel 2%, 10 ml urethral syringe to be delisted 1 November 2019)</em></td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE</strong></td>
</tr>
<tr>
<td>Inj 1% with adrenaline 1:100,000, 5 ml ampoule</td>
</tr>
<tr>
<td>Inj 1% with adrenaline 1:200,000, 20 ml vial</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:200,000, 20 ml vial</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE</strong></td>
</tr>
<tr>
<td>Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Nasal spray 5% with phenylephrine hydrochloride 0.5%</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE</strong></td>
</tr>
<tr>
<td>Crm 2.5% with prilocaine 2.5%</td>
</tr>
<tr>
<td>Patch 25 mcg with prilocaine 25 mcg</td>
</tr>
<tr>
<td>Crm 2.5% with prilocaine 2.5%, 5 g</td>
</tr>
<tr>
<td><strong>MEPIVACAINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Inj 3%, 1.8 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 3%, 2.2 ml dental cartridge</td>
</tr>
<tr>
<td><strong>PRILOCAINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Inj 0.5%, 50 ml vial</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule</td>
</tr>
<tr>
<td><em>(Citanest Inj 2%, 5 ml ampoule to be delisted 1 October 2019)</em></td>
</tr>
<tr>
<td><strong>PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN</strong></td>
</tr>
<tr>
<td>Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge</td>
</tr>
</tbody>
</table>
NERVOUS SYSTEM

ROPIVACAINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Details</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>8.80</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>9.20</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020</td>
<td>29.50</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 200 ml bag – 1% DV Sep-17 to 2020</td>
<td>39.00</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>9.90</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>12.15</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>10.55</td>
<td>Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>15.80</td>
<td>Ropivacaine Kabi</td>
</tr>
</tbody>
</table>

ROPIVACAINE HYDROCHLORIDE WITH FENTANYL

<table>
<thead>
<tr>
<th>Product Details</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Dec-17 to 2020</td>
<td>198.50</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Dec-17 to 2020</td>
<td>270.00</td>
<td>Naropin</td>
</tr>
</tbody>
</table>

TETRACAINE [AMETHOCAINE] HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Details</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 4%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Analgesics

Non-Opioid Analgesics

ASPIRIN
- Tab dispersible 300 mg – 1% DV Oct-19 to 2022 ........................................... 4.50 100 Ethics Aspirin

CAPSAICIN – Restricted see terms below
- Crm 0.075%......................................................................................................... 12.50 45 g Zostrix HP

METHOXYFLURANE – Restricted see terms below
- Soln for inhalation 99.9%, 3 ml bottle

NEFOPAM HYDROCHLORIDE
- Tab 30 mg

PARACETAMOL – Some items restricted see terms below
- Tab soluble 500 mg
- Tab 500 mg
- Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020 ........................................ 5.35 1,000 ml Paracare
- Oral liq 250 mg per 5 ml – 20% DV Aug-18 to 2020 ................................... 5.81 1,000 ml Paracare Double Strength

Paracetamol Kabi
- Inj 10 mg per ml, 100 ml vial – 1% DV Sep-17 to 2020 .................................. 8.40 10
- Suppos 25 mg ................................................................................................... 5.63 20 Biomed
- Suppos 50 mg ................................................................................................... 5.63 20 Biomed
- Suppos 125 mg – 1% DV Nov-18 to 2021 .................................................. 3.29 10 Gacet
- Suppos 250 mg – 1% DV Nov-18 to 2021 .................................................. 3.79 10 Gacet
- Suppos 500 mg – 1% DV Feb-19 to 2021 .................................................. 12.40 50 Gacet

Initiation
- Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Opioid Analgesics

#### ALFENTANIL

- **Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020**
  - Price: $34.38
  - Brand: Hameln

#### CODEINE PHOSPHATE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg</td>
<td>5.75</td>
<td>PSM</td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td>6.80</td>
<td>PSM</td>
</tr>
<tr>
<td>Tab 60 mg</td>
<td>13.50</td>
<td>PSM</td>
</tr>
</tbody>
</table>

#### DIHYDROCODEINE TARTRATE

- **Tab long-acting 60 mg – 1% DV Oct-19 to 2022**
  - Price: $8.60
  - Brand: DHC Continus

#### FENTANYL

- **Inj 10 mcg per ml, 10 ml syringe**
  - Price: $210.00
  - Manufacturer: Biomed

- **Inj 50 mcg per ml, 2 ml ampoule – 1% DV Nov-18 to 2021**
  - Price: $3.56
  - Brand: Boucher and Muir

- **Inj 10 mcg per ml, 50 ml bag**
  - Price: $210.00
  - Brand: Biomed

- **Inj 50 mcg per ml, 10 ml ampoule – 1% DV Nov-18 to 2021**
  - Price: $9.41
  - Brand: Boucher and Muir

- **Inj 20 mcg per ml, 50 ml bag – 1% DV Oct-18 to 2021**
  - Price: $18.74
  - Brand: Biomed

- **Inj 20 mcg per ml, 100 ml bag**
  - Price: $210.00
  - Manufacturer: Biomed

- **Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020**
  - Price: $2.95
  - Manufacturer: Fentanyl Sandoz

- **Patch 25 mcg per hour – 1% DV Oct-17 to 2020**
  - Price: $3.66
  - Manufacturer: Fentanyl Sandoz

- **Patch 50 mcg per hour – 1% DV Oct-17 to 2020**
  - Price: $6.65
  - Manufacturer: Fentanyl Sandoz

- **Patch 75 mcg per hour – 1% DV Oct-17 to 2020**
  - Price: $9.25
  - Manufacturer: Fentanyl Sandoz

- **Patch 100 mcg per hour – 1% DV Oct-17 to 2020**
  - Price: $11.40
  - Manufacturer: Fentanyl Sandoz

#### METHADONE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Sep-19 to 2022</td>
<td>1.40</td>
<td>Methatabs</td>
</tr>
<tr>
<td>Tab 5 mg - bottle pack</td>
<td>1.40</td>
<td>Methatabs</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-18 to 2021</td>
<td>5.79</td>
<td>Biodone</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Oct-18 to 2021</td>
<td>5.79</td>
<td>Biodone Forte</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Oct-18 to 2021</td>
<td>6.79</td>
<td>Biodone Extra Forte</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml, 1 ml vial</td>
<td>61.00</td>
<td>AFT</td>
</tr>
</tbody>
</table>

*Methatabs Tab 5 mg - bottle pack to be delisted 1 December 2019*

#### MORPHINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Dec-18 to 2021</td>
<td>9.28</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Dec-18 to 2021</td>
<td>16.24</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Dec-18 to 2021</td>
<td>19.44</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Dec-18 to 2021</td>
<td>27.74</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Product Description</td>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Manufacturer</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Morphine Sulfate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 10 mg</td>
<td>1.93</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg</td>
<td>2.80</td>
<td>Sevredol</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg</td>
<td>5.52</td>
<td>Sevredol</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>2.85</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 60 mg</td>
<td>5.60</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 100 mg</td>
<td>6.10</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Cap long-acting 10 mg</td>
<td>1.70</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 30 mg</td>
<td>2.50</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 60 mg</td>
<td>5.40</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 100 mg</td>
<td>6.38</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag</td>
<td>97.25</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe</td>
<td>24.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml syringe</td>
<td>50.75</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 30 ml syringe</td>
<td>135.00</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule</td>
<td>6.27</td>
<td>DBL Morphine Sulfate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>4.47</td>
<td>DBL Morphine Sulfate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 mg cassette</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg per ml, 1 ml ampoule</td>
<td>4.76</td>
<td>DBL Morphine Sulfate</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule</td>
<td>6.19</td>
<td>DBL Morphine Sulfate</td>
</tr>
<tr>
<td>Inj 200 mcg in 0.4 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mcg in 0.3 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine Tartrate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 80 mg per ml, 1.5 ml ampoule</td>
<td>42.72</td>
<td>DBL Morphine Tartrate</td>
</tr>
<tr>
<td>Oxycodeine Hydrochloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab controlled-release 5 mg</td>
<td>2.15</td>
<td>Oxycodeine Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 10 mg</td>
<td>2.15</td>
<td>Oxycodeine Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 20 mg</td>
<td>2.15</td>
<td>Oxycodeine Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 40 mg</td>
<td>3.20</td>
<td>Oxycodeine Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 80 mg</td>
<td>10.98</td>
<td>Oxycodeine Sandoz</td>
</tr>
<tr>
<td>Cap immediate-release 5 mg</td>
<td>1.88</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 10 mg</td>
<td>3.32</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 20 mg</td>
<td>5.81</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Oral liq 5 mg per 5 ml</td>
<td>11.20</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>7.28</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule</td>
<td>14.36</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td>30.60</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Paracetamol with Codeine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab paracetamol 500 mg with codeine phosphate 8 mg</td>
<td>18.21</td>
<td>Paracetamol + Codeine (Relieve)</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**PETHIDINE HYDROCHLORIDE**
- Tab 50 mg – 1% DV Sep-18 to 2021............................................. 4.46 10 PSM
- Inj 5 mg per ml, 10 ml syringe
- Inj 5 mg per ml, 100 ml bag
- Inj 10 mg per ml, 100 ml bag
- Inj 10 mg per ml, 50 ml syringe
- Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020.................. 4.98 5 DBL Pethidine Hydrochloride
- Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020.................. 5.12 5 DBL Pethidine Hydrochloride

**REMIFENTANIL**
- Inj 1 mg vial – 1% DV Oct-17 to 2020........................................... 13.95 5 Remifentanil-AFT
- Inj 2 mg vial – 1% DV Oct-17 to 2020......................................... 19.95 5 Remifentanil-AFT

**TRAMADOL HYDROCHLORIDE**
- Tab sustained-release 100 mg – 1% DV Sep-17 to 2020.................... 1.55 20 Tramal SR 100
- Tab sustained-release 150 mg – 1% DV Sep-17 to 2020.................... 2.10 20 Tramal SR 150
- Tab sustained-release 200 mg – 1% DV Sep-17 to 2020.................... 2.75 20 Tramal SR 200
- Cap 50 mg – 1% DV Sep-17 to 2020............................................. 2.25 100 Arrow-Tramadol
- Oral soln 10 mg per ml
- Inj 10 mg per ml, 100 ml bag
- Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020.................. 4.50 5 Tramal 50
- Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020.................. 4.50 5 Tramal 100

**Antidepressants**

### Cyclic and Related Agents

**AMITRIPTYLINE**
- Tab 10 mg – 1% DV Apr-18 to 2020............................................. 1.96 100 Arrow-Amitriptyline
- Tab 25 mg – 1% DV Apr-18 to 2020............................................. 1.52 100 Arrow-Amitriptyline
- Tab 50 mg – 1% DV Apr-18 to 2020............................................. 2.51 100 Arrow-Amitriptyline

**CLOMIPRAMINE HYDROCHLORIDE**
- Tab 10 mg – 1% DV Oct-18 to 2021............................................. 13.99 100 Apo-Clomipramine
- Tab 25 mg – 1% DV Oct-18 to 2021............................................. 9.46 100 Apo-Clomipramine

**DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Restricted:** For continuation only
- Tab 75 mg............................................................................... 11.19 100 Dopress
- Cap 25 mg............................................................................. 6.45 100 Dopress

(Dopress Tab 75 mg to be delisted 1 August 2020)
(Dopress Cap 25 mg to be delisted 1 January 2020)

**DOXEPIN HYDROCHLORIDE – Restricted:** For continuation only
- Cap 10 mg
- Cap 25 mg
- Cap 50 mg

**IMIPRAMINE HYDROCHLORIDE**
- Tab 10 mg............................................................................... 5.48 50 Tofranil
- Tab 25 mg............................................................................... 6.58 60 Tofranil

**MAPROTILINE HYDROCHLORIDE**
- Tab 25 mg
- Tab 75 mg
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### Mianserin Hydrochloride – Restricted: For continuation only
- **Tab 30 mg**

#### Nortriptyline Hydrochloride
- **Tab 10 mg – 1% DV Oct-19 to 2022**
  - $2.44 100 Norpress
- **Tab 25 mg – 1% DV Oct-19 to 2022**
  - $5.98 180 Norpress

### Monoamine-Oxidase Inhibitors - Non-Selective

#### Phenelzine Sulphate
- **Tab 15 mg**

#### Tranlycypromine Sulphate
- **Tab 10 mg**

### Monoamine-Oxidase Type A Inhibitors

#### Moclobemide
- **Tab 150 mg – 1% DV Apr-19 to 2021**
  - $6.40 60 Aurorix
- **Tab 300 mg – 1% DV Apr-19 to 2021**
  - $9.80 60 Aurorix

### Other Antidepressants

#### Mirtazapine
- **Tab 30 mg – 1% DV Oct-18 to 2021**
  - $2.63 30 Apo-Mirtazapine
- **Tab 45 mg – 1% DV Oct-18 to 2021**
  - $3.48 30 Apo-Mirtazapine

#### Venlafaxine
- **Cap 37.5 mg – 1% DV Jun-17 to 2020**
  - $6.38 84 Enlafax XR
- **Cap 75 mg – 1% DV Jun-17 to 2020**
  - $8.11 84 Enlafax XR
- **Cap 150 mg – 1% DV Jun-17 to 2020**
  - $11.16 84 Enlafax XR

### Selective Serotonin Reuptake Inhibitors

#### Citalopram Hydrobromide
- **Tab 20 mg – 1% DV Sep-18 to 2021**
  - $1.52 84 PSM Citalopram

#### Escitalopram
- **Tab 10 mg – 1% DV Dec-17 to 2020**
  - $1.11 28 Escitalopram-Apotex
- **Tab 20 mg – 1% DV Dec-17 to 2020**
  - $1.90 28 Escitalopram-Apotex

#### Fluoxetine Hydrochloride
- **Tab dispersible 20 mg, scored**
  - $2.47 30 Arrow-Fluoxetine
- **Cap 20 mg**
  - $1.99 90 Arrow-Fluoxetine

#### Paroxetine
- **Tab 20 mg**
  - $4.02 90 Apo-Paroxetine

#### Sertraline
- **Tab 50 mg**
  - $3.05 90 Arrow-Sertraline
- **Tab 100 mg**
  - $5.25 90 Arrow-Sertraline

### Antiepilepsy Drugs

### Agents for the Control of Status Epilepticus

#### Clonazepam
- **Inj 1 mg per ml, 1 ml ampoule**
  - $21.00 5 Rivotril

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
</table>

#### Diazepam

- **Inj 5 mg per ml, 2 ml ampoule**: 11.83
- **Rectal tubes 5 mg**: 40.87
- **Rectal tubes 10 mg**: 40.87

#### Lorazepam

- **Inj 2 mg vial**: 5
- **Inj 4 mg per ml, 1 ml vial**: 5

#### Paraldehyde

- **Inj 5 ml ampoule**: 5

#### Phenyltoin Sodium

- **Inj 50 mg per ml, 2 ml ampoule**: 88.63
- **Inj 50 mg per ml, 5 ml ampoule**: 133.92

#### Control of Epilepsy

##### Carbamazepine

- **Tab 200 mg**: 14.53
- **Tab long-acting 200 mg**: 16.98
- **Tab 400 mg**: 34.58
- **Tab long-acting 400 mg**: 39.17
- **Oral liq 20 mg per ml**: 26.37

##### Clobazam

- **Tab 10 mg**: 5

##### Clonazepam

- **Oral drops 2.5 mg per ml**: 5

##### Ethosuximide

- **Cap 250 mg**: 281.75
- **Oral liq 50 mg per ml**: 56.35

##### Gabapentin

- **Note**: Gabapentin not to be given in combination with pregabalin
- **Cap 100 mg – 1% DV Aug-18 to 2021**: 2.65
- **Cap 300 mg – 1% DV Aug-18 to 2021**: 4.07
- **Cap 400 mg – 1% DV Aug-18 to 2021**: 5.64

##### Lacosamide – Restricted see terms below

- **Tab 50 mg**: 25.04
- **Tab 100 mg**: 50.06
- **Tab 150 mg**: 75.10
- **Tab 200 mg**: 400.55
- **Inj 10 mg per ml, 20 ml vial**: 200.24

- **Initiation**
  - *Re-assessment required after 15 months*
  - Both:
    1. Patient has partial-onset epilepsy; and
    2. Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
continued...

with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

**Continuation**

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

### LAMOTRIGINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab dispersible 2 mg</td>
<td>6.74</td>
<td>Lamictal</td>
</tr>
<tr>
<td>Tab dispersible 5 mg</td>
<td>15.00</td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td>Tab dispersible 25 mg – 5% DV Oct-19 to 2022</td>
<td>20.40 30</td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td></td>
<td>29.09 30</td>
<td>Lamictal</td>
</tr>
<tr>
<td></td>
<td>2.76</td>
<td>Logem</td>
</tr>
<tr>
<td>Tab dispersible 50 mg – 5% DV Oct-19 to 2022</td>
<td>34.70 56</td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td></td>
<td>47.89 56</td>
<td>Lamictal</td>
</tr>
<tr>
<td></td>
<td>3.31</td>
<td>Logem</td>
</tr>
<tr>
<td>Tab dispersible 100 mg – 5% DV Oct-19 to 2022</td>
<td>59.90 56</td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td></td>
<td>79.16 56</td>
<td>Logem</td>
</tr>
<tr>
<td></td>
<td>4.40</td>
<td>Logem</td>
</tr>
</tbody>
</table>

(Arrow-Lamotrigine Tab dispersible 25 mg to be delisted 1 October 2019)
(Arrow-Lamotrigine Tab dispersible 50 mg to be delisted 1 October 2019)
(Lamictal Tab dispersible 50 mg to be delisted 1 October 2019)
(Arrow-Lamotrigine Tab dispersible 100 mg to be delisted 1 October 2019)
(Lamictal Tab dispersible 100 mg to be delisted 1 October 2019)

### LEVETIRACETAM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – 1% DV Aug-19 to 2022</td>
<td>4.99 60</td>
<td>Everet</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Aug-19 to 2022</td>
<td>8.79 60</td>
<td>Everet</td>
</tr>
<tr>
<td>Tab 750 mg – 1% DV Aug-19 to 2022</td>
<td>14.39 60</td>
<td>Everet</td>
</tr>
<tr>
<td>Tab 1,000 mg – 1% DV Aug-19 to 2022</td>
<td>18.59 60</td>
<td>Everet</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml – 1% DV Apr-18 to 2020</td>
<td>44.78 300 ml</td>
<td>Levetiracetam-AFT</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 5 ml vial – 1% DV Oct-19 to 2022</td>
<td>38.95 10</td>
<td>Levetiracetam-AFT</td>
</tr>
</tbody>
</table>

### PHENOBARBITONE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
<td>40.00 500</td>
<td>PSM</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Oct-18 to 2021</td>
<td>40.00 500</td>
<td>PSM</td>
</tr>
</tbody>
</table>

### PHENYTOIN

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PHENYTOIN SODIUM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 30 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 6 mg per ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PREGABALIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: Pregabalin not to be given in combination with gabapentin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 25 mg – 1% DV Jul-18 to 2021</td>
<td>2.25</td>
<td>56 Pregabalin Pfizer</td>
<td></td>
</tr>
<tr>
<td>Cap 75 mg – 1% DV Jul-18 to 2021</td>
<td>2.65</td>
<td>56 Pregabalin Pfizer</td>
<td></td>
</tr>
<tr>
<td>Cap 150 mg – 1% DV Jul-18 to 2021</td>
<td>4.01</td>
<td>56 Pregabalin Pfizer</td>
<td></td>
</tr>
<tr>
<td>Cap 300 mg – 1% DV Jul-18 to 2021</td>
<td>7.38</td>
<td>56 Pregabalin Pfizer</td>
<td></td>
</tr>
<tr>
<td><strong>PRIMIDONE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM VALPROATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab EC 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab EC 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 40 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 4 ml vial – 1% DV Sep-18 to 2021</td>
<td>9.98</td>
<td>1 Epilim IV</td>
<td></td>
</tr>
<tr>
<td><strong>STIRIPENTOL</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td>509.29</td>
<td>60 Diacomit</td>
<td></td>
</tr>
<tr>
<td>Powder for oral liq 250 mg sachet</td>
<td>509.29</td>
<td>60 Diacomit</td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1152)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paediatric neurologist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Re-assessment required after 6 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Patient has confirmed diagnosis of Dravet syndrome; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Continuation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paediatric neurologist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOPIRAMATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>11.07</td>
<td>60 Arrow-Topiramate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>26.04</td>
<td>Topamax</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.07</td>
<td>Topiramate Actavis</td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>18.81</td>
<td>60 Arrow-Topiramate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>44.26</td>
<td>Topamax</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.81</td>
<td>Topiramate Actavis</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>31.99</td>
<td>60 Arrow-Topiramate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>75.25</td>
<td>Topamax</td>
<td></td>
</tr>
<tr>
<td></td>
<td>31.99</td>
<td>Topiramate Actavis</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>55.19</td>
<td>60 Arrow-Topiramate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>129.85</td>
<td>Topamax</td>
<td></td>
</tr>
<tr>
<td></td>
<td>55.19</td>
<td>Topiramate Actavis</td>
<td></td>
</tr>
<tr>
<td>Cap sprinkle 15 mg</td>
<td>20.84</td>
<td>60 Topamax</td>
<td></td>
</tr>
<tr>
<td>Cap sprinkle 25 mg</td>
<td>26.04</td>
<td>60 Topamax</td>
<td></td>
</tr>
<tr>
<td><strong>VIGABATRIN</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1153)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Re-assessment required after 15 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Item restricted (see above); Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

1 Either:
   1.1 Patient has infantile spasms; or
   1.2 Both:
      1.2.1 Patient has epilepsy; and
      1.2.2 Either:
         1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
         1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Continuation

Both:

1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and

2 Either:
   2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Antimigraine Preparations**

**Acute Migraine Treatment**

**DIHYDROERGOTAMINE MESYLATE**

Inj 1 mg per ml, 1 ml ampoule

**ERGOTAMINE TARTRATE WITH CAFFEINE**

Tab 1 mg with caffeine 100 mg

**METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL**

Tab 5 mg with paracetamol 500 mg

**RIZATRIPTAN**

Tab orodispersible 10 mg – 1% DV Sep-17 to 2020 ......................................................... 5.26  30  Rizamelt

**SUMATRIPTAN**

Tab 50 mg – 1% DV Oct-19 to 2022 .............................................................................. 24.44  100  Apo-Sumatriptan

Tab 100 mg – 1% DV Oct-19 to 2022 ............................................................................ 46.23  100  Apo-Sumatriptan

Inj 12 mg per ml, 0.5 ml prefilled pen ........................................................................ 42.67  2  Clustran

**Prophylaxis of Migraine**

**PIZOTIFEN**

Tab 500 mcg ................................................................................................................ 23.21  100  Sandomigran
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

## Antinausea and Vertigo Agents

### Aprepitant – Restricted see terms below
- **Cap 2 x 80 mg and 1 x 125 mg – 1% DV Jul-18 to 2021**
  - **84.00**
  - **3**
  - **Emend Tri-Pack**

### BETAHISTINE DIHYDROCHLORIDE
- **Tab 16 mg – 1% DV Sep-17 to 2020**
  - **2.89**
  - **84**
  - **Vergo 16**

### CYCLIZINE HYDROCHLORIDE
- **Tab 50 mg – 1% DV Jan-19 to 2021**
  - **0.55**
  - **10**
  - **Nausicalm**

### CYCLIZINE LACTATE
- **Inj 50 mg per ml, 1 ml ampoule**
  - **14.95**
  - **5**
  - **Nausicalm**

### DOMPERIDONE
- **Tab 10 mg – 1% DV Mar-19 to 2021**
  - **2.25**
  - **100**
  - **Pharmacy Health**

### DROPERIDOL
- **Inj 2.5 mg per ml, 1 ml ampoule**
  - **35.00**
  - **10**
  - **Droperidol Panpharma**

### GRANISERON
- **Inj 1 mg per ml, 3 ml ampoule – 1% DV Dec-18 to 2020**
  - **0.40**
  - **1**
  - **Deva**

### HYOSCINE HYDROBROMIDE
- **Inj 400 mcg per ml, 1 ml ampoule**
  - **46.50**
  - **5**
  - **Hospira**
- **Patch 1.5 mg**
  - **14.11**
  - **2**
  - **Scopoderm TTS**

### METOCLOPRAMIDE HYDROCHLORIDE
- **Tab 10 mg – 1% DV Jan-18 to 2020**
  - **1.30**
  - **100**
  - **Metoclopramide Actavis 10**
- **Oral liq 5 mg per 5 ml**
- **Inj 5 mg per ml, 2 ml ampoule**
  - **13.56**
  - **10**
  - **Pfizer**

### ONDANSETRON
- **Tab 4 mg**
  - **3.36**
  - **50**
  - **Apo-Ondansetron**
- **Tab dispersible 4 mg – 1% DV Apr-18 to 2020**
  - **0.95**
  - **10**
  - **Ondansetron ODT-DRLA**
- **Tab 8 mg**
  - **4.77**
  - **50**
  - **Apo-Ondansetron**
- **Tab dispersible 8 mg – 1% DV Apr-18 to 2020**
  - **1.43**
  - **10**
  - **Ondansetron ODT-DRLA**
- **Inj 2 mg per ml, 2 ml ampoule**
  - **1.50**
  - **5**
  - **Ondansetron-Claris**
- **Inj 2 mg per ml, 4 ml ampoule**
  - **2.20**
  - **5**
  - **Ondansetron Kabi**

---

*Item restricted (see ➸ above); Item restricted (see ➸ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Price</strong> (ex man. excl. GST) Per</td>
</tr>
<tr>
<td><strong>Brand or Generic Manufacturer</strong></td>
</tr>
<tr>
<td><strong>NERVOUS SYSTEM</strong></td>
</tr>
</tbody>
</table>

### PROCHLORPERAZINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab buccal 3 mg</td>
<td>1% DV Mar-18 to 2020</td>
<td>$6.35</td>
<td>250</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>1% DV Mar-18 to 2020</td>
<td>$6.35</td>
<td>250</td>
</tr>
<tr>
<td>Inj 12.5 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suppos 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TROPISETRON</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 2 ml ampoule</td>
<td>1% DV Sep-18 to 2021</td>
<td>$8.95</td>
<td>1</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antipsychotic Agents

#### General

### AMISULPRIDE

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td>$4.56</td>
<td>30</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td>$14.75</td>
<td>60</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td>$27.70</td>
<td>60</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td></td>
<td>$65.53</td>
<td>60 ml</td>
</tr>
</tbody>
</table>

### ARIPIPRAZOLE

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>1% DV Aug-18 to 2021</td>
<td>$17.50</td>
<td>30</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>1% DV Aug-18 to 2021</td>
<td>$17.50</td>
<td>30</td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>1% DV Aug-18 to 2021</td>
<td>$17.50</td>
<td>30</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>1% DV Aug-18 to 2021</td>
<td>$17.50</td>
<td>30</td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td>1% DV Aug-18 to 2021</td>
<td>$17.50</td>
<td>30</td>
</tr>
</tbody>
</table>

### CHLORPROMAZINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td>$6.69</td>
<td>50</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td>$13.37</td>
<td>100</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td>$5.69</td>
<td>50</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td></td>
<td>$11.36</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CLOZAPINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td>$6.69</td>
<td>50</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td>$13.37</td>
<td>100</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td>$5.69</td>
<td>50</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td>$11.36</td>
<td>100</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td>$8.67</td>
<td>50</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td></td>
<td>$17.33</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### HALOPERIDOL

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mcg</td>
<td>1% DV Oct-19 to 2022</td>
<td>$6.23</td>
<td>100</td>
</tr>
<tr>
<td>Tab 1.5 mg</td>
<td>1% DV Oct-19 to 2022</td>
<td>$9.43</td>
<td>100</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>1% DV Oct-19 to 2022</td>
<td>$29.72</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml</td>
<td>1% DV Oct-19 to 2022</td>
<td>$23.84</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule</td>
<td>1% DV Oct-19 to 2022</td>
<td>$21.55</td>
<td>10</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(ex man. excl. GST) $</td>
<td>Per</td>
</tr>
<tr>
<td><strong>LEVOMEPROMAZINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Sep-19 to 2022</td>
<td>16.10</td>
<td>100 Nozinan</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-19 to 2022</td>
<td>41.75</td>
<td>100 Nozinan</td>
</tr>
<tr>
<td><strong>LEVOMEPROMAZINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 1 ml ampoule</td>
<td>47.89</td>
<td>10 Wockhardt</td>
</tr>
<tr>
<td><strong>LITHIUM CARBONATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td>34.30</td>
<td>500 Lithicarb FC</td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td>9.42</td>
<td>100 Douglas</td>
</tr>
<tr>
<td><strong>OLANZAPINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Sep-17 to 2020</td>
<td>0.64</td>
<td>28 Zypine</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Sep-17 to 2020</td>
<td>1.15</td>
<td>28 Zypine</td>
</tr>
<tr>
<td>Tab orodispersible 5 mg – 1% DV Sep-17 to 2020</td>
<td>1.25</td>
<td>28 Zypine ODT</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Sep-17 to 2020</td>
<td>1.65</td>
<td>28 Zypine</td>
</tr>
<tr>
<td>Tab orodispersible 10 mg – 1% DV Sep-17 to 2020</td>
<td>2.05</td>
<td>28 Zypine ODT</td>
</tr>
<tr>
<td>Inj 10 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PERICYAZINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>QUETIAPINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Sep-17 to 2020</td>
<td>1.79</td>
<td>90 Quetapel</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-17 to 2020</td>
<td>3.45</td>
<td>90 Quetapel</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Sep-17 to 2020</td>
<td>5.75</td>
<td>90 Quetapel</td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Sep-17 to 2020</td>
<td>9.60</td>
<td>90 Quetapel</td>
</tr>
<tr>
<td><strong>RISPERIDONE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 0.5 mg – 1% DV Dec-17 to 2020</td>
<td>1.86</td>
<td>60 Actavis</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Dec-17 to 2020</td>
<td>2.06</td>
<td>60 Actavis</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Dec-17 to 2020</td>
<td>2.29</td>
<td>60 Actavis</td>
</tr>
<tr>
<td>Tab 3 mg – 1% DV Dec-17 to 2020</td>
<td>2.50</td>
<td>60 Actavis</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Dec-17 to 2020</td>
<td>3.43</td>
<td>60 Actavis</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Sep-17 to 2020</td>
<td>7.66</td>
<td>30 ml Risperon</td>
</tr>
<tr>
<td><strong>ZIPRASIDONE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 20 mg – 1% DV Dec-18 to 2021</td>
<td>14.50</td>
<td>60 Zusdone</td>
</tr>
<tr>
<td>Cap 40 mg – 1% DV Sep-18 to 2021</td>
<td>24.70</td>
<td>60 Zusdone</td>
</tr>
<tr>
<td>Cap 60 mg – 1% DV Sep-18 to 2021</td>
<td>33.80</td>
<td>60 Zusdone</td>
</tr>
<tr>
<td>Cap 80 mg – 1% DV Sep-18 to 2021</td>
<td>39.70</td>
<td>60 Zusdone</td>
</tr>
<tr>
<td><strong>ZUCLOPENTHIXOL ACETATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ZUCLOPENTHIXOL HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>31.45</td>
<td>100 Clopixol</td>
</tr>
<tr>
<td><strong>Depot Injections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FLUPENTHIXOL DECANOATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 1 ml ampoule</td>
<td>13.14</td>
<td>5 Fluanxol</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 2 ml ampoule</td>
<td>20.90</td>
<td>5 Fluanxol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td>40.87</td>
<td>5 Fluanxol</td>
</tr>
</tbody>
</table>

* Item restricted (see ➥ above); Item restricted (see ➥ below) e.g. Brand indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HALOPERIDOL DECANOATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td>$28.39</td>
<td>5 Haldol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td>$55.90</td>
<td>5 Haldol Concentrate</td>
</tr>
<tr>
<td><strong>OLANZAPINE – Restricted</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 210 mg vial – 1% DV Oct-18 to 2021</td>
<td>$252.00</td>
<td>1 Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 300 mg vial – 1% DV Oct-18 to 2021</td>
<td>$414.00</td>
<td>1 Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 405 mg vial – 1% DV Oct-18 to 2021</td>
<td>$504.00</td>
<td>1 Zyprexa Relprevv</td>
</tr>
<tr>
<td><strong>PALIPERIDONE – Restricted</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg syringe</td>
<td>$194.25</td>
<td>1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 50 mg syringe</td>
<td>$271.95</td>
<td>1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 75 mg syringe</td>
<td>$357.42</td>
<td>1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 100 mg syringe</td>
<td>$435.12</td>
<td>1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 150 mg syringe</td>
<td>$435.12</td>
<td>1 Invega Sustenna</td>
</tr>
<tr>
<td><strong>PIPOTHIAZINE PALMITATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RISPERIDONE – Restricted</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg vial</td>
<td>$135.98</td>
<td>1 Risperdal Consta</td>
</tr>
<tr>
<td>Inj 37.5 mg vial</td>
<td>$178.71</td>
<td>1 Risperdal Consta</td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td>$217.56</td>
<td>1 Risperdal Consta</td>
</tr>
</tbody>
</table>

** Initiation **

*Re-assessment required after 12 months*

- Either:
  1. The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
  2. All of the following:
     1. The patient has schizophrenia; and
     2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
     3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation **

*Re-assessment required after 12 months*

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

** PALIPERIDONE – Restricted **

*See terms below*

- Either:
  1. The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
  2. All of the following:
     1. The patient has schizophrenia or other psychotic disorder; and
     2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
     3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation **

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

** PIPOTHIAZINE PALMITATE – Restricted: For continuation only **

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

** RISPERIDONE – Restricted **

*See terms on the next page*
**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

**→ Restricted (RS1380)**

**Initiation**

*Re-assessment required after 12 months*

Either:

1. The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
2. All of the following:
   1. The patient has schizophrenia or other psychotic disorder; and
   2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation**

*Re-assessment required after 12 months*

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

**ZUCLOPENTHIXOL DECANOATE**

| Inj 200 mg per ml, 1 ml ampoule | 19.80 | Clopixol |
| Inj 500 mg per ml, 1 ml ampoule | 5     | e.g. Clopixol Conc |

**Anxiolytics**

**BUSPIRONE HYDROCHLORIDE**

- Tab 5 mg – 1% DV Sep-18 to 2021 ············································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································································
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**NATALIZUMAB** – **Restricted** see terms below
- **Initiation**
  Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).
- **Inj 20 mg per ml, 15 ml vial**: 1,750.00 1 Tysabri

**TERIFLUNOMIDE** – **Restricted** see terms below
- **Initiation**
  Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).
- **Tab 14 mg**: 1,582.62 28 Aubagio

**Other Multiple Sclerosis Treatments**

**GLATIRAMER ACETATE** – **Restricted** see terms above
- **Initiation**
  Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).
- **Inj 40 mg prefilled syringe**: 2,275.00 12 Copaxone

**INTERFERON BETA-1-ALPHA** – **Restricted** see terms above
- **Initiation**
  Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).
- **Inj 6 million iu in 0.5 ml pen injector**: 1,170.00 4 Avonex Pen
- **Inj 6 million iu in 0.5 ml syringe**: 1,170.00 4 Avonex

**INTERFERON BETA-1-BETA** – **Restricted** see terms above
- **Initiation**
  Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).
- **Inj 8 million iu per ml, 1 ml vial**

**Sedatives and Hypnotics**

**CHLORAL HYDRATE**
- Oral liq 100 mg per ml
- Oral liq 200 mg per ml

**LORMETAZEPAM** – **Restricted**: For continuation only
- **Tab 1 mg**

**MELATONIN** – **Restricted** see terms on the next page
- **Tab modified-release 2 mg**: 28.22 30 Circadin
- **Tab 3 mg**
  Note: Only for use in compounding an oral liquid formulation, for in-hospital use only.
Restricted (RS1576)

Initiation – insomnia secondary to neurodevelopmental disorder

Psychiatrist, paediatrician, neurologist or respiratory specialist

Re-assessment required after 12 months

All of the following:

1. Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
2. Behavioural and environmental approaches have been tried or are inappropriate; and
3. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
4. Patient is aged 18 years or under.

Continuation – insomnia secondary to neurodevelopmental disorder

Psychiatrist, paediatrician, neurologist or respiratory specialist

Re-assessment required after 12 months

All of the following:

1. Patient is aged 18 years or under; and
2. Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
3. Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
4. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Initiation – insomnia where benzodiazepines and zopiclone are contraindicated

Both:

1. Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
2. For in-hospital use only.

MIDAZOLAM

Tab 7.5 mg
Oral liq 2 mg per ml
Inj 1 mg per ml, 5 ml ampoule – 1% DV Jan-19 to 2021 ......................................... 2.98 10 Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 1% DV Jan-19 to 2021 ......................................... 2.36 5 Mylan Midazolam

NITRAZEPAM – Restricted: For continuation only

Tab 5 mg ........................................................................................................ 5.22 100 Nitrados
(Nitrados Tab 5 mg to be delisted 1 September 2020)

PHENOBARBITONE

Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM

Tab 10 mg – 1% DV Sep-17 to 2020 ................................................................. 1.27 25 Normison

TRIAZOLAM – Restricted: For continuation only

Tab 125 mcg
Tab 250 mcg

ZOPICLOLONE

Tab 7.5 mg ......................................................................................................... 0.98 30 Zopiclone Actavis
Stimulants / ADHD Treatments

ATOMOXETINE – Restricted see terms below

- Cap 10 mg.................................................................107.03 28 Strattera
- Cap 18 mg.................................................................107.03 28 Strattera
- Cap 25 mg.................................................................107.03 28 Strattera
- Cap 40 mg.................................................................107.03 28 Strattera
- Cap 60 mg.................................................................107.03 28 Strattera
- Cap 80 mg.................................................................139.11 28 Strattera
- Cap 100 mg...............................................................139.11 28 Strattera

- Restricted (RS1371)

Initiation

All of the following:
1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2 Once-daily dosing; and
3 Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

CAFFEINE

- Tab 100 mg

DEXAMFETAMINE SULFATE – Restricted see terms below

- Tab 5 mg – 1% DV Oct-18 to 2021....................................................20.00 100 PSM

- Restricted (RS1169)

Initiation – ADHD
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

Initiation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
Patient suffers from narcolepsy.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
The treatment remains appropriate and the patient is benefiting from treatment.
### METHYLPHENIDATE HYDROCHLORIDE – Restricted see terms below

<table>
<thead>
<tr>
<th>Item name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand/Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab extended-release 18 mg</td>
<td>..............................</td>
<td>58.96</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18.20</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 27 mg</td>
<td>..............................</td>
<td>65.44</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.00</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 36 mg</td>
<td>..............................</td>
<td>71.93</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.40</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 54 mg</td>
<td>..............................</td>
<td>86.24</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>26.40</td>
<td></td>
</tr>
<tr>
<td>Tab immediate-release 5 mg</td>
<td>..............................</td>
<td>3.20</td>
<td>30</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg</td>
<td>..............................</td>
<td>3.00</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rubifen</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg</td>
<td>..............................</td>
<td>7.85</td>
<td>30</td>
</tr>
<tr>
<td>Tab sustained-release 20 mg</td>
<td>..............................</td>
<td>50.00</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10.95</td>
<td>30</td>
</tr>
<tr>
<td>Cap modified-release 10 mg</td>
<td>..............................</td>
<td>15.60</td>
<td>30</td>
</tr>
<tr>
<td>Cap modified-release 20 mg</td>
<td>..............................</td>
<td>20.40</td>
<td>30</td>
</tr>
<tr>
<td>Cap modified-release 30 mg</td>
<td>..............................</td>
<td>25.52</td>
<td>30</td>
</tr>
<tr>
<td>Cap modified-release 40 mg</td>
<td>..............................</td>
<td>30.60</td>
<td>30</td>
</tr>
</tbody>
</table>

#### Restricted (RS1294)

**Initiation – ADHD (immediate-release and sustained-release formulations)**
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

**Initiation – Narcolepsy (immediate-release and sustained-release formulations)**
Neurologist or respiratory specialist
*Re-assessment required after 24 months*
Patient suffers from narcolepsy.

**Continuation – Narcolepsy (immediate-release and sustained-release formulations)**
Neurologist or respiratory specialist
*Re-assessment required after 24 months*
The treatment remains appropriate and the patient is benefiting from treatment.

**Initiation – Extended-release and modified-release formulations**
Paediatrician or psychiatrist

Both:
1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
2. Either:
   2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
   2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

### MODAFINIL – Restricted see terms below

<table>
<thead>
<tr>
<th>Item name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand/Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>..............................</td>
<td>64.00</td>
<td>60</td>
</tr>
</tbody>
</table>

#### Restricted (RS1171)

**Initiation – Narcolepsy**
Neurologist or respiratory specialist
*Re-assessment required after 24 months*
All of the following:

continued…

---

*Item restricted (see above); Item restricted (see below) e.g. Brand indicates brand example only. It is not a contracted product.*
1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and

2 Either:
   2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
   2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3 Either:
   3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
   3.2 Methylphenidate and dexamphetamine are contraindicated.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
The treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE
Tab 5 mg – 1% DV Sep-17 to 2020 ................................................................. 4.34  90  Donepezil-Rex
Tab 10 mg – 1% DV Sep-17 to 2020 ............................................................... 6.64  90  Donepezil-Rex

RIVASTIGMINE – Restricted see terms below

Patch 4.6 mg per 24 hour ........................................................................... 90.00  30  Exelon
Patch 9.5 mg per 24 hour ........................................................................... 90.00  30  Exelon

Continuation – Dementia
Neurologist or respiratory specialist
Re-assessment required after 12 months
Both:
1 The treatment remains appropriate; and
2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Restricted see terms below

Tab 2 mg with naloxone 0.5 mg ................................................................. 57.40  28  Suboxone
Tab 8 mg with naloxone 2 mg ................................................................. 166.00  28  Suboxone

Continuation – Substance Dependence
Neurologist or respiratory specialist
Re-assessment required after 6 months
Both:
1 The patient has been diagnosed with opioid dependence; and
2 The patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.

continued...
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued…

**Initiation – Maintenance treatment**

All of the following:

1. Patient is opioid dependent; and
2. Patient will not be receiving methadone; and
3. Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4. Prescriber works in an opioid treatment service approved by the Ministry of Health.

#### BUPROPION HYDROCHLORIDE

- **Tab modified-release 150 mg – 1% DV Jun-17 to 2020**
  - Price: **$11.00** 30 **Zyban**

#### DISULFIRAM

- **Tab 200 mg**
  - Price: **$75.57** 100 **Antabuse**

#### NALTREXONE HYDROCHLORIDE – **Restricted** see terms below

- **Tab 50 mg – 1% DV Sep-17 to 2020**
  - Price: **$112.55** 30 **Naltraccord**

  **Restricted (RS1173)

- **Initiation – Alcohol dependence**

  Both:

  1. Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
  2. Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

#### NALTREXONE HYDROCHLORIDE – **Restricted** see terms below

- **Tab 50 mg – 1% DV Sep-17 to 2020**
  - Price: **$112.55** 30 **Naltraccord**

  **Restricted (RS1173)

- **Initiation – Alcohol dependence**

  Both:

  1. Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
  2. Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

#### NICOTINE – **Some items restricted** see terms below

- **Patch 7 mg per 24 hours – 1% DV Apr-18 to 2020**
  - Price: **$17.28** 28 **Habitrol**

  **Oral spray 1 mg per dose**

- **Lozenge 1 mg – 1% DV Apr-18 to 2020**
  - Price: **$18.27** 216 **Habitrol**

  **Mouth Spray**

- **Lozenge 2 mg – 1% DV Apr-18 to 2020**
  - Price: **$20.02** 216 **Habitrol**

  **e.g. Nicorette QuickMist**

- **Soln for inhalation 15 mg cartridge**

- **Gum 2 mg – 1% DV Apr-18 to 2020**
  - Price: **$36.39** 384 **Habitrol**

  **Fruit**

- **Gum 4 mg – 1% DV Apr-18 to 2020**
  - Price: **$42.07** 384 **Habitrol**

  **Mint**

  **Restricted (RS1310)

- **Initiation**

  Any of the following:

  1. For perioperative use in patients who have a 'nil by mouth' instruction; or
  2. For use within mental health inpatient units; or
  3. For acute use in agitated patients who are unable to leave the hospital facilities.

#### VARENICLINE – **Restricted** see terms below

- **Tab 0.5 mg × 11 and 1 mg × 42 – 1% DV Mar-19 to 2021**
  - Price: **$25.64** 53 **Varenicline Pfizer**

  **Tab 1 mg**

- **Tab 1 mg – 1% DV Mar-19 to 2021**
  - Price: **$27.10** 56 **Varenicline Pfizer**

  **Restricted (RS1511)

- **Initiation**

  All of the following:

  continued…
continued…

1. Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and

2. The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

3. Either:
   
   3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   
   3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and

4. The patient has not used funded varenicline in the last 12 months; and

5. Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and

6. The patient is not pregnant; and

7. The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.
Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>$</th>
<th>Per</th>
<th>Brand or Generic</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg vial</td>
<td>271.35</td>
<td>1</td>
<td>Ribomustin</td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg vial</td>
<td>1,085.38</td>
<td>1</td>
<td>Ribomustin</td>
<td></td>
</tr>
</tbody>
</table>

Initiation – treatment naive CLL

All of the following:

1. The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
2. The patient is chemotherapy treatment naive; and
3. The patient is unable to tolerate toxicity of full-dose FCR; and
4. Patient has ECOG performance status 0-2; and
5. Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
6. Bendamustine is to be administered at a maximum dose of 100 mg/m\(^2\) on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

All of the following:

1. The patient has indolent low grade NHL requiring treatment; and
2. Patient has a WHO performance status of 0-2; and
3. Either:
   3.1 Both:
      3.1.1 Patient is treatment naive; and
      3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
   3.2 All of the following:
      3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
      3.2.2 The patient has not received prior bendamustine therapy; and
      3.2.3 Either:
         3.2.3.1 Both:
            3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
            3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
         3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Continuation – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Both:

1. Patients have not received a bendamustine regimen within the last 12 months; and
2. Either:
   2.1 Both:
      2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
      2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

continued...
2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Note: ‘indolent, low-grade lymphomas’ includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström’s macroglobulinaemia.

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUSULFAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>89.25</td>
<td>100 Myleran</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CARMUSTINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg vial</td>
<td>1,387.00</td>
<td>1 BiCNU</td>
</tr>
<tr>
<td></td>
<td>1,380.00</td>
<td>Emcure</td>
</tr>
<tr>
<td><em>(Emcure Inj 100 mg vial to be delisted 1 October 2019)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLORAMBUCIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CYCLOPHOSPHAMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>79.00</td>
<td>50 Endoxan</td>
</tr>
<tr>
<td></td>
<td>158.00</td>
<td>100 Procytox</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Oct-18 to 2021</td>
<td>35.65</td>
<td>1 Endoxan</td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Oct-18 to 2021</td>
<td>71.25</td>
<td>1 Endoxan</td>
</tr>
<tr>
<td><strong>IFOSFAMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>96.00</td>
<td>1 Holoxan</td>
</tr>
<tr>
<td>Inj 2 g vial</td>
<td>180.00</td>
<td>1 Holoxan</td>
</tr>
<tr>
<td><strong>LOMUSTINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg</td>
<td>132.59</td>
<td>20 Ceenu</td>
</tr>
<tr>
<td>Cap 40 mg</td>
<td>399.15</td>
<td>20 Ceenu</td>
</tr>
<tr>
<td><strong>MELPHALAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>THIOTEPA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Anthracyclines and Other Cytotoxic Antibiotics

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLEOMYCIN SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15,000 iu vial – 1% DV Dec-18 to 2021</td>
<td>161.01</td>
<td>1 DBL Bleomycin Sulfate</td>
</tr>
<tr>
<td><strong>DACTINOMYCIN [ACTINOMYCIN D]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5 mg vial</td>
<td>166.75</td>
<td>1 Cosmegen</td>
</tr>
<tr>
<td><strong>DAUNORUBICIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml vial</td>
<td>130.00</td>
<td>1 Pfizer</td>
</tr>
<tr>
<td><strong>DOXORUBICIN HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td></td>
<td>1 Doxorubicin Ebewe</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 25 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 50 ml vial</td>
<td></td>
<td>1 Doxorubicin Ebewe</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021</td>
<td>56.15</td>
<td>1 Doxorubicin Ebewe</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Antimetabolites

<table>
<thead>
<tr>
<th>Antimetabolite</th>
<th>Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AZACITIDINE</strong></td>
<td><strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Inj 100 mg vial – 1% DV Dec-18 to 2021</td>
<td></td>
<td>139.00</td>
<td>Azacitidine Dr Reddy's</td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td>Haematologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Re-assessment required after 12 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All of the following:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Any of the following:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 The patient has performance status (WHO/ECOG) grade 0-2; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 The patient has an estimated life expectancy of at least 3 months.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Continuation</strong></td>
<td>Haematologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Re-assessment required after 12 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 No evidence of disease progression, and; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 The treatment remains appropriate and patient is benefitting from treatment.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CAPECITABINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 150 mg</td>
<td></td>
<td>11.15</td>
<td>Brinov</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td>62.28</td>
<td>Brinov</td>
</tr>
<tr>
<td><strong>CLADRIBINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td></td>
<td>5,249.72</td>
<td>Leustatin</td>
</tr>
<tr>
<td><strong>CYTARABINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 5 ml vial</td>
<td></td>
<td>400.00</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 20 ml vial – 1% DV Dec-18 to 2021</td>
<td></td>
<td>41.36</td>
<td>Pfizer</td>
</tr>
<tr>
<td><strong>FLUDARABINE PHOSPHATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td>412.00</td>
<td>Fludara Oral</td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td></td>
<td>525.00</td>
<td>Fludarabine Ebewe</td>
</tr>
</tbody>
</table>
## Oncology Agents and Immunosuppressants

<table>
<thead>
<tr>
<th>Price (ex mant. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### FLUOROURACIL

- **Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021**
- **Inj 50 mg per ml, 100 ml vial – 1% DV Oct-18 to 2021**

### GEMCITABINE

- **Inj 10 mg per ml, 100 ml vial**

### MERCAPTOPURINE

- **Tab 50 mg – 1% DV Jul-19 to 2022**
- **Oral suspension 20 mg per ml**

### METHOTREXATE

- **Tab 2.5 mg – 1% DV Jan-19 to 2021**
- **Tab 10 mg – 1% DV Jan-19 to 2021**
- **Inj 2.5 mg per ml, 2 ml vial**
- **Inj 7.5 mg prefilled syringe**
- **Inj 10 mg prefilled syringe**
- **Inj 15 mg prefilled syringe**
- **Inj 20 mg prefilled syringe**
- **Inj 25 mg prefilled syringe**
- **Inj 30 mg prefilled syringe**
- **Inj 25 mg per ml, 2 ml vial**
- **Inj 100 mg per ml, 10 ml vial**
- **Inj 100 mg per ml, 50 ml vial – 1% DV Sep-17 to 2020**

### PEMETREXED – **Restricted** see terms below

- **Inj 100 mg vial**
- **Inj 500 mg vial**

### Initiation – Mesothelioma

**Re-assessment required after 8 months**

- **Both:**
  1. Patient has been diagnosed with mesothelioma; and
  2. Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

### Continuation – Mesothelioma

**Re-assessment required after 8 months**

- **All of the following:**
  1. No evidence of disease progression; and
  2. The treatment remains appropriate and the patient is benefitting from treatment; and

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

**Initiation – Non small cell lung cancer**

*Re-assessment required after 8 months*

Both:

1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and

2 Either:

2.1 Both:

2.1.1 Patient has chemotherapy-naïve disease; and

2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or

2.2 All of the following:

2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and

2.2.2 Patient has not received prior funded treatment with pemetrexed; and

2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

**Continuation – Non small cell lung cancer**

*Re-assessment required after 8 months*

All of the following:

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefitting from treatment; and

3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

**THIOGUANINE**

Tab 40 mg

**Other Cytotoxic Agents**

**AMSACRINE**

Inj 50 mg per ml, 1.5 ml ampoule

Inj 75 mg

**ANAGRELIDE HYDROCHLORIDE**

Cap 0.5 mg

**ARSENIC TRIOXIDE**

Inj 1 mg per ml, 10 ml vial.................................................................4,817.00 10 AFT Phenasen

*(AFT Inj 1 mg per ml, 10 ml vial to be delisted 1 September 2019)*

**BORTEZOMIB – Restricted** see terms below

*Restricted (RS1189)*

Initiation – treatment naive multiple myeloma/amyloidosis

*Limited to 15 months treatment*

Both:

1 Either:

1.1 The patient has treatment-naive symptomatic multiple myeloma; or

1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis; and

2 Maximum of 9 treatment cycles.

continued…
continued...

Initiation – relapsed/refractory multiple myeloma/amyloidosis

Re-assessment required after 8 months

All of the following:

1 Either:
   1.1 The patient has relapsed or refractory multiple myeloma; or
   1.2 The patient has relapsed or refractory systemic AL amyloidosis; and

2 The patient has received only one prior frontline chemotherapy for multiple myeloma or amyloidosis; and

3 The patient has not had prior publicly funded treatment with bortezomib; and

4 Maximum of 4 treatment cycles.

Continuation – relapsed/refractory multiple myeloma/amyloidosis

Re-assessment required after 8 months

Both:

1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and

2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

1 A known therapeutic chemotherapy regimen and supportive treatments; or

2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.
continued...

2.2 Both:

2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and

3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Continuation

Haematologist

Re-assessment required after 6 months

Both:

1 No evidence of disease progression; and
2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

PEGASPARGASE – Restricted see terms below

Injection 750 iu per ml, 5 ml vial

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

3,005.00 1 Oncaspar

Initiation – Newly diagnosed ALL

Limited to 12 months treatment

All of the following:

1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
2 Pegasparagase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3 Treatment is with curative intent.

Initiation – Relapsed ALL

Limited to 12 months treatment

All of the following:

1 The patient has relapsed acute lymphoblastic leukaemia; and
2 Pegasparagase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3 Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN]

Injection 10 mg vial

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

980.00 50 Natulan

TEMOZOLOMIDE – Restricted see terms below

Capsules 5 mg and 20 mg

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

10.20 5 Orion Temozolomide

Capsule 100 mg

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

40.20 5 Orion Temozolomide

Capsule 250 mg

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

96.80 5 Orion Temozolomide

Initiation – High grade gliomas

Re-assessment required after 12 months

All of the following:

1 Either:

1.1 Patient has newly diagnosed glioblastoma multiforme; or

continued…
continued...

1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day.

**Continuation – High grade gliomas**

*Re-assessment required after 12 months*

Either:

1 Both:
   1.1 Patient has glioblastoma multiforme; and
   1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
2 All of the following:
   2.1 Patient has anaplastic astrocytoma*; and
   2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
   2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

**Initiation – Neuroendocrine tumours**

*Re-assessment required after 9 months*

All of the following:

1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
2 Temozolomide is to be given in combination with capecitabine; and
3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
4 Temozolomide to be discontinued at disease progression.

**Continuation – Neuroendocrine tumours**

*Re-assessment required after 6 months*

Both:

1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

**Initiation – ewing's sarcoma**

*Re-assessment required after 9 months*

Patient has relapse or refractory Ewing's sarcoma.

**Continuation – ewing's sarcoma**

*Re-assessment required after 6 months*

Both:

1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

**THALIDOMIDE – Restricted** see terms below

*Cap 50 mg*...........................................................................................................378.00 28 Thalomid
*Cap 100 mg*.........................................................................................................756.00 28 Thalomid

*Restricted (RS1192)*

**Initiation**

*Re-assessment required after 12 months*

Any of the following:

1 The patient has multiple myeloma; or
2 The patient has systemic AL amyloidosis*; or

continued…
The patient has erythema nodosum leprosum.

**Continuation**

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with * is an unapproved indication

**TRETINOIN**

- **Cap 10 mg**
  - 479.50
  - 100 Vesanoid

**Platinum Compounds**

<table>
<thead>
<tr>
<th>Platinum Compound</th>
<th>Price $(ex man. excl. GST)</th>
<th>Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOPLATIN</td>
<td>$45.20</td>
<td>Carboplatin Ebewe</td>
</tr>
<tr>
<td>CISPLATIN</td>
<td>$12.29</td>
<td>DBL Cisplatin</td>
</tr>
<tr>
<td>OXALIPLATIN</td>
<td>$46.32</td>
<td>Oxaliccord</td>
</tr>
</tbody>
</table>

**Protein-Tyrosine Kinase Inhibitors**

<table>
<thead>
<tr>
<th>Protein-Tyrosine Kinase Inhibitor</th>
<th>Price $(ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DASATINIB</td>
<td>$3,774.06</td>
<td>Sprycel</td>
</tr>
<tr>
<td>DASATINIB</td>
<td>$6,214.20</td>
<td>Sprycel</td>
</tr>
<tr>
<td>DASATINIB</td>
<td>$7,692.58</td>
<td>Sprycel</td>
</tr>
</tbody>
</table>

**Initiation**

- Haematologist or any relevant practitioner on the recommendation of a haematologist
- **Re-assessment required after 6 months**

Any of the following:

1. Both:
   1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
   1.2 Maximum dose of 140 mg/day; or

2. Both:
   2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
   2.2 Maximum dose of 140 mg/day; or

3. All of the following:
   3.1 The patient has a diagnosis of CML in chronic phase; and
   3.2 Maximum dose of 100 mg/day; and
   3.3 Any of the following:
      3.3.1 Patient has documented treatment failure* with imatinib; or
      3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
      3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
      3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

continued…
Continuation

Haematologist or any relevant practitioner on the recommendation of a haematologist

Re-assessment required after 6 months

All of the following:

1. Lack of treatment failure while on dasatinib*; and
2. Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
3. Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

ERLOTINIB – Restricted see terms below

Initiation

Re-assessment required after 4 months

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
3. Either:
   3.1 Patient is treatment naive; or
   3.2 Both:
      3.2.1 The patient has discontinued getitinib due to intolerance; and
      3.2.2 The cancer did not progress whilst on gefitinib; and
4. Erlotinib is to be given for a maximum of 3 months.

Continuation

Re-assessment required after 6 months

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Erlotinib is to be given for a maximum of 3 months.

GEFITINIB – Restricted see terms below

Initiation

Re-assessment required after 4 months

All of the following:

1. Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. Either:
   2.1 Patient is treatment naive; or
   2.2 Both:
      2.2.1 The patient has discontinued erlotinib due to intolerance; and
      2.2.2 The cancer did not progress whilst on erlotinib; and
3. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
4. Gefitinib is to be given for a maximum of 3 months.

Continuation

Re-assessment required after 6 months

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Gefitinib is to be given for a maximum of 3 months.
IMATINIB MESILATE

Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Tab 100 mg................................................................................................2,400.00 60 Glivec

Restricted (RS1402)

Initiation

Re-assessment required after 12 months

Both:

1. Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Maximum dose of 400 mg/day.

Continuation

Re-assessment required after 12 months

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Cap 100 mg – 1% DV Oct-17 to 2020...........................................................98.00 60 Imatinib-AFT
Cap 400 mg – 1% DV Oct-17 to 2020.........................................................197.50 30 Imatinib-AFT

LAPATINIB – Restricted see terms below

Tab 250 mg................................................................................................1,899.00 70 Tykerb

Restricted (RS1197)

Initiation

Re-assessment required after 12 months

Either:

1. All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   1.3 Lapatinib not to be given in combination with trastuzumab; and
   1.4 Lapatinib to be discontinued at disease progression; or
2. All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on trastuzumab; and
   2.4 Lapatinib not to be given in combination with trastuzumab; and
   2.5 Lapatinib to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
3. Lapatinib not to be given in combination with trastuzumab; and
4. Lapatinib to be discontinued at disease progression.

NILOTINIB – Restricted see terms on the next page

Cap 150 mg................................................................................................4,680.00 120 Tasigna
Cap 200 mg................................................................................................6,532.00 120 Tasigna
**Restricted (RS1437)**

**Initiation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
2. Either:
   2.1 Patient has documented CML treatment failure* with imatinib; or
   2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

**Continuation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

1. Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
2. Nilotinib treatment remains appropriate and the patient is benefitting from treatment; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

**PAZOPANIB – Restricted see terms below**

- Tab 200 mg................................................................................................1,334.70 30 Votrient
- Tab 400 mg................................................................................................2,669.40 30 Votrient

**Restricted (RS1198)**

**Initiation**

*Re-assessment required after 3 months*

All of the following:

1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 Both:
      2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
      2.3.2 The cancer did not progress whilst on sunitinib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis.

**Continuation**

*Re-assessment required after 3 months*

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>RUXOLITINIB – Restricted see terms below</td>
</tr>
<tr>
<td>✧ Tab 5 mg........................................................................ 2,500.00 56 Jakavi</td>
</tr>
<tr>
<td>✧ Tab 15 mg......................................................................... 5,000.00 56 Jakavi</td>
</tr>
<tr>
<td>✧ Tab 20 mg......................................................................... 5,000.00 56 Jakavi</td>
</tr>
</tbody>
</table>

**Initiation**
Haematologist

*Re-assessment required after 12 months*

All of the following:

1. The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocytopenia myelofibrosis; and
2. A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
3. A maximum dose of 20 mg twice daily is to be given.

**Continuation**
Haematologist

*Re-assessment required after 12 months*

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. A maximum dose of 20 mg twice daily is to be given.

SUNITINIB – Restricted see terms below

✧ Cap 12.5 mg........................................................................ 2,315.38 28 Sutent
✧ Cap 25 mg........................................................................... 4,630.77 28 Sutent
✧ Cap 50 mg.......................................................................... 9,261.54 28 Sutent

**Initiation – RCC**

*Re-assessment required after 3 months*

All of the following:

1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
   2.4 Both:
      2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
      2.4.2 The cancer did not progress whilst on pazopanib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis; and
6. Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

continued…
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

**Continuation – RCC**

*Re-assessment required after 3 months*

Both:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

**Initiation – GIST**

*Re-assessment required after 3 months*

Both:
1. The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Either:
   2.1 The patient’s disease has progressed following treatment with imatinib; or
   2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

**Continuation – GIST**

*Re-assessment required after 6 months*

Both:
1. The patient has responded to treatment or has stable disease as determined by Choi’s modified CT response evaluation criteria as follows:
   1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
   1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: GIST - It is recommended that response to treatment be assessed using Choi’s modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

### Taxanes

**DOCETAXEL**

- Inj 10 mg per ml, 2 ml vial – 1% DV Sep-17 to 2020 ........................................ 12.40 1 DBL Docetaxel
- Inj 10 mg per ml, 8 ml vial – 1% DV Sep-17 to 2020 ........................................ 26.95 1 DBL Docetaxel

**PACLITAXEL**

- Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020 ........................................... 47.30 5 Paclitaxel Ebewe
- Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020 .................................... 20.00 1 Paclitaxel Ebewe
- Inj 6 mg per ml, 25 ml vial ................................................................. 26.69 1 Paclitaxel Ebewe
- Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020 .................................... 35.35 1 Paclitaxel Ebewe
## Treatment of Cytotoxic-Induced Side Effects

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CALCIUM FOLINATE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>104.26 10 DBL Leucovorin Calcium</td>
</tr>
<tr>
<td>Inj 3 mg per ml, 1 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule</td>
<td>18.25 5 Calcium Folinate Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>4.55 1 Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td>7.33 1 Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 30 ml vial</td>
<td>22.51 1 Calcium Folinate Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 35 ml vial</td>
<td>20.95 1 Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml vial</td>
<td>67.51 1 Calcium Folinate Ebewe</td>
</tr>
<tr>
<td></td>
<td>60.00 1 Calcium Folinate Sandoz</td>
</tr>
<tr>
<td><strong>MESNA</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>273.00 50 Uromitexan</td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td>407.50 50 Uromitexan</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 4 ml ampoule</td>
<td>161.25 15 Uromitexan</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml ampoule</td>
<td>370.35 15 Uromitexan</td>
</tr>
<tr>
<td><strong>Vinca Alkaloids</strong></td>
<td></td>
</tr>
<tr>
<td><strong>VINBLASTINE SULPHATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td>186.46 5 Hospira</td>
</tr>
<tr>
<td><strong>VINCRISTINE SULPHATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml vial</td>
<td>74.52 5 DBL Vincristine Sulfate</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml vial</td>
<td>85.61 5 DBL Vincristine Sulfate</td>
</tr>
<tr>
<td><strong>VINORELBINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml vial</td>
<td>12.00 1 Navelbine</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>56.00 1 Navelbine</td>
</tr>
<tr>
<td><strong>Endocrine Therapy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>ABIRATERONE ACETATE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td>4,276.19 120 Zytiga</td>
</tr>
<tr>
<td><strong>Restricted (RS1658)</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Initiation
Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has prostate cancer; and
2. Patient has metastases; and
3. Patient's disease is castration resistant; and
4. Either:
   4.1 All of the following:
      4.1.1 Patient is symptomatic; and
      4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
      4.1.3 Patient has ECOG performance score of 0-1; and
      4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
   4.2 All of the following:

*continued...*
continued…

4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
4.2.2 Patient has ECOG performance score of 0-2; and
4.2.3 Patient has not had prior treatment with abiraterone.

**Continuation**

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

1. Significant decrease in serum PSA from baseline; and
2. No evidence of clinical disease progression; and
3. No initiation of taxane chemotherapy with abiraterone; and
4. The treatment remains appropriate and the patient is benefiting from treatment.

**BICALUTAMIDE**

Tab 50 mg – 1% DV Feb-18 to 2020..........................................................3.80 28 Binarex

**FLUTAMIDE**

Tab 250 mg ..........................................................................................119.50 100 Flutamin

**MEGESTROL ACETATE**

Tab 160 mg – 1% DV Oct-18 to 2021.......................................................63.53 30 Apo-Megestrol

**OCTREOTIDE – Some items restricted** see terms below

- Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020......................30.64 5 DBL Octreotide
- Inj 100 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020...................18.69 5 DBL Octreotide
- Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020...................72.50 5 DBL Octreotide
- Inj 10 mg vial .......................................................................................1,772.50 1 Sandostatin LAR
- Inj 20 mg vial .......................................................................................2,358.75 1 Sandostatin LAR
- Inj 30 mg vial .......................................................................................2,951.25 1 Sandostatin LAR

**Initiation – Malignant bowel obstruction**

All of the following:

1. The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2. Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
3. Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications

**Initiation – acromegaly**

*Re-assessment required after 3 months*

Both:

1. The patient has acromegaly; and
2. Any of the following:
   2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
   2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

**Continuation – acromegaly**

Both:

1. IGF1 levels have decreased since starting octreotide; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months

continued…

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

### Continued…

Treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

**Initiation – Other indications**

Any of the following:

1. VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or

2. Both:
   2.1 Gastrinoma; and
   2.2 Either:
      2.2.1 Patient has failed surgery; or
      2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

3. Both:
   3.1 Insulinomas; and
   3.2 Surgery is contraindicated or has failed; or

4. For pre-operative control of hypoglycaemia and for maintenance therapy; or

5. Both:
   5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide

### TAMOXIFEN CITRATE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Jan-19 to 2020</td>
<td>11.75</td>
<td>60</td>
<td>Tamoxifen Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jan-19 to 2020</td>
<td>5.60</td>
<td>60</td>
<td>Tamoxifen Sandoz</td>
</tr>
</tbody>
</table>

### Imaging Agents

#### AMINOLEVULINIC ACID HYDROCHLORIDE – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral soln, 30 mg per ml, 1.5 g vial</td>
<td>4,400.00</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>44,000.00</td>
<td>10</td>
</tr>
</tbody>
</table>

**Restricted (RS1565)**

**Initiation – high grade malignant glioma**

All of the following:

1. Patient has newly diagnosed, untreated, glioblastoma multiforme; and
2. Treatment to be used as adjuvant to fluorescence-guided resection; and
3. Patient's tumour is amenable to complete resection.

---

*Item restricted (see ➤ above); ➤ Item restricted (see ➤ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Immunosuppressants

Calcineurin Inhibitors

CICLOSPORIN

- Cap 25 mg.......................................................................................................44.63 50 Neoral
- Cap 50 mg.......................................................................................................88.91 50 Neoral
- Cap 100 mg...................................................................................................177.81 50 Neoral
- Oral liq 100 mg per ml...................................................................................198.13 50 ml Neoral
- Inj 50 mg per ml, 5 ml ampoule .................................................................276.30 10 Sandimmun

TACROLIMUS – Restricted see terms below

- Cap 0.5 mg......................................................................................................55.64 100 Tacrolimus Sandoz
- Cap 1 mg.......................................................................................................111.28 100 Tacrolimus Sandoz
- Cap 5 mg.......................................................................................................278.20 50 Tacrolimus Sandoz
- Inj 5 mg per ml, 1 ml ampoule

→ Restricted (RS1651)

Initiation – organ transplant recipients
Any specialist
For use in organ transplant recipients.

Initiation – non-transplant indications*
Any specialist
Both:
1. Patient requires long-term systemic immunosuppression; and
2. Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

Fusion Proteins

ETANERCEPT – Restricted see terms below

- Inj 25 mg vial – 5% DV Sep-19 to 2024.......................................................799.96 4 Enbrel
- Inj 50 mg autoinjector – 5% DV Sep-19 to 2024...............................1,599.96 4 Enbrel
- Inj 50 mg syringe – 5% DV Sep-19 to 2024.................................1,599.96 4 Enbrel

→ Restricted (RS1686)

Initiation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months

Either:
1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
2. All of the following:
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued
continued…

2.3 Patient has had severe active polyarticular JIA for 6 months duration or longer; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
2.5 Both:
   2.5.1 Either:
       2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
       2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
2.5.2 Physician’s global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis
Rheumatologist or named specialist

Re-assessment required after 6 months

Both:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

Initiation – rheumatoid arthritis
Rheumatologist

Re-assessment required after 6 months

Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
   1.2 Either:
       1.2.1 The patient has experienced intolerable side effects from adalimumab; or
       1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
   2.5 Any of the following:
       2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
       2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
       2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of continued…
continued…

leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints;
   or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the
   following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the
   date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of
   greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months

All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by
   toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline
   and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint
   count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months

Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab
      for ankylosing spondylitis; or
2 All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal
   anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing
   at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
   2.5 Either:
      2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by
      the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of
      less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left
      and right); or
      2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for
      age and gender (see Notes); and

continued…
continued...

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale. Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months

All of the following:

1. Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3. Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2. All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

continued…
continued...

2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:

1 Either:
   1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – severe chronic plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
All of the following:

1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and

2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab; or
   2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and

3 Patient must be reassessed for continuation after 3 doses.

Initiation – severe chronic plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:

1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.
Continuation – severe chronic plaque psoriasis
Dermatologist
*Re-assessment required after 6 months*

Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Either:
         1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
         1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
   1.2 Both:
      1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
      1.2.2 Either:
         1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
         1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – pyoderma gangrenosum
Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and
2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum
Dermatologist

All of the following:

1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses.

Initiation – adult-onset Still's disease
Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or

continued…
1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or

1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

---

### Monoclonal Antibodies

**ABCIXIMAB – Restricted** see terms below

- **Inj 2 mg per ml, 5 ml vial** ................................................................. 579.53

  1 ReoPro

  **Restricted (RS1202)**

**Initiation**

Either:

1. For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or

2. For use in patients undergoing intra-cranial intervention.

**ADALIMUMAB – Restricted** see terms below

- **Inj 20 mg per 0.4 ml syringe** ............................................................... 1,599.96
  2 Humira

- **Inj 40 mg per 0.8 ml pen** ................................................................. 1,599.96
  2 HumiraPen

- **Inj 40 mg per 0.8 ml syringe** ............................................................... 1,599.96
  2 Humira

  **Restricted (RS1687)**

**Initiation – juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:

1 Either:

1.1 Both:

1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and

1.1.2 Either:

1.1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or

2 All of the following:

2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and

2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued…
continued...

2.3 Patient has had severe active polyarticular JIA for 6 months duration or longer; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months

All of the following:

1 Patient has confirmed Crohn's disease; and

2 Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e); and

3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation – fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

Either:

1 The number of open draining fistulae have decreased from baseline by at least 50%; or

2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation – Crohn's disease - adults

Gastroenterologist

Re-assessment required after 3 months

All of the following:

1 Patient has severe active Crohn's disease; and

2 Any of the following:
   2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or

continued…
continued...

2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate.

**Continuation – Crohn’s disease - adults**

Gastroenterologist

*Re-assessment required after 3 months*

Both:

1 Either:
   1.1 Either:
      1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab;
      or
      1.1.2 CDAI score is 150 or less; or
   1.2 Both:
      1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
      1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – Crohn’s disease - children**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1 Paediatric patient has severe active Crohn’s disease; and
2 Either:
   2.1 Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate.

**Continuation – Crohn’s disease - children**

Gastroenterologist

*Re-assessment required after 3 months*

Both:

1 Any of the following:
   1.1 PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
   1.2 PCDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:

continued…
1.2.1 The patient has experienced intolerable side effects from etanercept; or
1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
2.5 Any of the following:
   2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
   2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

continued…
continued…

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or
1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2 All of the following:

2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Following 12 weeks’ initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
continued...

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from etanercept; or
   1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2 All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.5 Any of the following:
      2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
      2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
      2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
1 Either:
   1.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
Both:
1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from etanercept; or
   2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

Initiation – plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:
1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or

continued…
continued...

1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Either:
         1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
         1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
   1.2 Both:
      1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
      1.2.2 Either:
         1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
         1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

continued…
Continuation – pyoderma gangrenosum
Dermatologist
All of the following:
1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses.

Initiation – adult-onset Still’s disease
Rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still’s disease
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

AFLIBERCEPT – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>1,250.00</td>
<td>1 Eylea</td>
</tr>
</tbody>
</table>

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 3 months
Either:
1 All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

continued…
continued…

1.3 There is no structural damage to the central fovea of the treated eye; and
1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or

2 Either:
   2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 12 months
All of the following:
   1 Documented benefit must be demonstrated to continue; and
   2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
   3 There is no structural damage to the central fovea of the treated eye.

Initiation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 4 months
All of the following:
   1 Patient has centre involving diabetic macular oedema (DMO); and
   2 Patient’s disease is non-responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
   3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
   4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
   5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
   1 There is stability or two lines of Snellen visual acuity gain; and
   2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
   3 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
   4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
   5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB – Restricted see terms below

Initiation
For use in solid organ transplants.

BEVACIZUMAB – Restricted see terms below

Initiation
Either:
   1 Ocular neovascularisation; or
   2 Exudative ocular angiopathy.
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### CETUXIMAB – Restricted see terms below

- **Inj 5 mg per ml, 20 ml vial**: $364.00 1 Erbitux
- **Inj 5 mg per ml, 100 ml vial**: $1,820.00 1 Erbitux

- **Restricted (RS1613)**

  **Initiation**
  - Medical oncologist
  - All of the following:
    1. Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
    2. Patient is contraindicated to, or is intolerant of, cisplatin; and
    3. Patient has good performance status; and
    4. To be administered in combination with radiation therapy.

#### INFLIXIMAB – Restricted see terms below

- **Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020**: $806.00 1 Remicade

- **Restricted (RS1581)**

  **Initiation – Graft vs host disease**
  - Patient has steroid-refractory acute graft vs. host disease of the gut.

  **Initiation – rheumatoid arthritis**
  - Rheumatologist
  - Re-assessment required after 4 months
  - All of the following:
    1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
    2. Either:
      2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
      2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
    3. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

  **Continuation – rheumatoid arthritis**
  - Rheumatologist
  - Re-assessment required after 6 months
  - All of the following:
    1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
    2. Either:
      2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
      2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
    3. Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

  **Initiation – ankylosing spondylitis**
  - Rheumatologist
  - Re-assessment required after 3 months
  - Both:
    1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
    2. Either:
      2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
      2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

  *continued…*
**Continuation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

**Initiation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 4 months*

Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
2. Either:
   1.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   1.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

**Continuation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Both:

1. Either:
   1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**Initiation – severe ocular inflammation**

*Re-assessment required after 3 doses*

Both:

1. Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
2. Either:
   2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
   2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

**Initiation – chronic ocular inflammation**

*Re-assessment required after 3 doses*

Both:

1. Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
2. Either:
   2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
   2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective.

**Continuation – severe ocular inflammation**

*Re-assessment required after 12 months*

Any of the following:

continued…
continued…

1. The patient has had a good clinical response following 3 initial doses; or
2. The patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema), following 12 months’ treatment; or
3. The patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old, following 12 months’ treatment.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months

Any of the following:

1. The patient has had a good clinical response following 3 initial doses; or
2. The patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema), following 12 months’ treatment; or
3. The patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old, following 12 months’ treatment.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – Pulmonary sarcoidosis

Both:

1. Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
2. Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation – Crohn’s disease (adults)

Gastroenterologist
Re-assessment required after 3 months

All of the following:

1. Patient has severe active Crohn’s disease; and
2. Any of the following:
   2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate; and
5. Patient must be reassessed for continuation after 3 months of therapy.

Continuation – Crohn’s disease (adults)

Gastroenterologist
Re-assessment required after 6 months

Both:

1. Any of the following:
   1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
   1.2 CDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
   continued…
continued...

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – Crohn's disease (children)
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1 Paediatric patient has severe active Crohn's disease; and
2 Either:
   2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate; and
5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation – Crohn's disease (children)
Gastroenterologist
Re-assessment required after 6 months
Both:

1 Any of the following:
   1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
   1.2 PCDAI score is 15 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 4 months
Both:

1 Patient has confirmed Crohn's disease; and
2 Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e).

Continuation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 6 months
Both:

1 Either:
   1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

continued…
Initiation – acute severe fulminant ulcerative colitis
Gastroenterologist
Limited to 6 weeks treatment
Both:
1. Patient has acute, severe fulminant ulcerative colitis; and
2. Treatment with intravenous or high dose oral corticosteroids has not been successful.

Continuation – severe fulminant ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
Both:
1. Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 3 months
All of the following:
1. Patient has histologically confirmed ulcerative colitis; and
2. Either:
   2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
   2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
All of the following:
1. Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
2. Either:
   2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
   2.2 Patient is under 18 years and the PUCAI score has reduced by 3 points or more from the PUCAI score when the patient was initiated on infliximab; and
3. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis
Dermatologist
Re-assessment required after 3 doses
Either:
1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis.
continued…

psoriasis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or

2 All of the following:

2.1 Either:

2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Both:

1 Either:

1.1 Both:

1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
1.2.2 Either:

1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

continued…

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>166</td>
</tr>
</tbody>
</table>

continued...

**Initiation – neurosarcoidosis**
Neurologist

*Re-assessment required after 18 months*

All of the following:

1. Biopsy consistent with diagnosis of neurosarcoidosis; and
2. Patient has CNS involvement; and
3. Patient has steroid-refractory disease; and
4. Either:
   4.1 IV cyclophosphamide has been tried; or
   4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

**Continuation – neurosarcoidosis**
Neurologist

*Re-assessment required after 18 months*

Either:

1. A withdrawal period has been tried and the patient has relapsed; or
2. All of the following:
   2.1 A withdrawal period has been considered but would not be clinically appropriate; and
   2.2 There has been a marked reduction in prednisone dose; and
   2.3 Either:
      2.3.1 There has been an improvement in MRI appearances; or
      2.3.2 Marked improvement in other symptomology.

**Initiation – severe Behcet’s disease**

*Re-assessment required after 4 months*

All of the following:

1. The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
2. Either:
   2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
   2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
3. The patient is experiencing significant loss of quality of life.

**Notes:**

2. Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

**Continuation – severe Behcet’s disease**

*Re-assessment required after 6 months*

Both:

1. Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**OBINUTUZUMAB – Restricted** see terms on the next page

- Inj 25 mg per ml, 40 ml vial.................................................................5,910.00 1 Gazyva
**OMALIZUMAB – Restricted (RS1550)**

**Initiation**

Haematologist

*Limited to 6 months* treatment

All of the following:

1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
2. The patient is obinutuzumab treatment naive; and
3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
4. Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
5. Patient has good performance status; and
6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to $1.5 \times 10^9$ and platelets greater than or equal to $75 \times 10^9$.

OMALIZUMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$450.00</td>
<td>1 Xolair</td>
</tr>
</tbody>
</table>

**OMALIZUMAB – Restricted (RS1652)**

**Initiation – severe asthma**

Clinical immunologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

1. Patient must be aged 6 years or older; and
2. Patient has a diagnosis of severe asthma; and
3. Past or current evidence of atopy, documented by skin prick testing or RAST; and
4. Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/mL at baseline; and
5. Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
6. Either:
   6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
   6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
7. Patient has an Asthma Control Test (ACT) score of 10 or less; and
8. Baseline measurements of the patient’s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

**Continuation – severe asthma**

Respiratory specialist

*Re-assessment required after 6 months*

Both:

continued…

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

**Initiation – severe chronic spontaneous urticaria**

Clinical immunologist or dermatologist

*Re-assessment required after 6 months*

All of the following:

1 Patient must be aged 12 years or older; and
2 Either:
   2.1 Both:
      2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
      2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
3 Any of the following:
   3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
   3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
   3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
4 Either:
   4.1 Treatment to be stopped if inadequate response* following 4 doses; or
   4.2 Complete response* to 6 doses of omalizumab.

**Continuation – severe chronic spontaneous urticaria**

Clinical immunologist or dermatologist

*Re-assessment required after 6 months*

Either:

1 Patient has previously had a complete response* to 6 doses of omalizumab; or
2 Both:
   2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
   2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

**PERTUZUMAB – Restricted see terms below**

|$ Inj 30 mg per ml, 14 ml vial........................................................................................................3,927.00 1 Perjeta

**Initiation**

*Re-assessment required after 12 months*

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Either:
   2.1 Patient is chemotherapy treatment naive; or
   2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
3 The patient has good performance status (ECOG grade 0-1); and
4 Pertuzumab to be administered in combination with trastuzumab; and

continued…
continued...

5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
6 Pertuzumab to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

Both:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB – Restricted see terms below

Inj 10 mg per ml, 0.23 ml vial
Inj 10 mg per ml, 0.3 ml vial

Initiation – Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 3 months

Either:

1 All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and
   1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or
2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation – Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 12 months

All of the following:

1 Documented benefit must be demonstrated to continue; and
2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB – Restricted see terms below

Inj 10 mg per ml, 10 ml vial.................................................................1,075.50 2 Mabthera
Inj 10 mg per ml, 50 ml vial...............................................................2,688.30 1 Mabthera

Initiation – haemophilia with inhibitors

Haematologist

Any of the following:

1 Patient has mild congenital haemophilia complicated by inhibitors; or
2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or

continued…
continued...

3 Patient has acquired haemophilia.

**Continuation – haemophilia with inhibitors**

Haematologist

All of the following:

1. Patient was previously treated with rituximab for haemophilia with inhibitors; and
2. An initial response lasting at least 12 months was demonstrated; and

**Initiation – post-transplant**

Both:

1. The patient has B-cell post-transplant lymphoproliferative disorder*; and
2. To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

**Continuation – post-transplant**

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has B-cell post-transplant lymphoproliferative disorder*; and
3. To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

**Initiation – indolent, low-grade lymphomas or hairy cell leukaemia**

*Re-assessment required after 9 months*

Either:

1. Both:
   1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.2 To be used for a maximum of 6 treatment cycles; or
2. Both:
   2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: ‘Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ’Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

**Continuation – indolent, low-grade lymphomas or hairy cell leukaemia**

*Re-assessment required after 9 months*

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3. To be used for no more than 6 treatment cycles.

Note: ‘Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ’Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

**Initiation – aggressive CD20 positive NHL**

Either:

1. All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or
2. Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and

continued…
continued...

2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Continuation – aggressive CD20 positive NHL**

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has relapsed refractory/aggressive CD20 positive NHL; and
3. To be used with a multi-agent chemotherapy regimen given with curative intent; and
4. To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Initiation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

1. The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2. The patient is rituximab treatment naive; and
3. Either:
   3.1. The patient is chemotherapy treatment naive; or
   3.2. Both:
      3.2.1. The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
      3.2.2. The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
4. The patient has good performance status; and
5. The patient does not have chromosome 17p deletion CLL; and
6. Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles; and
7. It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

**Continuation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

1. The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
2. The patient has had an interval of 36 months or more since the commencement of initial rituximab treatment; and
3. The patient does not have chromosome 17p deletion CLL; and
4. It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
5. Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – rheumatoid arthritis - prior TNF inhibitor use**

Rheumatologist

*Limited to 4 months treatment*

All of the following:

1. Both:

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

continued...

1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:
   2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – rheumatoid arthritis - TNF inhibitors contraindicated
Rheumatologist
Limited to 4 months treatment

All of the following:

1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and

2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

5 Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6 Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab
Rheumatologist
Re-assessment required after 4 months

All of the following:

1 Any of the following:

continued…
continued...

1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Either:

1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has cold haemagglutinin disease*; and

2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:

2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and

2.2 An initial response lasting at least 12 months was demonstrated; and

2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.
continued…

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)
Haematologist
Re-assessment required after 4 weeks
Both:

1 Patient has warm autoimmune haemolytic anaemia*; and
2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are unapproved indications.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)
Haematologist
Re-assessment required after 4 weeks
Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
2 All of the following:
   2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)
Haematologist
Re-assessment required after 4 weeks
Both:

1 Either:
   1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
2 Any of the following:
   2.1 Treatment with steroids and splenectomy have been ineffective; or
   2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
   2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are unapproved indications.

Continuation – immune thrombocytopenic purpura (ITP)
Haematologist
Re-assessment required after 4 weeks
Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
2 All of the following:
   2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.
continued...

**Initiation – thrombotic thrombocytopenic purpura (TTP)**

*Haematologist*

*Re-assessment required after 4 weeks*

Either:

1. Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
2. Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

**Note:** Indications marked with * are unapproved indications.

**Continuation – thrombotic thrombocytopenic purpura (TTP)**

*Haematologist*

*Re-assessment required after 4 weeks*

**All of the following:**

1. Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
2. An initial response lasting at least 12 months was demonstrated; and

**Note:** Indications marked with * are unapproved indications.

**Initiation – pure red cell aplasia (PRCA)**

*Haematologist*

*Re-assessment required after 6 weeks*

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

**Note:** Indications marked with * are unapproved indications.

**Continuation – pure red cell aplasia (PRCA)**

*Haematologist*

*Re-assessment required after 6 weeks*

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

**Note:** Indications marked with * are unapproved indications.

**Initiation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

**All of the following:**

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. The total rituximab dose would not exceed the equivalent of 375 mg/m\(^2\) of body-surface area per week for a total of 4 weeks; and
3. Any of the following:
   3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
   3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
   3.3 Cyclophosphamide and methotrexate are contraindicated; or
   3.4 Patient is a female of child-bearing potential; or
   3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

**Note:** Indications marked with * are unapproved indications.

**Continuation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

**All of the following:**

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3. The total rituximab dose would not exceed the equivalent of 375 mg/m\(^2\) of body-surface area per week for a total of...
continued...

4 weeks.

Note: Indications marked with * are unapproved indications.

**Initiation – treatment refractory systemic lupus erythematosus (SLE)**
Rheumatologist or nephrologist
All of the following:
1. The patient has severe, immediately life- or organ-threatening SLE*; and
2. The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
3. The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
4. Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**
Rheumatologist or nephrologist
All of the following:
1. Patient’s SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2. The disease has subsequently relapsed; and
3. Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Initiation – Antibody-mediated renal transplant rejection**
Nephrologist
Patient has been diagnosed with antibody-mediated renal transplant rejection*.
Note: Indications marked with * are unapproved indications.

**Initiation – ABO-incompatible renal transplant**
Nephrologist
Patient is to undergo an ABO-incompatible renal transplant*.
Note: Indications marked with * are unapproved indications.

**Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient is a child with SDNS* or FRNS*; and
2. Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3. Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
4. Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
5. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

continued...

Note: Indications marked with a * are unapproved indications.

Initiation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:

1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2 Treatment with tacrolimus for at least 3 months has been ineffective; and
3 Genetic causes of nephrotic syndrome have been excluded; and
4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Continuation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:

1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

SECUKINUMAB – Restricted see terms below

$ Inj 150 mg per ml, 1 ml prefilled syringe.....................................................1,599.00 2 Cosentyx

≥ Restricted (RS1653)

Initiation – severe chronic plaque psoriasis, second-line biologic
Dermatologist
Re-assessment required after 4 months
All of the following:

1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
   2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation – severe chronic plaque psoriasis, second-line biologic
Dermatologist
Re-assessment required after 6 months
Both:

1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

continued…
continued…

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation – severe chronic plaque psoriasis, first-line biologic
Dermatologist
Re-assessment required after 4 months
All of the following:

1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – severe chronic plaque psoriasis, first-line biologic
Dermatologist
Re-assessment required after 6 months
Both:

1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

SILTUXIMAB – Restricted see terms below

|$ Inj 100 mg vial .............................................................. 770.57 | 1 Sylvant |
|$ Inj 400 mg vial .............................................................. 3,082.33 | 1 Sylvant |

→ Restricted (RS1525)

Initiation
Haematologist or rheumatologist
Re-assessment required after 6 months
All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman’s Disease; and
2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Continuation
Haematologist or rheumatologist
Re-assessment required after 12 months
The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.
TOCILIZUMAB – **Restricted** see terms below

1. **Inj 20 mg per ml, 4 ml vial**
   - Price: $220.00
   - Brand: Actemra

2. **Inj 20 mg per ml, 10 ml vial**
   - Price: $550.00
   - Brand: Actemra

3. **Inj 20 mg per ml, 20 ml vial**
   - Price: $1,100.00
   - Brand: Actemra

**Initiation – Rheumatoid Arthritis**

Reumatologist

**Re-assessment required after 6 months**

Either:

1. All of the following:
   1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and

   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and

1.3 Either:

1.3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or

1.3.2 Both:
   1.3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and

   1.3.2.2 Either:
      1.3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
      1.3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or

2. All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

2.2 Tocilizumab is to be used as monotherapy; and

2.3 Either:

   2.3.1 Treatment with methotrexate is contraindicated; or
   2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and

2.4 Either:

   2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
   2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

2.5 Either:

   2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
   2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.6 Either:

   2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.
**Continuation – Rheumatoid Arthritis**
Rheumatologist
*Re-assessment required after 6 months*
Either:

1. Following 6 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
2. On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

**Initiation – systemic juvenile idiopathic arthritis**
Rheumatologist
*Re-assessment required after 6 months*
Both:

1. Patient diagnosed with systemic juvenile idiopathic arthritis; and
2. Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

**Continuation – systemic juvenile idiopathic arthritis**
Rheumatologist
*Re-assessment required after 6 months*
Either:

1. Following up to 6 months’ initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
2. On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

**Initiation – adult-onset Still’s disease**
Rheumatologist
*Re-assessment required after 6 months*
Either:

1. Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still’s disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
2. All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation – adult-onset Still’s disease**
Rheumatologist
*Re-assessment required after 6 months*
The patient has a sustained improvement in inflammatory markers and functional status.

---

*continued…*
continued...

**Initiation – polyarticular juvenile idiopathic arthritis**

Rheumatologist

*Re-assessment required after 4 months*

Either:

1. Both:
   
   1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
   
   1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or

2. All of the following:

   2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
   
   2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

   2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.5 Both:

   2.5.1 Either:

   2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

   2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

   2.5.2 Physician’s global assessment indicating severe disease.

**Continuation – polyarticular juvenile idiopathic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Both:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2. Either:

   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or

   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

**Initiation – idiopathic multicentric Castleman’s disease**

Haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and

2. Treatment with an adequate trial of corticosteroids has proven ineffective; and

3. Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

**Continuation – idiopathic multicentric Castleman’s disease**

Haematologist or rheumatologist

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued...

**Initiation – cytokine release syndrome**

*Therapy limited to 3 doses*

Either:

1. All of the following:
   1.1 The patient is enrolled in the Children's Oncology Group AALL1331 trial; and
   1.2 The patient has developed grade 3 or 4 cytokine release syndrome (CRS) associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
   1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses; or

2. All of the following:
   2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
   2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
   2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

**TRASTUZUMAB – Restricted** see terms below

- Inj 150 mg vial ................................................................. 1,350.00 1 Herceptin
- Inj 440 mg vial ................................................................. 3,875.00 1 Herceptin

- Restricted (RS1554)

**Initiation – Early breast cancer**

*Limited to 12 months treatment*

All of the following:

1. The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and

2. Maximum cumulative dose of 106 mg/kg (12 months' treatment); and

3. Any of the following:
   3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
   3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
   3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
   3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
   3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

**Initiation – metastatic breast cancer (trastuzumab-naive patients)**

*Limited to 12 months treatment*

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2. Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and

3. Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and

continued…
continued...

3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

**Initiation — metastatic breast cancer (patients previously treated with trastuzumab)**

*Limited to 12 months treatment*

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

**Continuation — metastatic breast cancer**

*Re-assessment required after 12 months*

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and

3 Trastuzumab not to be given in combination with lapatinib; and

4 Trastuzumab to be discontinued at disease progression.

### Programmed Cell Death-1 (PD-1) Inhibitors

**NIVOLUMAB** — Restricted see terms below

<table>
<thead>
<tr>
<th>Format</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 4 ml vial</td>
<td></td>
<td>1,051.98</td>
<td>Opdivo</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td></td>
<td>2,629.96</td>
<td>Opdivo</td>
</tr>
</tbody>
</table>

*Restricted (RS1583)*

**Initiation**

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

1 Patient has metastatic or unresectable melanoma stage III or IV; and

2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and

3 The patient has ECOG performance score of 0-2; and

4 Either:

continued…
4.1 Patient has not received funded pembrolizumab; or
4.2 Both:
   4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
   4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
5 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and
6 Baseline measurement of overall tumour burden is documented (see Note); and
7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

Continuation
Medical oncologist
Re-assessment required after 4 months
All of the following:
1 Any of the following:
   1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
   1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
   1.3 Patient has stable disease according to RECIST criteria (see Note); and
2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
3 No evidence of progressive disease according to RECIST criteria (see Note); and
4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:
- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – Restricted see terms below
- Inj 25 mg per ml, 4 ml vial.................................................................4,680.00 1 Keytruda
- Inj 50 mg vial .................................................................................2,340.00 1 Keytruda
(Keytruda Inj 50 mg vial to be delisted 1 October 2019)

⇒ Restricted (RS1584)

Initiation
Medical oncologist
Re-assessment required after 4 months
All of the following:

continued…
continued...

1. Patient has metastatic or unresectable melanoma stage III or IV; and
2. Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
3. The patient has ECOG performance score of 0-2; and
4. Either:
   4.1 Patient has not received funded nivolumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on nivolumab; and
5. Pembrolizumab is to be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles); and
6. Baseline measurement of overall tumour burden is documented (see Note); and
7. Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

Continuation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1. Any of the following:
   1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
   1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
   1.3 Patient has stable disease according to RECIST criteria (see Note); and
2. Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
3. No evidence of progressive disease according to RECIST criteria (see Note); and
4. The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
5. Pembrolizumab will be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- **Complete Response**: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- **Partial Response**: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- **Progressive Disease**: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- **Stable Disease**: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)

Inj 50 mg per ml, 5 ml ampoule ................................................................. 2,351.25  5  ATGAM
ANTITHYMOCYTE GLOBULIN (RABBIT)
Inj 25 mg vial

AZATHIOPRINE
Tab 25 mg ................................................................. 9.66 100 Imuran
Tab 50 mg ................................................................. 10.58 100 Imuran
Inj 50 mg vial ........................................................... 60.00 1 Imuran

BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below
 insurgents 2 × 10⁸ CFU vial .......................................... 149.37 1 OncoTICE

EVEROLIMUS – Restricted see terms below
 Tab 5 mg ................................................................. 4,555.76 30 Afinitor
 Tab 10 mg .............................................................. 6,512.29 30 Afinitor

MYCOPHENOLATE MOFETIL
Tab 500 mg ............................................................... 25.00 50 CellCept
Cap 250 mg .............................................................. 25.00 100 CellCept
Powder for oral liq 1 g per 5 ml .................................. 187.25 165 ml CellCept
Inj 500 mg vial ........................................................ 133.33 4 CellCept

PICIBANIL
Inj 100 mg vial

SIROLIMUS – Restricted see terms below
 Tab 1 mg ................................................................. 749.99 100 Rapamune
 Tab 2 mg ................................................................. 1,499.99 100 Rapamune
 Oral liq 1 mg per ml .................................................. 449.99 60 ml Rapamune

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or

continued…
continued...

- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease
Antiallergy Preparations

Allergic Emergencies

ICATIBANT – Restricted see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,668.00</td>
<td>1 Firazyr</td>
</tr>
</tbody>
</table>

Initiation

Clinical immunologist or relevant specialist

Re-assessment required after 12 months

Both:

1. Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
2. The patient has undergone product training and has agreed upon an action plan for self-administration.

Continuation

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

BEE VENOM – Restricted see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,668.00</td>
<td>1 Firazyr</td>
</tr>
</tbody>
</table>

Initiation

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – Restricted see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,668.00</td>
<td>1 Firazyr</td>
</tr>
</tbody>
</table>

Initiation

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – Restricted see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,668.00</td>
<td>1 Firazyr</td>
</tr>
</tbody>
</table>

Initiation

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.26</td>
<td>200 dose Alanase</td>
</tr>
<tr>
<td>$6.00</td>
<td>200 dose Alanase</td>
</tr>
<tr>
<td>Product Name</td>
<td>Formulation</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Budesonide</td>
<td>Nasal spray 50 mcg per dose</td>
</tr>
<tr>
<td></td>
<td>Nasal spray 100 mcg per dose</td>
</tr>
<tr>
<td>Fluticasone Propionate</td>
<td>Nasal spray 50 mcg per dose</td>
</tr>
<tr>
<td>Ipratropium Bromide</td>
<td>Aqueous nasal spray 0.03%</td>
</tr>
<tr>
<td>Sodium Cromoglicate</td>
<td>Nasal spray 4%</td>
</tr>
</tbody>
</table>

**Antihistamines**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetirizine Hydrochloride</td>
<td>Tab 10 mg</td>
<td></td>
<td>1.01 100</td>
<td>Zista</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td>2.99 200 ml</td>
<td>Histaclear</td>
</tr>
<tr>
<td>Chlorpheniramine Maleate</td>
<td>Oral liq 0.4 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cypriheptadine Hydrochloride</td>
<td>Tab 4 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fexofenadine Hydrochloride</td>
<td>Tab 60 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 120 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 180 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loratadine</td>
<td>Tab 10 mg</td>
<td></td>
<td>1.28 100</td>
<td>Lorafix</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td>2.15 120 ml</td>
<td>Lorfast</td>
</tr>
<tr>
<td>Promethazine Hydrochloride</td>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td>1.68 50</td>
<td>Allersoothe</td>
</tr>
<tr>
<td></td>
<td>Tab 25 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td>1.89 50</td>
<td>Allersoothe</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml – 1% DV Sep-18 to 2021</td>
<td></td>
<td>2.69 100 ml</td>
<td>Allersoothe</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td></td>
<td>15.54 5</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

**Anticholinergic Agents**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipratropium Bromide</td>
<td>Aerosol inhaler 20 mcg per dose</td>
<td></td>
<td>3.35 20</td>
<td>Univent</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 250 mcg per ml, 1 ml ampoule</td>
<td></td>
<td>3.52 20</td>
<td>Univent</td>
</tr>
</tbody>
</table>

**Anticholinergic Agents with Beta-Adrenoceptor Agonists**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salbutamol with Ipratropium Bromide</td>
<td>Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose</td>
<td></td>
<td>5.20 20</td>
<td>Duolin</td>
</tr>
</tbody>
</table>
### RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

#### Long-Acting Muscarinic Agents

**GLYCOPPYRONIUM**
- Note: inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.
- Powder for inhalation 50 mcg per dose ............................................. 61.00 30 dose Seebri Breezhaler

**TIOTROPIUM BROMIDE**
- Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.
- Soln for inhalation 2.5 mcg per dose ............................................. 50.37 60 dose Spiriva Respimat
- Powder for inhalation 18 mcg per dose ............................................. 50.37 30 dose Spiriva

**UMECLIDINIUM**
- Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.
- Powder for inhalation 62.5 mcg per dose .............................................. 61.50 30 dose Incruse Ellipta

#### Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

- **Restricted (RS1518)**
  - **Initiation**
    - Re-assessment required after 2 years
    - Both:
      1. Patient has been stabilised on a long acting muscarinic antagonist; and
      2. The prescriber considers that the patient would receive additional benefit from switching to a combination product.

  - **Continuation**
    - Re-assessment required after 2 years
    - Both:
      1. Patient is compliant with the medication; and
      2. Patient has experienced improved COPD symptom control (prescriber determined).

  - Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

**GLYCOPPYRONIUM WITH INDACATEROL – Restricted see terms above**
- Powder for Inhalation 50 mcg with indacaterol 110 mcg .......................... 81.00 30 dose Ultibro Breezhaler

**TIOTROPIUM BROMIDE WITH OLODATEROL – Restricted see terms above**
- Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg .......................... 81.00 60 dose Spiolto Respimat

**UMECLIDINIUM WITH VILANTEROL – Restricted see terms above**
- Powder for inhalation 62.5 mcg with vilanterol 25 mcg .......................... 77.00 30 dose Anoro Ellipta

#### Antifibrotics

**NINTEDANIB – Restricted see terms below**
- Cap 100 mg. ................................................................. 2,554.00 60 Ofev
- Cap 150 mg. ................................................................. 3,870.00 60 Ofev

- **Restricted (RS1654)**
  - **Initiation** – idiopathic pulmonary fibrosis
  - Respiratory specialist
  - Re-assessment required after 12 months
  - All of the following:

  continued…
continued...

1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2 Forced vital capacity is between 50% and 90% predicted; and
3 Nintedanib is to be discontinued at disease progression (See Note); and
4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
5 Any of the following:
   5.1 The patient has not previously received treatment with pirfenidone; or
   5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
   5.3 Patient has previously received pirfenidone, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

**Continuation – idiopathic pulmonary fibrosis**
Respiratory specialist

**Re-assessment required after 12 months**

All of the following:

1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

**PIRFENIDONE – Restricted** see terms below

Cap 267 mg.................................................................3,645.00 270 Esbriet

**Initiation – idiopathic pulmonary fibrosis**
Respiratory specialist

**Re-assessment required after 12 months**

All of the following:

1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2 Forced vital capacity is between 50% and 80% predicted; and
3 Pirfenidone is to be discontinued at disease progression (See Notes); and
4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
5 Any of the following:
   5.1 The patient has not previously received treatment with nintedanib; or
   5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
   5.3 Patient has previously received nintedanib, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

**Continuation – idiopathic pulmonary fibrosis**
Respiratory specialist

**Re-assessment required after 12 months**

All of the following:

1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Products with Hospital Supply Status (HSS) are in **bold**

Expire date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th><strong>Beta-Adrenoceptor Agonists</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SALBUTAMOL</strong></td>
<td><strong>Price (ex man. excl. GST)</strong></td>
<td><strong>Brand or Generic Manufacturer</strong></td>
</tr>
<tr>
<td>Oral liq 400 mcg per ml – 1% DV Nov-18 to 2021</td>
<td>20.00</td>
<td>Ventolin</td>
</tr>
<tr>
<td>Inj 500 mcg per ml, 1 ml ampoule</td>
<td>3.80</td>
<td>SalAir</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td>6.00</td>
<td>Ventolin</td>
</tr>
<tr>
<td>Aerosol inhaler, 100 mcg per dose</td>
<td>3.93</td>
<td>Asthalin</td>
</tr>
<tr>
<td>Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>4.03</td>
<td>Asthalin</td>
</tr>
<tr>
<td>Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>TERBUTALINE SULPHATE</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 250 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cough Suppressants</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHOLCODINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Decongestants</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OXYMETAZOLINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous nasal spray 0.25 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous nasal spray 0.5 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PSEUDOEPHEDRINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 60 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous nasal spray isotonic</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE WITH SODIUM BICARBONATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln for nasal irrigation</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>XYLOMETAZOLINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous nasal spray 0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous nasal spray 0.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal drops 0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal drops 0.1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Inhaled Corticosteroids</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BECLOMETHASONE DIPROPIONATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 50 mcg per dose</td>
<td>8.54</td>
<td>Beclazone 50</td>
</tr>
<tr>
<td>Aerosol inhaler 100 mcg per dose</td>
<td>9.30</td>
<td>Qvar</td>
</tr>
<tr>
<td>Aerosol inhaler 250 mcg per dose</td>
<td>12.50</td>
<td>Beclazone 100</td>
</tr>
<tr>
<td>Aerosol inhaler 500 mcg per dose</td>
<td>15.50</td>
<td>Qvar</td>
</tr>
<tr>
<td>Aerosol inhaler 1000 mcg per dose</td>
<td>22.67</td>
<td>Beclazone 250</td>
</tr>
<tr>
<td><strong>BUDESONIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 250 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 500 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 200 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 400 mcg per dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Leukotriene Receptor Antagonists

**MONTELUKAST**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg</td>
<td>5.25</td>
<td>28</td>
<td>Apo-Montelukast</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>5.50</td>
<td>28</td>
<td>Apo-Montelukast</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Montelukast Mylan</strong></td>
</tr>
</tbody>
</table>

*(Apo-Montelukast Tab 5 mg to be delisted 1 January 2020)*

## Long-Acting Beta-Adrenoceptor Agonists

**EFORMOTEROL FUMARATE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 12 mcg per dose</td>
<td>4.25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EFORMOTEROL FUMARATE DIHYDRATE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)</td>
<td>4.25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDACATEROL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 150 mcg per dose</td>
<td>61.00</td>
<td>30 dose</td>
<td>Onbrez Breezhaler</td>
</tr>
<tr>
<td>Powder for inhalation 300 mcg per dose</td>
<td>61.00</td>
<td>30 dose</td>
<td>Onbrez Breezhaler</td>
</tr>
</tbody>
</table>

**SALMETEROL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 25 mcg per dose</td>
<td>9.90</td>
<td>120 dose</td>
<td>Meterol</td>
</tr>
<tr>
<td>Powder for inhalation 50 mcg per dose</td>
<td>25.00</td>
<td>60 dose</td>
<td>Serevent Accuhaler</td>
</tr>
</tbody>
</table>

## Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

**BUDESONIDE WITH EFORMOTEROL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg</td>
<td>4.68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg</td>
<td>8.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg</td>
<td>13.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg</td>
<td>13.60</td>
<td>120 dose</td>
<td>Flixotide</td>
</tr>
<tr>
<td>Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg</td>
<td>7.22</td>
<td>120 dose</td>
<td>Flixotide</td>
</tr>
</tbody>
</table>

**FLUTICASONE FUROATE WITH VILANTEROL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 100 mcg with vilanterol 25 mcg</td>
<td>44.08</td>
<td>30 dose</td>
<td>Breo Elipta</td>
</tr>
</tbody>
</table>

**FLUTICASONE WITH SALMETEROL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 50 mcg with salmeterol 25 mcg</td>
<td>14.58</td>
<td>120 dose</td>
<td>RexAir</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg with salmeterol 50 mcg</td>
<td>33.74</td>
<td>60 dose</td>
<td>Seretide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg with salmeterol 25 mcg</td>
<td>16.83</td>
<td>120 dose</td>
<td>RexAir</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg with salmeterol 50 mcg</td>
<td>44.08</td>
<td>60 dose</td>
<td>Seretide Accuhaler</td>
</tr>
</tbody>
</table>
### Mast Cell Stabilisers

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEDOCROMIL Aerosol inhaler 2 mg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CROMOGLICATE Aerosol inhaler 5 mg per dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Methylxanthines

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMINOPHYLLINE Inj 25 mg per ml, 10 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>124.37</td>
<td>5 DBL Aminophylline</td>
</tr>
<tr>
<td>CAFFEINE CITRATE Oral liq 20 mg per ml (caffeine 10 mg per ml)</td>
<td>14.85</td>
<td>25 ml Biomed</td>
</tr>
<tr>
<td>Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule</td>
<td>55.75</td>
<td>5 Biomed</td>
</tr>
<tr>
<td>THEOPHYLLINE Tab long-acting 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 80 mg per 15 ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mucolytics and Expectorants

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DORNASE ALFA – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$$$ Nebuliser soln 2.5 mg per 2.5 ml ampoule</td>
<td>250.00</td>
<td>6 Pulmozyme</td>
</tr>
<tr>
<td>$$$ Restricted (RS1352)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation – cystic fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The patient has cystic fibrosis and has been approved by the Cystic Fibrosis Panel.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation – significant mucus production Limited to 4 weeks treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Patient is an in-patient; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. The mucus production cannot be cleared by first line chest techniques.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation – pleural emphyema Limited to 3 days treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Patient is an in-patient; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Patient diagnoses with pleural emphyema.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE Nebuliser soln 7%, 90 ml bottle</td>
<td>23.50</td>
<td>90 ml Biomed</td>
</tr>
</tbody>
</table>

### Pulmonary Surfactants

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>BERACTANT Soln 200 mg per 8 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PORACTANT ALFA Soln 120 mg per 1.5 ml vial</td>
<td>425.00</td>
<td>1 Curosurf</td>
</tr>
<tr>
<td>Soln 240 mg per 3 ml vial</td>
<td>695.00</td>
<td>1 Curosurf</td>
</tr>
</tbody>
</table>

### Respiratory Stimulants

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOXAPRAM Inj 20 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>$</td>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

### Sclerosing Agents

**TALC**
- Powder
- Soln (slurry) 100 mg per ml, 50 ml

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## SENSORY ORGANS

### Anti-Infective Preparations

#### Antibacterials

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHLORAMPHENICOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 1%</td>
<td>2.48</td>
<td>Chlorsig</td>
</tr>
<tr>
<td>Ear drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td>1.54</td>
<td>Chlorafast</td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CIPROFLOXACIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.3% – 1% DV Jun-18 to 2020</td>
<td>9.99</td>
<td>Ciprofloxacin Teva</td>
</tr>
<tr>
<td><strong>FRAMYCETIN SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear/eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GENTAMICIN SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.3%</td>
<td>11.40</td>
<td>Genoptic</td>
</tr>
<tr>
<td><strong>PROPAMIDINE ISETHIONATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM FUSIDATE [FUSIDIC ACID]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td>5.29</td>
<td>Fucithalmic</td>
</tr>
<tr>
<td><strong>SULPHACETAMIDE SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOBRAMYCIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 0.3%</td>
<td>10.45</td>
<td>Tobrex</td>
</tr>
<tr>
<td>Eye drops 0.3%</td>
<td>11.48</td>
<td>Tobrex</td>
</tr>
</tbody>
</table>

#### Antifungals

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATAMYCIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antivirals

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACICLOVIR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 3%</td>
<td>14.92</td>
<td>ViruPOS</td>
</tr>
</tbody>
</table>

#### Combination Preparations

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIPROFLOXACIN WITH HYDROCORTISONE</strong></td>
<td>16.30</td>
<td></td>
</tr>
<tr>
<td>Ear drops ciprofloxacin 0.2% with 1% hydrocortisone</td>
<td>10 ml</td>
<td>Ciproxin HC Otic</td>
</tr>
<tr>
<td><strong>DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMIXIN B SULPHATE</strong></td>
<td>5.39</td>
<td>Maxitrol</td>
</tr>
<tr>
<td>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DEXAMETHASONE WITH TOBRAMYCIN</strong></td>
<td>12.64</td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.1% with tobramycin 0.3%</td>
<td>5 ml</td>
<td>Tobradex</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
FLUMETASONE PIVALATE WITH Clioquinol
Ear drops 0.02% with clioquinol 1%

TRIAMCINOLONE ACETONIDE WITH Gramicidin, Neomycin and Nystatin
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and
gramicidin 250 mcg per g ...........................................................................5.16 7.5 ml Kenacomb

Anti-Inflammatory Preparations

Corticosteroids

DEXAMETHASONE
Eye oint 0.1% ..........................................................................................5.86 3.5 g Maxidex
Eye drops 0.1% .........................................................................................4.50 5 ml Maxidex
Ocular implant 700 mcg.................................................................1,444.50 1 Ozurdex

Restricted (RS1606)
Initiation – Diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1 Patients have diabetic macular oedema with pseudophakic lens; and
2 Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3 Either:
   3.1 Patient’s disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a
   maximum of 3 implants per eye per year.

Continuation – Diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
Both:
1 Patient’s vision is stable or has improved (prescriber determined); and
2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a
   maximum of 3 implants per eye per year.

Initiation – Women of child bearing age with diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1 Patients have diabetic macular oedema; and
2 Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3 Patient is of child bearing potential and has not yet completed a family; and
4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a
   maximum of 3 implants per eye per year.

Continuation – Women of child bearing age with diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1 Patient’s vision is stable or has improved (prescriber determined); and
2 Patient is of child bearing potential and has not yet completed a family; and
3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a
   maximum of 3 implants per eye per year.
### SENSORY ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

#### Fluorometholone
- Eye drops 0.1% ................................................................................................. 3.09 5 ml FML

#### Prednisolone Acetate
- Eye drops 0.12% ................................................................................................. 7.00 5 ml Pred Forte
- Eye drops 1% .................................................................................................... 3.93 10 ml Prednisolone-AFT

#### Prednisolone Sodium Phosphate
- Eye drops 0.5%, single dose (preservative free) ............................................. 38.50 20 dose Minims Prednisolone

#### Non-Steroidal Anti-Inflammatory Drugs

**Diclofenac Sodium**
- Eye drops 0.1% ............................................................................................... 13.80 5 ml Voltaren Ophtha

**Ketorolac Trometamol**
- Eye drops 0.5%

#### Decongestants and Antiallergics

**Antiallergic Preparations**

**Levocabastine**
- Eye drops 0.05%

**Lodoxamide**
- Eye drops 0.1% ................................................................................................. 8.71 10 ml Lomide

**Olopatadine**
- Eye drops 0.1% ............................................................................................... 10.00 5 ml Patanol

**Sodium Cromoglicate**
- Eye drops 2%

#### Decongestants

**Naphazoline Hydrochloride**
- Eye drops 0.1% ................................................................................................. 4.15 15 ml Naphcon Forte

#### Diagnostic and Surgical Preparations

**Diagnostic Dyes**

**Fluorescein Sodium**
- Eye drops 2%, single dose
- Inj 10%, 5 ml vial .............................................................................................. 125.00 12 Fluorescite
- Ophthalmic strips 1 mg

**Fluorescein Sodium with Lignocaine Hydrochloride**
- Eye drops 0.25% with lignocaine hydrochloride 4%, single dose

**Lissamine Green**
- Ophthalmic strips 1.5 mg

**Rose Bengal Sodium**
- Ophthalmic strips 1%
## Irrigation Solutions

### MIXED SALT SOLUTION FOR EYE IRRIGATION

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.00</td>
<td>Balanced Salt Solution</td>
</tr>
</tbody>
</table>

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle

---

## Ocular Anaesthetics

### OXYBUPROCAINE HYDROCHLORIDE

Eye drops 0.4%, single dose

### PROXYMETACAINE HYDROCHLORIDE

Eye drops 0.5%

### TETRACAINE [AMETHOCAINE] HYDROCHLORIDE

Eye drops 0.5%, single dose

Eye drops 1%, single dose

---

## Viscoelastic Substances

### HYPROMELLOSE

Inj 2%, 1 ml syringe

Inj 2%, 2 ml syringe

### SODIUM HYALURONATE [HYALURONIC ACID]

- Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022 – 50.00 1 Healon GV
- Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-19 to 2022 – 50.00 1 Healon GV
- Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022 – 60.00 1 Healon 5
- Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022 – 28.50 1 Healon

### SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe – 64.00 1 Duovisc

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe – 74.00 1 Duovisc

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe – 67.00 1 Viscoat

---

## Other

### DISODIUM EDETA

- Inj 150 mg per ml, 20 ml ampoule
- Inj 150 mg per ml, 20 ml vial
- Inj 150 mg per ml, 100 ml vial
**SENSORY ORGANS**

<table>
<thead>
<tr>
<th>Sensory Organ</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RIBOFLAVIN 5-PHOSPHATE</strong>&lt;br&gt;Soln trans epithelial riboflavin&lt;br&gt;Inj 0.1%&lt;br&gt;Inj 0.1% plus 20% dextran T500</td>
<td></td>
</tr>
</tbody>
</table>

**Glaucoma Preparations**

### Beta Blockers

**BETAXOLOL**
- Eye drops 0.25% ............................................................... 11.80 5 ml Betoptic S
- Eye drops 0.5% ............................................................... 7.50 5 ml Betoptic

**TIMOLOL**
- Eye drops 0.25% – 1% DV Sep-17 to 2020 ............................................. 1.43 5 ml Arrow-Timolol
- Eye drops 0.25%, gel forming ......................................................... 3.30 2.5 ml Timoptol XE
- Eye drops 0.5% – 1% DV Sep-17 to 2020 ............................................. 1.43 5 ml Arrow-Timolol
- Eye drops 0.5%, gel forming .......................................................... 3.78 2.5 ml Timoptol XE

### Carbonic Anhydrase Inhibitors

**ACETAZOLAMIDE**
- Tab 250 mg – 1% DV Sep-17 to 2020 ............................................. 17.03 100 Diamox
- Inj 500 mg

**BRINZOLAMIDE**
- Eye drops 1%

**DORZOLAMIDE**
- Eye drops 2%

**DORZOLAMIDE WITH TIMOLOL**
- Eye drops 2% with timolol 0.5% – 1% DV Jan-19 to 2021 ................... 2.87 5 ml Dortimopt

### Miotics

**ACETYLCHOLINE CHLORIDE**
- Inj 20 mg vial with diluent

**PILOCARPINE HYDROCHLORIDE**
- Eye drops 1% ............................................................... 4.26 15 ml Isopto Carpine
- Eye drops 2% ............................................................... 5.35 15 ml Isopto Carpine
- Eye drops 2%, single dose
- Eye drops 4% ............................................................... 7.99 15 ml Isopto Carpine

### Prostaglandin Analogues

**BIMATOPROST**
- Eye drops 0.03% – 1% DV Feb-19 to 2021 .................................... 3.30 3 ml Bimatoprost Multichem

**LATANOPROST**
- Eye drops 0.005% – 1% DV Apr-19 to 2021 ................................ 1.57 2.5 ml Teva

**TRAVOPROST**
- Eye drops 0.004% – 1% DV Jan-18 to 2020 ................................... 7.30 5 ml Travopt

---

*Item restricted (see ➞ above); Item restricted (see ➞ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Sympathomimetics

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRACLONIDINE Eye drops 0.5%</td>
<td>$19.77</td>
<td>Iopidine</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE Eye drops 0.2% – 1% DV Feb-18 to 2020</td>
<td>$4.29</td>
<td>Arrow-Brimonidine</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE WITH TIMOLOL Eye drops 0.2% with timolol 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mydriatics and Cycloplegics

### Anticholinergic Agents

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATROPINE SULPHATE Eye drops 0.5%</td>
<td>$17.36</td>
<td>Atropt</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Sep-17 to 2020</td>
<td>$17.36</td>
<td>Atropt</td>
</tr>
<tr>
<td>CYCLOPENTOLATE HYDROCHLORIDE Eye drops 0.5%, single dose</td>
<td>$8.76</td>
<td>Cyclogyl</td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TROPICAMIDE Eye drops 0.5%</td>
<td>$7.15</td>
<td>Mydriacyl</td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td>$8.66</td>
<td>Mydriacyl</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Sympathomimetics

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHENYLEPHRINE HYDROCHLORIDE Eye drops 2.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 10%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ocular Lubricants

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOMER Ophthalmic gel 0.3%, single dose</td>
<td>$8.25</td>
<td>Poly Gel</td>
</tr>
<tr>
<td>Ophthalmic gel 0.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARMELLOSE SODIUM WITH PECTIN AND GELATINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE Eye drops 0.5%</td>
<td>$3.92</td>
<td>Methopt</td>
</tr>
<tr>
<td>HYPROMELLOSE WITH DEXTRAN Eye drops 0.3% with dextran 0.1%</td>
<td>$2.30</td>
<td>Poly-Tears</td>
</tr>
<tr>
<td>Eye drops 0.3% with dextran 0.1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MACROGOL 400 AND PROPYLENE GLYCOL Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose</td>
<td>$4.30</td>
<td>Systane Unit Dose</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## SENSORY ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

### PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN
Eye oint 42.5% with soft white paraffin 57.3%

### PARAFFIN LIQUID WITH WOOL FAT
Eye oint 3% with wool fat 3%

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.63</td>
<td>Poly-Visc</td>
</tr>
</tbody>
</table>

### POLYVINYL ALCOHOL
Eye drops 1.4%
Eye drops 3%

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.62</td>
<td>Vistil</td>
</tr>
<tr>
<td>$3.68</td>
<td>Vistil Forte</td>
</tr>
</tbody>
</table>

*(Vistil Eye drops 1.4% to be delisted 1 September 2019)*
*(Vistil Forte Eye drops 3% to be delisted 1 January 2020)*

### POLYVINYL ALCOHOL WITH POVIDONE
Eye drops 1.4% with povidone 0.6%, single dose

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.80</td>
<td>VitA-POS</td>
</tr>
</tbody>
</table>

### RETINOL PALMITATE
Oint 138 mcg per g

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.80</td>
<td>VitA-POS</td>
</tr>
</tbody>
</table>

### SODIUM HYALURONATE [HYALURONIC ACID]
Eye drops 1 mg per ml

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$22.00</td>
<td>Hylo-Fresh</td>
</tr>
</tbody>
</table>

### Other Otolological Preparations

#### ACETIC ACID WITH PROPYLENE GLYCOL
Ear drops 2.3% with propylene glycol 2.8%

#### DOCUSATE SODIUM
Ear drops 0.5%
## Agents Used in the Treatment of Poisonings

### Antidotes

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACETYLCYSTEINE</strong></td>
<td>Tab eff 200 mg</td>
<td>$58.76</td>
<td>DBL Acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Inj 200 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMYL NITRITE</strong></td>
<td>Liq 98% in 3 ml capsule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DIGOXIN IMMUNE FAB</strong></td>
<td>Inj 38 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 40 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHANOL</strong></td>
<td>Liq 96%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHANOL WITH GLUCOSE</strong></td>
<td>Inj 10% with glucose 5%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHANOL, DEHYDRATED</strong></td>
<td>Inj 100%, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 96%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FLUMAZENIL</strong></td>
<td>Inj 0.1 mg per ml, 5 ml ampoule</td>
<td>$132.68</td>
<td>Hameln</td>
</tr>
<tr>
<td></td>
<td>– 1% DV Dec-18 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HYDROXOCOBALAMIN</strong></td>
<td>Inj 5 g vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 g vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NALOXONE HYDROCHLORIDE</strong></td>
<td>Inj 400 mcg per ml, 1 ml ampoule</td>
<td>$22.60</td>
<td>DBL Naloxone Hydrochloride</td>
</tr>
<tr>
<td></td>
<td>– 1% DV Aug-18 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pralidoxime Iodide</strong></td>
<td>Inj 25 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM NITRITE</strong></td>
<td>Inj 30 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM THIOSULFATE</strong></td>
<td>Inj 250 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 250 mg per ml, 50 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SOYA OIL</strong></td>
<td>Inj 20%, 500 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 20%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antitoxins

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BOTULISM ANTITOXIN</strong></td>
<td>Inj 250 ml vial</td>
</tr>
<tr>
<td><strong>DIPHTHERIA ANTITOXIN</strong></td>
<td>Inj 10,000 iu vial</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Antivenoms

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>RED BACK SPIDER ANTIVENOM</td>
<td>Inj 500 u vial</td>
<td>$204</td>
<td></td>
</tr>
<tr>
<td>SNAKE ANTIVENOM</td>
<td>Inj 50 ml vial</td>
<td>$230</td>
<td></td>
</tr>
</tbody>
</table>

### Removal and Elimination

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARCOAL</td>
<td>Oral liq 200 mg per ml</td>
<td>$43.50</td>
<td>250 ml Carbasorb-X</td>
</tr>
<tr>
<td>DEFERASIROX (Restricted)</td>
<td>Tab 125 mg dispersible</td>
<td>$276.00</td>
<td>28 Exjade</td>
</tr>
<tr>
<td></td>
<td>Tab 250 mg dispersible</td>
<td>$552.00</td>
<td>28 Exjade</td>
</tr>
<tr>
<td></td>
<td>Tab 500 mg dispersible</td>
<td>$1,105.00</td>
<td>28 Exjade</td>
</tr>
<tr>
<td>DEFERIPRONE (Restricted)</td>
<td>Tab 500 mg</td>
<td>$533.17</td>
<td>100 Ferriprox</td>
</tr>
<tr>
<td></td>
<td>Oral liq 100 mg per ml</td>
<td>$266.59</td>
<td>250 ml Ferriprox</td>
</tr>
<tr>
<td>DESFERRIOXAMINE MESILATE</td>
<td>Inj 500 mg vial – 1% DV Mar-19 to 2021</td>
<td>$84.53</td>
<td>10 DBL Desferrioxamine Mesylate for Inj BP</td>
</tr>
<tr>
<td>DICOBALT EDETATE</td>
<td>Inj 15 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➤ above); ➤ Item restricted (see ➤ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*

---

**Antivenoms**

**RED BACK SPIDER ANTIVENOM**
- Inj 500 u vial

**SNAKE ANTIVENOM**
- Inj 50 ml vial

### Removal and Elimination

#### CHARCOAL
- Oral liq 200 mg per ml: $43.50 for 250 ml Carbasorb-X

#### DEFERASIROX (Restricted, see terms below)
- Tab 125 mg dispersible: $276.00 for 28 Exjade
- Tab 250 mg dispersible: $552.00 for 28 Exjade
- Tab 500 mg dispersible: $1,105.00 for 28 Exjade

#### DEFERIPRONE (Restricted, see terms below)
- Tab 500 mg: $533.17 for 100 Ferriprox
- Oral liq 100 mg per ml: $266.59 for 250 ml Ferriprox

#### DESFERRIOXAMINE MESILATE
- Inj 500 mg vial – 1% DV Mar-19 to 2021: $84.53 for 10 DBL Desferrioxamine Mesylate for Inj BP

#### DICOBALT EDETATE
- Inj 15 mg per ml, 20 ml ampoule
DIMERCAPROL
Inj 50 mg per ml, 2 ml ampoule

DIMERCAPTOSUCCINIC ACID
Cap 100 mg
e.g. PCNZ, Optimus Healthcare, Chemet
Cap 200 mg
e.g. PCNZ, Optimus Healthcare, Chemet

SODIUM CALCIUM EDETATE
Inj 200 mg per ml, 2.5 ml ampoule
Inj 200 mg per ml, 5 ml ampoule

Antiseptics and Disinfectants

CHLORHEXIDINE
Soln 4% .......................................................... 1.86 50 ml healthE
Soln 5% .......................................................... 15.50 500 ml healthE

CHLORHEXIDINE WITH CETRIMIDE
Crm 0.1% with cetrimide 0.5%
Foaming soln 0.5% with cetrimide 0.5%

CHLORHEXIDINE WITH ETHANOL
Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml .......................... 2.65 1 healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml .......................... 3.54 1 healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml ......................... 1.55 1 healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml ............................ 2.90 1 healthE
Soln 2% with ethanol 70%, staining (red) 100 ml ............................ 3.86 1 healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml .................... 5.45 1 healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml ............................ 5.90 1 healthE
Soln 2% with ethanol 70%, staining (red) 500 ml ............................ 9.56 1 healthE

IODINE WITH ETHANOL
Soln 1% with ethanol 70%, 100 ml ..................................................... 9.30 1 healthE

ISOPROPYL ALCOHOL
Soln 70%, 500 ml ..................................................... 5.65 1 healthE

POVIDONE-IODINE
Vaginal tab 200 mg
Restricted (RS1354)
Initiation
Rectal administration pre-prostate biopsy.
Oint 10% .......................................................... 3.27 25 g Betadine
Soln 10% .......................................................... 6.20 500 ml Betadine
2.95 100 ml Riodine
6.20 500 ml Riodine
Soln 5%
Soln 7.5%
Pad 10%
Swab set 10%

POVIDONE-IODINE WITH ETHANOL
Soln 10% with ethanol 30% ............................................. 10.00 500 ml Betadine Skin Prep
Soln 10% with ethanol 70%
### Contrast Media

#### Iodinated X-ray Contrast Media

**DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle</td>
<td>22.50</td>
<td>Gastrografin</td>
</tr>
<tr>
<td>Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle</td>
<td>80.00</td>
<td>Urografin</td>
</tr>
</tbody>
</table>

**DIATRIZOATE SODIUM**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 370 mg per ml, 10 ml sachet</td>
<td>156.12</td>
<td>Ioscan</td>
</tr>
</tbody>
</table>

**IODISED OIL**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 38% w/w (480 mg per ml), 10 ml ampoule</td>
<td>410.00</td>
<td>Lipiodol Ultra Fluid</td>
</tr>
</tbody>
</table>

**IODIXANOL**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>220.00</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>430.00</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>220.00</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>430.00</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 200 ml bottle</td>
<td>850.00</td>
<td>Visipaque</td>
</tr>
</tbody>
</table>

**IOHEXOL**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 240 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 20 ml bottle</td>
<td>57.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>150.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 20 ml bottle</td>
<td>59.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 75 ml bottle</td>
<td>114.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>150.00</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 200 ml bottle</td>
<td>290.00</td>
<td>Omnipaque</td>
</tr>
</tbody>
</table>

#### Non-iodinated X-ray Contrast Media

**BARIUM SULPHATE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet</td>
<td>507.50</td>
<td>E-Z-Cat Dry</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle</td>
<td>17.39</td>
<td>Varibar - Thin Liquid</td>
</tr>
<tr>
<td>Oral liq 600 mg per g (60% w/w), tube</td>
<td>36.51</td>
<td>E-Z-Paste</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v), bottle</td>
<td>155.35</td>
<td>Varibar - Honey</td>
</tr>
<tr>
<td>38.40</td>
<td>Varibar - Nectar</td>
<td></td>
</tr>
<tr>
<td>145.04</td>
<td>Varibar - Pudding</td>
<td></td>
</tr>
<tr>
<td>Enema 1,250 mg per ml (125% w/v), 500 ml bag</td>
<td>282.30</td>
<td>Liquibar</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 250 ml bottle</td>
<td>175.00</td>
<td>CT Plus+</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 450 ml bottle</td>
<td>220.00</td>
<td>CT Plus+</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle</td>
<td>441.12</td>
<td>Volumen</td>
</tr>
<tr>
<td>Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle</td>
<td>140.94</td>
<td>Readi-CAT 2</td>
</tr>
<tr>
<td>Powder for oral soln 97.65% w/w, 300 g bottle</td>
<td>237.77</td>
<td>X-Opaque-HD</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle</td>
<td>52.35</td>
<td>Tagitol V</td>
</tr>
<tr>
<td>Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle</td>
<td>91.77</td>
<td>Liquibar</td>
</tr>
</tbody>
</table>

**BARIUM SULPHATE WITH SODIUM BICARBONATE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet</td>
<td>102.93</td>
<td>E-Z-Gas II</td>
</tr>
</tbody>
</table>
### Paramagnetic Contrast Media

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CITRIC ACID WITH SODIUM BICARBONATE</strong></td>
<td>Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet</td>
<td></td>
<td></td>
<td>e.g. E-Z-GAS II</td>
</tr>
<tr>
<td><strong>GADOBENIC ACID</strong></td>
<td>Inj 334 mg per ml, 10 ml vial</td>
<td>324.74</td>
<td>10</td>
<td>Multihance</td>
</tr>
<tr>
<td></td>
<td>Inj 334 mg per ml, 20 ml vial</td>
<td>636.28</td>
<td>10</td>
<td>Multihance</td>
</tr>
<tr>
<td><strong>GADOBUTROL</strong></td>
<td>Inj 1 mmol per ml, 15 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe</td>
<td>120.00</td>
<td>5</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td></td>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe</td>
<td>180.00</td>
<td>5</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td></td>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe</td>
<td>700.00</td>
<td>10</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td><strong>GADOXETATE DISODIUM</strong></td>
<td>Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe</td>
<td>300.00</td>
<td>1</td>
<td>Primovist</td>
</tr>
<tr>
<td><strong>MEGLUMINE GADOPENTETATE</strong></td>
<td>Inj 469 mg per ml, 10 ml prefilled syringe</td>
<td>95.00</td>
<td>5</td>
<td>Magnevist</td>
</tr>
<tr>
<td></td>
<td>Inj 469 mg per ml, 10 ml vial</td>
<td>185.00</td>
<td>10</td>
<td>Magnevist</td>
</tr>
<tr>
<td><strong>MEGLUMINE IOTROXATE</strong></td>
<td>Inj 105 mg per ml, 100 ml bottle</td>
<td>150.00</td>
<td>100 ml</td>
<td>Biliscopin</td>
</tr>
</tbody>
</table>

### Ultrasound Contrast Media

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PERFLUTREN</strong></td>
<td>Inj 1.1 mg per ml, 1.5 ml vial</td>
<td>180.00</td>
<td>1</td>
<td>Definity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>720.00</td>
<td>4</td>
<td>Definity</td>
</tr>
</tbody>
</table>

### Diagnostic Agents

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ARGININE</strong></td>
<td>Inj 50 mg per ml, 500 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 300 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
VARIOUS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

HISTAMINE ACID PHOSPHATE
Nebuliser soln 0.6%, 10 ml vial
Nebuliser soln 2.5%, 10 ml vial
Nebuliser soln 5%, 10 ml vial

MANNITOL
Powder for inhalation
e.g. Aridol

METHACHOLINE CHLORIDE
Powder 100 mg

SECRETIN PENTAHYDROCHLORIDE
Inj 100 u ampoule

SINCALIDE
Inj 5 mcg per vial

**Diagnostic Dyes**

BONNEY'S BLUE DYE
Soln

INDIGO CARMINE
Inj 4 mg per ml, 5 ml ampoule
Inj 8 mg per ml, 5 ml ampoule

INDOCYANINE GREEN
Inj 25 mg vial

METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]
Inj 5 mg per ml, 10 ml ampoule

PATENT BLUE V
Inj 2.5%, 2 ml ampoule

Irrigation Solutions

CHLORHEXIDINE WITH CETRIMIDE
Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

**Restricted (RS1683)**

Initiation
*Re-assessment required after 3 months*

All of the following:
1. Patient has burns that are greater than 30% of total body surface area (BSA); and
2. For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
3. The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation
*Re-assessment required after 3 months*

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule – 1% DV

Aug-18 to 2021

GLYCINE
Irrigation soln 1.5%, 3,000 ml bag – 1% DV

Sep-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>240.35</td>
<td>5 Proveblue</td>
</tr>
<tr>
<td>440.00</td>
<td>5 Obex Medical</td>
</tr>
<tr>
<td>29.76</td>
<td>30 Pfizer</td>
</tr>
<tr>
<td>31.20</td>
<td>4 B Braun</td>
</tr>
<tr>
<td>Brand or Generic Manufacturer</td>
<td>Price (ex man. excl. GST)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>26.80</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 30 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>7.00</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>14.90</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
</tr>
<tr>
<td><strong>WATER</strong></td>
<td></td>
</tr>
<tr>
<td>Irrigation soln, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>28.80</td>
</tr>
<tr>
<td>Irrigation soln, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>17.30</td>
</tr>
<tr>
<td>Irrigation soln, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
</tr>
</tbody>
</table>

### Surgical Preparations

**BISMUTH SUBNITRATE AND IODOFORM PARAFFIN**
- Paste

**DIMETHYL SULFOXIDE**
- Soln 50%
- Soln 99%

**PHENOL**
- Inj 6%, 10 ml ampoule

**PHENOL WITH IOXAGLIC ACID**
- Inj 12%, 10 ml ampoule

**TROMETAMOL**
- Inj 36 mg per ml, 500 ml bottle

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Cardioplegia Solutions

#### ELECTROLYTES

<table>
<thead>
<tr>
<th>Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag</td>
<td></td>
<td>e.g. Custodiol-HTK</td>
</tr>
<tr>
<td>Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag</td>
<td></td>
<td>e.g. Cardioplegia Enriched Paed. Soln.</td>
</tr>
<tr>
<td>Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag</td>
<td></td>
<td>e.g. Cardioplegia Enriched Solution</td>
</tr>
<tr>
<td>Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag</td>
<td></td>
<td>e.g. Cardioplegia Solution AHB7832</td>
</tr>
<tr>
<td>Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag</td>
<td></td>
<td>e.g. Cardioplegia Electrolyte Solution</td>
</tr>
</tbody>
</table>

#### MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

| Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle | | |

#### MONOSODIUM L-ASPARTATE

| Inj 14 mmol per 10 ml, 10 ml | | |

#### Cold Storage Solutions

##### SODIUM WITH POTASSIUM

| Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag | | |

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Extemporaneously Compounded Preparations</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALUM Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARACHIS OIL [PEANUT OIL] Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASCORBIC ACID Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BENZOIN Tincture compound BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BISMUTH SUBGALLATE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BORIC ACID Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARBOXYMETHYLCELLULOSE Soln 1.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CETRIMIDE Soln 40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLORHEXIDINE GLUCONATE Soln 20 %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLOROFORM Liq BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CITRIC ACID Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLOVE OIL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COAL TAR Soln BP</td>
<td>32.95</td>
<td>Midwest 200 ml</td>
</tr>
<tr>
<td>CODEINE PHOSPHATE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COLLODION FLEXIBLE Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMPOUND HYDROXYBENZOATE Soln – 1% DV Aug-19 to 2022</td>
<td>30.00</td>
<td>Midwest 100 ml</td>
</tr>
<tr>
<td>CYSTEAMINE HYDROCHLORIDE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE Inj</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DITHRANOL Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLUCOSE [DEXTROSE] Powder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERIN WITH SODIUM SACCHARIN</td>
<td>30.95</td>
<td>473 ml</td>
<td>Ora-Sweet SF</td>
</tr>
<tr>
<td>GLYCERIN WITH SUCROSE</td>
<td>30.95</td>
<td>473 ml</td>
<td>Ora-Sweet</td>
</tr>
<tr>
<td>GLYCEROL</td>
<td>3.28</td>
<td>500 ml</td>
<td>healthE Glycerol BP Liquid</td>
</tr>
<tr>
<td>HYDROCORTISONE Powder – 1% DV Sep-17 to 2020</td>
<td>49.95</td>
<td>25 g</td>
<td>ABM</td>
</tr>
<tr>
<td>LACTOSE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM HYDROXIDE Paste</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MENTHOL Crystals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHADONE HYDROCHLORIDE Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHYL HYDROXYBENZOATE Powder</td>
<td>8.98</td>
<td>25 g</td>
<td>Midwest</td>
</tr>
<tr>
<td>METHYLCELLULOSE Powder – 1% DV Jul-19 to 2022</td>
<td>36.95</td>
<td>100 g</td>
<td>Midwest</td>
</tr>
<tr>
<td>METHYLCELLULOSE Suspension – 1% DV Jul-19 to 2022</td>
<td>30.95</td>
<td>473 ml</td>
<td>Ora-Plus</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SUCROSE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OLIVE OIL Liq</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARAFFIN Liq</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOBARBITONE SODIUM Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOL Liq</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PILOCARPINE NITRATE Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLYHEXAMETHYLENE BIGUANIDE Liq</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Povidone K30 Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SALICYLIC ACID Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SILVER NITRATE Crystals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM BICARBONATE Powder BP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Description</td>
<td>Price</td>
<td>Brand/Manufacturer</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-------</td>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>SODIUM CITRATE Powder</td>
<td>$21.75</td>
<td>Midwest</td>
<td></td>
</tr>
<tr>
<td>SODIUM METABISULFITE Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STARCH Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULPHUR Precipitated Sublimed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYRUP Liq (pharmaceutical grade)</td>
<td>$21.75</td>
<td>Midwest</td>
<td></td>
</tr>
<tr>
<td>THEOBROMA OIL Oint</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRI-SODIUM CITRATE Crystals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRICHLORACETIC ACID Grans</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UREA Powder BP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOOL FAT Oint, anhydrous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XANTHAN Gum 1%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZINC OXIDE Powder</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Food Modules

Carbohydrate

**Restricted (RS1467)**

Initiation – Use as an additive

Any of the following:

1. Cystic fibrosis; or
2. Chronic kidney disease; or
3. Cancer in children; or
4. Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5. Faltering growth in an infant/child; or
6. Bronchopulmonary dysplasia; or
7. Premature and post premature infant; or
8. Inborn errors of metabolism.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**CARBOHYDRATE SUPPLEMENT – Restricted** see terms above

- Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can

* e.g. Polycal

Fat

**Restricted (RS1468)**

Initiation – Use as an additive

Any of the following:

1. Patient has inborn errors of metabolism; or
2. Faltering growth in an infant/child; or
3. Bronchopulmonary dysplasia; or
4. Fat malabsorption; or
5. Lymphangiectasia; or
6. Short bowel syndrome; or
7. Infants with necrotising enterocolitis; or
8. Biliary atresia; or
9. For use in a ketogenic diet; or
10. Chyle leak; or
11. Ascites; or
12. Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted** see terms above

- Liquid 50 g fat per 100 ml, 200 ml bottle
- Liquid 50 g fat per 100 ml, 500 ml bottle

* e.g. Calogen

* e.g. Calogen

Item restricted (see ➥ above); Item restricted (see ➥ below)

* e.g. Brand indicates brand example only. It is not a contracted product.
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms on the previous page

- Liquid 50 g fat per 100 ml, 250 ml bottle
e.g. Liquigen
- Liquid 95 g fat per 100 ml, 500 ml bottle
e.g. MCT Oil

WALNUT OIL – Restricted see terms on the previous page

- Liq

PROTEIN

& Restricted (RS1469)
Initiation – Use as an additive
Either:
1. Protein losing enteropathy; or
2. High protein needs.

Initiation – Use as a module
For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

PROTEIN SUPPLEMENT – Restricted see terms above

- Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can
e.g. Protifar
- Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can
e.g. Protifar

OTHER SUPPLEMENTS

BREAST MILK FORTIFIER
- Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet
e.g. FM 85
- Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet
e.g. S26 Human Milk Fortifier
- Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet
e.g. Nutricia Breast Milk Fortifer

CARBOHYDRATE AND FAT SUPPLEMENT – Restricted see terms below

- Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can
e.g. Super Soluble Duocal

& Restricted (RS1212)
Initiation
Both:
1. Infant or child aged four years or under; and
2. Any of the following:
   2.1 Cystic fibrosis; or
   2.2 Cancer in children; or
   2.3 Faltering growth; or
   2.4 Bronchopulmonary dysplasia; or
   2.5 Premature and post premature infants.
NOTE:
While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:
- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN
Powder e.g. Feed Thickener
Karicare Aptamil

GUAR GUM
Powder e.g. Guarcol

MAIZE STARCH
Powder e.g. Resource Thicken Up; Nutilis

MALTODEXTRIN WITH XANTHAN GUM
Powder e.g. Instant Thick

MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID
Powder e.g. Easy Thick

Metabolic Products

★ Restricted (RS1232)
Initiation
Any of the following:
1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – Restricted see terms above

★ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  e.g. GA1 Anamix Infant
★ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
  e.g. XLYS Low TRY Maxamaid
### Homocystinuria Products

**AMINO ACID FORMULA (WITHOUT METHIONINE) – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per</td>
<td>100 g</td>
<td>400 g can</td>
<td></td>
<td></td>
<td>e.g. HCU Anamix Infant</td>
</tr>
<tr>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>100 g</td>
<td>500 g can</td>
<td></td>
<td></td>
<td>e.g. XMET Maxamaid</td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>100 g</td>
<td>500 g can</td>
<td></td>
<td></td>
<td>e.g. XMET Maxamum</td>
</tr>
<tr>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per</td>
<td>100 ml</td>
<td>125 ml bottle</td>
<td></td>
<td></td>
<td>e.g. HCU Anamix Junior</td>
</tr>
</tbody>
</table>

### Isovaleric Acidaemia Products

**AMINO ACID FORMULA (WITHOUT LEUCINE) – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per</td>
<td>100 g</td>
<td>400 g can</td>
<td></td>
<td></td>
<td>e.g. IVA Anamix Infant</td>
</tr>
<tr>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>100 g</td>
<td>500 g can</td>
<td></td>
<td></td>
<td>e.g. XLEU Maxamaid</td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>100 g</td>
<td>500 g can</td>
<td></td>
<td></td>
<td>e.g. XLEU Maxamum</td>
</tr>
</tbody>
</table>

### Maple Syrup Urine Disease Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per</td>
<td>100 g</td>
<td>400 g can</td>
<td></td>
<td></td>
<td>e.g. MSUD Anamix Infant</td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>100 g</td>
<td>500 g can</td>
<td></td>
<td></td>
<td>e.g. MSUD Maxamum</td>
</tr>
<tr>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per</td>
<td>100 ml</td>
<td>125 ml bottle</td>
<td></td>
<td></td>
<td>e.g. MSUD Anamix Junior LQ</td>
</tr>
</tbody>
</table>
### Special Foods

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### Phenylketonuria Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – Restricted** see terms on page 216

- **Tab 8.33 mg**
  - Powder 20 g protein, 2.5 g carbohydrate and 0.22 g fibre per 27.8 g sachet
  - e.g. Phlexy-10

- **Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet**
  - e.g. PKU Anamix Junior (van/choc/unfl)

- **Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can**
  - e.g. PKU Anamix Infant

- **Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet**
  - e.g. Phlexy-10

- **Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle**
  - e.g. PKU Lophlex LQ 10

- **Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle**
  - e.g. PKU Lophlex LQ 20

- **Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle**
  - e.g. PKU Anamix Junior LQ (Berry)

- **Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle**
  - e.g. PKU Lophlex LQ 20

- **Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle**
  - e.g. PKU Lophlex LQ 10

- **Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton**
  - e.g. Easiphen

- **Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot**
  - e.g. PKU Lophlex Sensations 20 (berries)

#### Propionic Acidaemia and Methylmalonic Acidaemia Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – Restricted** see terms on page 216

- **Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can**
  - e.g. MMA/PA Anamix Infant

- **Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can**
  - e.g. XMTVI Maxamaid

- **Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can**
  - e.g. XMTVI Maxamum
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

### Protein Free Supplements

**PROTEIN FREE SUPPLEMENT** – **Restricted** see terms on page 216

- Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can
  - *e.g.* Energivit

### Tyrosinaemia Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)** – **Restricted** see terms on page 216

- Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet
  - *e.g.* TYR Anamix Junior
- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - *e.g.* TYR Anamix Infant
- Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can
  - *e.g.* XPHEN, TYR Maxamaid
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  - *e.g.* TYR Anamix Junior LQ

### Urea Cycle Disorders Products

**AMINO ACID SUPPLEMENT** – **Restricted** see terms on page 216

- Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can
  - *e.g.* Dialamine
- Powder 79 g protein per 100 g, 200 g can
  - *e.g.* Essential Amino Acid Mix

### X-Linked Adrenoleukodystrophy Products

**GLYCEROL TRIERUCATE** – **Restricted** see terms on page 216

- Liquid, 1,000 ml bottle

**GLYCEROL TRIOLEATE** – **Restricted** see terms on page 216

- Liquid, 500 ml bottle

### Specialised Formulas

#### Diabetic Products

**→ Restricted (RS1215)**

**Initiation**

Any of the following:

1. For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2. For patients with pancreatic insufficiency; or
3. For patients who have, or are expected to, eat little or nothing for 5 days; or
4. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5. For use pre- and post-surgery; or
6. For patients being tube-fed; or
7. For tube-feeding as a transition from intravenous nutrition.
LOW-GI ENTERAL FEED 1 KCAL/ML – Restricted see terms on the previous page

- Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle.......................................................................................7.50 1,000 ml Glucerna Select RTH (Vanilla)
- Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag

LOW-GI ORAL FEED 1 KCAL/ML – Restricted see terms on the previous page

- Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, 237 ml Sustagen Diabetic (Vanilla)

Elemental and Semi-Elemental Products

- Elemental and Semi-Elemental Products

- Restriction (RS1216)

Initiation
Any of the following:

1. Malabsorption; or
2. Short bowel syndrome; or
3. Enterocutaneous fistulas; or
4. Eosinophilic enteritis (including oesophagitis); or
5. Inflammatory bowel disease; or
6. Acute pancreatitis where standard feeds are not tolerated; or
7. Patients with multiple food allergies requiring enteral feeding.

AMINO ACID ORAL FEED – Restricted see terms above

- Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet.........................4.50 80 g Vivonex TEN

AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted see terms above

- Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton

PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted see terms above

- Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag

PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML – Restricted see terms above

- Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle....18.06 1,000 ml Vital

PEPTIDE-BASED ORAL FEED – Restricted see terms above

- Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 400 g can
- Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 400 g can
PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted see terms on the previous page

1 Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton .......... 4.95 237 ml Peptamen OS
   1.0 (Vanilla)

Fat Modified Products

FAT-MODIFIED FEED – Restricted see terms below

1 Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g,
   400 g can  e.g. Monogen

Restricted (RS1470)
Initiation
Any of the following:
   1 Patient has metabolic disorders of fat metabolism; or
   2 Patient has a chyle leak; or
   3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of
   the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Hepatic Products

Restricted (RS1217)
Initiation
For children (up to 18 years) who require a liver transplant.

HEPATIC ORAL FEED – Restricted see terms above

1 Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can .......... 78.97 400 g Heparon Junior

High Calorie Products

Restricted (RS1317)
Initiation
Any of the following:
   1 Patient is fluid volume or rate restricted; or
   2 Patient requires low electrolyte; or
   3 Both:
      3.1 Any of the following:
         3.1.1 Cystic fibrosis; or
         3.1.2 Any condition causing malabsorption; or
         3.1.3 Faltering growth in an infant/child; or
         3.1.4 Increased nutritional requirements; and
      3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – Restricted see terms above

1 Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle .......... 5.50 500 ml Nutrison Concentrated
1 Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per
   100 ml, bottle ................................................................. 11.00 1,000 ml TwoCal HN RTH
   (Vanilla)

ORAL FEED 2 KCAL/ML – Restricted see terms above

1 Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per
   100 ml, bottle ................................................................. 1.90 200 ml Two Cal HN

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms below

- Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml,
  1,000 ml bag

**Initiation**

- Both:
  - 1 The patient has a high protein requirement; and
  - 2 Any of the following:
    - 2.1 Patient has liver disease; or
    - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
    - 2.3 Patient is fluid restricted; or
    - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms below

- Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per
  100 ml, 1,000 ml bag

**Initiation**

- Both:
  - 1 The patient has a high protein requirement; and
  - 2 Any of the following:
    - 2.1 Patient has liver disease; or
    - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
    - 2.3 Patient is fluid restricted; or
    - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

Infant Formulas

AMINO ACID FORMULA – **Restricted** see terms below

- Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can
- Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can
- Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can
- Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can ...53.00
- Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can ..........43.60
- Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can ..........53.00
- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ..........53.00
- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can .......53.00

**Initiation**

Any of the following:
continued...

1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
2 History of anaphylaxis to cows’ milk protein formula or dairy products; or
3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

Continuation
Both:

1 An assessment as to whether the infant can be transitioned to a cows’ milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – Restricted see terms below

Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can

e.g. Aptamil Gold+ Pepti Junior

FRUCTOSE-BASED FORMULA

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can

e.g. Galactomin 19

LACTOSE-FREE FORMULA

Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can

e.g. Karicare Aptamil Gold De-Lact

Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can

e.g. S26 Lactose Free
LOW-CALCIUM FORMULA

Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Restricted see terms below

- Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per
  100 ml, bottle .............................................................................................. $2.35 125 ml Infatrini

- Restricted (RS1614)

Initiation – Fluid restricted or volume intolerance with faltering growth

Both:

1. Either:
   1.1 The patient is fluid restricted or volume intolerant; or
   1.2 The patient has increased nutritional requirements due to faltering growth; and

2. Patient is under 18 months old and weighs less than 8 kg.

Note: ‘Volume intolerant’ patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

PRETERM FORMULA – Restricted see terms below

- Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle 0.75 $100 ml S26 LBW Gold RTF

- Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle

- Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle

- Restricted (RS1224)

Initiation

For infants born before 33 weeks’ gestation or weighing less than 1.5 kg at birth.

THICKENED FORMULA

Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can

Ketogenic Diet Products

HIGH FAT FORMULA – Restricted see terms below

- Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can 35.50 300 g Ketocal
  4:1 (Unflavoured)
  Ketocal 4:1 (Vanilla)

- Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can 35.50 300 g Ketocal
  3:1 (Unflavoured)

- Restricted (RS1225)

Initiation

For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Paediatric Products

- Restricted (RS1473)

Initiation

Both:

continued…
continued...

1. Child is aged one to ten years; and
2. Any of the following:
   2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2.2 Any condition causing malabsorption; or
   2.3 Faltering growth in an infant/child; or
   2.4 Increased nutritional requirements; or
   2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
   2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see terms on the previous page

- Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag.................................4.00 500 ml Nutrini Low Energy Multifibre

PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted see terms on the previous page

- Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag...........................................2.68 500 ml Pediasure RTH
e.g. Nutrini RTH

PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms on the previous page

- Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag...........................................6.00 500 ml Nutrini Energy Multi Fibre
e.g. Nutrini Energy RTH

PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms on the previous page

- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle................1.07 200 ml Pediasure (Chocolate)
Pediasure (Strawberry)
Pediasure (Vanilla)

- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can................1.34 250 ml Pediasure (Vanilla)

PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted see terms on the previous page

- Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle

- Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle
e.g. Fortini

Renal Products

LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted see terms below

- Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle..............................6.08 500 ml Nepro HP RTH

→ Restricted (RS1229)

Initiation
For patients with acute or chronic kidney disease.

LOW ELECTROLYTE ORAL FEED – Restricted see terms below

- Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can

→ Restricted (RS1227)

Initiation
For children (up to 18 years) with acute or chronic kidney disease.
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML

- Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton.................................................................2.67
- 220 ml Nepro HP (Strawberry)
- 220 ml Nepro HP (Vanilla)

**Restricted (RS1228)**

Initiation

For patients with acute or chronic kidney disease.

LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – **Restricted** see terms below

- Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton...........3.31
- 237 ml Novasource Renal (Vanilla)

- Liquid 3 g protein, 25.5 g carbohydrate and 10 g fat per 100 ml, 237 ml bottle
- Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton

**Restricted (RS1228)**

Initiation

For patients with acute or chronic kidney disease.

**Respiratory Products**

LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – **Restricted** see terms below

- Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle......1.66
- 237 ml Pulmocare (Vanilla)

**Restricted (RS1230)**

Initiation

For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

**Surgical Products**

HIGH ARGININE ORAL FEED 1.4 KCAL/ML – **Restricted** see terms below

- Liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton.................................................................4.00
- 178 ml Impact Advanced Recovery

**Restricted (RS1231)**

Initiation

Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.

PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – **Restricted** see terms below

- Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle.................................................................6.80
- 4 preOp

**Restricted (RS1415)**

Initiation

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

**Standard Feeds**

**Restricted (RS1214)**

Initiation

Any of the following:
For patients with malnutrition, defined as any of the following:

1. Any of the following:
   1.1 BMI < 18.5; or
   1.2 Greater than 10% weight loss in the last 3-6 months; or
   1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
2. For patients who have, or are expected to, eat little or nothing for 5 days; or
3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4. For use pre- and post-surgery; or
5. For patients being tube-fed; or
6. For tube-feeding as a transition from intravenous nutrition; or
7. For any other condition that meets the community Special Authority criteria.

**ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms on the previous page

- Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag..............7.00 1,000 ml Nutrison Energy
- Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

- Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can.............1.75 250 ml Ensure Plus HN
- Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag........7.00 1,000 ml Ensure Plus HN RTH
- Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag.................................................................................................7.00 1,000 ml Jevity HiCal RTH

**ENTERAL FEED 1 KCAL/ML – Restricted** see terms on the previous page

- Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle.........5.29 1,000 ml Osmolite RTH
- Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle..............................................................................................5.29 1,000 ml Jevity RTH
- Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag

- Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

**ENTERAL FEED 1.2 KCAL/ML – Restricted** see terms on the previous page

- Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag

**ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted** see terms on the previous page

- Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bag.................................................................................................5.29 1,000 ml Nutrison 800 Complete Multi Fibre
### ORAL FEED – Restricted see terms on page 226

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure (Chocolate)</td>
<td>$26.00 850 g</td>
</tr>
<tr>
<td>Ensure (Vanilla)</td>
<td>$8.54 857 g</td>
</tr>
<tr>
<td>Sustagen Hospital</td>
<td>$26.00 840 g</td>
</tr>
<tr>
<td>Formula Active (Choc)</td>
<td></td>
</tr>
<tr>
<td>Formula Active (Van)</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer’s surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.

### ORAL FEED 1 KCAL/ML – Restricted see terms on page 226

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure Plus (Vanilla)</td>
<td>$1.33 237 ml</td>
</tr>
<tr>
<td>Ensure Plus (Banana)</td>
<td>$1.26 200 ml</td>
</tr>
<tr>
<td>Ensure Plus (Chocolate)</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Fruit of the Forest)</td>
<td></td>
</tr>
<tr>
<td>e.g. Resource Fruit Beverage</td>
<td></td>
</tr>
</tbody>
</table>

### ORAL FEED 1.5 KCAL/ML – Restricted see terms on page 226

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure Plus (Vanilla)</td>
<td>$1.33 237 ml</td>
</tr>
<tr>
<td>Ensure Plus (Banana)</td>
<td>$1.26 200 ml</td>
</tr>
<tr>
<td>Ensure Plus (Chocolate)</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Fruit of the Forest)</td>
<td></td>
</tr>
<tr>
<td>e.g. Fortijuice</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortisip</td>
<td>$1.33 237 ml</td>
</tr>
<tr>
<td>Fortiip Multi Fibre</td>
<td></td>
</tr>
</tbody>
</table>

**e.g. Brand** indicates brand example only. **It is not a contracted product.**
Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – Restricted see terms below

Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemaglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe

– 0% DV Sep-17 to 2020 ..........................................................0.00 10 Infanrix IPV

Initiation
Any of the following:
1 A single dose for children up to the age of 7 who have completed primary immunisation; or
2 A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
4 Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted see terms below

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemaglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial

– 0% DV Sep-17 to 2020 ..........................................................0.00 10 Infanrix-hexa

Initiation
Any of the following:
1 Up to four doses for children up to and under the age of 10 for primary immunisation; or
2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe

– 0% DV Jul-17 to 2020 ..........................................................0.00 5 ADT Booster

Initiation
Any of the following:
1 For vaccination of patients aged 45 and 65 years old; or
2 For vaccination of previously unimmunised or partially immunised patients; or
continued…
  3 For revaccination following immunosuppression; or
  4 For boosting of patients with tetanus-prone wounds; or
  5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

BACILLUS CALMETTE-GUERIN VACCINE – Restricted see terms below

 vụ
Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent

**Restricted (RS1233)**

Initiation

All of the following:
  1 Living in a house or family with a person with current or past history of TB; and
  2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and
  3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.


DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted see terms below

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemaglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 0% DV Sep-17 to 2020

**Restricted (RS1493)**

Initiation

Any of the following:
  1 A single vaccine for pregnant woman between gestational weeks 28 and 38; or
  2 A course of up to four vaccines is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
  3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted see terms below

Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml

**Restricted (RS1520)**

Initiation

**Therapy limited to 1 dose**

Any of the following:
  1 For primary vaccination in children; or
  2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
  3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial –</th>
</tr>
</thead>
<tbody>
<tr>
<td>0% DV Jul-17 to 2020................................................................................0.00 1</td>
</tr>
</tbody>
</table>

→ Restricted (RS1481)

**Initiation**

Any of the following:

1. Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
2. One dose for close contacts of meningococcal cases; or
3. A maximum of two doses for bone marrow transplant patients; or
4. A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

| Inj 10 mcg in 0.5 ml syringe – 0% DV Jul-17 to 2020..........................0.00 1 |

→ Restricted (RS1482)

**Initiation**

Any of the following:

1. Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
2. One dose for close contacts of meningococcal cases; or
3. A maximum of two doses for bone marrow transplant patients; or
4. A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – Restricted see terms below

| mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe – 0% DV Sep-17 to 2020...............0.00 10 |

→ Restricted (RS1585)

**Initiation**

Either:

1. A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
2. Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV13.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terms below

| Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe...........................................0.00 1 |

→ Restricted (RS1586)

**Initiation – High risk children who have received PCV10**

*Therapy limited to 1 dose*

One dose is funded for high risk children (over the age of 17 months and under 18 years) who have previously received four doses of PCV10.

continued…
continued…

Initiation – High risk children aged under 5 years

*Therapy limited to 4 doses*

Both:

1. Up to an additional four doses (as appropriate) are funded for children aged under 5 years for (re-)immunisation; and
2. Any of the following:
   2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2.2 With primary immune deficiencies; or
   2.3 With HIV infection; or
   2.4 With renal failure, or nephrotic syndrome; or
   2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   2.6 With cochlear implants or intracranial shunts; or
   2.7 With cerebrospinal fluid leaks; or
   2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   2.10 Pre term infants, born before 28 weeks gestation; or
   2.11 With cardiac disease, with cyanosis or failure; or
   2.12 With diabetes; or
   2.13 With Down syndrome; or
   2.14 Who are pre-or post-splenectomy, or with functional asplenia.

Initiation – High risk adults and children 5 years and over

*Therapy limited to 4 doses*

Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation – Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

**PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25</td>
<td></td>
</tr>
</tbody>
</table>

* Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 0% DV Jul-17 to 2020…………………………………………………………0.00 1 Pneumovax 23

* Restricted (RS1587)*

Initiation – High risk patients

*Therapy limited to 3 doses*

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation – High risk children

*Therapy limited to 2 doses*

Both:

1. Patient is a child under 18 years for (re-)immunisation; and
2. Any of the following:
   2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2.2 With primary immune deficiencies; or
   2.3 With HIV infection; or
   2.4 With renal failure, or nephrotic syndrome; or
   2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   2.6 With cochlear implants or intracranial shunts; or
   2.7 With cerebrospinal fluid leaks; or
   2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   2.10 Pre term infants, born before 28 weeks gestation; or
   2.11 With cardiac disease, with cyanosis or failure; or
   2.12 With diabetes; or
   2.13 With Down syndrome; or
   2.14 Who are pre-or post-splenectomy, or with functional asplenia.

continued…
### VACCINES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**continued…**

<table>
<thead>
<tr>
<th>response; or</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2 With primary immune deficiencies; or</td>
</tr>
<tr>
<td>2.3 With HIV infection; or</td>
</tr>
<tr>
<td>2.4 With renal failure, or nephrotic syndrome; or</td>
</tr>
<tr>
<td>2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or</td>
</tr>
<tr>
<td>2.6 With cochlear implants or intracranial shunts; or</td>
</tr>
<tr>
<td>2.7 With cerebrospinal fluid leaks; or</td>
</tr>
<tr>
<td>2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or</td>
</tr>
<tr>
<td>2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or</td>
</tr>
<tr>
<td>2.10 Pre term infants, born before 28 weeks gestation; or</td>
</tr>
<tr>
<td>2.11 With cardiac disease, with cyanosis or failure; or</td>
</tr>
<tr>
<td>2.12 With diabetes; or</td>
</tr>
<tr>
<td>2.13 With Down syndrome; or</td>
</tr>
<tr>
<td>2.14 Who are pre-or post-splenectomy, or with functional asplenia.</td>
</tr>
</tbody>
</table>

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

**SALMONELLA TYPHI VACCINE – Restricted see terms below**

- Inj 25 mcg in 0.5 ml syringe
  - Restricted (RS1243)

**Initiation**

For use during typhoid fever outbreaks.

**Viral Vaccines**

**HEPATITIS A VACCINE – Restricted see terms below**

- Inj 720 ELISA units in 0.5 ml syringe – 0% DV Sep-17 to 2020 ........................ 0.00 1 Havrix Junior
- Inj 1440 ELISA units in 1 ml syringe – 0% DV Sep-17 to 2020 ........................ 0.00 1 Havrix
  - Restricted (RS1638)

**Initiation**

Any of the following:

1. Two vaccinations for use in transplant patients; or
2. Two vaccinations for use in children with chronic liver disease; or
3. One dose of vaccine for close contacts of known hepatitis A cases.

**HEPATITIS B RECOMBINANT VACCINE**

- Inj 5 mcg in 0.5 ml vial – 0% DV Jul-17 to 2020 ........................................... 0.00 1 HBvaxPRO
  - Restricted (RS1588)

**Initiation**

Any of the following:

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or

**continued…**
## VACCINES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

continued…

- for patients following non-consensual sexual intercourse; or
- For patients following immunosuppression; or
- For solid organ transplant patients; or
- For post-haematopoietic stem cell transplant (HSCT) patients; or
- Following needle stick injury.

**Inj 10 mcg in 1 ml vial**

- **Restricted (RS1588)**

  **Initiation**

  Any of the following:

  - For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
  - For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
  - For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
  - For HIV positive patients; or
  - For hepatitis C positive patients; or
  - For patients following non-consensual sexual intercourse; or
  - For patients following immunosuppression; or
  - For solid organ transplant patients; or
  - For post-haematopoietic stem cell transplant (HSCT) patients; or
  - Following needle stick injury.

- **Inj 20 mcg per 1 ml prefilled syringe**

  - **Restricted (RS1671)**

  **Initiation**

  Any of the following:

  - For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
  - For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
  - For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
  - For HIV positive patients; or
  - For hepatitis C positive patients; or
  - For patients following non-consensual sexual intercourse; or
  - For patients following immunosuppression; or
  - For solid organ transplant patients; or
  - For post-haematopoietic stem cell transplant (HSCT) patients; or
  - Following needle stick injury; or
  - For dialysis patients; or
  - For liver or kidney transplant patients.

- **Inj 40 mcg per 1 ml vial – 0% DV Jul-17 to 2020**

  - **Restricted (RS1413)**

  **Initiation**

  Both:

  - For dialysis patients; and
  - For liver or kidney transplant patient.

**HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV]**

- **Restricted** see terms on the next page

- **Inj 270 mcg in 0.5 ml syringe – 0% DV Jun-17 to 2020**

  - **Gardasil 9**
**VACCINES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**⇒ Restricted (RS1556)**

Initiation – Children aged 14 years and under

*Therapy limited to 2 doses*

Children aged 14 years and under.

**Initiation – other conditions**

Either:

1. Up to 3 doses for people aged 15 to 26 years inclusive; or
2. Both:
   1. People aged 9 to 26 years inclusive; and
   2. Any of the following:
      1. Up to 3 doses for confirmed HIV infection; or
      2. Up to 3 doses for transplant (including stem cell) patients; or
      3. Up to 4 doses for Post chemotherapy.

**INFLUENZA VACCINE**

- Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)..........................9.00 1 Fluarix Tetra

**⇒ Restricted (RS1675)**

Initiation – cardiovascular disease for patients aged 6 months to 35 months

Any of the following:

1. Ischaemic heart disease; or
2. Congestive heart failure; or
3. Rheumatic heart disease; or
4. Congenital heart disease; or
5. Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

**Initiation – chronic respiratory disease for patients aged 6 months to 35 months**

Either:

1. Asthma, if on a regular preventative therapy; or
2. Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

**Initiation – Other conditions for patients aged 6 months to 35 months**

Any of the following:

1. Diabetes; or
2. Chronic renal disease; or
3. Any cancer, excluding basal and squamous skin cancers if not invasive; or
4. Autoimmune disease; or
5. Immune suppression or immune deficiency; or
6. HIV; or
7. Transplant recipient; or
8. Neuromuscular and CNS diseases/ disorders; or
9. Haemoglobinopathies; or
10. Is a child on long term aspirin; or
11. Has a cochlear implant; or
12. Errors of metabolism at risk of major metabolic decompensation; or
13. Pre and post splenectomy; or
14. Down syndrome; or
15. Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness.

- Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).........................................90.00 10 Influvac Tetra
**VACCINES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

---

**Restricted (RS1674)**

**Initiation – People over 65**

The patient is 65 years of age or over.

**Initiation – cardiovascular disease for patients 3 years and over**

Any of the following:

1. Ischaemic heart disease; or
2. Congestive heart failure; or
3. Rheumatic heart disease; or
4. Congenital heart disease; or
5. Cerebro-vascular disease.

Note: Hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

**Initiation – chronic respiratory disease for patients 3 years and over**

Either:

1. Asthma, if on a regular preventative therapy; or
2. Other chronic respiratory disease with impaired lung function.

Note: Asthma not requiring regular preventative therapy is excluded from funding.

**Initiation – Other conditions for patients 3 years and over**

Either:

1. Any of the following:
   1.1 Diabetes; or
   1.2 Chronic renal disease; or
   1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
   1.4 Autoimmune disease; or
   1.5 Immune suppression or immune deficiency; or
   1.6 HIV; or
   1.7 Transplant recipient; or
   1.8 Neuromuscular and CNS diseases/disorders; or
   1.9 Haemoglobinopathies; or
   1.10 Is a child on long term aspirin; or
   1.11 Has a cochlear implant; or
   1.12 Errors of metabolism at risk of major metabolic decompensation; or
   1.13 Pre and post splenectomy; or
   1.14 Down syndrome; or
   1.15 Is pregnant; or
   1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
2. Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital.

---

**MEASLES, MUMPS AND RUBELLA VACCINE – Restricted see terms below**

Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent

0.5 ml – 0% DV Sep-17 to 2020 ...............................................................0.00 10 Priorix

**Restricted (RS1487)**

**Initiation – first dose prior to 12 months**

**Therapy limited to 3 doses**

Any of the following:

---

Item restricted (see ➥ above); Item restricted (see ➥ below)

e.g. Brand indicates brand example only. It is not a contracted product.

continued…
continued...

1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella.

**Initiation – first dose after 12 months**

*Therapy limited to 2 doses*

Any of the following:

1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

**POLIOMYELITIS VACCINE** – *Restricted* see terms **below**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 80 D-antigen units in 0.5 ml syringe – 0% DV Jul-17 to 2020</td>
<td>$0.00 1</td>
<td>IPOL</td>
</tr>
</tbody>
</table>

*Restricted (RS1398)*

**Initiation**

*Therapy limited to 3 doses*

Either:

1. For partially vaccinated or previously unvaccinated individuals; or
2. For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**RABIES VACCINE**

Inj 2.5 IU vial with diluent

**ROTAVIRUS ORAL VACCINE** – *Restricted* see terms **below**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – 0% DV Sep-17 to 2020</td>
<td>$0.00 10</td>
<td>Rotarix</td>
</tr>
</tbody>
</table>

*Restricted (RS1590)*

**Initiation**

*Therapy limited to 2 doses*

Both:

1. First dose to be administered in infants aged under 14 weeks of age; and
2. No vaccination being administered to children aged 24 weeks or over.

**VARICELLA VACCINE [CHICKENPOX VACCINE]** – *Restricted* see terms **below**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2000 PFU prefilled syringe plus vial – 0% DV Sep-17 to 2020</td>
<td>$0.00 10</td>
<td>Varilrix</td>
</tr>
</tbody>
</table>

*Restricted (RS1591)*

**Initiation – primary vaccinations**

*Therapy limited to 1 dose*

Either:

1. Any infant born on or after 1 April 2016; or
2. For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox).

**Initiation – other conditions**

*Therapy limited to 2 doses*

Any of the following:

1. Any of the following:
   - for non-immune patients:
### Diagnostic Agents

**TUBERCULIN PPD [MANTOUX] TEST**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 TU per 0.1 ml, 1 ml vial</td>
<td>0.00</td>
<td>Zostavax</td>
</tr>
</tbody>
</table>

Note: * immnosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

**VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted see terms below**

- Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine] ................................................................. 0.00 1 Zostavax

- **Restricted (RS1619)**
  - **Initiation – people aged 65 years**
    - Therapy limited to 1 dose
    - One dose for all people aged 65 years.
  - **Initiation – people aged between 66 and 80 years**
    - Therapy limited to 1 dose
    - One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 March 2020.

**Tubersol**
### Optional Pharmaceuticals

**NOTE:**

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at www.pharmac.govt.nz. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLOOD GLUCOSE DIAGNOSTIC TEST METER</td>
<td>$20.00</td>
<td>CareSens N Premier</td>
</tr>
<tr>
<td>1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips</td>
<td>$10.00</td>
<td>Caresens N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caresens N POP</td>
</tr>
<tr>
<td>BLOOD GLUCOSE DIAGNOSTIC TEST STRIP</td>
<td>$10.56</td>
<td>CareSens N</td>
</tr>
<tr>
<td>Blood glucose test strips</td>
<td></td>
<td>Caresens PRO</td>
</tr>
<tr>
<td>Test strips</td>
<td>$10.56</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLOOD KETONE DIAGNOSTIC TEST STRIP</td>
<td>$15.50</td>
<td>KetoSens</td>
</tr>
<tr>
<td>Test strips</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER</td>
<td>$20.00</td>
<td>CareSens Dual</td>
</tr>
<tr>
<td>Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic test strips</td>
<td>$10.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MASK FOR SPACER DEVICE</td>
<td>$2.20</td>
<td>e-chamber Mask</td>
</tr>
<tr>
<td>Small</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEAK FLOW METER</td>
<td>$9.54</td>
<td>Mini-Wright AFS Low Range</td>
</tr>
<tr>
<td>Low Range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal Range</td>
<td>$9.54</td>
<td>Mini-Wright Standard</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PREGNANCY TEST - HCG URINE</td>
<td>$12.00</td>
<td>Smith BioMed Rapid Pregnancy Test</td>
</tr>
<tr>
<td>Cassette</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM NITROPRUSSIDE</td>
<td>$22.00</td>
<td>Ketostix</td>
</tr>
<tr>
<td>Test strip</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPACER DEVICE</td>
<td>$2.95</td>
<td>e-chamber Turbo</td>
</tr>
<tr>
<td>220 ml (single patient)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>510 ml (single patient)</td>
<td>$5.12</td>
<td>e-chamber La Grande</td>
</tr>
<tr>
<td>800 ml</td>
<td>$6.50</td>
<td>Volumatic</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

- Symbols -

8-methoxypsoralen ........................................ 55

A -

A-Scabies ................................................ 52
Abacavir sulphate ........................................ 86
Abacavir sulphate with lamivudine ....................... 86
Abicimabant ............................................... 151
Abiraterone acetate ....................................... 142
Acarboside ................................................. 8
Accuretic 10 .............................................. 37
Accuretic 20 .............................................. 37
Acetazolamide ............................................. 200
Acetic acid
Extemporarily Compounded Preparations ............... 211

Genito-Urinary .......................................... 196
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid ......................................................... 57
Acetic acid with propylene glycol .......................... 202
Acetylcholine chloride ...................................... 200
Acetylecysteine ............................................ 203

Aciclovir
Infections .................................................. 89
Sensory...................................................... 196

Aciclovir-Claris ........................................... 89
Acid Citrate Dextrose A ................................ 30
Acidex ........................................................ 5
Acipimox ...................................................... 45
Acitretin ...................................................... 55

Acetaste ..................................................... 94
Actemra ...................................................... 179
Actinomycin D ............................................. 129
Adalat 10 ................................................... 42
Adalat Oros ................................................ 42
Adalimumab ................................................ 151
Adapalene .................................................... 52
Adefovir dipivoxil ......................................... 88
Adenosine ..................................................... 39
Adenuric ...................................................... 99
Adrenaline ................................................... 46

ADT Booster ............................................... 229
Adult diphtheria and tetanus vaccine ....................... 229

Advantan .................................................... 54
Advate ........................................................ 28
Adynovate ................................................... 28
Aerrane ........................................................ 104
Afinitor ....................................................... 186
Aflibercept ................................................... 158

Agents Affecting the Renin-Angiotensin System ........ 37
Agents for Parkinsonism and Related Disorders ........ 103

Agents Used in the Treatment of Poisonings .......... 203
Ajmaline ..................................................... 39
Alamast ....................................................... 188
Albendazole ................................................ 83
Aldurazyn .................................................... 15
Aleronate sodium ........................................... 94
Aleronate sodium with colecalciferol ..................... 94
Alfalcacidol .................................................. 21
Alfamino Junior ............................................ 222
Alfentanil ..................................................... 108
Alguclosidase alfa ......................................... 13
Alinia .......................................................... 84
Allersothe ................................................... 189
Allmercap .................................................... 131
Allopurinol ................................................... 98
Alpha tocopherol .......................................... 21
Alpha tocopherol acetate .................................. 22
Alpha-Adrenoceptor Blockers ............................. 38
Alphamox 125 ............................................. 76
Alphamox 250 ............................................. 76
Alprolix ....................................................... 27
Alprostadil hydrochloride ................................ 47
Alteplase ..................................................... 32
Alum .......................................................... 211
Aluminium chloride ................................ ........ 25
Aluminium hydroxide ................................ ...... 5
Aluminium hydroxide with magnesium hydroxide and simeticone .................................................. 5
Amantadine hydrochloride ................................ 103
AmBisome .................................................... 80
Ambrisentan ................................................ 48
Amethocaine
Nervous ....................................................... 107
Sensory ....................................................... 199
Amikacin ..................................................... 72
Amiloride hydrochloride ................................... 43
Amlodipine ................................................... 43
Amlodipine with furosemide ................................ 43
Amlodipine hydrochloride with hydrochlorothiazide .... 43
Aminoacylating acid hydrochloride ......................... 144
Aminophylline .............................................. 194
Amiodarone hydrochloride ................................ 39
Amisulpride .................................................. 117
 Amitriptyline ............................................... 110
Amlodipine ................................................... 41
Amorolfine .................................................... 51
Amoxicillin ................................................... 76
Amoxicillin with clavulanic acid ........................... 76

Amphotericin B
Alimentary ................................................... 19
Infections ..................................................... 80
Amsacrine .................................................... 132
Amfyl nitrite .................................................. 203
Anabolic Agents ............................................ 62
Aneasthetics ................................................ 104
Anagrelide hydrochloride .................................. 132
Algesics ....................................................... 107
Anastrozole ................................................ 144
Andriol Testocaps ......................................... 62
Androderm ................................................... 62
Androgen Agons and Antagonists ......................... 62
Anore Efilla .................................................. 190
Antabuse ..................................................... 126
Antacids and Antiflatulents ................................. 5
Anti-Infective Agents ...................................... 57
Anti-Infective Preparations
Dermatological ............................................. 51
Sensory ....................................................... 196
Anti-Inflammatory Preparations ......................... 197
Antiacne Preparations ..................................... 52
Antiallergy Preparations ................................... 188
Antitanaemcs ............................................... 23
Antiarhythmic ................................................. 39
Antibacterials ............................................... 72
Anticholinergic Agents .................................... 189
Anticholinesterases ........................................ 94
Antidepressants ............................................. 110
Antidiarrhoeals and Intestinal Anti-Inflammatory Agents .................................................. 5
Antiepilepsy Drugs .......................................... 111
Antifibrinolytics, Haemostatics and Local Sclerosants .................................................. 25
Antifibrotics ................................................... 190
Antifungals .................................................... 80
Antihypotensives .......................................... 40
Antimigraine Preparations ................................ 115
Antimycobacterials ......................................... 82
Antinausea and Vertigo Agents ............................. 116
Antiparasitics ............................................... 83
Antipruritic Preparations ................................... 52
Antipsychotic Agents ...................................... 117
Antiretrovirals ............................................... 85
Antirheumatoid Agents .................................... 94
Antisepsics and Disinfectants .............................. 205
Antispasmodics and Other Agents
Alterating Gut Motility .................................... 7
Antithrombotics ............................................. 29
Antithymocyte globulin (equine) ......................... 185
Antithymocyte globulin (rabbit) ......................... 186
Antilucerants ............................................... 7
<table>
<thead>
<tr>
<th>Antivirals</th>
<th>Arrow-Brimonidine</th>
<th>Avonex Pen</th>
<th>88</th>
<th>121</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiolytics</td>
<td>Arrow-Calcium</td>
<td>Azacitine</td>
<td>120</td>
<td>130</td>
</tr>
<tr>
<td></td>
<td>Arrow-Diazepam</td>
<td>Azacitine Dr Reddy's</td>
<td>120</td>
<td>130</td>
</tr>
<tr>
<td>Apida</td>
<td>Arrow-Fluoxetine</td>
<td>Azactam</td>
<td>111</td>
<td>78</td>
</tr>
<tr>
<td>Apida Solostar</td>
<td>Arrow-Lamotrigine</td>
<td>Azathioprine</td>
<td>113</td>
<td>186</td>
</tr>
<tr>
<td>Apo-Amlodipine</td>
<td></td>
<td>Azithromycin</td>
<td>77</td>
<td>74</td>
</tr>
<tr>
<td>Apo-Amoxi</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Azithromycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Ciclopirox</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Cilazapril</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Cilazapril/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Clarithromycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Clomipramine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Diclo SR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Diltiazem CD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Doxazosin</td>
<td>38</td>
<td></td>
<td>200</td>
<td>109</td>
</tr>
<tr>
<td>Apo-Folic Acid</td>
<td>110</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Gabapentin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Lefunomide</td>
<td>112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Megestrol</td>
<td>143</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Metoprol</td>
<td>41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Mirtazapine</td>
<td>111</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Montelukast</td>
<td>193</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Nadolol</td>
<td>41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Nicotinic Acid</td>
<td>94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Onandsetron</td>
<td>116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Oxybutynin</td>
<td>60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Paroxetine</td>
<td>111</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Perindopril</td>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Pindolol</td>
<td>41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Prazosin</td>
<td>38</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Prednisone</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Propranolol</td>
<td>41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Pyridoxine</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Ropinrole</td>
<td>104</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Sumatriptan</td>
<td>115</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo-Terazosin</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apomorphone hydrochloride</td>
<td>103</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apraclonidine</td>
<td>201</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aprepitant</td>
<td>116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aresoline</td>
<td>47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aprotinin</td>
<td>25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aqueous cream</td>
<td>53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arachis oil [Peanut oil]</td>
<td>211</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aratex</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alimentary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extemporaneously</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sensory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td>Sensory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritax</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Brimonidine</td>
<td>201</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Calcium</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Diazepam</td>
<td>120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Fluoxetine</td>
<td>111</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Lamotrigine</td>
<td>113</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Losartan &amp;</td>
<td>Hydrochlorothiazide</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Morphine LA</td>
<td>109</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Norfloxacin</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Ormidazole</td>
<td>84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Quinapril 10</td>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Quinapril 20</td>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Quinapril 5</td>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Roxithromycin</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Sertraline</td>
<td>111</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Timol</td>
<td>200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Tolterodine</td>
<td>61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Topiramate</td>
<td>114</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrow-Tramadol</td>
<td>110</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>132</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artemether with lumefantrine</td>
<td>84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artesunate</td>
<td>84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Articaine hydrochloride</td>
<td>105</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Articaine hydrochloride with</td>
<td>adrenaline</td>
<td>105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asacol</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asam</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascobic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Blood</td>
<td>31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Nervous</td>
<td>107</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthalin</td>
<td>192</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir sulphate</td>
<td>87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atenolol</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atenolol-AFT</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atovaqune with proguanil</td>
<td>hydrochloride</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atracurium besylate</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrop</td>
<td>201</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ativan</td>
<td>120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atomoxetine</td>
<td>123</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aztreonam</td>
<td>78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacillus calmette-guerin (BCG)</td>
<td>186</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balanced Salt Solution</td>
<td>199</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barium sulphate</td>
<td>206</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barium sulphate with sodium bicarbonate</td>
<td>206</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barrier Creams and Emollients</td>
<td>52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basilikimab</td>
<td>159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCG Vaccine</td>
<td>230</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BD PosiFlush</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclazone 100</td>
<td>192</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclazone 250</td>
<td>192</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclazone 50</td>
<td>192</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>188</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bee venom</td>
<td>188</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendamustine hydrochloride</td>
<td>128</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendrofluazide</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendrofluimethiazide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Bendrofluazide]</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BeneFIX</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzathine benzy/penicillin</td>
<td>76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benztropine mesylate</td>
<td>103</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzbramaron AL 100</td>
<td>99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzbramaron</td>
<td>99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzocaine</td>
<td>105</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzoin</td>
<td>211</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzyl peroxide</td>
<td>52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benztraxop</td>
<td>103</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzydamine hydrochloride</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzydamine hydrochloride with cetylpyridinium chloride</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzy/penicillin sodium [Penicillin G]</td>
<td>76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beracant</td>
<td>194</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta Cream</td>
<td>54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta Ointment</td>
<td>54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta Scalp</td>
<td>55</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-Adrenoceptor Agonists</td>
<td>192</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-Adrenoceptor Blockers</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betadine</td>
<td>205</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betadine Skin Prep</td>
<td>205</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celol</td>
<td>40</td>
</tr>
<tr>
<td>Centrally-Acting Agents</td>
<td>43</td>
</tr>
<tr>
<td>Cephalexin ABM</td>
<td>73</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>189</td>
</tr>
<tr>
<td>Cetomacrogol</td>
<td>53</td>
</tr>
<tr>
<td>Cetomacrogol with glycerol</td>
<td>53</td>
</tr>
<tr>
<td>Cetrimeid</td>
<td>211</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>160</td>
</tr>
<tr>
<td>Charcoal</td>
<td>204</td>
</tr>
<tr>
<td>Chemotherapeutic Agents</td>
<td>128</td>
</tr>
<tr>
<td>Chickenpox vaccine</td>
<td>237</td>
</tr>
<tr>
<td>Chlorafast</td>
<td>196</td>
</tr>
<tr>
<td>Chloral hydrate</td>
<td>121</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>129</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>78</td>
</tr>
<tr>
<td>Sensory</td>
<td>196</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>205</td>
</tr>
<tr>
<td>Chlorhexidine gluconate</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>19</td>
</tr>
<tr>
<td>Extemporaneously Compounded</td>
<td>211</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>57</td>
</tr>
<tr>
<td>Chlorhexidine with cetrimide</td>
<td>205, 208</td>
</tr>
<tr>
<td>Chlorhexidine with ethanol</td>
<td>205</td>
</tr>
<tr>
<td>Chloroform</td>
<td>211</td>
</tr>
<tr>
<td>Chloroquine phosphate</td>
<td>84</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>44</td>
</tr>
<tr>
<td>Chlorpheniramine maleate</td>
<td>189</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>117</td>
</tr>
<tr>
<td>Chlorsig</td>
<td>196</td>
</tr>
<tr>
<td>Chlortalidone [Chlortalidone]</td>
<td>44</td>
</tr>
<tr>
<td>Chlorthalidone</td>
<td>44</td>
</tr>
<tr>
<td>Choice Load 375</td>
<td>58</td>
</tr>
<tr>
<td>Choice TT380 Short</td>
<td>58</td>
</tr>
<tr>
<td>Choice TT380 Standard</td>
<td>58</td>
</tr>
<tr>
<td>Cholestyramine</td>
<td>45</td>
</tr>
<tr>
<td>Choline salicylate with cetylalum chloride</td>
<td>19</td>
</tr>
<tr>
<td>Choriongonadotropin alfa</td>
<td>66</td>
</tr>
<tr>
<td>Ciclopirox olamine</td>
<td>51</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>145</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>89</td>
</tr>
<tr>
<td>Cilazapril</td>
<td>37</td>
</tr>
<tr>
<td>Cilazapril with hydrochlorothiazide</td>
<td>37</td>
</tr>
<tr>
<td>Cilicaine</td>
<td>76</td>
</tr>
<tr>
<td>Cilicaine VK</td>
<td>76</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>7</td>
</tr>
<tr>
<td>Cinacalcet</td>
<td>62</td>
</tr>
<tr>
<td>Cinchocaine hydrochloride with hydrocortisone</td>
<td>6</td>
</tr>
<tr>
<td>Cipflox</td>
<td>77</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>77</td>
</tr>
<tr>
<td>Sensory</td>
<td>196</td>
</tr>
<tr>
<td>Ciprofloxacin Teva</td>
<td>196</td>
</tr>
<tr>
<td>Ciprofloxacin with hydrocortisone</td>
<td></td>
</tr>
<tr>
<td>Ciprox HC Otic</td>
<td>196</td>
</tr>
<tr>
<td>Circadin</td>
<td>121</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>136</td>
</tr>
<tr>
<td>Citalopram hydrobromide</td>
<td>111</td>
</tr>
<tr>
<td>Citastat</td>
<td>106</td>
</tr>
<tr>
<td>Citrate sodium</td>
<td>29</td>
</tr>
<tr>
<td>Citric acid</td>
<td>211</td>
</tr>
<tr>
<td>Citric acid with magnesium oxide and sodium picosulfate</td>
<td>11</td>
</tr>
<tr>
<td>Citric acid with sodium bicarbonate</td>
<td>207</td>
</tr>
<tr>
<td>Cladrabine</td>
<td>130</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>75</td>
</tr>
<tr>
<td>Clefane</td>
<td>61</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>78</td>
</tr>
<tr>
<td>Clindamycin ABM</td>
<td>78</td>
</tr>
<tr>
<td>Clinicians Multivit &amp; Mineral Boost</td>
<td>19</td>
</tr>
<tr>
<td>Clinicians Renal Vit</td>
<td>19</td>
</tr>
<tr>
<td>Clofazime</td>
<td>82</td>
</tr>
<tr>
<td>Clomazol</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>51</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>57</td>
</tr>
<tr>
<td>Clofilene citrate</td>
<td>65</td>
</tr>
<tr>
<td>Clomipramine hydrochloride</td>
<td>110</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>111–12, 120</td>
</tr>
<tr>
<td>Clonidine</td>
<td>43</td>
</tr>
<tr>
<td>Clonidine BNM</td>
<td>43</td>
</tr>
<tr>
<td>Clonidine hydrochloride</td>
<td>43</td>
</tr>
<tr>
<td>Clodipogrel</td>
<td>31</td>
</tr>
<tr>
<td>Clopine</td>
<td>117</td>
</tr>
<tr>
<td>Clopixol</td>
<td>118, 120</td>
</tr>
<tr>
<td>Clostridum botulinum type A toxin</td>
<td>100</td>
</tr>
<tr>
<td>Clotrimazole</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>51</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>57</td>
</tr>
<tr>
<td>Clove oil</td>
<td>211</td>
</tr>
<tr>
<td>Clozapine</td>
<td>117</td>
</tr>
<tr>
<td>Clozaril</td>
<td>117</td>
</tr>
<tr>
<td>Clustan</td>
<td>115</td>
</tr>
<tr>
<td>Co-trimoxazole</td>
<td>79</td>
</tr>
<tr>
<td>Coal tar</td>
<td>211</td>
</tr>
<tr>
<td>Coal tar with salicylic acid and sulphur</td>
<td>55</td>
</tr>
<tr>
<td>Cocaine hydrochloride</td>
<td>105</td>
</tr>
<tr>
<td>Cocaine hydrochloride with adrenaline</td>
<td>106</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>211</td>
</tr>
<tr>
<td>Nervous</td>
<td>108</td>
</tr>
<tr>
<td>Cogentin</td>
<td>103</td>
</tr>
<tr>
<td>Colaspase [L-asparaginase]</td>
<td>133</td>
</tr>
<tr>
<td>Colchicine</td>
<td>99</td>
</tr>
<tr>
<td>Colecalticel</td>
<td>21</td>
</tr>
<tr>
<td>Colestimethate</td>
<td>78</td>
</tr>
<tr>
<td>Colestipol hydrochloride</td>
<td>45</td>
</tr>
<tr>
<td>Colgout</td>
<td>99</td>
</tr>
<tr>
<td>Colifoam</td>
<td>6</td>
</tr>
<tr>
<td>Colestin sulphomethate</td>
<td></td>
</tr>
<tr>
<td>[Colestimethate]</td>
<td>78</td>
</tr>
<tr>
<td>Colisat-Link</td>
<td>78</td>
</tr>
<tr>
<td>Collodion flexible</td>
<td>211</td>
</tr>
<tr>
<td>Colloidal bismuth citrate</td>
<td>8</td>
</tr>
<tr>
<td>Colofac</td>
<td>7</td>
</tr>
<tr>
<td>Colony-Stimulating Factors</td>
<td>32</td>
</tr>
<tr>
<td>Coloxyl</td>
<td>12</td>
</tr>
<tr>
<td>Compound electrolytes</td>
<td>33, 35</td>
</tr>
<tr>
<td>Compound electrolytes with glucose</td>
<td></td>
</tr>
<tr>
<td>[Dextrose]</td>
<td>33, 36</td>
</tr>
<tr>
<td>Compound hydroxybenzoate</td>
<td>211</td>
</tr>
<tr>
<td>Compound sodium lactate</td>
<td></td>
</tr>
<tr>
<td>[Hartmann's solution]</td>
<td>33</td>
</tr>
<tr>
<td>Concerta</td>
<td>124</td>
</tr>
<tr>
<td>Condylone</td>
<td>56</td>
</tr>
<tr>
<td>Contraceptives</td>
<td>57</td>
</tr>
<tr>
<td>Contrast Media</td>
<td>206</td>
</tr>
<tr>
<td>Copaxone</td>
<td>121</td>
</tr>
<tr>
<td>Cordarone-X</td>
<td>39</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>54</td>
</tr>
<tr>
<td>Hormone Preparations</td>
<td>63</td>
</tr>
<tr>
<td>Corticotrelin (ovine)</td>
<td>66</td>
</tr>
<tr>
<td>Cosentynex</td>
<td>177</td>
</tr>
<tr>
<td>Cosmegen</td>
<td>129</td>
</tr>
<tr>
<td>Cough Suppressants</td>
<td>192</td>
</tr>
<tr>
<td>Creon 10000</td>
<td>10</td>
</tr>
<tr>
<td>Creon 25000</td>
<td>10</td>
</tr>
<tr>
<td>Crotamiton</td>
<td>52</td>
</tr>
<tr>
<td>Crystaderm</td>
<td>51</td>
</tr>
<tr>
<td>CT Plus+</td>
<td>206</td>
</tr>
<tr>
<td>Cubicin</td>
<td>78</td>
</tr>
<tr>
<td>Curam</td>
<td>76</td>
</tr>
<tr>
<td>Curosurf</td>
<td>194</td>
</tr>
<tr>
<td>Cvite</td>
<td>21</td>
</tr>
<tr>
<td>Cyclazine hydrochloride</td>
<td>116</td>
</tr>
<tr>
<td>Cyclazine lactate</td>
<td>116</td>
</tr>
<tr>
<td>Cyclogyl</td>
<td>201</td>
</tr>
<tr>
<td>Cyclophentolate hydrochloride</td>
<td>201</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>129</td>
</tr>
<tr>
<td>Cycloserine</td>
<td>82</td>
</tr>
<tr>
<td>Cyklonapron</td>
<td>26</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferasirox</td>
<td>204</td>
</tr>
<tr>
<td>Deferoxamine</td>
<td>204</td>
</tr>
<tr>
<td>Defibrotide</td>
<td>29</td>
</tr>
<tr>
<td>Definity</td>
<td>207</td>
</tr>
<tr>
<td>Demeclocycline hydrochloride</td>
<td>78</td>
</tr>
<tr>
<td>Denosumab</td>
<td>96</td>
</tr>
<tr>
<td>Deoleate</td>
<td>82</td>
</tr>
<tr>
<td>Deoxycoformycin</td>
<td>134</td>
</tr>
<tr>
<td>Depo-Medrol</td>
<td>64</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>58</td>
</tr>
<tr>
<td>Depo-Testosterone</td>
<td>62</td>
</tr>
<tr>
<td>Deprim</td>
<td>79</td>
</tr>
<tr>
<td>Dermol</td>
<td>54</td>
</tr>
<tr>
<td>Desferoxamine mesilate</td>
<td>204</td>
</tr>
<tr>
<td>Desfluorane</td>
<td>104</td>
</tr>
<tr>
<td>Desmopressin acetate</td>
<td>71</td>
</tr>
<tr>
<td>Desmopressin-PH&amp;T</td>
<td>71</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>63</td>
</tr>
<tr>
<td>DermAssist</td>
<td>197</td>
</tr>
<tr>
<td>Dexamethasone phosphate</td>
<td>63</td>
</tr>
<tr>
<td>Dexamethasone with framycetin and gramicidin</td>
<td>196</td>
</tr>
<tr>
<td>Dexamethasone with neomycin sulphate and polymyxin B sulphate</td>
<td>196</td>
</tr>
<tr>
<td>Dexamethasone with tobramycin</td>
<td>196</td>
</tr>
<tr>
<td>Dexametomidine</td>
<td>104</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>63</td>
</tr>
<tr>
<td>Dextrose</td>
<td>9</td>
</tr>
<tr>
<td>DHC Continus</td>
<td>108</td>
</tr>
<tr>
<td>Diabetes</td>
<td>8</td>
</tr>
<tr>
<td>Diazacarnit</td>
<td>114</td>
</tr>
<tr>
<td>Diagnostic Agents</td>
<td>114</td>
</tr>
<tr>
<td>Vaccines</td>
<td>238</td>
</tr>
<tr>
<td>Various</td>
<td>207</td>
</tr>
<tr>
<td>Dextrose with sodium citrate and citric acid [Acid Citrate Dextrose A]</td>
<td>30</td>
</tr>
<tr>
<td>Various</td>
<td>211</td>
</tr>
<tr>
<td>Dihydrocodeine tartrate</td>
<td>108</td>
</tr>
<tr>
<td>Dihydroergotamine mesylate</td>
<td>115</td>
</tr>
<tr>
<td>Dilazem hydrochloride</td>
<td>42</td>
</tr>
<tr>
<td>Dilzem</td>
<td>42</td>
</tr>
<tr>
<td>Dimethicane</td>
<td>51-52</td>
</tr>
<tr>
<td>Dimethyl fumarate</td>
<td>120</td>
</tr>
<tr>
<td>Dimethyl sulfoxide</td>
<td>209</td>
</tr>
<tr>
<td>Dinoprostone</td>
<td>59</td>
</tr>
<tr>
<td>Dipentum</td>
<td>6</td>
</tr>
<tr>
<td>Diphenamal meltsulfate</td>
<td>56</td>
</tr>
<tr>
<td>Diphenoxylate hydrochloride with atropine sulphate</td>
<td>5</td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>31</td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>31</td>
</tr>
<tr>
<td>Diphtheria antitoxin</td>
<td>203</td>
</tr>
<tr>
<td>Diphtheria, tetanus and pertussis vaccine</td>
<td>230</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis and polio vaccine</td>
<td>229</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenza type B vaccine</td>
<td>229</td>
</tr>
<tr>
<td>Dipiramidol</td>
<td>31</td>
</tr>
<tr>
<td>Disodium edetate</td>
<td>199</td>
</tr>
<tr>
<td>Disodium hydrogen phosphate with sodium dihydrogen phosphate</td>
<td>211</td>
</tr>
<tr>
<td>Disopyramide phosphate</td>
<td>39</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>126</td>
</tr>
<tr>
<td>Dithranol</td>
<td>211</td>
</tr>
<tr>
<td>Diuretic</td>
<td>43</td>
</tr>
<tr>
<td>Diurin</td>
<td>43</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>46</td>
</tr>
<tr>
<td>Dobutamine-hameln</td>
<td>46</td>
</tr>
<tr>
<td>Docaetaxel</td>
<td>141</td>
</tr>
<tr>
<td>Docusate sodium</td>
<td>12</td>
</tr>
<tr>
<td>Docusate sodium with sennosides</td>
<td>12</td>
</tr>
<tr>
<td>Dolutegrav</td>
<td>88</td>
</tr>
<tr>
<td>Domperidone</td>
<td>116</td>
</tr>
<tr>
<td>Donepezil hydrochloride</td>
<td>125</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>---</td>
</tr>
<tr>
<td>Donepezil-Rex .................................. 125</td>
<td></td>
</tr>
<tr>
<td>Dopamine hydrochloride ...................... 46</td>
<td></td>
</tr>
<tr>
<td>Dopress ........................................ 110</td>
<td></td>
</tr>
<tr>
<td>Dornase alfa .................................... 194</td>
<td></td>
</tr>
<tr>
<td>Dortimopt ....................................... 200</td>
<td></td>
</tr>
<tr>
<td>Dorzolamide ...................................... 200</td>
<td></td>
</tr>
<tr>
<td>Dorzolamide with timolol ...................... 200</td>
<td></td>
</tr>
<tr>
<td>Dostinex ......................................... 65</td>
<td></td>
</tr>
<tr>
<td>Dosulepin [Dothiepin] hydrochloride .......... 110</td>
<td></td>
</tr>
<tr>
<td>Dotarem .......................................... 207</td>
<td></td>
</tr>
<tr>
<td>Dothiepin ........................................ 110</td>
<td></td>
</tr>
<tr>
<td>Doxapram .......................................... 194</td>
<td></td>
</tr>
<tr>
<td>Doxazosin ......................................... 38</td>
<td></td>
</tr>
<tr>
<td>Doxepin hydrochloride ......................... 110</td>
<td></td>
</tr>
<tr>
<td>Doxine ............................................ 78</td>
<td></td>
</tr>
<tr>
<td>Doxorubicin Ebeve ................................ 129</td>
<td></td>
</tr>
<tr>
<td>Doxorubicin hydrochloride ..................... 129</td>
<td></td>
</tr>
<tr>
<td>Doxycycline ...................................... 78</td>
<td></td>
</tr>
<tr>
<td>DP Lotn HC ....................................... 54</td>
<td></td>
</tr>
<tr>
<td>DP-Allopurinol .................................. 98</td>
<td></td>
</tr>
<tr>
<td>Dr Reddy's Omeprazole ......................... 8</td>
<td></td>
</tr>
<tr>
<td>Droperidol ....................................... 116</td>
<td></td>
</tr>
<tr>
<td>Droperidol Panpharma ............................ 116</td>
<td></td>
</tr>
<tr>
<td>Drugs Affecting Bone ............................ 100</td>
<td></td>
</tr>
<tr>
<td>Metabolism ...................................... 94</td>
<td></td>
</tr>
<tr>
<td>Dual blood glucose and blood ketone diagnostic test meter .................. 239</td>
<td></td>
</tr>
<tr>
<td>Duolinc .......................................... 189</td>
<td></td>
</tr>
<tr>
<td>Duovisc .......................................... 199</td>
<td></td>
</tr>
<tr>
<td>Duride ............................................ 46</td>
<td></td>
</tr>
<tr>
<td>Dynastat ......................................... 102</td>
<td></td>
</tr>
<tr>
<td>Dysport .......................................... 100</td>
<td></td>
</tr>
<tr>
<td>- E - .............................................</td>
<td></td>
</tr>
<tr>
<td>e-chamber La Grande ............................ 239</td>
<td></td>
</tr>
<tr>
<td>e-chamber Mask ................................... 239</td>
<td></td>
</tr>
<tr>
<td>e-chamber Turbo ................................ 239</td>
<td></td>
</tr>
<tr>
<td>E-Mycin .......................................... 75</td>
<td></td>
</tr>
<tr>
<td>E-Z-Cat Dry ...................................... 206</td>
<td></td>
</tr>
<tr>
<td>E-Z-Gas II ....................................... 206</td>
<td></td>
</tr>
<tr>
<td>E-Z-Paste ........................................ 206</td>
<td></td>
</tr>
<tr>
<td>Econazole nitrate ................................ 51</td>
<td></td>
</tr>
<tr>
<td>Edrophonium chloride ......................... 94</td>
<td></td>
</tr>
<tr>
<td>Elavirenz ........................................ 85</td>
<td></td>
</tr>
<tr>
<td>Elavirenz with emtricitabine and tenofovir disoproxil .................. 86</td>
<td></td>
</tr>
<tr>
<td>Efficient ......................................... 31</td>
<td></td>
</tr>
<tr>
<td>Efomoterol fumarate ............................ 193</td>
<td></td>
</tr>
<tr>
<td>Efomoterol fumarate dihydrate .............. 193</td>
<td></td>
</tr>
<tr>
<td>Etreronacog alfa [Recombinant factor IX] ..... 27</td>
<td></td>
</tr>
<tr>
<td>Efudix ............................................ 56</td>
<td></td>
</tr>
<tr>
<td>Elaprase .......................................... 15</td>
<td></td>
</tr>
<tr>
<td>Elecare (Unflavoured) ......................... 222</td>
<td></td>
</tr>
<tr>
<td>Elecare (Vanilla) ............................... 222</td>
<td></td>
</tr>
<tr>
<td>Elecare LCP (Unflavoured) ..................... 222</td>
<td></td>
</tr>
<tr>
<td>Electrolytes .................................... 210</td>
<td></td>
</tr>
<tr>
<td>Elelyso .......................................... 17</td>
<td></td>
</tr>
<tr>
<td>Elocon ........................................... 54</td>
<td></td>
</tr>
<tr>
<td>Elocon Alchohol Free ......................... 54</td>
<td></td>
</tr>
<tr>
<td>Elnstrombopag ................................ 25</td>
<td></td>
</tr>
<tr>
<td>Emcure .......................................... 129</td>
<td></td>
</tr>
<tr>
<td>Emed Tri-Pack .................................. 116</td>
<td></td>
</tr>
<tr>
<td>EMLA ............................................. 106</td>
<td></td>
</tr>
<tr>
<td>Emtricitabine .................................... 86</td>
<td></td>
</tr>
<tr>
<td>Emtricitabine with tenofovir disoproxil .. 90</td>
<td></td>
</tr>
<tr>
<td>Emtriva .......................................... 86</td>
<td></td>
</tr>
<tr>
<td>Emulsifying ointment .......................... 53</td>
<td></td>
</tr>
<tr>
<td>Enalapril maleate ............................... 37</td>
<td></td>
</tr>
<tr>
<td>Enbrel ........................................... 145</td>
<td></td>
</tr>
<tr>
<td>Endocrine Therapy .............................. 142</td>
<td></td>
</tr>
<tr>
<td>Endoxan ......................................... 129</td>
<td></td>
</tr>
<tr>
<td>Enerlyte ......................................... 35</td>
<td></td>
</tr>
<tr>
<td>Engerix-B ....................................... 234</td>
<td></td>
</tr>
<tr>
<td>Enlafax XR ...................................... 111</td>
<td></td>
</tr>
<tr>
<td>Enoxaparin sodium .............................. 30</td>
<td></td>
</tr>
<tr>
<td>Ensure (Choclate) .............................. 228</td>
<td></td>
</tr>
<tr>
<td>Ensure (Vanilla) ................................ 228</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Banana) ........................... 228</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Chocolate) ....................... 228</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Tree of the Forest) ............ 228</td>
<td></td>
</tr>
<tr>
<td>Entresto 24/26 .................................. 38</td>
<td></td>
</tr>
<tr>
<td>Entresto 49/51 .................................. 38</td>
<td></td>
</tr>
<tr>
<td>Entresto 97/103 ................................ 38</td>
<td></td>
</tr>
<tr>
<td>Enzymes .......................................... 98</td>
<td></td>
</tr>
<tr>
<td>Ephedrine ........................................ 46</td>
<td></td>
</tr>
<tr>
<td>Epilim IV ........................................ 114</td>
<td></td>
</tr>
<tr>
<td>Epirubicin Ebeve ................................ 130</td>
<td></td>
</tr>
<tr>
<td>Epirubicin hydrochloride ..................... 130</td>
<td></td>
</tr>
<tr>
<td>Eplerenone ...................................... 43</td>
<td></td>
</tr>
<tr>
<td>Epoetin alfa .................................... 23</td>
<td></td>
</tr>
<tr>
<td>Epoetin beta .................................... 24</td>
<td></td>
</tr>
<tr>
<td>Epoprostenol .................................... 50</td>
<td></td>
</tr>
<tr>
<td>Eptacog alfa [Recombinant fraction VIIa] ... 27</td>
<td></td>
</tr>
<tr>
<td>Eptifibatide ..................................... 31</td>
<td></td>
</tr>
<tr>
<td>Erbitux ........................................... 160</td>
<td></td>
</tr>
<tr>
<td>Ergometrine maleate ......................... 59</td>
<td></td>
</tr>
<tr>
<td>Ergotamine tartrate with caffeine .......... 115</td>
<td></td>
</tr>
<tr>
<td>Ertolinib ........................................ 137</td>
<td></td>
</tr>
<tr>
<td>Ertapenem ....................................... 72</td>
<td></td>
</tr>
<tr>
<td>Erythrocin IV ................................... 75</td>
<td></td>
</tr>
<tr>
<td>Erythromycin (as ethylsuccinate) .......... 75</td>
<td></td>
</tr>
<tr>
<td>Erythromycin (as lactobionate) ............ 75</td>
<td></td>
</tr>
<tr>
<td>Erythromycin (as stearate) .................. 75</td>
<td></td>
</tr>
<tr>
<td>Estriol ........................................... 191</td>
<td></td>
</tr>
<tr>
<td>Escitalopram .................................... 111</td>
<td></td>
</tr>
<tr>
<td>Escitalopram-Apoxet ......................... 111</td>
<td></td>
</tr>
<tr>
<td>Esmolol hydrochloride ......................... 40</td>
<td></td>
</tr>
<tr>
<td>Estradiol ........................................ 64</td>
<td></td>
</tr>
<tr>
<td>Etanercept ..................................... 145</td>
<td></td>
</tr>
<tr>
<td>Ethambutol hydrochloride .................... 82</td>
<td></td>
</tr>
<tr>
<td>Ethanol ......................................... 203</td>
<td></td>
</tr>
<tr>
<td>Ethanol with glucose ......................... 203</td>
<td></td>
</tr>
<tr>
<td>Ethanol, dehydrated ............................ 203</td>
<td></td>
</tr>
<tr>
<td>Ethics Aspirin .................................. 107</td>
<td></td>
</tr>
<tr>
<td>Ethics Aspirin EC ............................... 31</td>
<td></td>
</tr>
<tr>
<td>Ethics Enalapril ................................ 37</td>
<td></td>
</tr>
<tr>
<td>Ethics Lisinopril ................................ 37</td>
<td></td>
</tr>
<tr>
<td>Ethinylloestriadiol ......................... 65</td>
<td></td>
</tr>
<tr>
<td>Ethinylloestriadiol with desogestrel .......... 57</td>
<td></td>
</tr>
<tr>
<td>Ethinylloestriadiol with levonorgestrel ...... 57</td>
<td></td>
</tr>
<tr>
<td>Ethinylloestriadiol with norethisterone ...... 57</td>
<td></td>
</tr>
<tr>
<td>Ethosuximide .................................. 112</td>
<td></td>
</tr>
<tr>
<td>Ethyl chloride .................................. 106</td>
<td></td>
</tr>
<tr>
<td>Etoamide ........................................ 104</td>
<td></td>
</tr>
<tr>
<td>Etopophos ...................................... 133</td>
<td></td>
</tr>
<tr>
<td>Etoposide ....................................... 133</td>
<td></td>
</tr>
<tr>
<td>Etoposide (as phosphate) ................. 133</td>
<td></td>
</tr>
<tr>
<td>Etoricoxib ...................................... 101</td>
<td></td>
</tr>
<tr>
<td>Etravirine ..................................... 85</td>
<td></td>
</tr>
<tr>
<td>Everel ........................................... 113</td>
<td></td>
</tr>
<tr>
<td>Everolimus ..................................... 186</td>
<td></td>
</tr>
<tr>
<td>Evista .......................................... 97</td>
<td></td>
</tr>
<tr>
<td>Exelon .......................................... 125</td>
<td></td>
</tr>
<tr>
<td>Exemestane .................................... 144</td>
<td></td>
</tr>
<tr>
<td>Exjade .......................................... 204</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations ...... 211</td>
<td></td>
</tr>
<tr>
<td>Eylea .......................................... 158</td>
<td></td>
</tr>
<tr>
<td>Ezetimibe ...................................... 45</td>
<td></td>
</tr>
<tr>
<td>Ezetimibe Sandoz ............................... 45</td>
<td></td>
</tr>
<tr>
<td>Ezetimibe with simvastatin ................... 45</td>
<td></td>
</tr>
<tr>
<td>- F - .............................................</td>
<td></td>
</tr>
<tr>
<td>Factor eight inhibitor bypassing fraction ..... 27</td>
<td></td>
</tr>
<tr>
<td>Febuxostat .................................... 99</td>
<td></td>
</tr>
<tr>
<td>FEIBA NF ....................................... 27</td>
<td></td>
</tr>
<tr>
<td>Felo 10 ER .................................... 42</td>
<td></td>
</tr>
<tr>
<td>Felo 5 ER .................................... 42</td>
<td></td>
</tr>
<tr>
<td>Felodipine ...................................... 42</td>
<td></td>
</tr>
<tr>
<td>Fentanyl ........................................ 17</td>
<td></td>
</tr>
<tr>
<td>Fentany ......................................... 108</td>
<td></td>
</tr>
<tr>
<td>Fentany Sandoz ................................ 108</td>
<td></td>
</tr>
<tr>
<td>Ferinject .................................... 17</td>
<td></td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferodan</td>
<td>18</td>
</tr>
<tr>
<td>Ferric carboxymaltose</td>
<td>17</td>
</tr>
<tr>
<td>Ferric subsulfate</td>
<td>26</td>
</tr>
<tr>
<td>Ferripox</td>
<td>204</td>
</tr>
<tr>
<td>Ferro-F-Tabs</td>
<td>17</td>
</tr>
<tr>
<td>Ferro-tab</td>
<td>17</td>
</tr>
<tr>
<td>Ferrogard</td>
<td>18</td>
</tr>
<tr>
<td>Ferrosis</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous fumarate</td>
<td>17</td>
</tr>
<tr>
<td>Ferrous fumarate with folic acid</td>
<td>17</td>
</tr>
<tr>
<td>Ferrous gluconate with ascorbic acid</td>
<td>17</td>
</tr>
<tr>
<td>Ferrous sulphate</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous sulphate with ascorbic acid</td>
<td>18</td>
</tr>
<tr>
<td>Fexofenadine hydrochloride</td>
<td>189</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>32</td>
</tr>
<tr>
<td>Finasteride</td>
<td>60</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>120</td>
</tr>
<tr>
<td>Firazyr</td>
<td>188</td>
</tr>
<tr>
<td>Flagyl</td>
<td>84</td>
</tr>
<tr>
<td>Flagyl-S</td>
<td>84</td>
</tr>
<tr>
<td>Flamine</td>
<td>51</td>
</tr>
<tr>
<td>Flecaidine acetate</td>
<td>39</td>
</tr>
<tr>
<td>Flecaidine Controlled Release Teva</td>
<td>39</td>
</tr>
<tr>
<td>Fleet Phosphate Enema</td>
<td>12</td>
</tr>
<tr>
<td>Flixonase Hayfever &amp; Allergy</td>
<td>189</td>
</tr>
<tr>
<td>Flexotide</td>
<td>193</td>
</tr>
<tr>
<td>Flixotide Accuhaler</td>
<td>193</td>
</tr>
<tr>
<td>Floaor</td>
<td>193</td>
</tr>
<tr>
<td>Florinef</td>
<td>63</td>
</tr>
<tr>
<td>Flunaxol</td>
<td>118</td>
</tr>
<tr>
<td>Fluarix Tetra</td>
<td>235</td>
</tr>
<tr>
<td>Flucl</td>
<td>76</td>
</tr>
<tr>
<td>Flucoxacinill</td>
<td>76</td>
</tr>
<tr>
<td>Flucxin</td>
<td>76</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>80</td>
</tr>
<tr>
<td>Fluconazole-Claris</td>
<td>80</td>
</tr>
<tr>
<td>Fluacytosine</td>
<td>82</td>
</tr>
<tr>
<td>Fludara Oral</td>
<td>130</td>
</tr>
<tr>
<td>Fludarabine Ebeve</td>
<td>130</td>
</tr>
<tr>
<td>Fludarabine phosphate</td>
<td>130</td>
</tr>
<tr>
<td>Fluocorticson acid</td>
<td>63</td>
</tr>
<tr>
<td>Fluids and Electrolytes</td>
<td>33</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>203</td>
</tr>
<tr>
<td>Flumetasone pivalate with clioquinol</td>
<td>197</td>
</tr>
<tr>
<td>Fluocortolone caproate with fluocortolone pivalate and cinchocaine</td>
<td>6</td>
</tr>
<tr>
<td>Fluoreosin sodium</td>
<td>198</td>
</tr>
<tr>
<td>Fluoreosin sodium with lignocaine hydrochloride</td>
<td>198</td>
</tr>
<tr>
<td>Fluorescite</td>
<td>198</td>
</tr>
<tr>
<td>Flurometholone</td>
<td>198</td>
</tr>
<tr>
<td>Flurodolone</td>
<td></td>
</tr>
<tr>
<td>Flurocortolone Ebeve</td>
<td></td>
</tr>
<tr>
<td>Flurocortolone sodium</td>
<td>56</td>
</tr>
<tr>
<td>Fluvetinhydrochloride</td>
<td>111</td>
</tr>
<tr>
<td>Flutethiolin decanoate</td>
<td>118</td>
</tr>
<tr>
<td>Flutamide</td>
<td>143</td>
</tr>
<tr>
<td>Flutamin</td>
<td>143</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>193</td>
</tr>
<tr>
<td>Fluticasone furoate with vilanterol</td>
<td>193</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>189</td>
</tr>
<tr>
<td>Fluticasone with salmeterol</td>
<td>193</td>
</tr>
<tr>
<td>FML</td>
<td>198</td>
</tr>
<tr>
<td>Foban</td>
<td>51</td>
</tr>
<tr>
<td>Folic acid</td>
<td>24</td>
</tr>
<tr>
<td>Fondaparinux sodium</td>
<td>30</td>
</tr>
<tr>
<td>Food Modules</td>
<td>214</td>
</tr>
<tr>
<td>Food/Fluid Thickeners</td>
<td>216</td>
</tr>
<tr>
<td>Forteo</td>
<td>98</td>
</tr>
<tr>
<td>Fortisip (Vanilla)</td>
<td>228</td>
</tr>
<tr>
<td>Fosamx</td>
<td>94</td>
</tr>
<tr>
<td>Fosamax Plus</td>
<td>94</td>
</tr>
<tr>
<td>Foscarnet sodium</td>
<td>89</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>78</td>
</tr>
<tr>
<td>Fragmin</td>
<td>29</td>
</tr>
<tr>
<td>Framycetin sulphate</td>
<td>196</td>
</tr>
<tr>
<td>Fresenius Kabi</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>33, 35</td>
</tr>
<tr>
<td>Various</td>
<td>209</td>
</tr>
<tr>
<td>Fresol 1% MCT/LCT</td>
<td>104</td>
</tr>
<tr>
<td>Frusemide</td>
<td>43</td>
</tr>
<tr>
<td>Frusemide-Claris</td>
<td>43</td>
</tr>
<tr>
<td>Fucidin</td>
<td>79</td>
</tr>
<tr>
<td>Fucithalamic</td>
<td>196</td>
</tr>
<tr>
<td>Funglipin</td>
<td>19</td>
</tr>
<tr>
<td>Furosemide [Frusemide]</td>
<td>43</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>51, 55</td>
</tr>
<tr>
<td>Infections</td>
<td>79</td>
</tr>
<tr>
<td>Sensory</td>
<td>196</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fuzac</td>
<td></td>
</tr>
<tr>
<td>Gabaopentin</td>
<td>112</td>
</tr>
<tr>
<td>Gaceta</td>
<td>107</td>
</tr>
<tr>
<td>Gadobenic acid</td>
<td>207</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>207</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>207</td>
</tr>
<tr>
<td>Gadoteric acid</td>
<td>207</td>
</tr>
<tr>
<td>Gadovist 1.0</td>
<td>207</td>
</tr>
<tr>
<td>Gadoxetate disodium</td>
<td>207</td>
</tr>
<tr>
<td>Galsulase</td>
<td>14</td>
</tr>
<tr>
<td>Galvumet</td>
<td>10</td>
</tr>
<tr>
<td>Galvus</td>
<td>10</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td>89</td>
</tr>
<tr>
<td>Gardasil 9</td>
<td>234</td>
</tr>
<tr>
<td>Gastrodenol</td>
<td>8</td>
</tr>
<tr>
<td>Gastrografin</td>
<td>206</td>
</tr>
<tr>
<td>Gazyva</td>
<td>166</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>137</td>
</tr>
<tr>
<td>Gelatine, succinylated</td>
<td>36</td>
</tr>
<tr>
<td>Gelofusine</td>
<td>36</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>131</td>
</tr>
<tr>
<td>Gemcitabine Ebeve</td>
<td>131</td>
</tr>
<tr>
<td>Gentamicin sulphate</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>72</td>
</tr>
<tr>
<td>Sensory</td>
<td>196</td>
</tr>
<tr>
<td>Gestrinone</td>
<td>65</td>
</tr>
<tr>
<td>Gelenta</td>
<td>120</td>
</tr>
<tr>
<td>Gent...........</td>
<td>57</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>121</td>
</tr>
<tr>
<td>Glaucoma Preparations</td>
<td>200</td>
</tr>
<tr>
<td>Geicaprevir with ibrentasvir</td>
<td>88</td>
</tr>
<tr>
<td>Gilbenclamide</td>
<td>10</td>
</tr>
<tr>
<td>Gliclazide</td>
<td>10</td>
</tr>
<tr>
<td>Gliloran</td>
<td>144</td>
</tr>
<tr>
<td>Glipizide</td>
<td>10</td>
</tr>
<tr>
<td>Glisec</td>
<td>138</td>
</tr>
<tr>
<td>Glidizide</td>
<td>10</td>
</tr>
<tr>
<td>Glucagen Hypokit</td>
<td>9</td>
</tr>
<tr>
<td>Glucagon hydrochloride</td>
<td>9</td>
</tr>
<tr>
<td>Glucerna Select (Vanilla)</td>
<td>220</td>
</tr>
<tr>
<td>Glucerna Select RTH (Vanilla)</td>
<td>220</td>
</tr>
<tr>
<td>Glucobay</td>
<td>8</td>
</tr>
<tr>
<td>Glucose [Dextrose]</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>9</td>
</tr>
<tr>
<td>Blood</td>
<td>33</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>211</td>
</tr>
<tr>
<td>Glucose with potassium chloride</td>
<td>34</td>
</tr>
<tr>
<td>Glucose with potassium chloride and sodium chloride</td>
<td>34</td>
</tr>
<tr>
<td>Glucose with sodium chloride</td>
<td>34</td>
</tr>
<tr>
<td>Glucose with sucrose and fructose</td>
<td>9</td>
</tr>
<tr>
<td>Glycerin with sodium saccharin</td>
<td>212</td>
</tr>
<tr>
<td>Glycerin with sucrose</td>
<td>212</td>
</tr>
<tr>
<td>Glycerol</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>12</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>212</td>
</tr>
<tr>
<td>Glycerol with paraffin</td>
<td>53</td>
</tr>
<tr>
<td>Glyceryl trinitrate</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>7</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>46</td>
</tr>
<tr>
<td>Glycin</td>
<td>208</td>
</tr>
<tr>
<td>Glycophyryniunm</td>
<td>190</td>
</tr>
<tr>
<td>Glycophyryniunm bromide</td>
<td>7</td>
</tr>
<tr>
<td>Glycophyrynium with indacaterol</td>
<td>190</td>
</tr>
<tr>
<td>Glycerin</td>
<td>71</td>
</tr>
<tr>
<td>Glytrin</td>
<td>46</td>
</tr>
</tbody>
</table>
Hyaluronic acid
Humatin..............................................
Humalog Mix 50....................................
Humalog Mix 25....................................
HPV..................................................
Hormone Replacement Therapy........
Histamine acid phosphate................
Histaclear..........................................
Hexamine hippurate...........................
Hepsera..............................................
Hepatitis B recombinant
vaccine ............................................
Haldol .............................................
Haldol Concentrate .........................
Haloperidol ........................................
Haloperidol decanoate.....................
Hartmann's solution ...........................
Harvoni ...........................................
Havrix .............................................
HBVaxPRO .........................................
Healon ............................................... 
Healon 5 ...........................................
Healon GV .........................................
healthE Calamine Aqueous Cream
BP ....................................................
healthE Dimethicone 10% .................
healthE Dimethicone 4% Lotion ...........
healthE Dimethicone 5% ...................
healthE Fatty Cream ...........................
healthE Glycerol BP Liquid ................
healthE Urea Cream ...........................
Heparin sodium ...................................
Heparinised saline ..............................
Heparon Junior ...................................
Hepatitis A vaccine ............................
Hepatitis B recombinant
vaccine ............................................
Hepsera ...........................................
Herceptin .......................................... 
Hexamine hippurate ...........................
Hibexer ........................................... 
Histaclolr .......................................... 
Histamine acid phosphate .................
Holoxan ...........................................
Hormone Replacement Therapy ..........
HPV ................................................
Humalog Mix 25 .................................
Humalog Mix 50 .................................
Human papillomavirus (6, 11, 16, 18,
31, 33, 45, 52 and 58) vaccine
[HPV] ..............................................
Humatin ...........................................
Humira .............................................
HumiraPen ........................................
Hyaluronic acid
Alimentary .........................................
Sensory .............................................

- I -

Ibiamox .............................................
Ibuprofen ........................................
Icatibant ...........................................
Idarubicin hydrochloride .................
Idarucizumab ...................................
Idursulfase ........................................
Ifosfamide .......................................
Ikorel ..............................................
Ilomedin .......................................... 
Iloprost ............................................
Imaging Agents .................................
Imatinib mesilate ..............................
Imatinib-AFT ....................................
Imiglurecaser ...................................
Impiperin with cilastatin .................
Impipenem+Clastatin RBX ..............
Impipamir hydrochloride .................
Imiquimod .........................................
Immune Modulators ........................... 
Imponsuspressants ...........................
Impact Advanced Recovery ............... 
Imuran .............................................
Incure Ellipta ....................................
Indacaterol ......................................
Indapamide ....................................... 
Indigo carmine .................................
Indinavir .......................................... 
Indocynanine green ............................
Indomethacin ...................................
Infanrix IPV ....................................... 
Infanrix-hexa ...................................
Infatinri ...........................................
Infliximab ....................................... 
Influenza vaccine ..............................
Influvac Tetra ...................................
Inhaled Corticosteroids .................
Inspra ..............................................
Insulin aspart .................................
Insulin aspart with insulin aspart
protamine...........................................
Insulin glargine ................................
Insulin glusine ................................
Insulin isophane ............................... 
Insulin lispro ...................................
Insulin lispro with insulin lispro
protamine........................................
Insulin neutral ...................................
Insulin neutral with insulin
isophane .........................................
Integrin ...........................................
Intlelence ........................................ 
Interferon alfa-2a .............................
Interferon alfa-2b ................................
Interferon beta-1-alpha .....................
Interferon beta-1-beta .....................
Interferon gamma .............................
Intra-uterine device ...........................
Invanz ..........................................
Invega Sustenna ............................... 
Iodine .............................................
Iodine with ethanol .........................
Iodised oil ....................................... 
Iodixanol ........................................ 
Iohexol .......................................... 
Iopidine ........................................ 
Ioscan ...........................................
IPOL .............................................. 
Ipratropium bromide ....................... 
Iressa ............................................ 
Irinotecan Actavis 100 .....................
Irinotecan hydrochloride ............... 
Iron polymaltose ................................
Iron sucrose ....................................
Irrigation Solutions .........................
Isetstress ........................................ 
Ismo-40 Retard ..................................
Ismo-20 ......................................... 
Isoniazid ......................................... 
Isoniazid with rifampin ....................
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isoprenaline [Isoproterenol]</strong></td>
</tr>
<tr>
<td>Isopropyl alcohol</td>
</tr>
<tr>
<td>Isoproterenol</td>
</tr>
<tr>
<td>Isoptin</td>
</tr>
<tr>
<td>Isopto Carpine</td>
</tr>
<tr>
<td>Isosorbide mononitrate</td>
</tr>
<tr>
<td>Isotretinoin</td>
</tr>
<tr>
<td>Ispaghula (psyllium) husk</td>
</tr>
<tr>
<td>Isradipine</td>
</tr>
<tr>
<td>Itch-Soothe</td>
</tr>
<tr>
<td>Itraconazole</td>
</tr>
<tr>
<td>Itrazole</td>
</tr>
<tr>
<td>Iverabradine</td>
</tr>
<tr>
<td>Ivermectin</td>
</tr>
<tr>
<td>- <strong>J</strong> -</td>
</tr>
<tr>
<td>Jadelle</td>
</tr>
<tr>
<td>Jakavi</td>
</tr>
<tr>
<td>Jevity HiCal RTH</td>
</tr>
<tr>
<td>Jevity RTH</td>
</tr>
<tr>
<td>Juno Pemetrexed</td>
</tr>
<tr>
<td>- <strong>K</strong> -</td>
</tr>
<tr>
<td>Kaletra</td>
</tr>
<tr>
<td>Kenacort</td>
</tr>
<tr>
<td>Kenacort-A 10</td>
</tr>
<tr>
<td>Kenacort-A 40</td>
</tr>
<tr>
<td>Kenalog in Orabase</td>
</tr>
<tr>
<td>Ketalar</td>
</tr>
<tr>
<td>Ketamine</td>
</tr>
<tr>
<td>Ketocal 3:1 (Unflavoured)</td>
</tr>
<tr>
<td>Ketocal 4:1 (Unflavoured)</td>
</tr>
<tr>
<td>Ketocal 4:1 (Vanilla)</td>
</tr>
<tr>
<td>Ketoconazole</td>
</tr>
<tr>
<td>Dermatological</td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>Ketoprofen</td>
</tr>
<tr>
<td>Ketorolac trometamol</td>
</tr>
<tr>
<td>KetoSens</td>
</tr>
<tr>
<td>Ketostix</td>
</tr>
<tr>
<td>Keytruda</td>
</tr>
<tr>
<td>Kivexa</td>
</tr>
<tr>
<td>Klacid</td>
</tr>
<tr>
<td>Klean Prep</td>
</tr>
<tr>
<td>Kogene FS</td>
</tr>
<tr>
<td>Konakion MM</td>
</tr>
<tr>
<td>Konsyl-D</td>
</tr>
<tr>
<td>Kuvan</td>
</tr>
<tr>
<td>- <strong>L</strong> -</td>
</tr>
<tr>
<td>L-asparaginase</td>
</tr>
<tr>
<td>L-ornithine L-aspartate</td>
</tr>
<tr>
<td>Labetalol</td>
</tr>
<tr>
<td>Lacosamide</td>
</tr>
<tr>
<td>Lactose</td>
</tr>
<tr>
<td>Lactulose</td>
</tr>
<tr>
<td>Laevolac</td>
</tr>
<tr>
<td>Lamicalt</td>
</tr>
<tr>
<td>Lamivudine</td>
</tr>
<tr>
<td>Lamotrigine</td>
</tr>
<tr>
<td>Lanoxin</td>
</tr>
<tr>
<td>Lanoxin PG</td>
</tr>
<tr>
<td>Lansoprazole</td>
</tr>
<tr>
<td>Lantus</td>
</tr>
<tr>
<td>Lantus SoloStar</td>
</tr>
<tr>
<td>Lanzol Relief</td>
</tr>
<tr>
<td>Lapatinib</td>
</tr>
<tr>
<td>Laronidase</td>
</tr>
<tr>
<td>Latanoprost</td>
</tr>
<tr>
<td>Lax-Suppositories</td>
</tr>
<tr>
<td>Lax-Tabs</td>
</tr>
<tr>
<td>Laxatives</td>
</tr>
<tr>
<td>Laxsol</td>
</tr>
<tr>
<td>Ledipasvir with sofosbuvir</td>
</tr>
<tr>
<td>Leflunomide</td>
</tr>
<tr>
<td>Lenalidomide</td>
</tr>
<tr>
<td>Letrole</td>
</tr>
<tr>
<td>Letrozole</td>
</tr>
<tr>
<td>Leukotriene Receptor Antagonists</td>
</tr>
<tr>
<td>Leunase</td>
</tr>
<tr>
<td>Leuprolrel acetate</td>
</tr>
<tr>
<td>Leustatin</td>
</tr>
<tr>
<td>Levetiracetam</td>
</tr>
<tr>
<td>Levetiracetam-AFT</td>
</tr>
<tr>
<td>Levlen ED</td>
</tr>
<tr>
<td>Levocabastine</td>
</tr>
<tr>
<td>Levocarnitine</td>
</tr>
<tr>
<td>Levodopa with benserazide</td>
</tr>
<tr>
<td>Levodopa with carbipoda</td>
</tr>
<tr>
<td>Leveompromazine</td>
</tr>
<tr>
<td>Levempromazine</td>
</tr>
<tr>
<td>Levempromazine hydrochloride</td>
</tr>
<tr>
<td>Levonorgestrel</td>
</tr>
<tr>
<td>Levosimendan</td>
</tr>
<tr>
<td>Levothyroxetine</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine]</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine]</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with adrenaline</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with chlorhexidine</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with phenylephrine</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] with prilocaine</td>
</tr>
<tr>
<td>Lidocaine-Claris</td>
</tr>
<tr>
<td>Ligocaine</td>
</tr>
<tr>
<td>Lincomycin</td>
</tr>
<tr>
<td>Linzolid</td>
</tr>
<tr>
<td>Linezolid Kabi</td>
</tr>
<tr>
<td>Loresal Intrathecal</td>
</tr>
<tr>
<td>Lothyrone sodium</td>
</tr>
<tr>
<td>Lipizal</td>
</tr>
<tr>
<td>Lipid-Modifying Agents</td>
</tr>
<tr>
<td>Lipiodol Ultra Fluid</td>
</tr>
<tr>
<td>Liquibar</td>
</tr>
<tr>
<td>Lisinopril</td>
</tr>
<tr>
<td>Lissamine green</td>
</tr>
<tr>
<td>Lithicarb FC</td>
</tr>
<tr>
<td>Lithium carbonate</td>
</tr>
<tr>
<td>LMX4</td>
</tr>
<tr>
<td>Local Preparations for Anal and Rectal Disorders</td>
</tr>
<tr>
<td>Locado</td>
</tr>
<tr>
<td>Locado Crelo</td>
</tr>
<tr>
<td>Locado Lipcream</td>
</tr>
<tr>
<td>Lodi</td>
</tr>
<tr>
<td>Lodoxamide</td>
</tr>
<tr>
<td>Logem</td>
</tr>
<tr>
<td>Lomeide</td>
</tr>
<tr>
<td>Lomustine</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor Agonists</td>
</tr>
<tr>
<td>Loniten</td>
</tr>
<tr>
<td>Loperamide hydrochloride</td>
</tr>
<tr>
<td>Lolipanivir with ritonavir</td>
</tr>
<tr>
<td>Lorafix</td>
</tr>
<tr>
<td>Loradamine</td>
</tr>
<tr>
<td>Lorazepam</td>
</tr>
<tr>
<td>Lorfast</td>
</tr>
<tr>
<td>Lormetazepam</td>
</tr>
<tr>
<td>Lorstat</td>
</tr>
<tr>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Losartan potassium</td>
</tr>
<tr>
<td>Losartan potassium with hydrochlorothiazide</td>
</tr>
<tr>
<td>Lovir</td>
</tr>
<tr>
<td>Lucrin Depot 1-month</td>
</tr>
<tr>
<td>Lucrin Depot 3-month</td>
</tr>
<tr>
<td>Lydern</td>
</tr>
<tr>
<td>- <strong>M</strong> -</td>
</tr>
<tr>
<td>m-Amoxclav</td>
</tr>
<tr>
<td>m-Esol</td>
</tr>
<tr>
<td>Mabthera</td>
</tr>
<tr>
<td>Macrogl 3350 with ascorbic acid, potassium chloride and sodium chloride</td>
</tr>
<tr>
<td>Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride</td>
</tr>
<tr>
<td>Macrogl 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate</td>
</tr>
<tr>
<td>Macrogl 400 and propylene</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Morphine hydrochloride ........................................ 108
Morphine sulphate ................................................. 109
Morphine tartrate ..................................................... 109
Motetis ................................................................. 103
Mouth and Throat ...................................................... 18
Movifeno ............................................................... 103
Moxifloxacin ........................................................... 77
Mozobil ................................................................. 32
Mucolytics and Expectorants ............................ 194
Mucosothe .............................................................. 106
Multithance ............................................................. 207
Multiple Sclerosis Treatments .......................... 120
Multivitamin and mineral supplement ............ 19
Multivitamin renal .................................................... 19
Multivitamins .......................................................... 20
Mupirocin ............................................................... 51
Muscle Relaxants and Related Agents ............. 100

Mydriacyl ............................................................. 201
Mylan Atenolol ......................................................... 40
Mylan Clopimphen .................................................. 65
Mylan Midazolam ..................................................... 122
Mylan Forte ............................................................ 198
Mynapot ................................................................. 129
Myosyde ................................................................. 13

N -
Nadolol ................................................................. 41
Naglazyme ............................................................... 14
Naloxyone hydrochloride ....................................... 203
Natracord ............................................................... 126
Naltrexone hydrochloride ....................................... 126
Naphazoline hydrochloride .................................... 198
Naphcon Forte ........................................................ 198
Naprosyn SR 1000 ................................................... 102
Naprosyn SR 750 ....................................................... 102
Naproxen ............................................................... 102
Naropin ................................................................. 107
Natalizumab ............................................................ 121
Natamycin .............................................................. 196
Natulan ................................................................. 134
Nausafex ............................................................... 117
Nausicalm .............................................................. 116
Navelbine .............................................................. 142
Nedocromil ............................................................. 194
Nefopam hydrochloride .......................................... 107
Neisvac-C .............................................................. 231
Neo-B12 ................................................................. 21
Neocate Gold (Unflavoured) ............................. 222
Neocate Junior Vanilla ............................................ 222
Neoral ................................................................. 145
Neostigmine metilsulfate ........................................ 94
Neostigmine metilsulfate with glycopyrronium bromide ........................................ 94
Neosynephrine HCL ............................................... 47
Neuro HP (Strawberry) ......................................... 226
Neuro HP (Vanilla) ............................................... 226
Neuro HP RTH ...................................................... 225
Neulastim ............................................................. 33
Neupogen ............................................................. 32
NeuroTabs ............................................................ 17
Nevirapine ............................................................ 86
Nevirapine Alphapharm ........................................ 86
Nicardipine hydrochloride ..................................... 42
Nicorandil ............................................................ 47
Nicotine ............................................................... 126
Nicotinic acid ......................................................... 45
Nifedipine ............................................................. 42
Nifuran ................................................................. 79
Nilotinib ............................................................... 138
Nilstat ................................................................. 57
Nistat

Alimentary ............................................................ 19
Genito-Urinary ....................................................... 77
Infections ............................................................. 80

Nimodipine ............................................................ 42
Nintedanib ............................................................ 190
Nitazoxamide ......................................................... 84
Nitratos ................................................................. 122
Nitrates ............................................................... 46
Nitrazepam ........................................................... 122
Nitroderm TTS 10 .................................................. 46
Nitroderm TTS 5 ................................................... 46
Nitrofurantoin ......................................................... 79
Nitroglycerin Pump Spray ....................................... 46
Nivestim ............................................................... 32
Nivolumab ........................................................... 183
Nodia ................................................................. 5
Noflam 250 .......................................................... 102
Noflam 500 .......................................................... 102
Non-Steroidal Anti-Inflammatory Drugs ........ 101
Nonacog alfa [Recombinant factor IX] ................ 28
Nonacog gamma, [Recombinant factor IX] ........... 28
Noradrenaline ......................................................... 47
Noradrenaline BNM ............................................... 47
Norethisterone .........................................................

Genito-Urinary ....................................................... 58
Hormone Preparations .......................................... 65
Norethisterone with mestranol ................................ 57
Norflex ............................................................... 100
Norfloxacin .......................................................... 77
Nordiy 28 ............................................................. 58
Normison ............................................................ 122
Norpress ............................................................. 111
Nortripyline hydrochloride ..................................... 111

Norvir ................................................................. 87
Novosource Renal (Vanilla) .............................. 226
Novatretin ........................................................... 55
NovoMix 30 FlexPen ................................................ 9
NovoRapid FlexPen ................................................ 9
NovoSeven RT .................................................... 27
N oxafil ................................................................. 80
Nozinan ............................................................... 118
Nutriene Energy Multi Fibre ............................. 225
Nutriene Low Energy Multifibre RTH .................. 225
Nutrison 800 Complete Multi Fibre .................... 227
Nutrition Concentrated ......................................... 221
Nutrition Energy .................................................... 227
Nyefax Retard .......................................................... 42
Nystatin

Alimentary ............................................................ 19
Dermatological ....................................................... 51
Genito-Urinary ....................................................... 57
Infections ............................................................. 80


O -
Omeprazole actavis 20 .......................................... 108
Omeprazole actavis 10 .......................................... 107
Omeprazole .......................................................... 280
Omalizumab .......................................................... 60
Obinutuzumab .......................................................... 166
Obstetric Preparations ............................................ 59
Octocog alfa [Recombinant factor VIII] (Advate) .. 28
Octocog alfa [Recombinant factor VIII] (Kogenate FS) .. 28
Octtreotide ............................................................. 143
Ocular Lubricants .................................................... 201
Oestradiol ............................................................. 64–65
Oestradiol valerate .................................................. 64
Oestradiol with norethisterone acetate ............ 64
Oestriol

Genito-Urinary ....................................................... 60
Hormone Preparations .......................................... 65
Oestrogens ........................................................... 60
Oestrogens (conjugated equine) ......................... 64
Oestrogens with medroxyprogesterone acetate .. 65

Ofev ................................................................. 190
Oil in water emulsion ............................................. 53
Oily phenol [Phenol oily] ......................................... 7
Olanzapine ............................................................ 118–119
Olive oil ............................................................... 212
Olapatadine ............................................................ 198
Olsalazine ............................................................. 8
Omalizumab ............................................................ 167
Omeprazole ........................................................... 8
Omeprazole actavis 10 ........................................... 8
Omeprazole actavis 20 ........................................... 8
Omeprazole actavis 40 ........................................... 8
Omeprazole IV .......................................................... 8


- 250 -

- 250 -
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omniscan .................................. 207</td>
</tr>
<tr>
<td>Omnipaque .................................. 206</td>
</tr>
<tr>
<td>Omnitrope .................................. 66</td>
</tr>
<tr>
<td>Ontrez Breezhaler ...................... 193</td>
</tr>
<tr>
<td>Oncaspargus ................................. 134</td>
</tr>
<tr>
<td>OncoTICE .................................... 186</td>
</tr>
<tr>
<td>Ondansetron .................................. 116</td>
</tr>
<tr>
<td>Ondansetron Kabi ............................. 116</td>
</tr>
<tr>
<td>Ondansetron ODT-DRLA ..................... 116</td>
</tr>
<tr>
<td>Ondansetron-Claris .......................... 116</td>
</tr>
<tr>
<td>One-Alpha ...................................... 21</td>
</tr>
<tr>
<td>Opdivo .......................................... 183</td>
</tr>
<tr>
<td>Optional Pharmaceuticals ................. 239</td>
</tr>
<tr>
<td>Ora-Blend ....................................... 212</td>
</tr>
<tr>
<td>Ora-Blend SF ................................... 212</td>
</tr>
<tr>
<td>Ora-Plus ......................................... 212</td>
</tr>
<tr>
<td>Ora-Sweet ......................................... 212</td>
</tr>
<tr>
<td>Ora-Sweet SF ..................................... 212</td>
</tr>
<tr>
<td>Oratane .......................................... 52</td>
</tr>
<tr>
<td>Orion Temozolomide .......................... 134</td>
</tr>
<tr>
<td>Orimod .......................................... 84</td>
</tr>
<tr>
<td>Orphenadrine citrate ....................... 100</td>
</tr>
<tr>
<td>Oruvail SR ....................................... 102</td>
</tr>
<tr>
<td>Osel tamivir .................................... 91</td>
</tr>
<tr>
<td>Osmolite RTH ................................... 227</td>
</tr>
<tr>
<td>Other Cardiac Agents ...................... 46</td>
</tr>
<tr>
<td>Other Endocrine Agents .................... 65</td>
</tr>
<tr>
<td>Other Oestrogen Preparations .......... 65</td>
</tr>
<tr>
<td>Other Otological Preparations .......... 202</td>
</tr>
<tr>
<td>Other Progestogen Preparations ....... 65</td>
</tr>
<tr>
<td>Other Skin Preparations ................. 56</td>
</tr>
<tr>
<td>Ovestin ......................................... 60</td>
</tr>
<tr>
<td>Ox-Pam ......................................... 120</td>
</tr>
<tr>
<td>Oxalic cord ...................................... 136</td>
</tr>
<tr>
<td>Oxaliplatin .................................... 136</td>
</tr>
<tr>
<td>Oxandrolone .................................... 62</td>
</tr>
<tr>
<td>Oxazepam ....................................... 120</td>
</tr>
<tr>
<td>Oxpentifylline .................................. 47</td>
</tr>
<tr>
<td>Oxybuprocaine hydrochloride ............ 199</td>
</tr>
<tr>
<td>Oxybutynin ..................................... 60</td>
</tr>
<tr>
<td>Oxycodeone hydrochloride ............... 109</td>
</tr>
<tr>
<td>Oxycodeone Sandoz ......................... 109</td>
</tr>
<tr>
<td>Oxyhydrozine hydrochloride ............ 192</td>
</tr>
<tr>
<td>OxyNorm ......................................... 109</td>
</tr>
<tr>
<td>Oxytocin ........................................ 59</td>
</tr>
<tr>
<td>Oxytocin BNM .................................. 59</td>
</tr>
<tr>
<td>Oxytocin with ergometrine maleate ...... 59</td>
</tr>
<tr>
<td>Ozurdex ............................................ 197</td>
</tr>
<tr>
<td>Pacifen .......................................... 100</td>
</tr>
<tr>
<td>Paclitaxel ....................................... 141</td>
</tr>
<tr>
<td>Paclitaxel Ebewe .............................. 141</td>
</tr>
<tr>
<td>Paliperidone ................................... 119</td>
</tr>
<tr>
<td>Pamidronate disodium ...................... 94</td>
</tr>
<tr>
<td>Pamisol .......................................... 94</td>
</tr>
<tr>
<td>Pancreatic enzyme ......................... 10</td>
</tr>
<tr>
<td>Pancuronium bromide ...................... 100</td>
</tr>
<tr>
<td>Pantoprazole .................................... 8</td>
</tr>
<tr>
<td>Panzop Relief ................................... 8</td>
</tr>
<tr>
<td>Papaverine hydrochloride ................ 47</td>
</tr>
<tr>
<td>Paper wasp venom ........................... 188</td>
</tr>
<tr>
<td>Para-aminosalicylic Acid ................ 83</td>
</tr>
<tr>
<td>ParaCare ......................................... 107</td>
</tr>
<tr>
<td>Paracare Double Strength ............... 107</td>
</tr>
<tr>
<td>Paracetamol ..................................... 107</td>
</tr>
<tr>
<td>Paracetamol Kabi ............................. 107</td>
</tr>
<tr>
<td>Paracetamol with codeine ............... 109</td>
</tr>
<tr>
<td>Parafﬁn ........................................... 202</td>
</tr>
<tr>
<td>Parafﬁn liquid with soft white parafﬁn.. 202</td>
</tr>
<tr>
<td>Parafﬁn liquid with wool fat .......... 202</td>
</tr>
<tr>
<td>Parafﬁn with wool fat ................. 53</td>
</tr>
<tr>
<td>Paraldehyde .................................... 112</td>
</tr>
<tr>
<td>Parecoxib ...................................... 102</td>
</tr>
<tr>
<td>Paromomycin ................................... 72</td>
</tr>
<tr>
<td>Paroxetine ...................................... 111</td>
</tr>
<tr>
<td>Paser ............................................. 83</td>
</tr>
<tr>
<td>Patanol .......................................... 198</td>
</tr>
<tr>
<td>Patent blue V ................................... 208</td>
</tr>
<tr>
<td>Paxam .......................................... 120</td>
</tr>
<tr>
<td>Pazopanib ...................................... 139</td>
</tr>
<tr>
<td>Peak flow meter ............................. 239</td>
</tr>
<tr>
<td>Peanut oil ..................................... 211</td>
</tr>
<tr>
<td>Pedialyte - Bubblegum ................... 36</td>
</tr>
<tr>
<td>Pediasure (Chocolate) ................... 225</td>
</tr>
<tr>
<td>Pediasure (Strawberry) ................. 225</td>
</tr>
<tr>
<td>Pediasure (Vanilla) ....................... 225</td>
</tr>
<tr>
<td>Pediasure RTH ................................. 225</td>
</tr>
<tr>
<td>Pegaspargase ................................... 134</td>
</tr>
<tr>
<td>Pegasil .......................................... 92</td>
</tr>
<tr>
<td>Pegylated interferon alfa-2a ........... 92</td>
</tr>
<tr>
<td>Pegmexizumab ................................. 184</td>
</tr>
<tr>
<td>Pemetrexed ..................................... 131</td>
</tr>
<tr>
<td>Penicillamine .................................. 94</td>
</tr>
<tr>
<td>Penicillin G .................................... 76</td>
</tr>
<tr>
<td>Penicillin V .................................... 76</td>
</tr>
<tr>
<td>Pentacrinat .................................... 84</td>
</tr>
<tr>
<td>Pentagastrin ................................... 65</td>
</tr>
<tr>
<td>Pentamidine isethionate ................ 84</td>
</tr>
<tr>
<td>Pentasa .......................................... 6</td>
</tr>
<tr>
<td>Pentostatin [Decoycoxformycin] ........ 134</td>
</tr>
<tr>
<td>Pentoxifylline [Oxpentifylline] ........... 47</td>
</tr>
<tr>
<td>Peptamen OS 1.0 (Vanilla) .............. 221</td>
</tr>
<tr>
<td>Peptisol ......................................... 7</td>
</tr>
<tr>
<td>Perluftren ...................................... 207</td>
</tr>
<tr>
<td>Perhexiline maleate ...................... 42</td>
</tr>
<tr>
<td>Pericyazine ................................... 118</td>
</tr>
<tr>
<td>Perindopril .................................... 37</td>
</tr>
<tr>
<td>Perjeta ......................................... 168</td>
</tr>
<tr>
<td>Permethrin ..................................... 52</td>
</tr>
<tr>
<td>Perrigo .......................................... 56</td>
</tr>
<tr>
<td>Pertuzumab .................................... 168</td>
</tr>
<tr>
<td>Peteha .......................................... 83</td>
</tr>
<tr>
<td>Pethidine hydrochloride ............... 110</td>
</tr>
<tr>
<td>Pexig ............................................ 42</td>
</tr>
<tr>
<td>Pfizer Exemestane ......................... 144</td>
</tr>
<tr>
<td>Pharmacy Health SLS-free .............. 53</td>
</tr>
<tr>
<td>Pharmacy Health Sorboleine with Glycerin .. 53</td>
</tr>
<tr>
<td>Phenol ........................................... 209</td>
</tr>
<tr>
<td>Phenol oily ...................................... 7</td>
</tr>
<tr>
<td>Phenelzine sulphate ...................... 111</td>
</tr>
<tr>
<td>Phenindione ................................... 30</td>
</tr>
<tr>
<td>Pheno bitone .................................. 113</td>
</tr>
<tr>
<td>Phenoxybenzamine hydrochloride ....... 38</td>
</tr>
<tr>
<td>Phenoxymethylpenicillin [Penicillin V] ................... 76</td>
</tr>
<tr>
<td>Phentolamine mesylate ................. 38</td>
</tr>
<tr>
<td>Phenytoin ...................................... 47</td>
</tr>
<tr>
<td>Phenytoin sodium ............................. 113</td>
</tr>
<tr>
<td>Pholodine ...................................... 192</td>
</tr>
<tr>
<td>Phosphorus ..................................... 36</td>
</tr>
<tr>
<td>Phyto menadione .............................. 29</td>
</tr>
<tr>
<td>Picibanil ....................................... 186</td>
</tr>
<tr>
<td>Pilocarpine hydrochloride ............... 200</td>
</tr>
<tr>
<td>Pilocarpine nitrate ......................... 212</td>
</tr>
<tr>
<td>Pimafucort ..................................... 55</td>
</tr>
<tr>
<td>Pindolol ........................................ 41</td>
</tr>
<tr>
<td>Pine tar with trolamine laurilsulfate ... 55</td>
</tr>
<tr>
<td>and fluorescein ......................... 55</td>
</tr>
<tr>
<td>Pinetarsol ...................................... 55</td>
</tr>
<tr>
<td>Pilocazine ....................................... 10</td>
</tr>
<tr>
<td>Pimecrolimus ................................. 76</td>
</tr>
<tr>
<td>Pipithiazine palmitate ................... 119</td>
</tr>
<tr>
<td>PipTaz Sandoz ................................. 76</td>
</tr>
<tr>
<td>Pirfenidone ..................................... 191</td>
</tr>
<tr>
<td>Pituitary and Hypothalamic Hormones and Analogues .... 66</td>
</tr>
<tr>
<td>Pivmecillinam .................................. 79</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Salbutamol with ipratropium bromide........................................ 189
Salicylic acid............................................................. 212
Salmeterol ............................................................................. 193
Salmonella typhi vaccine...................................................... 233
Sandimmun .......................................................................... 145
Sandomigran ...................................................................... 115
Sandoz .................................................................................. 143
Sapropterin Dihydrochloride ..................................................... 16
Scalp Preparations ................................................................ 55
Scandone 3% ........................................................................ 106
Sclerosing Agents ................................................................. 195
Scopoderm TTS .................................................................... 116
Sebizeole ................................................................................ 51
Secretin pentahydrochloride ................................................... 208
Secukinumab ........................................................................ 177
Sedatives and Hypnotics .......................................................... 121
Selenium hydrochloride .......................................................... 104
Sennosides .......................................................................... 62
Senspar ................................................................................ 117
Serendine .............................................................................. 193
Serevent .............................................................................. 193
Serevent Accuhaler ................................................................. 193
Seretide ................................................................................ 193
Seretide Accuhaler ................................................................. 193
Sertaline ................................................................................ 111
Sevoflurane .......................................................................... 105
Sevredol ............................................................................... 109
Silver nitrate ........................................................................... 178

Rivastigmine ................................................................. 119
Risperidone ................................................................. 118–119
Risperon ................................................................................ 118
Ritalin .................................................................................... 124
Ritalin LA ............................................................................ 124
Ritalin SR ............................................................................ 124
Ritonavin .............................................................................. 87
Rituximab ............................................................................ 169
Rivaroxaban ........................................................................... 30
Rivastigmine ........................................................................ 125
Rivotril ............................................................................... 111
RIVUSBIS ........................................................................... 28
Rizamelt ............................................................................... 115
RizatRIPTAN ....................................................................... 115
Rocuronium bromide ............................................................. 100
Rolin ..................................................................................... 144
Ropinirole hydrochloride ......................................................... 104
Ropivacaine hydrochloride ....................................................... 107
Ropivacaine hydrochloride with fentanyl ................................... 107
Ropivacaine Kabi .................................................................. 107
Rose bengal sodium ............................................................... 198
Rotarix ................................................................................. 237
Rotavirus oral vaccine ............................................................. 237
Roxane .................................................................................. 5
Roxithromycin ...................................................................... 75
Rubifen ................................................................................. 124
Rubifen SR ............................................................................ 124
Rulide D ............................................................................... 75
Rurioctocog alfa pegol [Recombinant fibroblast growth factor VIII] .. 28
Ruoxolinib .......................................................................... 140
Salbutamol with ipratropium bicarbonate.................................. 5
Sodium aurothiomalate ........................................................... 94
Sodium benzoate ................................................................. 16
Sodium bicarbonate ............................................................... 34, 36
Blood .................................................................................... 34, 36
Extemporaneously Compounded Preparations ........................... 212
Sodium calcium edetate ........................................................ 205
Sodium chloride ......................................................................
Blood .................................................................................... 35–36
Respiratory .......................................................................... 192, 194
Various ................................................................................ 209
Sodium chloride with sodium bicarbonate ............................... 192
Sodium citrate ........................................................................
Alimentary ............................................................................. 6
Extemporaneously Compounded Preparations ........................... 213
Sodium citrate with sodium chloride and potassium chloride .... 30
Sodium citrate with sodium lauryl sulphoacetate ....................... 12
Sodium citro-trtarate ............................................................... 60
Sodium cromoglicate ..............................................................
Alimentary ............................................................................. 6
Respiratory .......................................................................... 189, 194
Sensory ............................................................................... 198
Sodium dihydrogen phosphate ................................................
[Sodium acid phosphate] ........................................................ 35
Sodium fluoride ...................................................................... 17
Sodium fusidate [Fusidic acid] ..................................................
Dermatological ..................................................................... 51
Sodium hypochlorite ............................................................... 206
Sodium metabisulfite ............................................................ 213
Sodium nitrite ........................................................................... 203
Sodium nitroprusside .............................................................
Cardiovascular ..................................................................... 47
Sodium polystyrene sulphonate ............................................... 12
Sodium polyvinyl lactate ........................................................ 36
Sodium stibogluconate ........................................................... 85
Sodium tetradecyl sulphate ..................................................... 26
Sodium thiosulfate .................................................................. 203
Sodium valproate ................................................................. 114
Sodium with potassium .......................................................... 210
Sol... ...................................................................................... 117
Solifenacin Mylan ................................................................. 60
INDEX: Generic Chemicals and Brands

- S -

Solifenacin succinate .......................... 60
Solu-Cortef .......................................... 63
Solu-Medrol ........................................... 64
Solu-Medrol Act-O-Vial ......................... 64
Somatropin ........................................... 66
Sotalol .................................................. 41
Soya oil ................................................ 203
Spacer device ........................................ 239
Span-K ................................................. 36
Specialised Formulas .............................. 219
Spirolactone .......................................... 44
Sprycel ............................................... 136
Standard Feeds ..................................... 226
Staphlix ............................................... 76
Starch .................................................. 213
Stavudine ............................................. 86
Sterculia with frangula ........................... 12
Steroclear ............................................ 189
Stesolid ............................................... 112
Stimulants / ADHD Treatments .................. 123
Stripenol .............................................. 114
Stocrin ................................................. 85
Strattera ............................................. 123
Streptomycin sulphate ............................ 72
Stromectol ........................................... 83
Suboxone ............................................. 125
Sucralfate ............................................ 8
Sucrose ............................................... 108
Sugammadex ........................................ 100
Sulfadiazine silver .................................. 51
Sulfasalazine ........................................... 6
Sulindac .............................................. 102
Sulphacetamide sodium ........................... 196
Sulphadiazine ....................................... 79
Sulphur ............................................... 213
Sulpiride .............................................. 117
Sumatriptan ......................................... 115
Sunitinib .............................................. 140
Sunscrean, proprietary ............................ 56
Suprane ............................................... 104
Surgical Preparations .............................. 209
Sustagen Diabetic (Vanilla) ....................... 220
Sustagen Hospital Formula Active (Choc) .... 228
Sustagen Hospital Formula Active (Van) ...... 228
Sutent .................................................. 140
Suxamethonium chloride .......................... 100
Sylvant ................................................. 178
Symetrel .............................................. 103
Sympathomimetics .................................. 46

- T -

Tacrolimus .......................................... 145
Tagamet ............................................... 206
Talc .................................................... 195
Taliglucerase alfa ................................... 17
Tambocor ............................................. 39
Tambocor CR ........................................ 39
Tamoxifen ............................................ 144
Tamsulosin hydrochloride ....................... 60
Tamsulosin-Rex ..................................... 60
Tarceva ............................................... 137
Tasigna ............................................... 138
Tasmac ............................................... 104
Tecfidera ............................................ 120
Tegretol .............................................. 112
Tegretol CR .......................................... 112
Teicoplanin ......................................... 79
Temazepam .......................................... 122
Temozolomide ...................................... 134
Teoneplase ......................................... 32
Tenofovir disoproxil .............................. 88
Tenofovir Disoproxil Teva ....................... 88
Tenoxicam ........................................... 102
Terazosin ............................................ 39
Terbutaline .......................................... 59
Terbutaline sulphate .............................. 192
Terfilunomide ....................................... 121
Teriparatide ........................................ 98
Terlpressin .......................................... 71
Testosterone ......................................... 62
Testosterone cipionate ............................ 62
Testosterone esters ............................... 62
Testosterone undecanoate ....................... 62
Tetraclenazine ...................................... 103
Tetracaine [Amethocaine] hydrochloride ... 107
Tetracaine [Tetracistaclin] ........................ 66
Tetracosactrin ...................................... 66
Tetracycline ......................................... 78
Tetracycline ......................................... 78
Thalidomide ......................................... 135
Thalomid ............................................. 135
Thebromba oil ...................................... 213
Theophylline ........................................ 194
Thiamine hydrochloride ........................... 21
Thiocholine .......................................... 132

- T -

Thiopental [Thiopentone] sodium ............... 105
Thiopentone ......................................... 105
Thiotepa ............................................. 129
Thrombin ............................................. 26
Thymol glycine ..................................... 19
Thyroid and Antithyroid Preparations ........... 70
Thyrotropin alfa .................................... 66
Ticagrelor ............................................ 31
Ticarcillin with clavulanic acid .................. 76
Ticlopidine .......................................... 31
Tigecycline .......................................... 78
Tilcotil ............................................... 102
Timolol ................................................ 200
Timolol maleate .................................... 41
Timoptol XE ......................................... 200
Tiotropium bromide ............................... 190
Tobradex ............................................ 196
Tobramycin Infections ............................. 72
Sensory ............................................... 196
Tobramycin Mylan .................................. 72
Tobrex ............................................... 196
Tocilizumab ......................................... 179
Tofranil .............................................. 110
Tolcapone .......................................... 104
Tolterodine tartrate ................................ 61
Topamax ............................................. 114
Topicaine ............................................ 106
Topical Products for Joint and Muscular Pain... 102
Topiramate .......................................... 114
Topiramate Actavis ................................. 114
Tracrium ............................................. 100
Tramadol hydrochloride ......................... 110
Tramal 100 .......................................... 110
Tramal 50 ............................................ 110
Tramadol SR 100 ..................................... 110
Tramal SR 150 ....................................... 110
Tramal SR 200 ....................................... 110
Tranexamic acid ..................................... 26
Tranexamic-AFT ..................................... 26
Tranylcyromine sulphate ......................... 111
Trastuzumab ........................................ 182
Travoprost .......................................... 200
Travopt ............................................... 200
Treatments for Dementia ......................... 125
Treatments for Substance Dependence .......... 125

254
<table>
<thead>
<tr>
<th>Chemical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zoladex</td>
<td>66</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td></td>
</tr>
<tr>
<td>Hormone Preparations</td>
<td>63</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>94</td>
</tr>
<tr>
<td>Zoledronic acid Mylan</td>
<td>63</td>
</tr>
<tr>
<td>Zopiclone</td>
<td>122</td>
</tr>
<tr>
<td>Zopiclone Actavis</td>
<td>122</td>
</tr>
<tr>
<td>Zostavax</td>
<td>238</td>
</tr>
<tr>
<td>Zostrix</td>
<td>102</td>
</tr>
<tr>
<td>Zostrix HP</td>
<td>107</td>
</tr>
<tr>
<td>Zuclopenthixol acetate</td>
<td>118</td>
</tr>
<tr>
<td>Zuclopenthixol decanoate</td>
<td>120</td>
</tr>
<tr>
<td>Zuclopenthixol hydrochloride</td>
<td>118</td>
</tr>
<tr>
<td>Zusdone</td>
<td>118</td>
</tr>
<tr>
<td>Zyban</td>
<td>126</td>
</tr>
<tr>
<td>Zypine</td>
<td>118</td>
</tr>
<tr>
<td>Zypine ODT</td>
<td>118</td>
</tr>
<tr>
<td>Zyprexa Relprevv</td>
<td>119</td>
</tr>
<tr>
<td>Zytiga</td>
<td>142</td>
</tr>
<tr>
<td>Zyvox</td>
<td>79</td>
</tr>
</tbody>
</table>